docetaxel anhydrous has been researched along with Cancer of Prostate in 1699 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 20 (1.18) | 18.2507 |
| 2000's | 530 (31.19) | 29.6817 |
| 2010's | 835 (49.15) | 24.3611 |
| 2020's | 314 (18.48) | 2.80 |
| Authors | Studies |
|---|---|
| Aglianò, AM; Carradori, S; D'Ascenzio, M; De Monte, C; Giantulli, S; Guglielmi, P; Mollica, A; Morrone, S; Scarpa, S; Secci, D; Silvestri, I | 1 |
| Goodin, S; Guo, J; He, Y; Huang, H; Li, D; Liu, J; Liu, T; Wu, X; Yu, L; Zhang, K; Zheng, X | 1 |
| Arnst, KE; Banerjee, S; Deng, S; Kumar, G; Li, GB; Li, W; Miller, DD; Wang, Y; White, SW; Yang, J; Yang, L | 1 |
| Bassetto, M; Brancale, A; Ferla, S; Khandil, S; McGuigan, C; Pertusati, F; Westwell, AD | 1 |
| Beloglazkina, EK; Ber, AP; Borisova, YA; Chepikova, OE; Erofeev, A; Gorelkin, P; Khazanova, ES; Khudyakov, AD; Kolmogorov, VS; Kovalev, S; Machulkin, AE; Majouga, AG; Nimenko, EA; Pankratov, AA; Petrov, SA; Plotnikova, EA; Pokrovsky, VS; Polshakov, VI; Shafikov, RR; Skvortsov, DA; Smirnova, GB; Uspenskaya, AA; Vaneev, AN; Zamyatnin, AA; Zyk, NU; Zyk, NV | 1 |
| Andreassen, BK; Fosså, SD; Storås, AH; Ursin, G | 1 |
| Li, J; Tie, C; Wang, Z | 1 |
| Carpenter, V; Faber, AC; Gewirtz, DA; Harada, H; Min Lee, S; Murray, G; Reed, J; Saleh, T; Souers, A | 1 |
| Kan, Y; Li, B; Lu, M; Ma, S; Mao, L; Wang, J; Wei, F; Wu, C; Xu, Z | 1 |
| Chen, H; Gao, K; He, HH; Hou, X; Huang, H; Karnes, RJ; Li, Y; Pan, Y; Shi, Q; Wang, C; Wang, D; Wang, L; Wang, Y; Wei, T; Weroha, SJ; Xie, H; Yan, Y; Ye, W; Zhang, J; Zhang, P; Zhao, SM | 1 |
| Dai, L; Liang, J; Liu, Q; Ma, W; Shen, T; Wei, D; Zhang, J; Zhang, L; Zhao, Y; Zheng, Y | 1 |
| Allen, T; Armstrong, AJ; Chen, X; Foo, WC; Freedman, JA; George, DJ; Gregory, S; Gupta, S; Hsu, DS; Huang, J; Inman, BA; Kittles, RA; Li, Y; McCall, SJ; Owzar, K; Patierno, BM; Patierno, SR; Qin, X; Somarelli, JA; Ware, KE; Wise, JP; Wise, S; Xu, L; Zhang, D | 1 |
| Lévesque, JC; Maltais, R; Perreault, M; Poirier, D; Roy, J; Sato, S | 1 |
| Alkashgari, HR; Casiano, CA; Diaz Osterman, CJ; Elix, CC; Mahler, M; Martinez, SR; McMullen, JRW; Ochoa, PT; Ortiz-Hernandez, GL; Roy, S; Sanchez-Hernandez, ES; Soto, U | 1 |
| Attard, G; Birtle, A; Brawley, CD; Chowdhury, S; Clarke, NW; Cook, AD; Dearnaley, DP; Fackrell, D; Gale, J; Gilbert, DC; Gillessen, S; Gray, E; Hoskin, P; James, ND; Jones, RJ; Langley, RE; Macnair, A; Malik, ZI; Matheson, D; McPhail, N; Millman, R; Morgans, AK; Murphy, L; O'Sullivan, JM; Parker, CC; Parmar, MKB; Perna, C; Protheroe, A; Pugh, C; Rudman, S; Rush, HL; Russell, JM; Sydes, MR; Tanguay, JS; Tolan, S; Vengalil, S; Wagstaff, J | 1 |
| Ameye, F; Baekelandt, F; Bamelis, B; De Roock, W; Denies, E; Duck, L; Filleul, B; Fransis, K; Ghysel, C; Hollebosch, S; Joniau, S; Lambert, E; Logghe, P; Lumen, N; Ost, D; Remondo, C; Sautois, B; Schatteman, P; Van Bruwaene, S; van Praet, C; van Wambeke, S; Vandenbroucke, F; Vergauwe, E; Wynendaele, W | 1 |
| Habrowska-Górczyńska, DE; Kowalska, K; Kozieł, MJ; Piastowska-Ciesielska, AW | 1 |
| Byeon, S; Jeon, HG; Jeon, SS; Kim, H; Lee, HM; Lee, SI; Park, SH; Seo, SI | 1 |
| Ahmed, A; Dai, J; Escara-Wilke, J; Keller, ET; Keller, J; Mizokami, A; Schnepp, PM; Shelley, G | 1 |
| Lai, J; Xin, J; Zhang, W | 1 |
| Duan, Z; Gu, H | 1 |
| Chen, C; Feng, WB | 1 |
| Chen, H; Guo, S; Jiang, X; Liu, R; Niu, Y; Wang, S; Wang, Y; Xu, Y; Zhang, Y | 1 |
| Ginman, C; Hjälm-Eriksson, M; Huttunen, T; Kellokumpu-Lehtinen, PL; Lehtonen, M; Sormunen, J; Thellenberg-Karlsson, C | 1 |
| Goodin, S; Li, D; Liu, W; Ma, YY; Sheng, Z; Wang, X; Wu, M; Wu, P; Xuetao, X; Zhang, K; Zhao, DG; Zheng, X | 1 |
| Armstrong, AJ; Dzimitrowicz, HE | 1 |
| Adamchuk, H; Blayney, DW; Chen, M; Du, L; Ginn, G; Huang, L; Kirtbaya, DV; Mohanlal, R; Ogenstad, S; Zhang, Q | 1 |
| Li, S; Liu, Z; Wang, G; Xing, J; Xing, Z; Yu, G | 1 |
| Abu-Lafi, S; Asli, S; Falah, A; Falah, M; Rayan, A; Rayan, M; Shadafny, S | 1 |
| Dalhaug, A; Haukland, E; Nieder, C; Stanisavljevic, L | 1 |
| Alekseev, B; Crawford, ED; Cruz, F; Fizazi, K; Fu, C; Hussain, M; Joensuu, H; Kopyltsov, E; Kuss, I; Li, R; Maughan, BL; Méndez-Vidal, MJ; Montesa-Pino, Á; Park, CH; Parnis, F; Saad, F; Smith, MR; Sternberg, CN; Suzuki, H; Tammela, TLJ; Thiele, S; Tombal, B; Uemura, M; Utriainen, T; Ye, D | 1 |
| Chuu, CP; Fu, YK; Hour, TC; Huang, SH; Kuo, YY; Lin, CY; Tseng, JC; Wang, BJ | 1 |
| Chiba, S; Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Horikawa, Y; Ishida, T; Kashima, S; Kimura, T; Koizumi, A; Kumazawa, T; Maita, S; Narita, S; Nomura, K; Ohyama, C; Okane, K; Sato, H; Shimoda, J; Suzuki, T; Takayama, K; Yamamoto, R; Yanagisawa, T | 1 |
| Cheng, K; Duan, F; Feng, DP; Fu, JX; Wang, MQ; Xin, H; Ye, HY; Yu, HK; Yuan, B; Zhang, JL; Zhang, XJ | 1 |
| Han, L; Li, J; Liu, Y; Wang, S | 1 |
| Gao, P; Huang, J; Jiang, S; Liu, Q; Wang, H; Yao, L; Zhang, T; Zhang, X | 1 |
| Egen, L; Erben, P; Goly, N; GROß-Weege, M; Grüne, B; Hartung, F; Herrmann, J; Honeck, P; Jarczyk, J; Kowalewski, KF; Kriegmair, M; Mühlbauer, J; Neuberger, M; Nientiedt, M; Nitschke, K; Nuhn, P; Skladny, J; VON Hardenberg, J; Walach, MT; Waldbillig, F; WEIß, C; Wessels, F; Westhoff, N; Worst, TS | 1 |
| Abadie-Lacourtoisie, S; Berdah, JF; Berthold, D; Bossi, A; Calabro, F; Carles, J; Chand-Fouche, ME; El Kouri, C; Escande, A; Fizazi, K; Fléchon, A; Foulon, S; Freixa, SV; Gravis, G; Hasbini, A; Jamaluddin, M; Kacso, G; Laguerre, B; Latorzeff, I; Magne, N; Martin, E; McDermott, R; Mourey, L; Priou, F; Rieger, I; Ronchin, P; Rosello, A; Roubaud, G; Schlurmann, F; Silva, M; Supiot, S; Thiery-Vuillemin, A; Tombal, B | 1 |
| Varisli, L | 1 |
| Briganti, A; Bryniarski, P; Compérat, E; D'Amico, AV; Gandaglia, G; Joniau, S; Laukhtina, E; Leapman, MS; Massard, C; Merseburger, AS; Mori, K; Mostafaei, H; Ploussard, G; Pradere, B; Quhal, F; Rajwa, P; Roubaud, G; Saad, F; Shariat, SF; Shim, SR; Spratt, DE; Tsaur, I; van den Bergh, RCN; Yanagisawa, T | 1 |
| Bilen, MA; Brown, JR; Carthon, B; Caulfield, S; Hadadi, A; Kucuk, O; Lafollette, J; Liu, Y; Moore, M; Nazha, B; Russler, G; Smith, KE; Wan, L; Yantorni, L | 1 |
| Alexander, GC; Ballreich, J; Brawley, OW; Hong, H; Paller, CJ; Wang, L | 1 |
| Cui, Q; Dai, M; Dong, Z; Huang, C; Josephraj, S; Kyei-Baffour, K; Liu, JY; Peery, R; Zhang, JT | 1 |
| Chen, Y; Gao, D; Han, Y; Lin, Y; Lin, Z; Wang, F; Wang, P; Wang, Y; Yuan, H; Zhang, L | 1 |
| Atsuta, M; Egawa, S; Enei, Y; Habuchi, T; Hata, K; Hatakeyama, S; Iwamoto, Y; Iwatani, K; Kimura, T; Matsukawa, A; Miki, J; Mori, K; Nakazono, M; Narita, S; Nishikawa, H; Ohyama, C; Otsuka, T; Sakanaka, K; Sano, T; Shariat, SF; Tsuzuki, S; Yanagisawa, T | 1 |
| Barbier, MC; Haile, SR; Menges, D; Puhan, MA; Schwenkglenks, M; Sivec-Muniz, S; Tomonaga, Y; Yebyo, HG | 1 |
| Bataillard, T; Fagnoni, P; Nerich, V; Pelloux-Prayer, R; Thiery-Vuillemin, A; Vincent, A | 1 |
| Crawford, D; Farrington, T; Fizazi, K; Hussain, M; Manarite, J; Muslin, D; Saad, F; Smith, MR; Sternberg, CN; Tombal, B | 1 |
| Chen, L; Cheng, L; Hou, T; Li, X; Li, Y; Song, Y; Xing, Y | 1 |
| Ali, A; Amos, CL; Attard, G; Bahl, A; Birtle, A; Brawley, CD; Capaldi, L; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Dearnaley, DP; Din, O; Douis, H; Ford, D; Gale, J; Gilbert, DC; Gillessen, S; Gilson, C; Henry, A; Hoskin, P; Hoyle, A; James, ND; Jones, RJ; Kagzi, M; Langley, RE; Lydon, A; Malik, ZI; Mason, MD; Matheson, D; Millman, R; O'Sullivan, JM; Paisey, SA; Parikh, O; Parker, CC; Parmar, MKB; Pudney, D; Ramani, V; Rauchenberger, M; Robson, P; Rush, H; Russell, JM; Srihari, NN; Sweeney, H; Sydes, MR; Tanguay, J | 1 |
| Alcaraz, A; Alekseev, B; Armstrong, AJ; Azad, A; Ganguli, A; Gomez-Veiga, F; Haas, GP; Holzbeierlein, J; Iguchi, T; Ivanescu, C; Petrylak, D; Ramaswamy, K; Rosbrook, B; Shore, ND; Stenzl, A; Szmulewitz, RZ; Villers, A | 1 |
| Chen, Z; Keilholz, U; Pachnikova, G; Przybilla, D; Schäfer, R; Wang, H; Wu, Y; Xu, Y; Zhu, S | 1 |
| Guo, Y; Lai, H; Long, Z; Lu, J; Lv, D; Mao, X; Wang, S; Wu, K; Zhong, C; Zhong, W; Zhou, X | 1 |
| Kartolo, A; Tannock, IF; Vera Badillo, FE | 1 |
| Bloomquist, C; Byrne, JD; DeSimone, J; Hagan, CT; Kim, I; Knape, NM; Mecham, S; Tu, L; Wagner, K; Wang, AZ | 1 |
| Egawa, S; Habuchi, T; Hata, K; Hatakeyama, S; Hoshi, S; Ishi, N; Ishidoya, S; Ito, A; Kawamura, S; Kimura, T; Mitsuzuka, K; Miura, Y; Narita, S; Ohyama, C; Tanaka, T; Tsuchiya, N; Yanagisawa, T | 1 |
| Chang, CP; Chiu, SC; Cho, DY; Hsiao, CH; Huang, SH; Lin, CC; Pan, Y; Shen, YC; Shih, HJ; Shih, PH; Wu, SC | 1 |
| Aben, KKH; Creemers, SG; Hamberg, P; Kiemeney, LA; van den Berkmortel, FWPJ; van Oort, IM; Van Santvoort, B | 1 |
| Klaassen, Z; Lajkosz, K; Malone, S; Morgan, SC; Ong, M; Roy, S; Saad, F; Sayyid, R; Spratt, DE; Sun, Y; Wallis, CJD | 1 |
| Blas, L; Eto, M; Shiota, M | 1 |
| Feng, Y; Jiang, J; Li, S; Li, Z; Wu, E; Wu, H; Yang, L; Zhang, J; Zhang, W | 1 |
| Ahmed, I; Amos, CL; Attard, G; Au, C; Birtle, AJ; Brawley, CD; Brock, SJ; Chowdhury, S; Clarke, NW; Cross, W; Das, P; Dearnaley, DP; Ford, VA; Gilbert, DC; Gillessen, S; Gray, EK; Hughes, RJ; Ingleby, FC; James, ND; Jones, RJ; Langley, RE; Macnair, A; Malik, ZI; Manetta, CB; Mason, MD; Matheson, DJ; McLaren, DB; Mestre, RP; Millman, R; Nikapota, AD; O'Sullivan, JM; Parker, CC; Parmar, MKB; Peedell, C; Perna, C; Protheroe, AS; Ritchie, AWS; Rush, HL; Russell, JM; Sundar, S; Sydes, MR; Tanguay, JS; Tolan, SP; Wagstaff, J; Wallace, JB; Wylie, JP; Zarkar, A | 1 |
| Crawford, ED | 1 |
| Amsberg, GV; Böhmer, D; Krabbe, LM; Krause, BJ; Merseburger, AS; Perner, S | 1 |
| Alexander, A; Barta, I; Beckham, W; Bromma, K; Chithrani, DB; Dos Santos, N; Krishnan, S | 1 |
| Celenkoglu, G; Sayin, M | 1 |
| Belladelli, F; Fallara, G; Malavaud, B; Marandino, L; Martini, A; Montorsi, F; Necchi, A; Nocera, L; Ploussard, G; Raggi, D; Robesti, D | 1 |
| Bokemeyer, C; Busenbender, T; Dyshlovoy, SA; Graefen, M; Grebnev, BB; Guzii, AG; Hauschild, J; Makarieva, TN; Maurer, T; Menshov, AS; Oh-Hohenhorst, SJ; Popov, RS; Shubina, LK; Stonik, VA; Strewinsky, N; Tilki, D; von Amsberg, G | 1 |
| Guo, Z; Lu, X; Qin, L; Wang, H; Wu, J; Yang, F; Yang, N | 1 |
| Gao, X; Hu, X; Huang, C; Li, H; Miao, Y; Song, J; Sun, S; Wang, B; Wei, X; Xu, H; Yuan, Y; Zhang, Q; Zhang, W; Zhang, X; Zhao, W; Zheng, J | 1 |
| Ciccarese, C; Fizazi, K; Gillessen, S; Iacovelli, R; Sternberg, CN; Tortora, G | 1 |
| Chen, Y; Lu, T; Luo, J; Xu, Z; Xue, H | 1 |
| Dong, Z; Guo, J; Pan, W; Tian, C; Wang, H; Wang, Y; Yan, J | 1 |
| Egawa, S; Fukuokaya, W; Gandaglia, G; Kawada, T; Kimura, T; Laukhtina, E; Mori, K; Mostafaei, H; Motlagh, RS; Pallauf, M; Pradere, B; Quhal, F; Rajwa, P; Shariat, SF; Shim, SR; Thibault, C; Yanagisawa, T | 1 |
| Ahn, KS; Alharbi, SA; Chinnathambi, A; Deivasigamani, A; Hui, KM; Jung, YY; Mohan, CD; Rangappa, KS; Sethi, G; Zhang, J | 1 |
| Azad, AA; Chen, K; Kostos, L | 1 |
| Guo, Z; Hu, X; Liu, Z; Lv, R; Meng, L; Yan, L; Zhang, Y | 1 |
| Fujita, K; Matsumura, N; Minami, T; Nishimoto, M; Tahara, H; Uemura, H; Yoshimura, K | 1 |
| Chun, FKH; Hoeh, B; Karakiewicz, PI; Mandel, P; Preisser, F; Steuber, T; Tian, Z; Tilki, D; Wenzel, M | 1 |
| Azuma, H; Burton, F; Carducci, MA; Chakraborty, G; Chen, YH; Davicioni, E; Frank, D; Hirani, R; Kantoff, PW; Lee, GM; Liu, G; Mazzu, YZ; Nandakumar, S; Rajanala, SH; Stopsack, KH; Sweeney, CJ; Wang, XV; Yoshikawa, Y | 1 |
| Agarwal, N; Antonarakis, ES; Fisher, V; Graf, RP; Li, G; Mathew Thomas, V; Nussenzveig, RH; Oxnard, GR; Ross, JS; Sayegh, N; Schrock, AB; Swami, U; Tripathi, N; Tukachinsky, H | 1 |
| Fan, B; Li, M; Pei, L; Song, X; Tan, X; Zhang, A | 1 |
| Altavilla, A; Cattrini, C; De Giorgi, U; Di Maio, M; Maiello, E; Maiorano, BA; Mennitto, A; Messina, C; Roviello, G | 1 |
| Chen, B; Daba, M; Gao, X; Li, Q; Liu, B; Liu, J; Miao, J; Song, G; Wang, Z; Wu, B; Yuan, X; Zeng, K | 1 |
| Baccaglini, W; Carneiro, A; Christofe, NM; Glina, FPA; Lemos, GC; Olivares, R; Rodrigues, AF; Sanchez-Salas, R; Teles, SB | 1 |
| Briganti, A; Ceci, F; Chlosta, P; Gandaglia, G; Heidegger, I; Karakiewicz, PI; Kasivisvanathan, V; Kawada, T; Kesch, CV; Laukhtina, E; Marra, G; Montorsi, F; Nyiriadi, P; Ploussard, G; Rajwa, P; Shariat, SF; Soeterik, TFW; Trinh, QD; Valerio, M; van den Bergh, RCN; Yanagisawa, T; Zattoni, F | 1 |
| Bokemeyer, C; Busenbender, T; Dyshlovoy, SA; Girich, EV; Graefen, M; Hauschild, J; Hoffer, K; Kriegs, M; von Amsberg, G; Yurchenko, AN | 1 |
| Bektic, J; Burtscher, T; Fritz, J; Heidegger, I; Horninger, W; Kafka, M; Ladurner, M; Schmitz, M | 1 |
| Barbier, MC; Haile, SR; Menges, D; Puhan, MA; Schwenkglenks, M; Tomonaga, Y; Yebyo, HG | 1 |
| An, LJ; Guo, H; Han, XQ; Huang, AF; Jiang, YJ; Liu, CM; Shao, ZC; Su, MQ; Wu, ZP; Zhu, BH | 1 |
| Catapano, J; Czyż, J; Kędracka-Krok, S; Luty, M; Madeja, Z; Piwowarczyk, K; Pudełek, M; Siedlar, M; Wróbel, T | 1 |
| Azad, AA; Bolton, D; Lawrentschuk, N; Murphy, DG; Pan, HYC; Sathianathen, NJ; Siva, S; Tran, B | 1 |
| Chen, X; Dong, Q; Feng, J; Jiang, X; Li, Y; Liu, M; Nik Nabil, WN; Song, Z; Xi, Z; Xu, H; Zhou, H | 1 |
| Baboudjian, M; Barret, E; Beauval, JB; Brureau, L; Créhange, G; Dariane, C; Fiard, G; Fromont, G; Gauthé, M; Mathieu, R; Ploussard, G; Renard-Penna, R; Roubaud, G; Rouprêt, M; Ruffion, A; Sargos, P | 1 |
| Azad, AA; Chen, K; Jenjitranant, P; Kasivisvanathan, V; Kelly, BD; Lawrentschuk, N; McVey, A; Murphy, DG; O'Brien, J | 1 |
| Habuchi, T; Hamaya, T; Hashimoto, Y; Hata, K; Hatakeyama, S; Kimura, T; Narita, S; Ohyama, C; Okamoto, T; Ozaki, K; Tanaka, T; Togashi, K; Yamamoto, H; Yanagisawa, T; Yoneyama, T | 1 |
| Burdett, S; Fisher, DJ; Tierney, JF; Vale, C; White, IR | 1 |
| De Maeseneer, D; De Man, K; Fonteyne, V; Lambert, E; Lumen, N; Van Praet, C; Verbeke, S; Villeirs, G | 1 |
| Guo, B; Guo, J; He, Z; Peng, J; Xie, J; Yuan, Y; Zhou, Y | 1 |
| Buttigliero, C; Fiorica, F; Grigolato, D; Munoz, F; Muraro, M; Tucci, M; Turco, F | 1 |
| Berdyshev, DV; Bokemeyer, C; Dmitrenok, PS; Dyshlovoy, SA; Graefen, M; Guzii, AG; Hauschild, J; Kudryashova, EK; Makarieva, TN; Menshov, AS; Popov, RS; Shubina, LK; Strewinsky, N; von Amsberg, G | 1 |
| Donix, L; Dubrovska, A; Erb, HHH; Erdmann, K; Fuessel, S; Linke, D; Peitzsch, C; Pfeifer, M; Thomas, C | 1 |
| Cao, Y; Chen, Z; Dai, J; Wu, Y; Xiao, L; Zhang, W | 1 |
| Alimohamed, N; Hotte, SJ; Jiang, DM; Sridhar, SS; Stecca, CE; Veitch, Z; Wood, L | 1 |
| Enei, Y; Fukuokaya, W; Habuchi, T; Hara, S; Hata, K; Hatakeyama, S; Kimura, T; Matsukawa, A; Miki, J; Miyajima, K; Mori, K; Nakazono, M; Narita, S; Ohyama, C; Otsuka, T; Sano, T; Shariat, SF; Yanagisawa, T; Yata, Y | 1 |
| Kim, JY; Lee, HJ; Lee, JL; Park, I; Park, K; Shin, SH | 1 |
| Álvarez-Ossorio, JL; Borque-Fernando, A; Calleja-Hernández, MA; Cózar-Olmo, JM; Gómez-Iturriaga, A; Pérez-Fentes, DA; Puente-Vázquez, J; Rodrigo-Aliaga, M; Unda, M | 1 |
| Alves Ribeiro, M; Araújo, TG; Cordeiro, AO; da Silva Filho, AA; da Silva Guimarães, G; de Souza Costa, D; de Vasconcelos Azevedo, FVP; Gazolla, MC; Goulart, LR; Moreira Campos, I; Pereira Zoia, MA; Soares Mota, ST; Vecchi, L | 1 |
| Chun, FKH; Hoeh, B; Mandel, P; Wenzel, M | 1 |
| Guo, S; Jiang, X; Liu, R; Xu, Y | 1 |
| Berlin, IG; Jennings, CC; Kenealey, J; Shin, S | 1 |
| Huang, Q; Li, C; Luo, Z; Wu, T; Zeng, J; Zhang, J; Zhang, Y; Zhang, Z; Zhao, H; Zhu, S | 1 |
| Agarwal, N; Blauer-Peterson, CJ; Diessner, BJ; El-Chaar, NN; Hong, A; Nimke, D; Ramaswamy, K; Sandin, R; Swami, U | 1 |
| Bögemann, M; Crawford, ED; Cruz, F; Fizazi, K; Hussain, M; Joensuu, H; Kalebasty, AR; Kapur, S; Kopyltsov, E; Kuss, I; Saad, F; Shore, N; Smith, MR; Srinivasan, S; Sternberg, CN; Suzuki, H; Tombal, B; Verholen, F; Ye, D | 1 |
| Abkenar, ZO; Babaei, R; Entezari, M; Hashemi, M; Hushmandi, K; Khorrami, R; Nabavi, N; Nejad, MM; Rahmanian, P; Rajabi, R; Rashidi, M; Ren, J; Rezaei, S; Sadi, FH; Shafiee, SS; Taheriazam, A; Talebi, Y; Zandieh, MA | 1 |
| Boegemann, M | 1 |
| Deng, Y; Han, C; Hu, B; Hu, P; Liu, J; Liu, X; Wang, T; Xia, Q; Yang, B | 1 |
| Beretta, G; Montagnani Marelli, M; Moretti, RM | 1 |
| Abe, H; Amiya, Y; Hayashi, S; Kaneko, Y; Kimura, N; Nakatsu, H; Shima, T; Suzuki, N; Takei, A; Tetsuka, T; Uchida, T | 1 |
| Omrčen, T | 1 |
| Armstrong, AJ; McManus, HD | 1 |
| Bristow, RG; Oing, C | 1 |
| Gourdin, T; Velayati, A | 1 |
| Jana, P; Kondapi, AK; Muj, C; Mukhopadhyay, S | 1 |
| Li, F; Li, X; Song, D; Wu, J; Xue, X; Zheng, C | 1 |
| Agarwal, N; Gebrael, G; Swami, U; Thomas, VM | 1 |
| Cardoso, AM; Coelho, RS; Maia, CJ; Nascimento, D; Passarinha, LA; Rocha, SM; Socorro, S | 1 |
| Chun, FKH; Garcia, CC; Hoeh, B; Karakiewicz, PI; Mandel, P; Steuber, T; Tian, Z; Tilki, D; Wenzel, M | 1 |
| Attard, G; Davicioni, E; Den, RB; Hakansson, A; Hamid, AA; Ho, J; Karnes, RJ; Kishan, AU; Lee Kiang Chua, M; Li, EV; Liu, Y; Lotan, TL; Proudfoot, JA; Reiter, RE; Ross, AE; Schaeffer, EM; Spratt, DE; Sweeney, CJ; Tran, PT; Weiner, AB; Zhang, JH; Zhao, X | 1 |
| Bossi, A; Brown, B; Buckley, D; Cookson, MS; George, DJ; Lu, S; Saad, F; Saltzstein, DR; Selby, B; Shore, ND; Tombal, B; Tutrone, R | 1 |
| Aaltomaa, S; Ahlgren, G; Andrén, O; Brasso, K; Castellanos, E; Damber, JE; de Wit, R; Holmberg, E; Jellvert, Å; Josefsson, A; Luukkaa, M; Meidahl Petersen, P; Seke, M; Verhagen, P; Widmark, A | 1 |
| Alkashgari, HR; Casiano, CA; Elix, CC; Martinez, SR; Ochoa, PT; Ortiz-Hernandez, GL; Sanchez-Hernandez, ES; Zhang, L | 1 |
| Abdel-Aty, H; Alzouebi, M; Amos, CL; Attard, G; Birtle, A; Brawley, C; Brown, LC; Brown, MD; Cathomas, R; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Das, P; Dearnaley, DP; Diaz-Montana, C; Gale, J; Gilbert, D; Gillessen, S; Gilson, C; Grant, W; Gray, E; Hoyle, A; Jain, Y; James, ND; Jones, C; Jones, RJ; Langley, RE; Malik, Z; Mason, MD; Matheson, D; Millman, R; Montazeri, AH; Murphy, C; Murphy, L; O'Sullivan, JM; Parikh, O; Parkar, N; Parker, CC; Parmar, MKB; Pedley, I; Pezaro, C; Pugh, C; Robinson, A; Rush, H; Russell, JM; Sachdeva, A; Saxby, H; Srihari, N; Sydes, MR; Tanguay, J; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A | 1 |
| Choksi, AU; Haltstuch, D; Hurwitz, ME; Kim, IY; Leapman, MS; Lokeshwar, SD; Press, BH; Rahman, SN; Syed, J | 1 |
| Chang, J; De Man, K; Deek, M; Delrue, L; DeWeese, T; English, K; Feng, FY; Fonteyne, V; Hodges, T; Joniau, S; Kiess, A; Lane, B; Lotan, T; Lumen, N; Mendes, AA; Ost, P; Pienta, K; Pomper, M; Rana, Z; Ren, L; Rowe, S; Shetty, AC; Song, DY; Song, Y; Sutera, P; Sweeney, C; Tran, PT; Van der Eecken, K; Verbeke, S | 1 |
| Amin, MB; Balogh, AG; Feng, FY; Garzotto, MG; Gomella, LG; Hannan, R; Horwitz, EM; Jones, CU; Karrison, TG; Michalski, JM; Pervez, N; Purdy, J; Reaume, MN; Rodgers, JP; Rodrigues, GB; Rosenthal, SA; Sandler, HM; Sartor, O; Souhami, L; Williams, SG | 1 |
| Ghamande, SS; Klaassen, Z; Wallis, CJD | 1 |
| Jiang, DM; Mittal, A; Ong, M; Sridhar, SS | 1 |
| Dai, J; Escara-Wilke, J; Keller, ET; Robinson, T; Zimmermann, J | 1 |
| Hiratsuka, K; Iwamoto, H; Izumi, K; Kadomoto, S; Mizokami, A; Naito, R; Nakata, H; Natsagdorj, A; Shigehara, K; Yaegashi, H | 1 |
| Arai, S; Fujizuka, Y; Hori, K; Koike, H; Matsui, H; Miyazawa, Y; Nomura, M; Sekine, Y; Suzuki, K; Tsuji, Y | 1 |
| Hindié, E | 1 |
| Bu, Y; Lei, Y; Liu, Y; Qiao, D; Tang, Y; Zhang, C; Zhang, Y | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Brihoum, M; Chinet-Charrot, P; Cojean-Zelek, I; Culine, S; Davin, JL; Delva, R; Deplanque, G; Drubay, D; Faivre, L; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Grosse-Goupil, M; Houede, N; Krakowski, I; Labourey, JL; Lagrange, JL; Laguerre, B; Lavaud, P; Legouffe, E; Lesaunier, F; Linassier, C; Martin, AL; Mourey, L; Orlando, V; Oudard, S; Priou, F; Rolland, F; Teuff, GL; Theodore, C | 1 |
| Nguyen, P; Pomerantz, M; Wala, J | 1 |
| Bothiraja, C; Korake, S; Pawar, A | 1 |
| Everaerts, W; Joniau, S; Van den Broeck, T | 1 |
| Benedicto, A; Hernandez-Unzueta, I; Márquez, J; Sanz, E; Telleria, U | 1 |
| Guo, H; Li, S; Lin, B; Tu, M; Wang, R; Wang, X; Wu, Y; Xie, W; Zhang, J | 1 |
| Bhana, R; Billy Graham Mariam, N; Choudhury, A; Elumalai, T; Hoskin, P; Hughes, S; Maitre, P; Mistry, H; Portner, R; Sabar, M; Thippu Jayaprakash, K; Wickramasinghe, K; Young, T | 1 |
| Arici, S; Can, O; Güven, O; Karyağar, S; Özülker, T | 1 |
| Bianchi, A; Fukuokaya, W; Kawada, T; Kimura, T; Kramer, G; Laukhtina, E; Majdoub, M; Mori, K; Petrov, P; Pradere, B; Quhal, F; Rajwa, P; Shariat, SF; von Deimling, M; Yanagisawa, T | 1 |
| Bai, L; Tao, N; Zhang, W | 1 |
| Guo, B; Meng, F; Wang, Z; Yan, W; Yang, J; Zhong, Z | 1 |
| Bianchi, A; Kawada, T; Kimura, T; Laukhtina, E; Majdoub, M; Mori, K; Mostafaei, H; Pallauf, M; Pradere, B; Quhal, F; Rajwa, P; Sari Motlagh, R; Shariat, SF; Shim, SR; von Deimling, M; Yanagisawa, T | 1 |
| Al Hussein Al Awamlh, B; Barocas, DA; Chang, SS; Cortese, BD; Dusetzina, SB; Luckenbaugh, AN; Moses, KA; Penson, DF; Scarpato, KR; Talwar, R | 1 |
| Boher, JM; Burdett, S; Chen, YH; Clarke, NW; Fisher, DJ; Fizazi, K; Godolphin, PJ; Gravis, G; James, ND; Liu, G; Matheson, D; Murphy, L; Oldroyd, RE; Parmar, MKB; Rogozinska, E; Rydzewska, LH; Sfumato, P; Sweeney, CJ; Sydes, MR; Tierney, JF; Tombal, B; Vale, CL; White, IR | 1 |
| Beckstead, R; Cutshall, ZA; Dougherty, M; Haaland, B; Kohli, M; Kohli, R; Nelson, RE; Yoo, M | 1 |
| Arcangeli, S; Caballero, B; Couñago, F; Gómez-Aparicio, MA; López-Campos, F; Lozano, AJ; Maldonado, X; Moreno, E; Scorsetti, M; Suarez, V; Zafra, J | 1 |
| Bai, L; Bowen, NJ; Chen, Y; Cook, N; Danaher, A; Du, Y; Fu, H; Kucuk, O; Li, D; Li, X; Osunkoya, AO; Qui, M; Wu, D; Wu, JM; Wu, Y; Xie, ZR; Zhao, R | 1 |
| Eterović, D; Jozić, T; Omrčen, T; Vrdoljak, E | 1 |
| Lee, A | 1 |
| Liu, F; Liu, S; Liu, T; Mei, J; Zhang, G; Zhou, Z | 1 |
| Erdogan, S; Serttas, R | 1 |
| Gao, H; Gu, J; Liu, W; Qu, C; Sun, H; Wang, H; Wang, X; Wang, Z; Wen, H; Yang, Z | 1 |
| Alkashgari, HR; Casiano, CA; Chen, Z; Diaz Osterman, CJ; Kremsky, I; Martinez, SR; Ochoa, PT; Ortiz-Hernandez, GL; Sanchez-Hernandez, ES; Suzuki, T; Unternaehrer, JJ; Wang, C | 1 |
| Chen, Y; Guo, B; Meng, F; Ni, D; Yang, G; Yang, J; Zhong, Z | 1 |
| Fujimoto, N; Harada, K; Minato, A; Miyamoto, H; Nagata, Y; Tomisaki, I; Tsubonuma, Y | 1 |
| Bergh, A; Freyhult, E; Josefsson, A; Spyratou, V; Thellenberg-Karlsson, C; Welén, K; Wikström, P | 1 |
| Andreassen, BK; Fosså, SD; Storås, AH; Tsuruda, K | 1 |
| Bialkowska, A; Gordon, C; Hillowe, A; Kaczocha, M; Ojima, I; Rizzo, RC; Trotman, LC; Wang, L | 1 |
| Chen, MH; D'Amico, AV; Huang, J; Loffredo, M; McMahon, E; Nguyen, P; Orio, P; Sayan, M; Xie, W | 1 |
| Fang, G; Pang, Y; Wang, X; Zhou, Q | 1 |
| Callan, B; Callan, JF; Kelly, P; Logan, K; McHale, AP; McKaig, T; McKeown, S; Nesbitt, H; O'Rourke, D; O'Sullivan, JM | 1 |
| Almeida, AM; Aydos, RD; Gonçalves, AF; Neves, MB; Ramalho, RT; Selzler, M | 1 |
| Brihoum, M; D'Amico, AV; Eastham, JA; Feng, FY; Fizazi, K; James, ND; Kwak, L; Mahal, BA; Ravi, P; Sandler, HM; Sweeney, C; Xie, W | 1 |
| Aghamir, SMK; Akbari, MR; Baghdadabad, LZ; Farashah, PD; Ghajar, HA; Mirzaei, A; Rahimnia, R; Taheri, D; Yasseri, AF | 1 |
| Yildirim, S; Yilmaz, C | 1 |
| Ji, M; Li, W; Li, Z; Quan, C | 1 |
| Beck, JR; Correa, AF; Geynisman, DM; Handorf, EA; Ramamurthy, C | 1 |
| Babasaki, T; Goto, K; Han, X; Hayashi, T; Inoue, S; Kawaguchi, T; Matsubara, A; Sekino, Y; Shiota, M; Teishima, J; Yasui, W | 1 |
| Åström, L; Fransson, AS; Franzen, L; Ginman, C; Hjälm-Eriksson, M; Huttunen, T; Kellokumpu-Lehtinen, PL; Leskinen, MJ; Thellenberg-Karlsson, C; Zeke, M | 1 |
| George, DJ | 1 |
| Chi, C; Dong, B; Karnes, RJ; Pan, J; Qian, H; Sha, J; Shao, X; Wang, Y; Xu, F; Xue, W; Zhu, Y | 1 |
| Bian, P; Dou, Z; Jia, Z; Li, W; Pan, D | 1 |
| Jiang, W; Liu, M; Liu, Y; Qu, S; Yao, X | 1 |
| Chano, T; Hanada, E; Ii, H; Kageyama, S; Kawauchi, A; Nakata, S; Takagi, H; Taniguchi, K; Yoshiya, T | 1 |
| Elabbady, A; Elsaqa, M; Sharafeldeen, M | 1 |
| Chen, H; Lin, H; Lin, J; Liu, H; Liu, L; Luo, L; Shen, Z; Yang, M | 1 |
| Ali, A; Amos, CL; Attard, G; Beesley, S; Birtle, A; Brawley, CD; Brown, J; Calvert, J; Capaldi, L; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; Dearnaley, DP; Douis, H; Gale, J; Gibbs, S; Gilbert, D; Gillessen, S; Hoyle, A; Ingleby, FC; James, ND; Jones, RJ; Langley, RE; Lydon, A; MacNair, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Nikapota, A; O'Sullivan, JM; Omlin, A; Parikh, O; Parker, CC; Parmar, MKB; Protheroe, A; Ritchie, AWS; Rudman, S; Rush, H; Russell, JM; Simms, M; Srihari, NN; Sydes, MR; Tanguay, JS; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A | 1 |
| Hoshino, H; Inamura, SO; Ito, H; Kobayashi, M; Taga, M; Tsuchiyama, K; Yokoyama, O | 1 |
| Ali, A; Clarke, NW; Parker, CC | 1 |
| Shen, Z; Xu, J; Zhang, C; Zhou, L | 1 |
| Arai, Y; Habuchi, T; Hatakeyama, S; Narita, S; Ohyama, C; Okamoto, T | 1 |
| Gao, Y; Labhasetwar, V; Midura, RJ; Rahman, MT; Rozic, R; Sharifi, N; Vijayaraghavalu, S | 1 |
| Guo, S; Jia, Y; Jiang, X; Li, X; Ma, B; Xu, Y; Zhang, Y; Zhao, Y | 1 |
| Abnous, K; Afsharzadeh, M; Babaei, M; Hashemi, M; Ramezani, M | 1 |
| Aggarwal, R; Bok, RA; Carvajal, L; Chen, HY; Gordon, JW; Kurhanewicz, J; Larson, PEZ; Lee, P; Ohliger, MA; Slater, JB; Small, EJ; van Criekinge, M; Vigneron, DB; Zhu, Z | 1 |
| Autorino, R; Castellan, P; Cindolo, L; Di Nicola, M; Marchioni, M; Novara, G; Paul, AK; Primiceri, G; Schips, L; Veccia, A | 1 |
| Cao, T; Fu, Y; Gao, Y; Li, X; Liu, Y; Peng, Y; Qi, X; Yin, L; Yuan, B; Zhang, S; Zhu, Q | 1 |
| Aghighi, M; Crossland, D; Samankan, S; Taherian, M | 1 |
| Ahmed, H; Day, RM; Di Maggio, F; Ho, HMK; Paliashvili, K; Sathasivam, S | 1 |
| Broggini, M; Cisse, O; Falasca, M; Guffanti, F; Gulluni, F; Hirsch, E; Maffucci, T; Mavrommati, I; Oh, LCR; Quraishi, M; Sarvananthan, A; Schlatter, JN; Suthanthirakumaran, M | 1 |
| Adomat, H; Beraldi, E; Bidnur, S; Bowden, M; Fazil, L; Gleave, ME; Jackson, JK; Kesch, C; Moskalev, I; Schmitt, V; Thi, M; Yago, V | 1 |
| Bai, Y; Chang, K; Chen, Y; Ding, D; Feng, K; Gao, K; Huang, H; Jiao, D; Li, Y; Ma, J; Mo, R; Ren, S; Shi, Q; Sun, H; Sun, Y; Wang, C; Zhang, L; Zhang, P; Zhao, SM; Zhao, X; Zhu, Y | 1 |
| Dufès, C; Hewit, K; James, D; Leung, HY; Munnings-Tomes, S; Patel, R; Rushworth, LK; Shanks, E; Somani, S; Straube, A | 1 |
| Chen, A; Ji, J; Liu, N; Qiu, H; Shao, Z; Wen, X; Yao, H; Yao, S; Zhang, L; Zhang, X | 1 |
| Chang, P; Hua, L; Miao, C; Ni, H; Tang, Q; Wu, C; Xi, P; Zhou, X | 1 |
| Chen, S; Lin, Y; Liu, X; Lv, R; Min, Z; Qiao, X; Ran, W; Wang, J; Yang, J; Zhang, X; Zhu, S | 1 |
| Klaassen, Z; Wallis, CJD | 1 |
| Chen, G; Chen, QH; Jiang, Z; Wang, G; Zhang, Q | 1 |
| Beretov, J; Bucci, J; Cheung, BB; Duan, W; Graham, P; Li, Y; Malouf, D; Ni, J | 1 |
| Asay, S; Barnes, B; Graham, A; Hollingsworth, S; Kenealey, JD; Michaelis, DJ; Oblad, RV | 1 |
| Beraldi, E; Bidnur, S; Bowden, M; Gleave, ME; Jackson, JK; Kesch, C; Schmitt, V; Yago, V | 1 |
| Ardizzoni, A; Battelli, N; Conti, A; Di Nunno, V; Massari, F; Mollica, V; Montironi, R; Santoni, M | 1 |
| Gao, WQ; Li, L; Liu, L; Liu, Y; Tong, Y; Wang, F | 1 |
| Beltran, H; Morris, MJ | 1 |
| Cookson, MS; Parker, DC | 1 |
| Aiello, P; Balsari, A; Giussani, M; Regondi, V; Ripamonti, F; Rossini, A; Tagliabue, E; Triulzi, T | 1 |
| Bartzatt, R | 1 |
| Chen, X; Ge, X; Qin, W; Shi, C; Tan, D; Wu, P; Xu, R; Zhang, C; Zhao, Y | 1 |
| Fong, L; Nicholson, LT | 1 |
| Agarwal, P; Angara, B; Bhowmick, NA; Billet, S; Duong, F; Haldar, S; Madhav, A; Mishra, R; Placencio-Hickok, VR; Posadas, EM; Thiruvalluvan, M; Tighiouart, M | 1 |
| von Amsberg, G | 1 |
| Bossé, D; Canil, C; Koczka, K; Kushnir, I; Mallick, R; Ong, M; Reaume, NM | 1 |
| Cai, Z; Chen, C; Jiang, F; Li, J; Lin, Z; Liu, Z; Wan, Y; Xi, M; Zheng, Y; Zhong, W; Zhou, X; Zhu, J; Zhuo, Y | 1 |
| Brady-Nicholls, R; Enderling, H; Gatenby, RA; Gerke, TA; Nagy, JD; Wang, AZ; Zhang, J; Zhang, T | 1 |
| Eftekhari, S; Montazeri, H; Tarighi, P | 1 |
| Chen, K; Deng, G; Feng, S; He, H; Jiang, K; Jiang, P; Ma, L; Shao, J | 1 |
| Habuchi, T; Hiroshima, Y; Inoue, T; Kanda, S; Koizumi, A; Matsuda, Y; Mingguo, H; Nanjo, H; Nara, T; Narita, S; Numakura, K; Saito, M; Sato, H; Satoh, S; Tsuchiya, N | 1 |
| Galsky, MD; Martini, A; Montorsi, F; Oh, WK; Pfail, J | 1 |
| Albiges, L; Baciarello, G; Blanchard, P; Bosset, PO; Bossi, A; Colomba, E; Dumont, C; Fizazi, K; Lavaud, P; Loriot, Y; Massard, C; Nenan, S | 1 |
| Chen, H; Deshmukh, D; Fang, S; Qiu, Y; Xu, J; Yang, X | 1 |
| Assi, T; Farhat, F; Kattan, C; Kattan, J; Rassy, E | 1 |
| Ahmed, AT; Aronow, WS; Batra, KK; Lad, TE; Mullane, M; Pathak, S; Psutka, SP; Thekkekara, R; Yadav, U; Yim, B | 1 |
| Aragon-Ching, JB; Dreicer, R | 1 |
| Baston, C; Gingu, C; Guler-Margaritis, SS; Preda, A; Sinescu, I | 1 |
| Bismarck, E; Hammerer, P; Merseburger, AS; Schrader, AJ | 1 |
| Dong, BJ; Gao, WQ; Wang, F; Wang, N; Wang, Y; Zhu, Y | 1 |
| Azad, AA; Kwan, EM | 1 |
| Kato, M | 1 |
| Buonerba, C; Crocetto, F; De Placido, S; Di Lorenzo, G; Dolce, P; Facchini, S; Ferro, M; Imbimbo, C; Longo, N; Lucarelli, G; Marinelli, A; Mirone, V; Montella, L; Scafuri, L; Sonpavde, G; Terracciano, D; Vaia, A; Verde, A | 1 |
| Bai, Y; Balk, SP; Bhatt, RS; Bubley, GJ; Calagua, C; Corey, E; Giannakakou, P; Gianolio, DA; Gjyrezi, A; Khanna, P; Kung, J; Mace, S; Montgomery, B; Voznesensky, O; Wu, J; Xie, F | 1 |
| Cao, HF; Chen, DY; Cheng, L; Dong, JF; Dong, LX; Wang, Y; Yue, CF | 1 |
| Dai, J; Jiang, H; Keller, ET; Mizokami, A; Schnepp, PM; Shelley, G; Wakim, N | 1 |
| Chang, EM; Deville, C; Feng, FY; Kishan, AU; Koontz, BF; Nickols, NG; Ost, P; Parikh, NR; Phillips, R; Raldow, AC; Reiter, RE; Rettig, MB; Spratt, DE; Steinberg, ML; Tran, PT; Vapiwala, N | 1 |
| Al-Jamal, WT; Borges, JC; Chorilli, M; de Lima, FT; de Oliveira, CS; Eloy, JO; Marchetti, JM; Nogueira, KAB; Petrilli, R; Raspantini, G; Ruiz, A; Santos, E | 1 |
| Búzová, D; Červený, J; Culig, Z; Drápela, S; Fedr, R; Hampl, A; Khirsariya, P; Krejčí, L; Paruch, K; Puhr, M; Souček, K; Suchánková, T; van Weerden, WM; Watson, WR | 1 |
| Huang, X; Liu, T; Luo, Y; Wang, L; Wang, X; Xie, C; Zheng, H; Zi, H | 1 |
| Alishahi, Z; Esmaeili, F; Ghaffari, SH; Hamzehlou, S; Karimi, B; Kashani, B; Momeny, M; Mousavi, SA; Mousavipak, SH; Nasrollahzadeh, A; Sabourinejad, Z; Sankanian, G; Shamsaiegahkani, S; Yousefi, H; Zandi, Z | 1 |
| Adashek, JJ; Bhowmick, N; Chung, LW; Figlin, RA; Freedland, SJ; Freeman, M; Gong, J; Posadas, E; Reed, JP; Tandon, A | 1 |
| Dang, Q; Jiang, Y; Lv, S; Wang, N; Wei, Q; Wen, H; Wu, D | 1 |
| Alizadeh Zarei, M; Rafiei Dehbidi, G; Takhshid, MA | 1 |
| Hamilou, Z | 1 |
| Beltran, H; Clinton, SK; Coleman, J; Eastham, JA; Evans, CP; George, S; Gleave, M; Hahn, OM; Halabi, S; Heller, G; Hillman, DW; Mohler, JL; Monk, JP; Morris, MJ; Parsons, JK; Sanda, MG; Small, EJ; Szmulewitz, RZ; Taplin, ME; Watt, CR | 1 |
| Wan, Z; Wang, L; Xie, F; Zhang, G; Zhang, H | 1 |
| Baltz, JO; Jellinek, NJ; Vatanchi, M | 1 |
| Bryce, AH; Carducci, MA; Chen, YH; DiPaola, RS; Dreicer, R; Eisenberger, MA; Garcia, JA; Harshman, L; Hussain, M; Jarrard, DM; Liu, G; Plimack, ER; Sweeney, CJ; Vogelzang, NJ | 1 |
| Griebling, TL | 1 |
| Keklikcioglu Cakmak, N; Tas, A | 1 |
| Chan, KK; Chung, I; Fei-Lei Chung, F; Hassan Abdul Razack, A; Hii, LW; Leong, CO; Lim, WM; Mai, CW; Nalairndran, G | 1 |
| Carducci, MA; DiPaola, RS; Drake, CG; Fichorova, RN; Hamid, AA; Harshman, LC; Santone, G; Sweeney, CJ; Wang, VX | 1 |
| Baruah, M; Garnaik, B; Giram, P; Khandwekar, A; Koratkar, S; Sharma, N; Shitole, AA | 1 |
| Bruzzese, F; Budillon, A; Ciardiello, C; Ciliberto, G; Costantini, S; De Rienzo, S; Di Gennaro, E; Grumetti, L; Iannelli, F; Leone, A; Lombardi, R; Mancini, R; Milone, MR; Moccia, T; Pucci, B; Roca, MS; Sorice, A; Vitagliano, C | 1 |
| Bushell, M; Clark, W; Hall, H; Harle, V; Leung, HY; Patel, R; Repiscak, P; Rushworth, LK; Shaw, R | 1 |
| Aberlenc, A; Bawa, O; Chauchereau, A; Farace, F; Faugeroux, V; Honore, A; Lacroix, L; Laplace-Builhe, C; Marty, V; Oulhen, M; Pawlikowska, P; Pommier, AL; Rouffiac, V; Scoazec, JY; Tayoun, T | 1 |
| Anzellini, D; De Sanctis, V; Marinelli, L; Massaro, M; Montalto, A; Osti, MF; Reverberi, C; Valeriani, M | 1 |
| Benelli, A; Campodonico, F; De Censi, A; Ennas, M; Foppiani, L; Grillo-Ruggieri, F; Introini, C; Piccardo, A; Schiavone, C; Squillace, L; Zanardi, S; Zigoura, E | 1 |
| Chen, ML; Huang, CM; Lai, CJ; Lin, YH; Lin, YN | 1 |
| Beer, TM; Beltran, H; Bergman, AM; Bianchini, D; Castro, E; Chi, KN; Conteduca, V; Cotait Maluf, F; De Giorgi, U; Di Lorenzo, G; Gillessen, S; Hansen, AR; Higano, C; Karalis, K; Klingbiel, D; Kuppen, MCP; Lavaud, P; Le, ML; Ledet, E; Martinez Chanza, N; Mehra, N; Morales-Barrera, R; Oh, WK; Omlin, A; Pezaro, C; Sartor, O; Schär, S; Schmid, S; Suzuki, H; Sweeney, C; Tsao, CK; Tucci, M; Vargas Pivato de Almeida, D; Yip, SM; Zivi, A; Zürrer-Härdi, U | 1 |
| Cheng, Y; Ji, QF; Liu, DZ; Liu, M; Mei, QB; Yang, Q; Zhou, SY | 1 |
| Alajati, A; Alimonti, A; Antonarakis, ES; Attanasio, G; Borrelli, C; Brina, D; Colucci, M; D'Ambrosio, M; De Marzo, AM; Dettwiler, S; Egger, G; Elia, AR; Garcia-Escudero, R; Guccini, I; Losa, M; Moch, H; Moor, AE; Mosole, S; Pasquini, E; Pernigoni, N; Revandkar, A; Rinaldi, A; Rüschoff, JH; Sheibani-Tezerji, R; Troiani, M; Wild, P | 1 |
| Rizzo, M | 1 |
| Ding, Y; Li, X; Qian, S; Wu, Y; Zhang, S | 1 |
| Chae, JW; Cho, CW; Kang, NW; Kim, DD; Kim, DH; Kim, H; Lee, HS; Lee, JY; Lee, W; Song, GY | 1 |
| Asemota, H; Barker, J; Delgoda, R; Erhabor, J; Foster, K; Kendal-Smith, A; Langat, MK; Matsabisa, M; Oyenihi, O; Rademan, S | 1 |
| Das, CK; Kumar, R; Kumar, S; Mittal, BR; Singh, H | 1 |
| Buonerba, C; Busetto, GM; Caraglia, M; Crocetto, F; de Cobelli, O; De Placido, S; Di Lorenzo, G; Dolce, P; Facchini, BA; Ferro, M; Klain, M; La Civita, E; Lucarelli, G; Onofrio, L; Porreca, A; Scafuri, L; Sonpavde, G; Terracciano, D; Verde, A; Zappavigna, S | 1 |
| Fontana, F; Limonta, P; Marzagalli, M; Montagnani Marelli, M; Moretti, RM; Raimondi, M | 1 |
| Cheng, Y; Cui, W; Huang, Q; Liu, R; Meng, L; Wang, Y; Zhang, Y; Zhu, Y | 1 |
| Ayari, J; Balti, M; Ben Abdallah, I; Ben Hassen, M; Ben Nasr, S; Doghri, Y; Fendri, S; Haddaoui, A; Trigui, E; Zribi, A | 1 |
| Kurokawa, T; Maeda, H; Takeda, K; Urushihara, H | 1 |
| Avcı, S; Kırca, M; Ozpolat, B; Soylu, H; Ustunel, I | 1 |
| Agarwal, N; Coletta, AM; Sayegh, N | 1 |
| Cook, LM; Frieling, JS; Lawrence, HR; Lawrence, NJ; Li, T; Lo, CH; Lynch, CC; McGuire, JJ; Muhammad, A | 1 |
| Ravi Shankaran, D; Thambiraj, S; Vijayalakshmi, R | 1 |
| Amini, M; Atyabi, F; Dinarvand, R; Goodarzi, N; Saeedian Moghadam, E; Saniee, F; Shabani Ravari, N | 1 |
| Aronen, H; Jambor, I; Laakso, H; Liimatainen, T; Liljenbäck, H; Merisaari, H; Minn, H; Poutanen, M; Roivainen, A; Sierra, A; Virtanen, H; Ylä-Herttuala, E | 1 |
| Abouassaly, R; Bryk, DJ; Ericson, K; Fascelli, M; Haywood, SC; Khanna, A; Murthy, PB; O'Connor, LP; Yerram, NK | 1 |
| Tagawa, ST | 1 |
| Chou, CW; Cummings, BS; Finnerty, MC; Ingram, LM; Mansoura, M | 1 |
| Ali, A; Amos, C; Attard, G; Brawley, CD; Calvert, J; Clarke, NW; Cook, A; Dearnaley, D; Douis, H; Gillessen, S; Haran, ÁM; Hoyle, A; James, ND; Mason, MD; Parker, CC; Parmar, MKB; Sydes, MR | 1 |
| Arranz, JA; Castro, E; Climent, MA; Gallardo, E; González Del Alba, A; Gonzalez-Billalabeitia, E; Lorente, D; Maroto, JP; Méndez-Vidal, MJ; Vazquez, S | 1 |
| Cao, C; Dai, G; Qin, P; Xu, L; Yang, D; Zhu, J | 1 |
| Azad, AA; Brown, S; Davis, ID; Evans, M; Evans, S; Millar, J; Murphy, DG; Papa, N; Parente, P; Tran, B; Wong, S | 1 |
| Bravo-Cuellar, A; Cancino-Marentes, ME; Cruz-Gálvez, CC; Hernández-Flores, G; Orozco-Alonso, E; Ortiz-Lazareno, PC; Sierra-Díaz, E; Solís-Martínez, RA; Villaseñor-García, MM | 1 |
| Akihama, S; Aoyama, Y; Chiba, S; Habuchi, T; Hatakeyama, S; Honma, N; Horikawa, Y; Igarashi, R; Ishida, T; Ito, R; Koizumi, A; Kubo, K; Kumazawa, T; Maita, S; Muto, Y; Nakamura, K; Narita, S; Ohyama, C; Okane, K; Sato, H; Shimoda, J; Suzuki, T; Takahashi, S; Takahashi, Y | 1 |
| Beguinot, F; Cennamo, M; Crocetto, F; Ferro, M; Formisano, P; Guadagno, E; Imbimbo, C; Insabato, L; La Civita, E; Liguoro, P; Liotti, A; Mirone, V; Palmieri, A; Terracciano, D | 1 |
| Akaza, H; Lim, J; Malek, R; Ong, TA; Onozawa, M; Saad, M | 1 |
| Cao, Y; Cheng, J; Dong, B; He, J; Ji, Y; Li, W; Ma, Z; Pan, J; Shangguan, X; Shen, K; Wang, Q; Xin, Z; Xue, W; Yue, Z; Zhang, W; Zheng, Q | 1 |
| Bouchal, J; Gachechiladze, M; Kharaishvili, G; Kral, M; Kurfurstova, D; Mickova, A; Mistrik, M; Pokryvkova, B; Soucek, K; Vacek, O | 1 |
| Angelucci, A; Bologna, M; Clementi, L; Martellucci, S; Mattei, V; Muzi, P; Sabetta, S | 1 |
| Briganti, A; Chun, FKH; Collà Ruvolo, C; Graefen, M; Karakiewicz, PI; Kluth, LA; Mandel, P; Nocera, L; Roos, FC; Saad, F; Shariat, SF; Tian, Z; Tilki, D; Wenzel, M; Würnschimmel, C | 1 |
| Cho, NH; Choi, K; Choi, YD; Giancotti, FG; Ham, WS; Han, H; Heo, JE; Jang, WS; Lee, HH; Moon, YJ; Rha, KH | 1 |
| Fujita, Y; Hishida, S; Iinuma, K; Ito, M; Kato, T; Kawakami, K; Koie, T; Miura, Y; Mizutani, K; Nakane, K; Takai, M; Tsuchiya, T | 1 |
| Gu, Y; He, M; Peng, Y; Qu, F; Wang, G; Xue, M; Zhou, F | 1 |
| Li, EV; Morgans, AK; Prizment, AE; Ryan, CJ; Siddiqui, MR; Weiner, AB | 1 |
| Inoue, T; Kato, M; Masui, S; Nishikawa, K; Sasaki, T; Sugimura, Y; Yoshio, Y | 1 |
| Chen, H; Jiang, Z; Meng, R; Shi, S; Wang, Y; Wu, S; Xu, L | 1 |
| Crehange, G; Geoffrois, L; Gravis, G; Hennequin, C; Kleinclauss, F; Limat, S; Morgans, AK; Nerich, V; Oudard, S; Pelloux-Prayer, R; Schiele, P; Thiery-Vuillemin, A | 1 |
| Gui, Q; Li, M; Shen, Y; Zhang, H; Zhang, J | 1 |
| Greer, JA; Lage, DE; Lee, RJ; Michaelson, MD; Sweeney, CJ; Temel, JS | 1 |
| Armstrong, AJ; Carducci, MA; Cohn, ED; Filipenko, J; Gleave, M; Heller, G; Hilden, P; Lacuna, K; Morris, MJ; Mota, JM; Saad, F; Scher, HI; Shore, N | 1 |
| Ding, J; Dong, S; Hou, D; Li, N; Peng, Y; Song, Y; Wang, H; Wang, L; Yang, Z; Zhang, Z | 1 |
| Chen, M; Li, SY; Liu, LQ; Liu, RJ; Xu, B | 1 |
| Chen, Y; Danaher, A; Du, Y; Fu, H; Gera, L; Kucuk, O; Li, X; Liu, D; Lou, L; Mamouni, K; Osunkoya, AO; Sautto, G; Wilson, LM; Wu, D; Xie, ZR; Yang, Y; Zhang, S; Zhou, J | 1 |
| Bilen, MA; Brown, JT; Carthon, B; Caulfield, S; Kucuk, O; Lafollette, J; Liu, Y; Moore, M; Nazha, B; Russler, G; Smith, KER; Wan, L; Yantorni, L | 1 |
| Attard, G; Carducci, MA; Chen, YH; Davicioni, E; Den, R; DiPaola, R; Dittamore, R; Feng, F; Hamid, AA; Huang, HC; Liu, G; Spratt, DE; Sweeney, CJ; Tran, PT; Van Allen, EM; Wang, V | 1 |
| Gota, V; Gurjar, M; Joshi, A; Mehta, P; Nookala, M; Noronha, V; Patil, A; Patil, M; Patil, V; Prabhash, K; Shriyan, B | 1 |
| Abufaraj, M; Egawa, S; Karakiewicz, PI; Kimura, T; Kramer, G; Laukhtina, E; Mori, K; Mostafaei, H; Pradere, B; Quhal, F; Sari Motlagh, R; Schuettfort, VM; Shariat, SF | 1 |
| Biggart, S; Cole, A; Grey, A; Hounsell, AR; Jain, S; McGarry, CK; Mitchell, D; O'Sullivan, JM; Prise, KM; Turner, PG | 1 |
| Akabane, S; Babasaki, T; Hayashi, T; Katsuya, N; Kobayashi, G; Matsubara, A; Oue, N; Sekino, Y; Sentani, K; Shiota, M; Taniyama, D; Teishima, J; Thang Pham, Q; Yasui, W | 1 |
| Boso, S; Freire-Garabal, M; Gago, P; García, C; Martínez, MC; Novio, S; Núñez-Iglesias, MJ; Pérez-Muñuzuri, ME; Santiago, JL | 1 |
| Kawakami, A; Matsushita, Y; Miyake, H; Sato, R; Watanabe, H; Watanabe, K | 1 |
| Bryce, AH; Costello, BA; Egan, JB; Ho, TH; Hwang, SR; Kosiorek, HE; McNatty, AL; Moore, CN; Riaz, IB; Sharpsten, RK; Singh, P; Stewart, GA; Velez, MG | 1 |
| Chao, OS; Goodman, OB | 1 |
| Chen, H; Chen, J; Chen, L; Huang, B; Huang, Z; Li, W; Mo, C; Ou, W; Shao, L; Su, Q; Wang, Z; Zhang, X; Zhao, G | 1 |
| Abdul Razack, AH; Chung, FF; Chung, I; Hii, LW; Leong, CO; Lim, WM; Looi, CK; Mai, CW; Nalairndran, G | 1 |
| Brunotte, SJ; Ganser, A; Ivanyi, P; Kappler, P; Morgan, MA; Reuter, CWM | 1 |
| Giatromanolaki, A; Kakouratos, C; Karakasiliotis, I; Kassela, K; Koukourakis, MI; Lamprou, I; Mitrakas, AG; Tsolou, A; Xanthopoulou, ET; Zois, CE | 1 |
| Alcaraz, A; Alekseev, B; Armstrong, AJ; Azad, AA; Gomez-Veiga, F; Haas, GP; Holzbeierlein, J; Iguchi, T; Lee, HJ; Petrylak, DP; Rosbrook, B; Shore, ND; Stenzl, A; Szmulewitz, RZ; Villers, A | 1 |
| Alarcon de la Lastra-Romero, C; Alegre-Del Rey, EJ; Gil-Sierra, MD; Sánchez-Hidalgo, M | 1 |
| Chen, J; Chen, N; Chen, X; Dai, J; He, B; Liang, J; Liu, Z; Ni, Y; Nie, L; Shen, P; Sun, G; Tao, R; Wang, Z; Zeng, H; Zhang, H; Zhang, M; Zhang, X; Zhao, J; Zhu, S; Zhu, X | 1 |
| Cicero, G; DE Luca, R; Dieli, F; Dorangricchia, P | 1 |
| Badiozamani, KR; Beyer, DC; Harris, J; Horwitz, EM; Hurwitz, MD; Lawton, CAF; Michalski, JM; Roof, K; Sandler, HM; Sartor, O; Shayegan, B; Sperduto, PW; Xiao, Y; Zhang, Q | 1 |
| Kwon, G; Le, B; Malinowski, RL; Marker, PC; Powers, GL; Schumacher, N; Steinke, L; Tam, YT | 1 |
| Sidaway, P | 2 |
| Awasthi, S; Horne, D; Jain, D; Singhal, J; Singhal, P; Singhal, SS | 1 |
| Horiike, K; Mabuchi, M; Nakao, S; Shimizu, T; Tanaka, A; Tsujikawa, K; Ueda, M; Ueda, Y; Yamaoka, K; Yoshida, Y | 1 |
| Breaker, K; Flaig, TW; Gao, D; Kessler, ER; Lam, ET; Wacker, M; Wold, M | 1 |
| Bergin, ART; de Souza, P; Hovey, E; Lloyd, A; Marx, G; Parente, P; Rapke, T | 1 |
| Andika, R; Ariwicaksono, SC; Hafizar, H; Hidianingsih, S; Hotasi, SL; Patandung, R; Rahardjo, HE; Rahman, F; Sembiring, MGA | 1 |
| Armstrong, A; De, W; Lin, JZ; Wang, ZJ; Wu, HF; Xu, WZ; Zheng, M; Zhu, JG | 1 |
| Cheng, W; Ghosh, R; Gong, J; Kumar, AP; Li, L; Li, X; Wang, J; Xie, J; Zhang, J; Zhang, Y; Zhang, Z | 1 |
| Boudon, J; Créhange, G; Loiseau, A; Millot, N; Mirjolet, C | 1 |
| Hata, S; Iwasaki, K; Mimata, H; Nomura, T; Sato, F; Sato, R; Yamasaki, M | 1 |
| Alshaker, H; Arafat, T; Böhler, T; Kawano, Y; Mills, R; Pchejetski, D; Wang, Q; Winkler, M | 1 |
| Alegre Del Rey, EJ; Asensi Díez, R; García de Paredes Esteban, JC | 1 |
| Albers, P; Goebell, PJ; Grimm, MO; Klier, J; König, F; Machtens, S; Ohlmann, CH; Schostak, M; Schrader, AJ | 1 |
| Armstrong, CM; Cucchiara, V; Evans, CP; Gao, AC; Gu, X; Liu, C; Lombard, AP; Lou, W | 1 |
| Berge, V; Dong, HP; Eide, L; Fan, Q; Goscinski, MA; Huang, R; Kan, Q; Kvalheim, G; Li, X; Li, Y; Lu, J; Nesland, JM; Slipicevic, A; Suo, Z; Wang, J; Zhang, H | 1 |
| Alshaker, H; Böhler, T; Chao, Y; Cooper, C; Pchejetski, D; Srivats, S; Wang, Q | 1 |
| Beerlage, HP; Bloemendal, HJ; Boerma, MO; Bos, MMEM; Coenen, JLLM; Cordia, I; de Vos, AI; de Wit, R; Geenen, MM; Gerritsen, WR; Hendriks, MP; Peters, FPJ; Polee, MB; Spermon, R; Tick, LW; Uyl-de Groot, CA; van de Wouw, AJ; van den Berg, P; van den Bergh, ACM; van den Bosch, J; van den Eertwegh, AJM; van Moorselaar, RJA; Westgeest, HM | 1 |
| Boher, JM; Culine, S; Fizazi, K; Gravis, G; Habibian, M; Joly, F; Marino, P; Oudard, S; Sfumato, P | 1 |
| Chavez-Munoz, C; Chiao, M; D'Costa, NM; Frees, S; Jackson, JK; Moskalev, I; Raven, PA; Shademani, A; So, AI; Struss, WJ; Tan, Z; Zachkani, P | 1 |
| Hamid, AA; Sweeney, CJ | 1 |
| Boccardo, F; Messina, C; Messina, M | 1 |
| Chung, KH; Jung, EJ; Kim, CW | 1 |
| Beresford, MJ; Jefferies, ER; Sarmah, P; Thompson, AL | 1 |
| Annala, M; Beja, K; Beltran, H; Chedgy, EC; Collins, CC; Donoghue, A; Eastham, J; Fazli, L; Gleave, ME; Halabi, S; Mo, F; Morris, M; Sboner, A; Sigouros, M; Taplin, ME; Warner, EW; Wyatt, AW | 1 |
| Alekseev, BY; Fomicheva, KA; Galatenko, AV; Galatenko, VV; Knyazev, EN; Makarova, YA; Nyushko, KM; Shkurnikov, MY; Vechorko, VI | 1 |
| Chen, CY; Kao, CL; Liu, CM; Lo, YC; Tseng, YT | 1 |
| Boidot, R; Boudon, J; Chevrier, S; Collin, B; Créhange, G; Joy, PA; Loiseau, A; Martin, E; Millot, N; Mirjolet, C; Oudot, A | 1 |
| Carceles-Cordon, M; Cordon-Cardo, C; Domingo-Domenech, J; Mohr, L; Rodriguez-Bravo, V; Woo, J | 1 |
| Alhasso, A; Carruthers, R; Cascales, A; Dodds, D; Glen, H; Jones, RJ; Lamb, C; Laskey, J; MacLeod, N; Marashi, H; McKay, S; Neilson, S; Rulach, RJ; Russell, JM; Sadoyze, A; Sidek, N; Venugopal, B; Wallace, J; White, L | 1 |
| James, ND; Spears, MR; Sydes, MR | 1 |
| Ohlmann, CH | 2 |
| Bhindi, B; Boorjian, SA; Chandrasekar, T; Farrell, AM; Goldberg, H; Karnes, RJ; Klaassen, Z; Kulkarni, GS; Satkunasivam, R; Wallis, CJD | 1 |
| Chen, R; Chen, W; Fu, Y; Li, J; Li, L; Lu, W; Su, H; Yang, L; Yao, Y; Zhou, T | 1 |
| Gao, Q; Zheng, J | 1 |
| Arima, K; Ishii, K; Kajiwara, S; Kanda, H; Kato, M; Matsuoka, I; Miki, M; Sasaki, T; Shiraishi, T; Sugimura, Y | 1 |
| Li, X; Li, Y; Tian, X; Wang, Z; Zhang, G; Zhu, C | 1 |
| Hua, H; Li, S; Liu, D; Liu, T; Song, L; Zhang, N; Zhao, Y | 1 |
| Aggarwal, R | 1 |
| Hsiao, PW; Hsiao, YW; Hsieh, SC; Tsai, CH; Tsai, MH; Tzeng, SF; Yang, YC | 1 |
| Aoun, F; Assi, T; Bakouny, Z; El Rassy, E; Kattan, J; Sleilaty, G | 1 |
| Carducci, MA; Chen, YH; Cooney, M; Dipaola, R; Dreicer, R; Eisenberger, M; Garcia, JA; Hahn, N; Harshman, LC; Hussain, M; Jarrard, D; Kohli, M; Liu, G; Picus, J; Plimack, ER; Shevrin, D; Sweeney, CJ; Vogelzang, NJ | 1 |
| Antonarakis, ES; Armstrong, AJ; McNamara, M; Sweeney, C | 1 |
| Atkins, KM; Chen, MH; D'Amico, AV; Kantoff, PW; Loffredo, M; Renshaw, AA; Small, EJ; Wu, J | 1 |
| Bhardwaj, S; Varma, S | 1 |
| Chambers, KF; Clements, JA; Doran, MR; Futrega, K; Mosaad, EO | 1 |
| Hu, X; Liu, X; Nesa, EU; Niu, H; Tian, K; Xu, Q; Yuan, H; Zhang, X; Zhu, D; Zhu, S | 1 |
| Chang, J; Hou, J; Liu, H; Song, X; Zhao, Z | 1 |
| Bilhim, T; Costa, NV; Fernandes, L; Oliveira, AG; Pisco, J; Ribeiro, MP | 1 |
| Abdel-Rahman, O; Cheung, WY | 2 |
| Cheng, C; Gao, W; Hong, Z; Hu, Y; Lin, S; Shi, Z; Zhang, X; Zhu, A | 1 |
| Ci, X; Clermont, PL; Collins, CC; Dong, X; Gout, PW; Hao, J; Lin, D; Qu, S; Wang, Y; Wu, R; Xue, H | 1 |
| Carducci, MA; Chen, YH; Cooney, MM; DiPaola, RS; Dreicer, R; Eisenberger, M; Garcia, JA; Hahn, NM; Hussain, M; Jarrard, DF; Kohli, M; Kyriakopoulos, CE; Liu, G; Picus, J; Plimack, ER; Shevrin, DH; Sweeney, CJ; Vogelzang, NJ | 1 |
| Albrecht, H; Eldi, P; Garg, S; Guo, X; Hayball, JD; Song, Y; Zhang, W | 1 |
| Cai, C; Duan, X; Kong, Z; Lai, Y; Li, S; Wu, W; Xu, S; Zeng, T; Zhao, Z | 1 |
| Enomoto, M; Ishizaki, T; Kasuya, K; Katsumata, K; Kuwahara, H; Matsudo, T; Murakoshi, Y; Shigoka, M; Tsuchida, A; Wada, T | 1 |
| Ahlgren, GM; Angelsen, A; Borre, M; Flodgren, P; Iversen, JR; Jonsson, E; Kellokumpu-Lehtinen, P; Sengelov, L; Sverrisdottir, A; Tammela, TLJ | 1 |
| Amini-Khoei, H; Ghasemi, S; Lorigooini, Z; Wibowo, J | 1 |
| Boher, JM; Carducci, MA; Chen, YH; DiPaola, R; Dreicer, R; Eisenberger, MJ; Fizazi, K; Garcia, JA; Gravis, G; Habibian, M; Hussain, MHM; Jarrard, DM; Joly, F; Kohli, M; Liu, G; Oudard, S; Picus, J; Soulie, M; Sweeney, C; Vogelzang, NJ | 1 |
| Abdel-Rahman, O; Kassem, L; Shohdy, KS | 1 |
| Feng, Q; He, P; Wang, Y | 1 |
| Carducci, MA; Cella, D; Chen, YH; DiPaola, RS; Garcia, JA; Gartrell, BA; Hussain, M; Jarrard, DF; Morgans, AK; Patrick-Miller, LJ; Plimack, ER; Sweeney, CJ | 1 |
| Amos, C; Attard, G; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Chowdhury, S; Clarke, NW; Cross, W; de Bono, JS; Dearnaley, DP; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Gillessen, S; Gilson, C; Hughes, R; James, ND; Jones, R; Lester, JF; Malik, ZI; Mason, MD; Matheson, D; McLaren, D; Millman, R; Nikapota, A; O'Sullivan, J; Parikh, O; Parker, CC; Parmar, MKB; Peedell, C; Protheroe, A; Ritchie, AWS; Rudman, SM; Russell, JM; Shaffer, R; Sheehan, D; Simms, M; Spears, MR; Srihari, N; Strebel, R; Sundar, S; Sydes, MR; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J | 1 |
| Gourdin, T | 2 |
| Chen, N; Chen, W; Qian, J; Shen, S | 1 |
| Bangs, R; Basch, E; Celano, P; Hotte, SJ; Loblaw, A; Milowsky, MI; Morris, MJ; Rathkopf, D; Rumble, RB | 1 |
| He, XZ; Lu, H; Xu, HY; Xue, D; Zhou, CX | 1 |
| de Fata Chillón, FR; Diez Caballero, F; Gúrpide, A; Pérez-Gracia, JL; Villacampa, F | 1 |
| Beguinot, F; Calì, G; Conza, D; Cosimato, V; Formisano, P; Insabato, L; Liotti, A; Luongo, G; Mirra, P; Secondo, A; Terracciano, D; Ulianich, L | 1 |
| Chan, K; Chan, M; Chan, T; Lam, D; Law, K; Lee, EKC; Poon, DMC | 1 |
| Chen, Z; Li, X; Lin, Q; Ma, X; Wu, X; Zou, L | 1 |
| He, S; Li, H; Luo, X; Tao, M; Xu, K; Zhang, L; Zhong, W | 1 |
| Lillard, JW; Singh, R; Singh, SK | 1 |
| Efstathiou, E | 1 |
| Albiges, L; Bernard, B; Francini, E; Gray, KP; Harshman, LC; Kantoff, PW; Shaw, GK; Sweeney, CJ; Taplin, ME; Valença, L; Xie, W | 1 |
| DE, W; Li, JM; Lin, JZ; Wang, ZJ; Wu, HF; Zhu, JG | 1 |
| Cao, T; Fan, X; Gao, Y; Li, X; Liu, Y; Peng, Y; Yang, Y; Yin, L; Yu, X; Yuan, B; Zhu, Q | 1 |
| Gupta, S; Kanwal, R; Shukla, S; Walker, E | 1 |
| Burdett, S; Carpenter, JR; Clarke, NW; Fisher, DJ; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LH; Spears, MR; Sweeney, CJ; Sydes, MR; Tierney, JF; Vale, CL; White, IR | 1 |
| Chambers, K; Clements, J; Doran, MR; Futrega, K; Mosaad, E | 1 |
| Jones, RJ | 1 |
| Eisenberger, MA; Isaacsson Velho, P | 1 |
| Aguiar, P; Haaland, B; Lopes, G; Tan, PS | 1 |
| Christensen, M; Doughty, H; Kenealey, J; Lawson, J; Oblad, R | 1 |
| Armstrong, CM; Cucchiara, V; Evans, CP; Gao, AC; Liu, C; Liu, L; Lombard, AP; Lou, W; Yang, JC; Zhao, R | 1 |
| Chen, Y; Du, Y; Fu, H; Kavuri, S; Kucuk, O; Li, X; Mamouni, K; Wu, D; Yang, Y | 1 |
| Bao, Y; Deng, L; Jin, K; Li, J; Liao, X; Liu, Z; Qiu, S; Tu, X; Wei, Q; Yang, L | 1 |
| Csizmarik, A; Darr, C; Hadaschik, B; Krafft, U; Kramer, G; Küronya, Z; Maj-Hes, A; Nyirady, P; Reis, H; Sevcenco, S; Shariat, SF; Szarvas, T; Tschirdewahn, S | 1 |
| Dang, Q; Jiang, YD; Li, Q; Ou, YH; Tan, WL; Zhuang, YJ | 1 |
| Fizazi, K; Hamilou, Z; Saad, F | 1 |
| Akaza, H; Buchan, NC; Chiong, E; Chung, BH; Davis, ID; Kanesvaran, R; Khochikar, M; Le Chuyen, V; Letran, J; Lojanapiwat, B; Murphy, DG; Ng, CF; Ong, T; Pu, YS; Saad, M; Schubach, K; Türkeri, L; Umbas, R; Williams, S; Ye, DW | 1 |
| Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG | 1 |
| D'Andrea, D; Shariat, SF; Soria, F | 1 |
| Alexandre, J; Astorg, F; Boudou-Rouquette, P; Chabanol, H; Du Mortier, C; Goldwasser, F; Huillard, O; Musenghesi, B; Prin, L; Rondeau, A; Villeminey, C | 1 |
| Astone, M; Beigh, FH; Deng, Y; Ferrari, MG; Ganaie, AA; Hoeppner, LH; Hussain, T; Konety, BR; Koochekpour, S; Maqbool, R; Morrissey, C; Murugan, P; Parray, AS; Saleem, M; Siddique, HR; Umbreen, S | 1 |
| Pachynski, RK; Xu, L | 1 |
| Guo, YX; Kong, F; Lin, ZM; Liu, YQ; Lou, HX; Sun, DQ; Wang, Q; Wang, RM; Wang, SK; Xu, QQ; Yuan, HQ | 1 |
| Aizawa, T; Ishibashi, N; Maebayashi, T; Sakaguchi, M | 1 |
| Hofer, MD | 1 |
| Abogunrin, S; De Porre, P; Diels, J; Feyerabend, S; Fizazi, K; Ito, T; Koufopoulou, M; Li, T; Roiz, J; Saad, F; Van Sanden, S | 1 |
| Cartea, ME; Freire-Garabal, M; García-Santiago, C; Novio, S; Núñez-Iglesias, MJ; Soengas, P; Velasco, P | 1 |
| Chang, C; Chou, F; Lin, C; Luo, J; Niu, Y; Tian, J; Xing, EZ; Yeh, S; Zuo, L | 1 |
| Bolognini, C; Gassian, N; Klajer, E; Loriot, Y; Meynard, G; Thiery-Vuillemin, A | 1 |
| Gillessen, S; Mottet, N; Yu, EY | 1 |
| Aldabo, R; Bellmunt, J; Bonfill, T; Carles, J; de Portugal, T; Doménech, M; Figols, M; Font, A; Foro, P; Gallardo, E; García, J; Luque, R; Maciá, S; Maldonado, X; Maroto, P; Mellado, B; Méndez, MJ; Morales-Barrera, R; Sáez, MI; Suárez, C | 1 |
| Bryant, DM; Hewit, K; James, D; Leung, HY; Markert, EK; Martinez, RS; Sandilands, E; Shanks, E | 1 |
| Ali, A; Alonzi, R; Amos, CL; Attard, G; Bahl, A; Birtle, A; Brawley, CD; Chowdhury, S; Clarke, NW; Cross, W; Dearnaley, DP; Din, O; Douis, H; Eswar, C; Gale, J; Gannon, MR; Gillessen, S; Gilson, C; Hoyle, AP; James, ND; Jones, RJ; Jonnada, S; Khaksar, S; Langley, RE; Lester, JF; Malik, ZI; Mason, MD; Matheson, D; Millman, R; O'Sullivan, JM; Parikh, OA; Parker, CC; Parmar, MKB; Pedley, ID; Pudney, DM; Ritchie, AWS; Russell, JM; Sheehan, DJ; Srihari, NN; Sydes, MR; Thalmann, GN; Tran, ATH | 1 |
| Chi, KN; Eigl, BJ; Finch, D; Khalaf, D; Kollmannsberger, CK; Lavoie, JM; Noonan, K; Vergidis, J; Zou, K; Zulfiqar, M | 1 |
| Arai, Y; Habuchi, T; Inoue, T; Kanda, S; Kawamura, S; Koie, T; Mitsuzuka, K; Nanjo, H; Nara, T; Narita, S; Numakura, K; Ohyama, C; Saito, M; Satoh, S; Tochigi, T; Tsuchiya, N | 1 |
| Jaal, J; Kase, M; Lust, H; Saar, M; Sak, K | 1 |
| Duckham, BR; Gater, A; Grant, L; Ito, T; Ribbands, AJ | 1 |
| Kalantzis, ED; Scorilas, A; Vassilacopoulou, D | 1 |
| Lin, F; Mahato, RI; Wang, X; Wen, D | 1 |
| Eto, M; Inokuchi, J; Kobayashi, T; Namitome, R; Shiota, M; Tatsugami, K | 1 |
| Kretschmer, A; Todenhöfer, T | 1 |
| Boher, JM; Braamse, AMJ; Buffart, LM; Dekker, J; Fizazi, K; Gravis, G; Habibian, M; Joly, F; Konings, IRHM; Marino, P; Oudard, S; Schuurhuizen, CSEW; Soulie, M; Verheul, HMW | 1 |
| Choueiri, TK; Feng, FY; Hoffman, KE; King, MT; Mahal, BA; Martin, NE; Mouw, KW; Muralidhar, V; Nguyen, PL; Orio, PF; Spratt, DE; Trinh, QD; Yang, DD | 1 |
| Conroy, M; Greally, M; MacEneaney, O; McCaffrey, J; O’Keane, C | 1 |
| Feng, X; Huang, H; Li, M; Wang, L; Xie, X; Xu, X; Yu, J; Zhou, Y | 1 |
| Al-Jassar, G; de Freitas, HM; Hadi, M; Henry-Szatkowski, M; Ito, T; Lloyd, AJ; Nafees, B | 1 |
| Bai, J; Cheng, B; Li, B; Li, H; Lin, K; Qiu, X; Wang, W; Yang, G | 1 |
| Chen, Y; Gera, L; Kucuk, O; Li, X; Liu, H; Mamouni, K; Wu, AY; Wu, D; Yang, Y; Zhang, S | 1 |
| Bossé, D; Canil, C; Koczka, K; Kushnir, I; Ong, M; Reaume, MN; Sabri, E | 1 |
| Dondossola, E; Friedl, P; Logothetis, CJ; Navone, N; Paindelli, C | 1 |
| Vogelzang, NJ | 2 |
| Abraham, C; Banu, E; Beuzeboc, P; Bozec, L; Caty, A; Culine, S; Delva, R; Deplanque, G; Elaidi, R; Ferrero, JM; Gomez, P; Gravis, G; Hardy-Bessard, AC; Houede, N; Krakowski, I; Lagrange, JL; Latorzeff, I; Linassier, C; Miglianico, L; Mouret, L; Muracciole, X; Oudard, S; Priou, F; Ravaud, A; Rolland, F; Sevin, E; Voog, E; Zylberait, D | 1 |
| Halabi, S; Parelukar, WR; Rydzewska, L; Tierney, JF; Vale, CL | 1 |
| Aragon-Ching, JB; Finianos, A | 1 |
| Buonerba, C; Di Lorenzo, G; Fizazi, K; Pagliuca, M | 1 |
| Feng, FY; Fizazi, K; Vicier, C | 1 |
| de Freitas, HM; Hadi, M; Hall, F; Ito, T; Kerr, C; Lanar, S; Lloyd, AJ; Nafees, B; Penton, J; Pham, TP | 1 |
| Lü, Z; Wang, X; Wu, H; Xu, Q; Zhu, Q | 1 |
| James, ND | 1 |
| Austin, RH; Axelrod, R; Lin, KC; Pienta, KJ; Sturm, JC; Sun, Y; Torga, G | 1 |
| Aguiar, PN; Barreto, CMN; Giglio, AD; Gutierres, BS; Lopes, GL; Simko, S; Tan, PS | 1 |
| Chen, P; Jin, J; Wang, J; Yang, C; Zhang, W | 1 |
| Géczi, L; Küronya, Z; Maráz, A | 1 |
| Parikh, RR; Saraiya, B | 1 |
| Hersi, F; Noreddin, AM; Nunes, ACF; Omar, HA; Tolba, MF | 1 |
| Bai, S; Dong, Y; Hu, C; Lyu, J; Xia, H; Yu, X; Zhan, Y; Zhang, BY; Zhao, L | 1 |
| Chuu, CP; Hour, TC; Lai, CJ; Liao, WY; Lin, CY; Wang, HD | 1 |
| Arcicasa, M; Bortolus, R; Buttazzi, L; Fratino, L; Lo Re, G; Maruzzi, D; Matrone, F; Morlacco, A; Zattoni, F | 1 |
| Bae, S; Jain, S; Kapur, N; Lillard, JW; Mir, H; Singh, S; Sonpavde, GP | 1 |
| Cheng, WC; Chiu, FY; Fang, SH; Hsieh, KL; Huang, KH; Huang, MY; Huang, SP; Li, CY; Lin, IL; Liu, PL; Su, CC; Yeh, HC | 1 |
| Kretschmer, A; Tilki, D | 1 |
| Bilir, A; Dibirdik, I; Doganlar, O; Doganlar, ZB; Erdogan, S; Turkekul, K | 1 |
| Gattass, CR; Martins, CA; Rocha, GDG; Takiya, CM | 1 |
| Battaglia, A; De Meerleer, G; Devos, G; Everaerts, W; Joniau, S; Moris, L; Tosco, L; Van den Broeck, T | 1 |
| Choi, SY; Joung, JY; Kim, CS; Kim, SH; Kwon, WA; Lee, JE; Lee, KH; Seo, HK | 1 |
| Ahmed, AA; Dai, J; Escara-Wilke, J; Keller, ET; Palande, M; Robinson, T | 1 |
| Hammerer, P; Manka, L | 1 |
| Cao, Z; Xu, L; Zhao, S | 1 |
| De Abreu Lourenco, R; Williams, SG | 1 |
| Alzouebi, M; Attard, G; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, PR; Cook, A; Cross, WR; Dearnaley, DP; Gale, J; Gannon, MR; Gibbs, S; Graham, JD; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MKB; Peedell, C; Protheroe, A; Ritchie, AWS; Robinson, A; Russell, JM; Sculpher, MJ; Sideris, E; Simms, MS; Srihari, NN; Srinivasan, R; Staffurth, JN; Sundar, S; Sydes, MR; Thalmann, GN; Tolan, S; Tran, ATH; Tsang, D; Wagstaff, J; Woods, BS | 1 |
| Li, J; Liu, Y; Shi, G; Tang, M; Wang, B; Wang, Q; Wang, X; Xu, G; Yang, Z; Yu, W; Zhang, J; Zhang, L | 1 |
| Chouahnia, K; Culine, S; Fossey-Diaz, V; Guetz, GD; Landre, T; Taleb, C | 1 |
| Chapin, BF; Ranasinghe, WKB; Reichard, CA | 1 |
| Aragon-Ching, JB | 2 |
| Feng, FY; Hu, C; Rosenthal, SA; Sandler, HM; Sartor, O | 1 |
| Ching, T; Garmire, LX; Garofano, K; Ji, Y; Knox, T; Latham, P; Lee, NH; Nguyen, K; Olender, J; Rhim, J; Wang, BD | 1 |
| Abbas, F; Al Dousari, S; Al Hallaq, Y; Al Hamdani, N; Alameh, W; Ashou, R; Assaf, G; Bachir, B; Bitar, N; Bulbul, M; Dagher, C; Dbouk, H; El Khoury, C; El-Hajj, A; Faddoul, S; Farha, G; Farhat, F; Geara, F; Ghazal, H; Gillessen, S; Haidar, M; Hussain, HK; Ibrahim, K; Jabbour, M; Khauli, R; Mukherji, D; Nasr, R; Nemer, E; Omlin, A; Rabah, D; Said, R; Sakr, G; Sayyid, K; Shamseddine, A; Temraz, S; Wazzan, W; Youssef, B; Zouain, N | 1 |
| Liu, Z; Song, Y; Zhao, L | 1 |
| Amato, RJ; Saxena, S; Stepankiw, M | 1 |
| Batra, SK; Johansson, SL; Mimeault, M | 1 |
| Bubley, G; Buckle, G; Ernstoff, MS; Kantoff, PW; Morganstern, DE; Nakabayashi, M; Taplin, ME; Walsh, W; Xie, W | 1 |
| Cakar, B; Cirak, Y; Sarsik, B; Sen, S; Simsir, A; Uslu, R | 1 |
| Lorch, A | 1 |
| Hirai, K; Inoue, T; Matsuura, K; Mimata, H; Moriyama, M; Nomura, T; Sato, F; Sato, R; Yamasaki, M | 1 |
| Fizazi, K; Fizazi, KS; Gleave, M; Higano, CS; McIntosh, S; Miller, K; Morris, T; Moul, JW; Nathan, FE; Nelson, JB; Pemberton, K | 1 |
| Albiges, L; Attard, G; Bianchini, D; De Bono, JS; Fizazi, K; Ileana, E; Loriot, Y; Massard, C; Patrikidou, A; Pezaro, C; Sandhu, S | 1 |
| Matsubara, A; Mochizuki, H; Mutaguchi, K; Nagamatsu, H; Oka, K; Seki, M; Shoji, K; Teishima, J; Yasumoto, H | 1 |
| Chang, C; Chen, Y; Ding, XF; Huang, CK; Lee, SO; Li, G; Lin, SJ; Luo, J; Shan, YX; Wang, R; Yang, DR; Zhu, J | 1 |
| Arima, R; Fujita, M; Goto, T; Saiki, S; Uchida, K | 1 |
| Deng, Y; Karnes, RJ; Konety, BR; Mukhtar, H; Parray, A; Saleem, M; Siddique, HR; Tarapore, RS; Wang, L | 1 |
| Cortes Vizcaino, V; Gil Salom, M; Moratalla Charcos, LM; Osca Garcia, JM; Pastor Navarro, T | 1 |
| Ahn, H; Hong, JH; Hong, S; Jeong, IG; Kim, CS; Lee, JL; You, D | 1 |
| Brown, LG; Corey, E; Kirk, PS; Koreckij, T; Nguyen, HM; Snyder, LA; Vessella, RL | 1 |
| Choueiri, TK; Fennessy, FM; Galsky, MD; Kantoff, PW; Khine, K; Nakabayashi, M; Oh, WK; Ross, RW; Taplin, ME; Tempany, CM; Xie, W | 1 |
| Frear, M; Gong, C; Kwon, S; Malmstrom, R; Nguyen, N; Pon, V; Srinivas, S; Wilson, L; Zhong, L | 1 |
| Battaglia, M; Bettocchi, C; Ditonno, P; Fanelli, M; Galleggiante, V; Germinario, CA; Larocca, AM; Lucarelli, G; Maiorano, E; Rutigliano, M; Selvaggi, FP; Spilotros, M; Vavallo, A | 1 |
| Akino, H; Aoki, Y; Ishida, H; Ito, H; Kusukawa, N; Ooyama, N; Tanase, K; Yokoyama, O | 1 |
| Chow, A; Emmenegger, U; Francia, G; Kerbel, RS; Man, S; Wong, A | 1 |
| Auerbach, E; Corman, JM; Dahl, K; Olgac, S; Porter, C; Vuky, J | 1 |
| Arén, O; Bavbek, S; Birtle, A; Elliott, T; Fizazi, K; Fléchon, A; Gil, T; Gravis, G; Hatteville, L; Ivanov, S; Karlsson, CT; Karyakin, O; Magherini, E; Matveev, V; Orlandi, F; Petrylak, D; Rosenthal, M; Skoneczna, I; Tannock, IF; Tombal, B; Viana, L | 1 |
| Autio, KA; Carrasquillo, JA; Heller, G; Hong, C; Larson, SM; Morris, MJ; Pandit-Taskar, N; Rathkopf, DE; Scher, HI; Slovin, SF; Stephenson, RD | 1 |
| Dejima, T; Inokuchi, J; Kashiwagi, E; Naito, S; Shiota, M; Song, Y; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A | 1 |
| Huang, X; Li, S; Wang, L; Wang, X; Xia, Z; Yang, Z; Zhang, L; Zheng, X | 1 |
| Fujita, K; Hatano, K; Kaneda, Y; Murakami, K; Nagahara, A; Nakai, Y; Nakayama, M; Nimura, K; Nonomura, N; Tsuchiya, M; Uemura, M; Yamaguchi, S | 1 |
| Aparicio, AM; Goldkorn, A; Quinn, DI | 1 |
| Bian, XJ; Dai, B; Ma, CG; Shen, YJ; Wang, JY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y | 1 |
| Antonarakis, ES; McMahan, ZH; Nadal, R | 1 |
| Li, W; Su, YS; Wang, H; Yu, L; Zhao, J | 1 |
| Boothman, DA; Fazli, L; Gleave, M; He, D; Hsieh, JT; Pong, RC; Wu, K; Xiao, G; Xie, D; Zhang, T; Zou, Y | 1 |
| Abdel-Naim, AB; Abdel-Rahman, SZ; Al-Abd, AM; Azab, SS; Esmat, A; Khalifa, AE; Mosli, HA; Tolba, MF | 1 |
| Arranz, JÁ; Bellmunt, J; Gallardo, E; León, LÁ; Maroto, JP | 1 |
| Agarwal, N; Carducci, MA; Garzotto, MG; Goldkorn, A; Higano, CS; Hussain, M; Lara, PN; Mack, PC; Moinpour, CM; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, PW; Van Veldhuizen, PJ; Vogelzang, NJ | 1 |
| Altavilla, A; Bracarda, S; Cascinu, S; Cortesi, E; Iacovelli, R; Procopio, G; Santoni, M | 1 |
| Cathomas, R | 1 |
| Aggarwal, R; Carducci, M; George, D; Halabi, S; Kantoff, P; Kelly, WK; Mahoney, JF; Millard, F; Monk, JP; Morris, MJ; Small, EJ; Stadler, WM | 1 |
| Attard, G; Bianchini, D; de Bono, JS; Dearnaley, D; Ferraldeschi, R; Lorente, D; Mukherji, D; Omlin, A; Parker, C; Pezaro, CJ; Sandhu, S; Van As, N; Zaidi, S | 1 |
| de Wit, R; Eisenberger, MA; Epstein, JI; Huang, P; Kattan, MW; Kibel, AS; Schweizer, MT; Sternberg, CN | 1 |
| Autio, KA; Basch, EM; Beer, TM; Bennett, AV; Carducci, MA; Fruscione, M; George, DJ; Jia, X; Kane, RC; Logothetis, CJ; Morris, MJ; Rogak, L; Scher, HI; Sit, L | 1 |
| Gan, W; He, DL; Ji, HH; Jia, HT; Li, L; Li, YF; Xie, S; Zhang, SF; Zhang, TT | 1 |
| Bahl, A; Biernacka, KM; Gillatt, D; Holly, JM; Perks, CM; Persad, RA; Uzoh, CC; Zeng, L | 1 |
| Cella, D; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Harland, S; Kheoh, T; Logothetis, CJ; Molina, A; Scher, HI; Staffurth, J; Sternberg, CN | 1 |
| Heidenreich, A; Pfister, D; Porres, D | 1 |
| Ishiguro, H; Itcho, N; Kasai, H; Kawai, K; Kobayashi, N; Kubota, Y; Kurioka, D; Okamoto, D; Sato, A; Uemura, H; Watanabe, M | 1 |
| Button, MR; Evans, J; Kumar, S; Lester, JF; Palaniappan, N; Smith, C; Staffurth, J; Tanguay, JS; Thomas, BM | 1 |
| Kopeček, J; Rhim, JS; Yang, J; Zhou, Y | 1 |
| Akino, H; Inamura, S; Ito, H; Kusukawa, N; Oyama, N; Taga, M; Tsuchiyama, K; Yokoyama, O | 1 |
| Beer, TM; Harzstark, AL; Liu, G; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK | 1 |
| Breen, L; Carleton, LA; Dunne, G; Giles, FJ; Glynn, SA; Gorman, AM; Lewis, JD; McLaughlin, F; O'Connell, E; Sullivan, FJ; Toner, AP | 1 |
| Beckham, TH; Cheng, JC; Liu, X; Lu, P; Marrison, ST; Norris, JS | 1 |
| Huang, X; Li, S; Wang, L; Wang, X; Yang, Z; Zhang, L; Zheng, X | 1 |
| Fiala, O; Fínek, J; Holubec, L; Matějka, VM; Mrázková, P | 1 |
| Fujimoto, N; Fukumoto, R; Hayashi, T; Koide, T; Oka, D; Soda, T | 1 |
| Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J | 1 |
| Kopeček, J; Kopečková, P; Peng, ZH; Salama, ME; Sima, M | 1 |
| Bastide, C; Beuzeboc, P; Brenot-Rossi, I; Bruyère, F; Guy, L; Karsenty, G; Mongiat-Artus, P | 1 |
| Blakely, K; Chow, A; Emmenegger, U; Goda, T; Hoang, VC; Liu, SK; Rocha, M; Taeb, S; Tran, E; Wong, A | 1 |
| Aieta, M; Bracarda, S; Buonerba, C; Di Lorenzo, G; Mirone, V | 1 |
| Duan, X; Gui, Z; Iliakis, G; Kong, Z; Li, S; Liang, Y; Wu, W; Yang, D; Zeng, S; Zhu, H | 1 |
| Cui, D; Li, E; Lu, Y; Xia, S; Yu, J; Zhao, F; Zhao, Y; Zhu, Y | 1 |
| Bahl, A; Castellano, D; Chen, I; Chow Maneval, E; Daugaard, G; Gschwend, J; Houede, N; Jones, R; Laestadius, F; Lechuga, MJ; Maurina, T; Michaelson, MD; Ostler, P; Ou, YC; Oudard, S; Paolini, J; Saad, F; Sengeløv, L; Stenzl, A; Ullèn, A; Wang, SL | 1 |
| Abdi, E; Bonaventura, A; Craft, P; de Souza, P; Hill, A; Hovey, E; Lloyd, A; Marx, G; Michele, A; Parente, P; Rapke, T | 1 |
| Saggar, JK; Tannock, IF | 1 |
| Berger, R; Carducci, MA; Eisenberger, MA; Gottfried, M; Keizman, D; Leibowitz-Amit, R; Peer, A; Sella, A; Sinibaldi, V | 1 |
| D'Amico, AV | 1 |
| Aragon-Ching, JB; El-Bahesh, E; Elkon, J; Gupta, K | 1 |
| Best, AM; Hao, G; Stafford, JH; Sun, X; Thorpe, PE | 1 |
| Chaudhary, U; Golshayan, AR; Keane, TE; Kraft, AS; Marshall, DT; Ramey, S | 1 |
| Collins, CC; Gao, AC; Gout, PW; Liu, C; Qu, S; Wang, K; Wang, Y; Wu, R; Xue, H | 1 |
| Huang, MP; Lin, YR; Tang, P; Xie, KJ; Zhou, P | 1 |
| Bortolus, R; Garbeglio, A; Ghadjar, P; Giannarini, G; Gnech, M; Guttilla, A; Palumbo, V; Valent, F; Zattoni, F | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Bousquet, G; Dauba, J; Delva, R; Deplanque, G; El Kouri, C; Esterni, B; Eymard, JC; Ferrero, JM; Fizazi, K; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Krakowski, I; Labourey, JL; Laguerre, B; Latorzeff, I; Linassier, C; Machiels, JP; Marino, P; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulie, M; Suc, E; Théodore, C; Zanetta, S | 1 |
| Fizazi, KS; Halabi, S; Kaplan, EB; Kelly, WK; Lin, CY; Morris, MJ; Moul, JW; Small, EJ | 1 |
| Hashimoto, Y; Hatakeyama, S; Imai, A; Iwamura, H; Koie, T; Ohyama, C; Tanaka, T; Tanaka, Y; Tokui, N; Yamamoto, H; Yoneyama, T; Yoshikawa, K | 1 |
| Petrylak, DP | 7 |
| Gao, ZG; Jin, MJ; Jin, TX; Jin, ZH; Piao, SJ; Yin, XZ | 1 |
| Gao, X; Jing, T; Sun, Y; Wang, F; Xu, C; Zhang, C | 1 |
| Taneja, SS | 2 |
| Bellezza, I; Gatticchi, L; Grottelli, S; Mierla, AL; Minelli, A | 1 |
| Anai, S; Fujii, T; Fujimoto, K; Konishi, N; Shimada, K; Tanaka, N | 1 |
| Autenrieth, M; Eiber, M; Gschwend, JE; Heck, MM; Herkommer, K; Horn, T; Krause, BJ; Kübler, HR; Maurer, T; Retz, M; Thalgott, M; Treiber, U | 1 |
| Duncker-Rohr, V; Freund, U; Momm, F | 1 |
| Agarwal, N; Carducci, MA; Cote, RJ; Datar, RH; Ely, B; Fink, LM; Garzotto, M; Goldkorn, A; Higano, CS; Hussain, M; Lara, P; Mack, PC; Monk, JP; Quinn, DI; Tangen, CM; Thompson, IM; Twardowski, P; Van Veldhuizen, PJ; Vogelzang, NJ; Xu, T | 1 |
| Fong, L; Friedlander, TW | 1 |
| Armstrong, AJ; Bacon, K; Creel, P; George, DJ; Hobbs, G; Hurwitz, H; McManus, TJ; Peer, CJ; Petros, WP; Younis, IR; Yu, JJ | 1 |
| Alcaraz, A; Bermudo, R; Codony-Servat, J; Donovan, M; Fernández, PL; Font, A; Gallardo, E; Gascón, P; Jiménez, N; Lozano, JJ; Marín-Aguilera, M; Mellado, B; Mengual, L; Pereira, MV; Puig, P; Reig, Ò; Ribal, MJ | 1 |
| Lee, HJ; Ryu, H | 1 |
| Deng, J; Lou, H; Niu, L; Tian, K; Yuan, H; Zhou, N; Zhu, F | 1 |
| Boyer, MJ; Castillo, L; Chiam, K; Clark, SJ; Daly, RJ; Gurney, H; Horvath, LG; Lee, BY; Lin, HM; Mahon, KL; Mallesara, G; Marx, G; Nguyen, Q; Pavlakis, N; Stockler, MR; Swarbrick, A | 1 |
| Daverede, L; Harnden, P; Jagdev, SP; Paul, A; Ralph, C; Trainor, S; Trigonis, I; Vasudev, NS; Weston, M | 1 |
| Mizokami, A; Namiki, M | 1 |
| Limonta, P; Martini, PG; Marzagalli, M; Montagnani Marelli, M; Moretti, RM; Taylor, DM | 1 |
| Ahn, H; Ahn, JH; Choi, MK; Hong, BS; Hong, JH; Hong, SW; Jeong, IG; Kim, Y; Lee, JL; Lee, KH; Song, C | 1 |
| Chen, L; Qiu, X; Wang, R; Xie, X | 1 |
| Huang, X; Lynn, KD; Thorpe, PE; Yin, Y | 1 |
| Farach-Carson, MC; Fong, EL; Harrington, DA; Martinez, M; Mikos, AG; Navone, NM; Yang, J | 1 |
| Bi, L; Huang, J; Li, K; Li, Z; Liu, C; Xu, C; Xu, K; Zhou, B | 1 |
| Boissier, E; Loriot, Y; Massard, C; Vignot, S | 1 |
| Branch, DR; Neschadim, A; Pritzker, KP; Pritzker, LB; Silvertown, JD; Summerlee, AJ; Trachtenberg, J | 1 |
| Behrman, SW; Chauhan, SC; Ganju, A; Jaggi, M; Khan, S; Yallapu, MM | 1 |
| Cui, Y; Lou, H; Niu, L; Tian, K; Xu, X; Young, CY; Yuan, H; Zhang, D | 1 |
| Cho, HJ; Kim, DD; Kim, JS; Lee, JY | 1 |
| Adachi, T; Imada, K; Inokuchi, J; Kiyoshima, K; Koga, H; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yamaguchi, A; Yokomizo, A | 1 |
| Bobowski, K; Gires, O; Klocker, H; Mack, B; Martowicz, A; Massoner, P; Puhr, M; Thomm, T; Untergasser, G | 1 |
| Kalamida, D; Koukourakis, MI; Mitrakas, AG | 1 |
| Guillen, KP; Harrison, RG; Kurkjian, C | 1 |
| Corcoran, C; O'Driscoll, L; Rani, S | 1 |
| Atmaca, H; Bozkurt, E; Dirican, A; Erten, C; Karaca, B; Uslu, R | 1 |
| Benzonana, LL; Bevan, C; Brown, R; Huang, H; Ma, D; Perry, NJ; Watts, HR; Zhao, H | 1 |
| Alimonti, A; Catapano, C; Chen, JJ; Collado, M; D'Antuono, R; Da Silva-Alvarez, S; Di Mitri, D; Eisenberger, M; Garcia-Escudero, R; Grassi, F; Guccini, I; Jost, TR; Montani, E; Pinton, S; Sarti, M; Toso, A; Zhang, Z | 1 |
| Kregel, S; Szmulewitz, RZ; Vander Griend, DJ | 1 |
| Bhardwaj, G; Changou, C; Chintapalli, S; Evans, CP; Guo, W; Kumaresan, P; Kung, HJ; Lam, KS; Liu, R; Ma, AH; Mazloom, A; Patterson, R; Sanchez, E; Xiao, K; Xiao, W; Yang, JC; Yeh, CT | 1 |
| Beer, TM; Coleman, I; Garzotto, M; Gordon, RR; Gulati, R; Harris, WP; Higano, CS; Huang, CY; Lange, PH; Lucas, JM; Nelson, PS; Sim, HG; True, LD; Vessella, R; Wu, M | 1 |
| Burchardt, M; Preuss, M; Ritter, CA; Stope, MB; Streitbörger, A; Walther, R; Weiss, M; Zimmermann, U | 1 |
| Alimonti, A; Catapano, CV; Civenni, G; Di Mitri, D; Garcia-Escudero, R; Grassi, F; Guccini, I; Jarrossay, D; Kalathur, M; Marini, C; Montani, E; Pandolfi, PP; Pinton, S; Proietti, M; Revandkar, A; Sarti, M; Scanziani, E; Toso, A; Zhang, J | 1 |
| Azuma, H; Cox, ME; Fazli, L; Ghaffari, M; Gleave, ME; Ibuki, N; Levitzki, A; Pandey, M; Reuveni, H | 1 |
| Buijs, JT; De Krijger, RR; De Morrée, ES; Dezentjé, VO; Gelderblom, H; Smit, VT; van der Pluijm, G; Van Weerden, WM; Wissing, MD | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Boher, JM; Bousquet, G; Dauba, J; Delva, R; Deplanque, G; El Kouri, C; Eymard, JC; Ferrero, JM; Fizazi, K; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Krakowski, I; Labourey, JL; Laguerre, B; Latorzeff, I; Linassier, C; Machiels, JP; Marino, P; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulie, M; Suc, E; Théodore, C; Walz, J; Zanetta, S | 1 |
| Atmaca, H; Degirmenci, M; Karaca, B; Kisim, A; Sanli, UA; Sezgin, C; Uslu, R; Uzunoglu, S; Varol, U | 1 |
| Clarke, NW; De Bono, JS; Dearnaley, DP; Gale, J; Hetherington, J; Hoskin, PJ; James, ND; Jones, RJ; Laing, R; Lester, JF; Mason, MD; McLaren, D; Parker, CC; Parmar, MKB; Ritchie, AWS; Russell, JM; Spears, MR; Strebel, RT; Sydes, MR; Thalmann, GN | 1 |
| Antonarakis, ES; Suzman, DL | 1 |
| Armstrong, AJ | 1 |
| Bhosle, S; Brown, SG; Chaudhary, J; Hunt, A; Knowell, AE; Patel, D | 1 |
| Arichi, N; Harada, M; Harashima, N; Hiraki, M; Naora, K; Nishimura, N; Shiina, H; Tamaki, H | 1 |
| Guo, B; Padi, SK; Tindall, DJ; Zhang, Q | 1 |
| Chowdhury, S; Malik, Z; Staffurth, J; Sweeney, C; Voskoboynik, M | 1 |
| Chen, KR; Hayakawa, N; Honda, A; Ito, Y; Kosaka, T; Maeda, T; Nagata, H; Nakamura, S; Okata, U; Oya, M | 1 |
| Andrews, J; Arora, S; Bhardwaj, A; Carter, JE; McClellan, S; Singh, AP; Singh, S; Srivastava, SK; Tyagi, N | 1 |
| Bansal, N; Bertino, JR; Farley, NJ; Lewis, J; Wu, L; Youssoufian, H | 1 |
| Barlaam, B; Barry, ST; Castriotta, L; Cosulich, S; Crafter, C; Cumberbatch, M; D'Cruz, C; Davies, BR; Dry, H; Ellston, R; Fitzek, M; Foster, E; Green, S; Hancox, U; Hanson, L; Harrington, EA; Lawson, M; Lenaghan, C; Ogilvie, D; Powell, S; Smith, PD; Trigwell, C; Ward, L; Wedge, SR | 1 |
| Bijnsdorp, IV; Geldof, AA; Hoekstra, OS; Oprea-Lager, DE; van de Ven, PM; van den Eertwegh, AJ; van Kanten, MP; van Moorselaar, RJ | 1 |
| Carducci, MA; Friedman, PN; Halabi, S; Hertz, DL; Jiang, C; Kelley, MJ; Kelly, WK; Mahoney, JF; McLeod, HL; Morris, MJ; Mulkey, FA; Owzar, K; Patel, JN; Ratain, MJ; Small, EJ | 1 |
| Culig, Z; Eder, IE; Geley, S; Heidegger, I; Hoefer, J; Kern, J; Klocker, H; Neuwirt, H; Puhr, M; Schäfer, G | 1 |
| Kopeček, J; Yang, J; Zhang, R; Zhou, Y | 1 |
| Chenchik, A; Kandel, ES; Makhanov, M; Matveev, V; Zynda, ER | 1 |
| Barlow, WE; Etzioni, RB; Hershman, DL; LeBlanc, M; Martin, D; Ramsey, SR; Unger, JM | 1 |
| Burchardt, M; Fussek, S; Knabbe, C; Oswald, S; Preuß, M; Rauschenberger, L; Saupe, M; Stope, MB; Walther, R; Zimmermann, U | 1 |
| Agarwal, N; Pal, SK; Reese, Z; Straubhar, A | 1 |
| Coleman, I; Coleman, R; Gomez-Sarosi, LA; Huber, RM; Lucas, JM; Nelson, PS; Zhao, S | 1 |
| Saad, F | 1 |
| Egawa, S; Hata, K; Ishii, G; Kasai, K; Kimura, T; Omono, H; Suzuki, M | 1 |
| Gravis, G; Salem, N; Walz, J | 1 |
| Bertelli, G; Jones, RM; Morgan, C | 1 |
| Heber, D; Henning, SM; Vadgama, JV; Wang, P | 1 |
| Dreicer, R; Gao, T; Klein, EA; Yerram, NK; Zhao, B | 1 |
| Batra, SK; Datta, K; Johansson, SL; Lin, MF; Mimeault, M; Muniyan, S; Rachagani, S; Seshacharyulu, P | 1 |
| Anoopkumar-Dukie, S; Bernaitis, N; Chess-Williams, R; Christie, D; Davey, AK; Forbes, A; McDermott, CM; McFarland, AJ; Perkins, AV; Pickard, RD; Spencer, BH | 1 |
| Cathomas, R; De Bono, JS; Gillessen, S; Omlin, A; Rothermundt, C; Sartor, O; Shen, L; Su, Z | 1 |
| Dreicer, R | 1 |
| Bai, L; Chen, F; Chen, J; Dong, Q; Hu, Q; Ma, Z; Shen, Y | 1 |
| Rexer, H | 6 |
| Fu, B; Li, Y; Liu, WP; Wang, GX; Xi, HB | 1 |
| Akıncı, MB; Aksoy, S; Dede, DS; Ozdemir, NY; Şendur, MA; Ulas, A; Yalçın, B; Zengin, N | 1 |
| Azimi, A; Baltatzis, G; Chioureas, D; Fonseca, P; Hultenby, K; Kharaziha, P; Lennartsson, L; Nilsson, S; Panaretakis, T; Rutishauser, D; Ullén, A; Yachnin, J; Zubarev, R | 1 |
| Alva, AS; Boes, JL; Brisset, JC; Chenevert, TL; Galbán, CJ; Galbán, S; Hoff, BA; Hussain, M; Jacobson, JA; Johnson, TD; Meyer, CR; Nicolay, K; Pienta, KJ; Rehemtulla, A; Ross, BD; Schakel, T | 1 |
| Benatar-Haserfaty, J; Durán Paz, S; Moreno Casanova, I | 1 |
| Dong, H; Krco, C; Kwon, ED; Sobol, I; Thompson, RH | 1 |
| Bubley, GJ; Gray, KP; Hayes, JH; Hussain, A; Kantoff, PW; McKay, RR; Rosenberg, JE; Taplin, ME | 1 |
| Chen, N; Chen, X; Chen, Z; Gong, J; Gui, H; Li, X; Liao, B; Liu, J; Liu, L; Liu, Z; Peng, Z; Shen, P; Wei, Q; Xu, M; Zeng, H; Zhang, P; Zhang, X; Zhao, T; Zhou, Q | 1 |
| Albiges, L; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Atmaca, H; Bozkurt, E; Degirmenci, M; Karabulut, B; Karaca, B; Ozveren, A; Sanli, UA; Uslu, R | 1 |
| Adams, DJ; Barui, AK; Kulhari, H; Naidu Vegi, GM; Patra, CR; Pooja, D; Shrivastava, S; Sistla, R; Telukutala, SR | 1 |
| Cheng, S; Cheon, P; Chow, E; Chow, R; DeAngelis, C; Emmenegger, U; Giotis, A; Lowe, J; McDonald, R; Pasetka, M; Pulenzas, N; Rowbottom, L; Stinson, J; Thavarajah, N | 1 |
| Hernandez-Aya, LF; Hussain, M | 1 |
| Armstrong, C; Gao, AC; Liu, C; Lou, W; Sandher, A; Zhu, Y | 1 |
| Fizazi, K; Jenkins, C; Tannock, IF | 1 |
| Dams-Kozłowska, H; Dondajewska, E; Kazimierczak, U; Kotlarski, M; Kozłowska, A; Kwiatkowska, E; Mackiewicz, A; Mackiewicz, J; Nowicka-Kotlarska, A; Wysocki, PJ | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Chinet-Charrot, P; Cojean-Zelek, I; Culine, S; Davin, JL; Delva, R; Deplanque, G; Faivre, L; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Habibian, M; Houede, N; Krakowski, I; Labourey, JL; Lagrange, JL; Laguerre, B; Laplanche, A; Legouffe, E; Lesaunier, F; Linassier, C; Martin, AL; Mourey, L; Oudard, S; Priou, F; Ravaud, A; Rolland, F; Theodore, C | 1 |
| Bansal, N; Bertino, JR; DiPaola, RS; Mishra, PJ; Stein, M | 1 |
| Akaza, H; Attard, G; Beer, TM; Beltran, H; Chinnaiyan, AM; Daugaard, G; Davis, ID; de Bono, JS; De Santis, M; Drake, CG; Eeles, RA; Efstathiou, E; Fanti, S; Fizazi, K; Gillessen, S; Gleave, ME; Halabi, S; Heidenreich, A; Hussain, M; James, ND; Lecouvet, FE; Logothetis, CJ; Mastris, K; Nelson, PS; Nilsson, S; Oh, WK; Olmos, D; Omlin, A; Padhani, AR; Parker, C; Rubin, MA; Sartor, O; Schalken, JA; Scher, HI; Sella, A; Shore, ND; Small, EJ; Smith, MR; Soule, HR; Sternberg, CN; Suzuki, H; Sweeney, CJ; Tannock, IF; Tombal, B | 1 |
| Fu, L; Huang, W; Li, H; Liang, Z; Liu, R; Luo, R; Wu, J; Xiao, X; Xie, F; Zhao, P; Zhu, X; Zhu, Y | 1 |
| Golstov, AA; Hirayama, T; Karanika, S; Karantanos, T; Kurosaka, S; Li, L; Park, S; Tanimoto, R; Thompson, TC; Wang, J; Yang, G | 1 |
| Azzabi, AS; Durkan, G; Frew, JA; Leung, HY; McMenemin, RM; Pedley, ID; Rajan, P; Soomro, NA; Stockley, J; Wilson, JM | 1 |
| Arichi, N; Harada, Y; Hiraki, M; Mitsui, Y; Shiina, H; Yasumoto, H | 1 |
| Kiss, A; Klotz, LH; Sasaki, H; Sugar, LM; Venkateswaran, V | 1 |
| Cui, D; Dai, J; Keller, ET; Keller, JM; Mizokami, A; Xia, S | 1 |
| Liu, S; Tian, C; Wang, H; Wang, Y; Yan, J; Zhang, X | 1 |
| Back, JB; Bernardo, MM; Chen, YQ; Dean, I; Dzinic, SH; Han, X; Heath, E; Irish, J; Jakupovic, B; Kaplun, A; Li, X; Mujagic, A; Sakr, W; Sheng, S; Van Buren, E | 1 |
| Bonomi, M; Ceresoli, GL; De Vincenzo, F; Sauta, MG; Zucali, PA | 1 |
| Beer, TM; Graff, JN | 2 |
| Carducci, M; Chen, YH; Cooney, MM; DiPaola, RS; Dreicer, R; Eisenberger, M; Garcia, JA; Hahn, N; Hussain, M; Jarrard, DF; Kohli, M; Liu, G; Picus, J; Shevrin, D; Sweeney, CJ; Vogelzang, NJ; Wong, YN | 1 |
| Baker, H | 1 |
| Ansa-Addo, EA; Inal, J; Jorfi, S; Kholia, S; Lange, S; Stratton, D; Valley, S | 1 |
| Adams, DJ; Kulhari, H; Kuncha, M; Pooja, D; Singh, MK; Sistla, R | 1 |
| Ferreira, AC; Gimba, ER; Klumb, CE; Mattos, RM; Nakamura, KD; Nasciutti, LE; Palumbo, A; Tilli, TM; Wanderley, JL | 1 |
| Bertaglia, V; Buttigliero, C; Di Maio, M; Fiori, C; Porpiglia, F; Scagliotti, GV; Tucci, M; Vignani, F | 1 |
| Crabb, S; Davda, R; Hughes, S; Jones, R; Payne, H; Troup, J | 1 |
| Chen, M; Chen, S; Guan, H; Huang, Y; Liu, C; Lu, K; Tao, T; Xu, B; Zhang, L; Zhang, X | 1 |
| Buijs, JT; Culig, Z; Grimm, S; Hemmer, DM; Hwang, MS; Kroon, J; Marijt, KA; Masood, M; Meijer, OC; Metselaar, JM; Puhr, M; Storm, G; van der Horst, G; van der Pluijm, G | 1 |
| Ammannagari, N; Danchaivijitr, P; George, S; Javvaji, C | 1 |
| Chung, LW; Huang, WC; Li, X; Wu, JB | 1 |
| Chowdhury, S; Gilson, C; Kirby, R; Manickavasagar, T | 1 |
| Baciuchka, M; Berdah, JF; Blanchard, P; Culine, S; Davin, JL; Deniau-Alexandre, E; Faivre, L; Ferrero, JM; Fizazi, K; Habibian, M; Houédé, N; Krakowski, I; Laguerre, B; Laplanche, A; Lesaunier, F; Mesgouez-Nebout, N; Mourey, L; Rolland, F; Salem, N; Théodore, C | 1 |
| Albiges, L; Beuzeboc, P; Boher, JM; Culine, S; Delva, R; Deplanque, G; Ferrero, JM; Fizazi, K; Gravis, G; Habibian, M; Joly, F; Krakowski, I; Laguerre, B; Latorzeff, I; Mourey, L; Oudard, S; Priou, F; Rolland, F; Soulié, M; Théodore, C | 1 |
| Chang, LS; Dang, Q; Li, C; Li, L; Xie, H | 1 |
| Alabiso, O; Bedussi, F; Berruti, A; Ferrari, L; Ferrari, V; Marchioro, G; Memo, M; Mosca, A; Sigala, S; Terrone, C; Valcamonico, F; Volta, AD | 1 |
| Chowdhury, S; Gilson, C; Sydes, MR | 1 |
| Bartůňková, J; Bieblová, J; Fučíková, J; Indrová, M; Mikyšková, R; Moserová, I; Reiniš, M; Šímová, J; Špíšek, R; Štěpánek, I; Truxová, I | 1 |
| Albiges, L; Burdett, S; Clarke, NW; Fisher, D; Fizazi, K; Gravis, G; James, ND; Mason, MD; Parmar, MKB; Rydzewska, LHM; Sweeney, CJ; Sydes, MR; Tierney, JF; Tombal, B; Vale, CL | 1 |
| Alzouebi, M; Amos, C; Attard, G; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Clarke, NW; Cook, A; Cross, W; de Bono, J; Dearnaley, DP; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; James, ND; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McKinna, F; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Parmar, MK; Peedell, C; Protheroe, A; Ritchie, AW; Robinson, AJ; Russell, JM; Spears, MR; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Sydes, MR; Thalmann, G; Tolan, S; Tsang, D; Wagstaff, J | 1 |
| Claros, M; Nathanson, L; Ramachandran, K; Singal, R; Speer, C | 1 |
| Choi, MK; Hwang, JE; Joung, JY; Kim, JE; Kim, YH; Lee, KH; Lee, SJ; Park, WS; Shin, SP | 1 |
| Anand, M; Armstrong, AJ; Bratt, L; Carducci, MA; Creel, P; Davis, K; George, DJ; Halabi, S; Healy, P; Hobbs, C; Kim, S; Koontz, BF; Lee, WR; Moul, JW; Mundy, K; Nguyen, M; Reimer, B; Stein, M; Tran, PT; Wood, S | 1 |
| Collard, O; De Laroche, G; Falk, AT; Fournel, P; Guillot, A; Magné, N; Merrouche, Y; Méry, B; Moriceau, G; Pacaut, C; Trone, JC | 1 |
| Andronis, L; Barton, D; Beesley, S; Billingham, LJ; Birtle, A; Brown, J; Chakraborti, P; Collins, S; Daunton, A; Goranitis, I; Hussain, S; James, ND; McLaren, D; O'Sullivan, J; Parker, C; Pirrie, SJ; Pope, AM; Porfiri, E; Russell, M; Staffurth, J; Stanley, A; Wylie, J | 1 |
| Ashikari, D; Fujimura, T; Fujiwara, K; Homma, Y; Horie-Inoue, K; Ikeda, K; Inoue, S; Ito, A; Kumagai, J; Murata, T; Obinata, D; Takada, S; Takahashi, S; Takayama, K; Urano, T; Yamada, Y | 1 |
| Barsoum, IB; Black, M; Cotechini, T; Craig, AW; Graham, CH; Koti, M; Macdonald-Goodfellow, SK; Petroff, M; Siemens, DR; Truesdell, P | 1 |
| Imkamp, F; Mamijev, E; Moiseenko, V; Nosov, A; Novikov, R; Petrov, S; Reva, S; Tolkach, Y; Veliev, E | 1 |
| Crabb, SJ; Davda, R; Hughes, S; Jones, R; Payne, H; Troup, J | 1 |
| Hattori, Y; Kawahara, T; Kondo, K; Miyoshi, Y; Moriyama, M; Noguchi, K; Takebayashi, S; Teranishi, J; Uemura, H; Yao, M; Yokomizo, Y; Yoneyama, S | 1 |
| Jin, Z; Li, B; Li, H; Liu, C; Ou, X; Xu, Y; Zhang, Y; Zhou, H | 1 |
| Hershman, DL; Lee, SM; Lim, EA; Moinpour, CM; Unger, J; Zhong, X | 1 |
| Kimura, G | 1 |
| Bogatyreva, L; Hauschke, D; Michalska, M; Schultze-Seemann, S; Wetterauer, U; Wolf, P | 1 |
| Miller, RE; Sweeney, CJ | 1 |
| Allory, Y; Carpentier, G; Céraline, J; Courty, J; De La Taille, A; Destouches, D; Maillé, P; Marchand, C; Sader, M; Semprez, F; Soyeux, P; Terry, S; Vacherot, F | 1 |
| Choi, HG; Jeong, JH; Kim, JO; Thapa, RK; Yong, CS; Youn, YS | 1 |
| Scher, HI | 2 |
| Liu, Y; Ma, T; Xiao, P; Xu, Y; Zhang, H; Zhou, C | 1 |
| Chen, Z; Gera, L; Kucuk, O; Li, X; Mamouni, K; Wu, D; Zhang, S | 1 |
| Behrman, SW; Boya, VKN; Chauhan, SC; Chowdhury, P; Ganju, A; Hafeez, BB; Jaggi, M; Johnson, NR; Khalilzad-Sharghi, V; Khan, S; Nagesh, PKB; Othman, SF; Yallapu, MM; Zafar, N | 1 |
| Harada, M; Ogura, T; Tamaki, H; Tanaka, Y | 1 |
| Li, L; Wang, J; Wang, Y; Xu, L; Xue, P; Zhou, J | 1 |
| Dittmar, R; Du, M; Huang, CC; Kohli, M; Liu, H; Shenoy, N; Wang, L; Wang, Y; Xia, Y | 1 |
| Barber, J; Button, M; Catlow, C; Kumar, S; Mason, MD; Palaniappan, N; Smith, C; Staffurth, J; Tanguay, JS | 1 |
| Li, Q; Wen, F; Wheeler, JRC; Wu, YF; Zheng, HR | 1 |
| Elshimali, Y; Heber, D; Henning, SM; Magyar, CE; Vadgama, JV; Wang, P | 1 |
| Buttitta, L; Cackowski, FC; Decker, AM; Jung, Y; Kana, LA; Lee, E; Morgan, TM; Taichman, RS; Wang, J; Yumoto, K | 1 |
| Butte, AJ; Geifman, N | 1 |
| Bersanelli, M; Buti, S | 1 |
| Adediran, S; Choi, EY; Dan, HC; Hussain, A; Lapidus, RG; Liu, P; Liu, X; Wang, X; Zhang, Y | 1 |
| Adler, AI; Goodall, M; Kelly, V; Lovett, R | 1 |
| Butler, L; Hollande, F; Mølck, C; Paquet-Fifield, S; Sloan, E; Ventura, S; Xie, J | 1 |
| Sternberg, CN | 2 |
| Borges Dos Reis, R; Botrel, TE; Clark, O; Ferreira, U; Horta Bretas, FF; Lima Pompeo, AC; Sadi, MV | 1 |
| Chen, H; Chen, Q; Li, H | 1 |
| Kajiwara, M; Moriyama, H; Yonehara, S | 1 |
| Benjamin, CJ; Chokshi, S; Chung, PH; Dreher, MR; Linehan, WM; Negussie, AH; Pinto, PA; Ranjan, A; Volkin, D; Wood, BJ; Yeram, N | 1 |
| Adcock, AF; Edmondson, R; Yang, L | 1 |
| Chang, C; Cui, Y; Hu, S; Jin, J; Li, L; Li, X; Luo, J; Sun, Y; Yeh, S | 1 |
| Chen, Z; Gao, S; Gu, F; Hu, C; Tai, Z; Zhu, Q | 1 |
| Galsky, MD; Oh, WK; Tsao, CK | 1 |
| Gschwend, J; Miller, K; Ohlmann, CH | 1 |
| Drudi, F; Fantini, M; Gianni, L; Montanari, F; Santelmo, C; Sartori, S; Stocchi, L; Tamburini, E; Tassinari, D | 1 |
| Aebersold, R; Aitchison, JD; Blattmann, P; Brusniak, MY; Campbell, DS; Carapito, C; Chu, CS; Demir, E; Deutsch, EW; Grimes, B; Hood, L; Hoopmann, MR; Huang, CY; Kapousouz, M; Kusebauch, U; Lam, H; Moritz, RL; Picotti, P; Ratushny, AV; Rinner, O; Sander, C; Shteynberg, D; Slagel, J; Spicer, DA; Stevens, J; Sun, Z; Tran, T | 1 |
| Clarke, NW; James, ND; Parmar, MK; Ritchie, AW; Sydes, MR | 1 |
| Chow, MS; Hao, J; Huang, Y; Lam, CW; Lau, B; Liu, M; Ravula, R; Shi, L; Song, Y; Wang, J; Wang, Z; Yeung, S | 1 |
| Chaudhary, J; Gorantla, Y; Joshi, J; Korang-Yeboah, M; Morton, D; Nagappan, P; Pallaniappan, R; Patel, D; Sharma, P | 1 |
| Ellis, L; Foley, K; Malangone-Monaco, E; McKenzie, S; Varker, H; Wilson, KL | 1 |
| Amaral, CL; Bajgelman, MC; Freitas, LB; Pavan, IC; Simabuco, FM; Tamura, RE; Tavares, MR | 1 |
| Naidu Sugnanam, KK; O'Hagan, S; Turner, NH | 1 |
| Aghai, A; Böttcher, R; Burger, H; de Morrée, ES; de Ridder, CM; de Wit, R; Gibson, AA; Mathijssen, RH; Sparreboom, A; van Soest, RJ; van Weerden, WM; Wiemer, EA | 1 |
| Cavallini, L; Chiarugi, P; Giannoni, E; Ippolito, L; Marini, A; Morandi, A; Pietrovito, L; Pintus, G; Puhr, M; Schrader, T; Taddei, ML | 1 |
| Arnold, RD; Cummings, BS; Glenn, TC; Kolli, RT; Moore, M; Scholpa, NE | 1 |
| Bharali, DJ; Cui, H; Mian, BM; Mousa, SA; Sudha, T | 1 |
| Tran, N; Wong, HL; Xue, HY | 1 |
| Alavi, S; Deng, M; Duensing, S; Hagedorn, S; Kirfel, J; Konantz, M; Kristiansen, G; Lengerke, C; Perner, S; Queisser, A; Schaefer, T; Vogel, W; von Mässenhausen, A; Wang, H | 1 |
| Bristow, R; Joshua, AM; Milosevic, MF; Smith, AD; Truong, M; Yip, P | 1 |
| Albiges, L; Audenet, F; Barthelemy, P; Beuzeboc, P; Fléchon, A; Gravis, G; Irani, J; Linassier, C; Oudard, S; Rebillard, X; Richaud, P; Rouprêt, M; Rozet, F; Thiery Vuillemin, A; Timsit, MO; Vincendeau, S | 1 |
| Beer, TM; Bergstrom, CP; Ellis, WJ; Garzotto, M; Graff, JN; Higano, CS; Ho, CM; Ruffell, B | 1 |
| Ma, B; Wang, X; Yang, B | 1 |
| Duensing, S; Heller, M; Hohenfellner, M; Li, J; Mang, J; Merkle, K; Schüler, J; Tolstov, Y | 1 |
| Barsoom, SH; Bowman, KJ; Hernandez, C; Hurley, S; Jones, GD; Lynam-Lennon, N; Marignol, L; Marples, B; McDermott, N; Meunier, A; Mooney, B; Nortey, G | 1 |
| Bolton, D; Corfield, J; Crozier, J; Joshua, AM; Lawrentschuk, N | 1 |
| James, ND; Ritchie, AWS; Sydes, MR | 1 |
| Bahl, A; Biernacka, KM; Gillatt, D; Holly, JM; Perks, CM; Persad, RA | 1 |
| Lin, DW; Yu, EY | 1 |
| Alumkal, JJ; Beer, TM; Graff, JN | 1 |
| Alshaker, H; Arafat, T; Böhler, T; Cooper, C; Kawano, Y; Pchejetski, D; Wang, Q; Winkler, M | 1 |
| Aziz, T; Chow, MJ; Cutz, JC; Jayasekera, D; Kapoor, A; Major, P; Tang, D; Wei, F; Wong, N; Yan, J; Zheng, M | 1 |
| Du, M; Kohli, M; Lieberman, R; Meng, H; Nevalainen, M; Pan, J; Shenoy, NK; Wang, L; Wang, Y; You, M; Zhang, P; Zhang, Q | 1 |
| Dillon, C; Frazier, N; Ghandehari, H; Payne, A; Subrahmanyam, N | 1 |
| Atala, A | 1 |
| Fu, P; Li, Q; Wen, F; Yang, Y; Zhang, P | 1 |
| Hua, H; Liang, Q; Sun, P; Sun, Q; Zhang, N; Zhang, X; Zhao, Y | 1 |
| Fujimura, T; Homma, Y; Inoue, S; Misawa, A; Suzuki, Y; Takayama, KI | 1 |
| Bernard, B; Carducci, MA; Chen, YH; Mitchell, EP; Muralidhar, V; Nguyen, PL; Pettaway, CA; Sridhar, SS; Sweeney, CJ | 1 |
| Dai, J; Escara-Wilke, J; Keller, ET; Keller, JM; Mizokami, A; Osisami, M; Zhang, M | 1 |
| Liu, JZ; Luo, XH; Wang, H; Yan, CY; Yin, FY | 1 |
| Bloemendal, HJ; de Klerk, JM; Geldof, AA; Hendrikse, NH; Lange, R; Paap, M; ter Heine, R; Tromp, AM; van Wieringen, WN | 1 |
| Jia, Y; Liu, S; Liu, X; Pan, W; Tian, C; Wang, H; Wang, Y; Yan, J | 1 |
| Bugler, J; Culig, Z; Fabre, A; Hanrahan, K; Murphy, K; Murphy, L; O'Neill, A; Prencipe, M; Puhr, M; Watson, RW | 1 |
| Belz, J; Castilla-Ojo, N; Kumar, R; Sridhar, S | 1 |
| Cheng, Y; Ding, X; Jia, X; Jiang, J; Li, Y; Sharma, A; Wang, G; Xie, G | 1 |
| Banerjee, S; Chowdhury, I; Lillard, JW; Singh, R; Singh, SK | 1 |
| Acosta, EP; Banerjee, S; Lillard, JW; Singh, R; Singh, SK | 1 |
| Aherne, ST; Boland, A; Clynes, M; Doolan, P; Fitzpatrick, JM; Hurley, G; Kay, E; Lundon, DJ; Madden, SF; Morrissey, C; O'Neill, A; Prencipe, M; Watson, RW | 1 |
| Chlopicki, S; Denslow, A; Gebicki, J; Maciejewska, M; Marcinek, A; Nowak, M; Switalska, M; Wietrzyk, J | 1 |
| Bacich, DJ; Cummings, JL; O'Keefe, DS; Sobek, KM | 1 |
| Cheng, T; Ernst, S; Karakiewicz, P; North, S; Perrotte, P; Ruether, D; Saad, F; Winquist, E | 1 |
| Azim, HA; Mok, T | 1 |
| Fosså, SD | 1 |
| Chi, KN; Chin, JL; Gleave, ME; Klotz, L; Saad, F; Winquist, E | 1 |
| Choueiri, MB; Do, KA; Kim, J; Lee, YC; Lin, SH; Logothetis, CJ; Mathew, P; Navone, NM; Tu, SM; Wen, S; Ye, X; Yu-Lee, LY | 1 |
| Burich, RA; Holland, WS; Mack, PC; Tepper, C; Vinall, RL; White, RW | 1 |
| Smith, MR | 1 |
| Baker, SD; Carducci, MA; Collins, C; Curley, T; Denmeade, SR; Eisenberger, MA; Fleisher, M; Halter, M; Heller, G; Kelsen, M; Morris, MJ; Pili, R; Rathkopf, D; Scher, HI; Slovin, SF | 1 |
| Armstrong, AJ; de Wit, R; Eisenberger, M; Halabi, S; Tannock, IF | 1 |
| Banu, A; Banu, E; Bouziane, A; Fischer, AM; Helley, D; Oudard, S; Scotte, F | 1 |
| Lopez-Beltran, A; Montironi, R | 1 |
| Cumashi, A; Iacobelli, S; Lattanzio, R; Natoli, C; Piantelli, M; Rossi, C; Tinari, N | 1 |
| Cao, W; Namiki, K; Porvasnik, S; Rosser, CJ; Sakai, Y; Shiverick, KT; Urbanek, C | 1 |
| Armstrong, A; Canon, J; Dougall, WC; Jones, J; Miller, RE; Roudier, M | 1 |
| Amadori, D; Arienti, C; Brigliadori, G; Carloni, S; Fabbri, F; Rosetti, M; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Berthold, DR; De Dosso, S | 1 |
| Aragon-Ching, J; Baum, CE; Dahut, W; Deeken, J; Figg, WD; Price, DK; Sissung, TM; Sparreboom, A; Steinberg, SM | 1 |
| Asakura, T; Fujinami, K; Goto, A; Jinza, S; Okajima, K; Onuki, T; Senga, Y; Yamashita, Y | 1 |
| Dai, Y; Ji, M; Ji, Q; Lawrence, T; Liu, M; Meng, Y; Pienta, K; Tang, W; Wu, X; Xu, L | 1 |
| Biasco, G; Brandi, G; Danesi, R; de Rosa, F; Montini, GC | 1 |
| Brown, I; Heys, SD; Schofield, AC; Shaikh, IA; Wahle, KW | 1 |
| Dienes, HP; Engelmann, U; Gerharz, M; Heidenreich, A; Markert, E; Ohlmann, CH; Pfister, D | 1 |
| Beardsley, EK; Chi, KN | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Rosenthal, MA | 1 |
| Beuzeboc, P; Bompas, E; Ferrero, JM; Fizazi, K; Fléchon, A; Gravis, G; Italiano, A; Joly, F; Ortholan, C; Oudard, S; Pouessel, D | 1 |
| De Santis, M; Fink, E; Hobisch, A; Höltl, W; Krainer, M; Kramer, G; Marei, IC; Neumann, HJ; Rauchenwald, M; Reissigl, A; Schmeller, N; Stackl, W | 1 |
| Anderson, J; Clarke, NW; Dearnaley, DP; Dwyer, J; James, ND; Mason, MD; Masters, J; Morgan, RC; Parmar, MK; Popert, RJ; Sanders, K; Stansfeld, J; Sydes, MR | 2 |
| Atmaca, H; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S | 3 |
| Johnston, PG; Longley, DB; Waugh, DJ; Wilson, C; Wilson, T | 1 |
| Fleshner, NE; Kurin, M; Medin, JA; Symes, JC | 1 |
| Bonny, MA; Clausse, M; D'Hondt, L; Dopchie, C; Duck, L; Filleul, B; Honhon, B; Jousten, P; Kerger, J; Machiels, JP; Marcelis, L; Mazzeo, F; Moxhon, AM; Tombal, B; Verhoeven, D; Verschaeve, V | 1 |
| Ansari, J; Bliss, J; Glaholm, J; Hussain, SA; Tanguay, JS; Zarkar, A | 1 |
| Biggs, DD; Clamon, GH; Dawson, NA; Halabi, S; Kelly, WK; Kessinger, A; Nanus, DM; Ou, SS; Small, EJ; Vogelzang, N | 1 |
| Armstrong, AJ; Creel, P; George, DJ; Gockerman, JP; Haley, S; Hurwitz, H; Jaffe, TA; Moore, C; Petros, W; Sleep, D; Turnbull, J; Yenser, S | 1 |
| Bucana, C; Fidler, IJ; Horne, E; Jones, D; Lee, YC; Lin, SH; Logothetis, CJ; Mathew, P; Morris, MJ; Oh, WK; Thall, PF; Wen, S | 1 |
| Brechbiel, MW; Davis, ID; Kelly, MP; Lee, FT; Lee, ST; Scott, AM; Smyth, FE | 1 |
| Haines, I | 1 |
| Cho, KS; Chung, J; Han, KS; Jeong, IG; Joung, JY; Kim, TS; Lee, KH; Seo, HK; Yang, SO | 1 |
| Kovel, S; Sella, A; Skoneczna, I; Sternberg, CN | 1 |
| Azzouz, F; Borges-Gonzales, S; Desta, Z; Flockhart, DA; Jason, RD; Li, L; McLeod, HL; Nguyen, A; Shen, C; Skaar, T; Sweeney, CJ; Yu, M | 1 |
| Gouverneur, E; Grgic, A; Kamradt, J; Kirsch, CM; Lehmann, J; Nestle, U; Pinkert, J; Stöckle, M; Suttmann, H; Zwergel, U | 1 |
| Fidler, IJ; Horne, E; Langley, R; Mathew, P; Oborn, CJ; Papadopoulos, JN; Pettaway, CA; Pisters, LL; Thall, PF; Wen, S; Williams, DL; Wood, CG | 1 |
| Daignault, S; Dunn, RL; Escara-Wilke, J; Friedman, J; Ignatoski, KM; Keller, ET; Smith, DC; Zhang, X | 1 |
| Beheshti, B; Lu, Y; Zhang, J; Zhang, X | 1 |
| de las Pozas, A; Gomez, LA; Perez-Stable, C; Reiner, T | 1 |
| Johnston, PG; Maxwell, P; McKeown, SR; O'Rourke, D; O'Sullivan, JM; Scullin, P; Seaton, A; Waugh, DJ; Wilson, C; Wilson, RH; Worthington, J | 1 |
| Lebret, T; Méjean, A; Timsit, MO | 1 |
| Bangma, C; de Wit, R; van Weerden, WM | 1 |
| Fowler, DH; Medin, JA; Siatskas, C; Symes, JC | 1 |
| Kirby, R; Xia, SJ | 1 |
| Atmaca, H; Baran, Y; Cengiz, E; Erten, C; Gorumlu, G; Gul, MK; Karabulut, B; Karaca, B; Kucukzeybek, Y; Sanli, UA; Uslu, R; Uzunoglu, S | 1 |
| Moreira, JN; Pinto, AC; Simões, S | 1 |
| Donaldson, GW; Moinpour, CM; Nakamura, Y | 1 |
| Corman, J; Isacson, C; Kozlowski, P; Picozzi, V; Porter, C; Vaughan, M; Vuky, J | 1 |
| Bold, RJ; Bowles, TL; Chuang, FY; Coates, JM; Gandour-Edwards, R; Jung, JU; Kim, RH; Kung, HJ; McNerney, GP; Sutcliffe, J | 1 |
| Bagalà, C; Barone, C; Bianchetti, S; Cassano, A; Fabiano, A; Landriscina, M; Piscazzi, A; Quirino, M; Schinzari, G; Sica, G | 1 |
| Bologna, M; D'Alessandro, AM; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Vicentini, C | 1 |
| Arwert, L | 1 |
| Eymard, JC; Fizazi, K; Oudard, S | 1 |
| Fabritius, M; Ip, C; Wu, Y | 1 |
| Gopisetty, G; Gordian, E; Hader, C; Navarro, L; Ramachandran, K; Reis, IM; Schulz, WA; Singal, R | 1 |
| Andrieu, JM; Banu, A; Banu, E; Kacso, G; Levy, E; Medioni, J; Oudard, S; Scotte, F; Wasserman, J | 1 |
| Albanell, J; Bellmunt, J; Carles, J | 1 |
| Chenevert, TL; Galbán, CJ; Lee, KC; Neeley, C; Nicolay, K; Pienta, KJ; Rehemtulla, A; Ross, BD; Rozel, S; Snyder, LA; Sud, S | 1 |
| Calabro, F; Carpentier, P; Collette, L; Daugaard, G; Dumez, H; Gil, T; Graham, J; Lacombe, D; Sella, A; Skoneczna, I; Sternberg, CN; Van Poppel, H | 1 |
| Adomat, H; Bally, MB; Eberding, A; Fazli, L; Guns, ET; Hurtado-Coll, A; Jia, W; Musende, AG; Wood, C | 1 |
| Balbi, C; Barboro, P; Benelli, R; Ferrari, N; Monteghirfo, S | 1 |
| Economopoulos, T; Floros, T; Gouveris, P; Kamposioras, K; Karageorgopoulou, S; Koumarianou, A; Papatsibas, G; Papaxoinis, G; Pectasides, D; Pectasides, E; Psyrri, A; Tountas, N; Xiros, N | 1 |
| Beer, TM; Harzstark, AL; Hussain, M; Mathew, P; Pagliaro, LC; Rosenberg, JE; Ryan, CJ; Ryan, CW; Sharib, J; Small, EJ; Smith, DC; Weinberg, VK | 1 |
| Holzapfel, K; Krause, BJ; Müller, SA; Seidl, C; Senekowitsch-Schmidtke, R; Treiber, U | 1 |
| Gao, X; Li, X; Liao, B; Liu, Y; Ouyang, B; Sun, Q; Wen, X; Wu, J; Yuan, X | 1 |
| Carrasquillo, J; Curley, T; Delacruz, A; Divgi, CR; Gignac, GA; Heller, G; Hong, C; Jia, X; Kelly, WK; Larson, S; Morris, MJ; O'Donoghue, J; Pandit-Taskar, N; Rathkopf, D; Scher, HI; Schwartz, L; Slovin, S; Solit, D; Stephenson, RD | 1 |
| Beuzeboc, P; Bouzy, J; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Haddad, V; Laplanche, A; Loriot, Y; Lumbroso, J; Massard, C; Theodore, C; Tournay, E | 1 |
| de Riese, W; Filleur, S; Haynes, A; Klatte, T; Nelius, T | 1 |
| Hegele, A; Hofmann, R; Olbert, PJ; Schrader, AJ; Weil, C | 1 |
| Akdas, AM; Burch, PA; Crawford, ED; Dipaola, RS; Donnelly, BJ; Goldman, B; Higano, CS; Hussain, M; Petrylak, DP; Small, EJ; Sundram, SK; Tangen, C; Wilding, G | 1 |
| Arima, K; Hasegawa, Y; Kato, M; Kise, H; Nishikawa, K; Soga, N; Sugimura, Y; Yamada, Y | 1 |
| Dror Michaelson, M; Gurski, C; Kantoff, PW; Kaufman, DS; Michaelson, SZ; Oh, WK; Olivier, K; Regan, MM; Smith, MR; Spicer, B | 1 |
| Berry, W; Fleming, M; Galsky, MD; Hutson, TE; Kondagunta, GV; Simon, K; Sonpavde, G | 1 |
| Bossi, A; De La Motte Rouge, T; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C; Serrate, C | 1 |
| Abratt, RP; Bodrogi, I; Federico, MH; Horti, J; Pover, GM; Sanders, N; Stenzl, A; Widmark, A | 1 |
| Johnson, MM; Jones, D; Logothetis, CJ; Mathew, P; Tu, SM; Wong, FC | 1 |
| Kovel, S; Sella, A; Yarom, N; Zisman, A | 1 |
| Ahmad, A; Ali, S; Banerjee, S; Kong, D; Rahman, KM; Sakr, WA; Wang, Z | 1 |
| Al Hasan, SA; Cher, ML; Dickow, B; Eliason, J; Heilbrun, LK; Marur, S; Smith, DW; Vaishampayan, UN | 1 |
| Heidenreich, A | 2 |
| Castellón, EA; Contreras, HR; Huidobro, C; McCubrey, JA; Mendoza, P; Sánchez, C; Vergara, J | 1 |
| Boytim, M; Dhillon, N; Dorr, R; Hersh, E; Hong, D; Kurzrock, R; La Paglia, A; Moulder, S; Naing, A; Ng, C; Tse, S; Wheler, J | 1 |
| Durairaj, C; Kadam, R; Kompella, UB; Sundaram, S | 1 |
| Hadaschik, BA; Thomas, C; Thüroff, JW; Wiesner, C | 1 |
| Clarke, NW; Dearnaley, DP; James, ND; Mason, MD; Morgan, RC; Parmar, MK; Royston, P; Sanders, K; Sydes, MR | 1 |
| Cuvillier, O; Kohama, T; Nunes, J; Pchejetski, D; Salunkhe, V; Sauer, L; Skalska, L; Waxman, J | 1 |
| Bishop, WR; Hsieh, Y; Kirschmeier, P; Liu, G; Long, BJ; Marrinan, CH; Taylor, SA | 1 |
| Bander, NH; Guo, M; Kim, S; Kuroda, K; Liu, H; Navarro, V | 1 |
| Hosoki, S; Inoue, A; Matsumoto, A; Miyazaki, K; Nagata, M; Nozumi, K; Yamaguchi, K; Yokoi, S | 1 |
| Brown, LG; Corey, E; Koreckij, T; Nguyen, H; Vessella, RL; Yu, EY | 1 |
| Carr, R; Chi, KN; Ellard, SL; Kollmannsberger, C; Le, L; Michels, J; Murray, N; Tomlinson Guns, ES | 1 |
| Asmar, L; Bernold, D; Berry, WR; Boehm, KA; Fleming, MT; Galsky, MD; Hutson, TE; Periman, PO; Sonpavde, G; Weckstein, D; Zhan, F | 1 |
| Habuchi, T; Numakura, K; Takahashi, N; Tsuchiya, N | 1 |
| Filleur, S; Nelius, T | 1 |
| Goloubeva, O; Hussain, A; Khan, MA; Lee, D; Tang, Y; Wang, L | 1 |
| Dahut, WL; Figg, WD; Ning, YM | 1 |
| Fung, AS; Tannock, IF; Wu, L | 1 |
| Almaguel, F; Casiano, CA; Daniels, TR; De Leon, M; Leoh, LS; Lilly, MB; Mediavilla-Varela, M; Pacheco, FJ; Padilla, A; Perez, J; Sahakian, E; Wall, NR | 1 |
| Alcaraz, A; Aparicio, LA; Areal, J; Fernandez, PL; Font, A; Gallardo, E; Gascon, P; Hannaoui, N; Lorenzo, JR; Mellado, B; Sousa, A; Veiga, FJ | 1 |
| Gupta, NP; Nayyar, R; Sharma, N | 1 |
| Yuasa, T | 1 |
| Boyer, MJ; Breit, SN; Brown, DA; Henshall, SM; Horvath, LG; Kaplan, W; Lee, BY; Marx, GM; Molloy, MP; Pavlakis, N; Stockler, MR; Sutherland, RL; Zhao, L | 1 |
| Halldén, G | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W | 1 |
| Crisci, A; Della Melina, A; Molinara, E; Neri, B; Nicitat, G; Pantaleo, P; Rangan, S; Raugei, A; Villari, D | 1 |
| Bohrer, L; Chen, S; Gan, L; Huang, H; Sun, Z; Wang, Y; Watahiki, A | 1 |
| Cho, JS; Han, SB; Hong, JT; Jung, JK; Lee, SY; Lee, YM; Moon, DC; Oh, KW; Yoo, HS; Yuk, DY | 1 |
| Ide, H; Kikuchi, E; Kono, H; Miyajima, A; Nagata, H; Nakagawa, K; Nakashima, J; Ohigashi, T; Oya, M | 1 |
| Finter, F; Gust, K; Küfer, R; Rinnab, L | 1 |
| Beer, TM; Garzotto, M; Higano, CS; Huang, CY; Myrthue, A; Nelson, PS; Pittsenbarger, J; Qian, DZ; Rademacher, BL | 1 |
| Bentzen, L; Buch-Hansen, TZ; Hansen, S; Hoeyer, M; Jensen, NV; Saxe, C; Sengeloev, L | 1 |
| Arlen, PM; Cereda, V; Chen, C; Dahut, WL; Gulley, JL; Halabi, S; Higgins, JP; Hodge, JW; Jones, E; Jones, JL; Madan, RA; Parnes, H; Pazdur, MP; Poole, DJ; Schlom, J; Skarupa, L; Steinberg, SM; Tsang, KY; Vergati, M; Wright, JJ | 1 |
| Ohlmann, CH; Stöckle, M | 1 |
| Fujisawa, M; Furukawa, J; Kumano, M; Miyake, H; Terakawa, T | 1 |
| Begbie, S; Boyce, A; de Souza, P; Harvie, R; Khasraw, M; Lim, V; Marx, G; McCowatt, S; Parnis, F; Pavlakis, N; Underhill, C | 1 |
| Noguchi, K; Sakairi, T; Shakuto, S; Yoshida, Y | 1 |
| Harris, LD; Pettaway, CA; Song, R | 1 |
| Al'bitskiĭ, IA; Fastovets, SV; Gafanov, RA; Kaprin, AD | 1 |
| Araki, H; Hara, T; Hattori, M; Hikichi, Y; Imai, Y; Kouno, J; Nishiwaki, M; Ushio, K; Yamaoka, M | 1 |
| Armstrong, AJ; de Wit, R; Eisenberger, M; George, DJ; Halabi, S; Tannock, IF | 1 |
| Alumkal, J; Beer, TM; Eilers, KM; Ryan, C; Ryan, CW; Sun, J | 1 |
| Cormier, T; Dahut, WL; Deeken, JF; Figg, WD; Liewehr, DJ; Miao, X; Price, DK; Sissung, TM; Steinberg, SM; Tran, K | 1 |
| Chen, Z; Corey, DR; Hsieh, JT; Koeneman, KS; Li, Y; Li, ZZ; Malaeb, BS; Shay, JW; Thompson, MG | 1 |
| Chen, Z; Koeffler, HP; Mishra, DK; Sarkissyan, M; Vadgama, JV; Wu, Y | 1 |
| Cho, JS; Choi, SS; Han, SB; Hong, JT; Kim, SM; Lee, SY; Oh, KW; Son, SM; Yoo, HS; Yoon, DY; Yun, YP | 1 |
| Armstrong, AJ; George, DJ | 1 |
| Habermehl, GK; Iczkowski, KA; Tang, Y; Yang, K | 1 |
| Dahut, WL; Figg, WD; Kluetz, PG | 1 |
| Sonpavde, G; Sternberg, CN | 1 |
| Kita, K; Kubota, Y; Makiyama, K; Miyake, M; Murakami, T; Nakaigawa, N; Ogawa, T; Sano, F; Terao, H; Uemura, H; Yanagisawa, M; Yao, M | 1 |
| Khatri, A; Russell, PJ; Singh, P; Yam, M | 1 |
| Mavridis, K; Scorilas, A; Talieri, M | 1 |
| Beer, TM; Fazli, L; Garzotto, M; Higano, CS; Janeba, N; Lange, PH; Lieberman, S; O'Brien, C; Rademacher, BL | 1 |
| Efstathiou, E; Logothetis, CJ | 1 |
| Chu, FM; Dreicer, R; Foster, B; Fracasso, PM; Lang, Z; Picus, J | 1 |
| Anand, A; Bubley, GJ; Danila, DC; de Bono, JS; Denmeade, SR; Fleisher, M; Haqq, C; Kheoh, T; Koscuiszka, M; Larson, SM; Molina, A; Morris, MJ; Ryan, CJ; Scher, HI; Schwartz, LH; Smith, MR; Taplin, ME | 1 |
| Attard, G; Danila, DC; de Bono, JS; Dearnaley, D; Fong, PC; Hunt, J; Kheoh, T; Lee, G; Messiou, C; Molife, LR; Molina, A; Olmos, D; Oommen, NB; Parker, C; Reid, AH; Ryan, CJ; Scher, HI; Small, E; Swennenhuis, JF; Terstappen, LW | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Mimeault, M | 1 |
| Singh, SV; Xiao, D | 1 |
| Liu, QJ; Lü, WC; Shang, DH; Tian, Y; Xu, XH; Zhang, YH | 1 |
| Palapattu, GS; Sonpavde, G | 1 |
| Anand, A; Dzik-Jurasz, A; Hu, J; Rathkopf, D; Ross, RW; Scher, HI; Tanaka, E; Wong, BY; Woo, MM; Yang, W | 1 |
| Arakawa, S; Fujisawa, M; Matsumoto, O; Shigemura, K; Yasufuku, T | 1 |
| Fenner, M; Ganser, A; Grünwald, V; Ivanyi, P; Morgan, MA; Reuter, CW | 1 |
| Beuzeboc, P; Eymard, JC; Ferrero, JM; Gravis, G; Joly, F; Krakowski, I; Oudard, S; Priou, F; Theodore, C; Thill, L; Zannetti, A | 1 |
| Beer, TM; Garzotto, M; Higano, CS; O'Brien, C; Rademacher, BL; True, LD | 1 |
| Arlen, PM; Chen, CC; Dahut, WL; Figg, WD; Gulley, JL; Jones, E; Kim, YS; Latham, L; Lee, MJ; Madan, RA; Ning, YM; Parnes, HL; Steinberg, SM; Sun, H; Trepel, JB; Woo, S; Wright, JJ | 1 |
| Galsky, MD; Vogelzang, NJ | 1 |
| Beer, TM; Garzotto, M; Geng, H; Harvey, CT; Huang, CY; Lafortune, MC; Myrthue, A; Nelson, PS; Pittsenbarger, J; Qian, DZ; Rademacher, BL | 1 |
| Bander, NH; Farokhzad, OC; Gu, FX; Huynh-Le, M; Kantoff, PW; Langer, R; Radovic-Moreno, AF; Wang, AZ; Yuet, K; Zhang, L | 1 |
| Ajiboye, AS; Arlen, PM; Chen, X; Dahut, WL; Figg, WD; Gulley, JL; Parnes, HL; Price, DK; Steinberg, SM; Woo, S; Wright, JJ; Zhu, W | 1 |
| de Wit, R; Doyle, GV; Gratama, JW; Miller, MC; Onstenk, W; Rao, C; Schmitz, PI; Sleijfer, S; Strijbos, MH; Terstappen, LW | 1 |
| Engelmann, U; Epplen, R; Heidenreich, A; Ohlmann, CH; Stöckle, M | 1 |
| Hamada, R; Hatano, T; Koga, S; Nakagami, Y; Ohori, M; Sakamoto, N; Tachibana, M | 1 |
| Fujikawa, A; Ito, Y; Kawai, M; Kishi, H; Kobayashi, K; Komiya, A; Matsumoto, T; Moriyama, M; Nakamura, M; Noguchi, S; Ohgo, Y; Ohta, J; Okajima, K; Onuki, T; Osaka, K; Sakai, N; Tajiri, T; Umemoto, S; Yokomizo, Y; Yokonishi, T; Yumura, Y | 1 |
| Clingan, P; Dreicer, R; Goel, S; Leach, J; Mainwaring, PN; Pili, R; Rosenthal, MA; Srinivas, S; Van Hazel, G; Wong, S | 1 |
| Bossi, A; Chauchereau, A; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Loriot, Y; Massard, C | 1 |
| Benchikh El Fegoun, A; Culine, S; Lechevallier, E | 1 |
| Ekblad, M; Halldén, G; Holford, A; Lemoine, NR; Miranda, E; Pizarro, MT; Radhakrishnan, S | 1 |
| Cheng, JQ; Djeu, JY; Fritz, D; Gilvary, DL; Pernazza, D; Sahakian, E; Sallman, DA; Trougakos, I; Wei, S; Zhong, B | 1 |
| Buck, AK; Herrmann, K; Krause, BJ; Nawroth, R; Schuster, T; Schwaiger, M; Senekowitsch-Schmidtke, R; Souvatzoglou, M; Treiber, U; Weber, AW; Weirich, G; Wester, HJ; Ziegler, SI | 1 |
| Barnetson, R; Doyle, B; Fleming, J; Kozielski, F; Leung, HY; Robson, CN; Singh, BL; Stockley, J; Wiltshire, C | 1 |
| Jeng, MH; Kao, C; Li, X; Liu, Y; Roger, P; Tang, Y | 1 |
| Manoharan, M; Singal, R; Talebi, TN | 1 |
| Dalhaug, A; Haukland, E; Nieder, C; Pawinski, A | 1 |
| Correa, PD; Paterson, C; Russell, JM | 1 |
| Anido, U; Areses, MC; Carballo, AM; Gómez, A; León, L | 1 |
| Crea, F; Danesi, R; Duhagon Serrat, MA; Farrar, WL; Hurt, EM; Thomas, SB | 1 |
| Buonerba, C; Di Lorenzo, G; Palmieri, G | 1 |
| Agus, DB; Gross, ME; Jiang, Y; Palma, JF; Wang, Y | 1 |
| Dai, B; Ma, CG; Shen, YJ; Shi, GH; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Hashine, K; Kusuhara, Y; Miura, N; Numata, K; Shirato, A; Sumiyoshi, Y | 1 |
| Aieta, M; Altieri, V; Autorino, R; Buonerba, C; Cartenì, G; De Placido, S; Di Lorenzo, G; Faiella, A; Ferro, M; Marinelli, A; Masala, D; Palmieri, G; Perdonà, S; Rescigno, P; Riccardi, N; Rizzo, M; Scagliorini, S; Scognamiglio, F | 1 |
| Khosla, P; Shrestha, A; Wei, Y | 1 |
| Canil, CM; Chen, EX; Chi, KN; Ernst, S; Hotte, SJ; Juhasz, A; Moore, MJ; Murray, P; Sridhar, SS; Wang, L; Yen, Y; Zwiebel, JA | 1 |
| de las Pozas, A; Parrondo, R; Perez-Stable, C; Rai, P; Reiner, T | 1 |
| Drouin, SJ; Houédé, N; Rouprêt, M; Wallerand, H | 1 |
| Brunello, A; Extermann, M; Kapoor, R | 1 |
| Groshen, S; Jadvar, H; Lin, E; Markland, FS; Pinski, J; Swenson, S; Wang, Q; Ye, W | 1 |
| Arkenau, HT; de Bono, JS; Demers, L; Fong, PC; Gualberto, A; Karavasilis, V; Leitzel, K; Lipton, A; Molife, LR; Olmos, D; Paccagnella, L; Postel-Vinay, S; Reid, AH; Shaw, HM; Spicer, J; Vidal, L; Yap, TA; Yin, D | 1 |
| Abrahamsson, PA; Cervin, C; Dizeyi, N; Johnsson, M; Tiberg, F; Tinzl, M | 1 |
| Fang, Y; Gao, X; Guo, W; Ling, Y; Liu, W; Luo, Y; Pang, J; Wei, K; Wen, X | 1 |
| Bochicchio, AM; Budillon, A; Caraglia, M; Catalano, A; Facchini, G; Ferrari, E; Gentilini, D; Iaffaioli, RV; Leopardo, D; Marra, L; Marra, M; Morabito, A; Nasti, G; Perrone, F; Piccirillo, MC; Striano, S; Tortoriello, A; Vitale, G | 1 |
| Ahn, H; Ahn, JH; Eun Kim, J; Hong, B; Hyuk Hong, J; Kim, CS; Lee, DH; Lee, J; Lee, JL; Song, C | 1 |
| Bradley, D; Daignault, S; Dunn, R; Egorin, MJ; Hussain, M; Kalemkerian, GP; Schneider, BJ; Smith, DC | 1 |
| Bally, MB; Eberding, A; Guns, ET; Jia, W; Musende, AG; Ramsay, E | 1 |
| Aigner, A; Czubayko, F; Frömberg, A; Gutsch, D; Schulze, D; Vollbracht, C; Weiss, G | 1 |
| Ambrosetti, D; Bourcier, C; Durivault, J; Guyot, M; Hannoun-Levi, JM; Ortholan, C; Pagès, G; Safe, S | 1 |
| Chi, KN; Eigl, BJ; Eisenhauer, EA; Gleave, ME; Hotte, SJ; North, S; Powers, J; Saad, F; Tannock, I; Tu, D; Yu, EY | 1 |
| Beretov, J; Chen, H; Cozzi, PJ; Delprado, WJ; Hao, J; Li, Y; Madigan, MC; Russell, PJ; Xiao, W | 1 |
| Beko, G; Blázovics, A; Horváth, A; Nyirády, P; Romics, I; Sárdi, E; Székely, E; Szentmihályi, K; Szucs, M | 1 |
| Beer, TM; Garzotto, M; Horbinski, CM; Kyprianou, N; Qian, DZ; Zhu, ML | 1 |
| Abbruzzese, A; Caraglia, M; Maglio, G; Marra, M; Ostacolo, L; Quaglia, F; Ungaro, F; Zappavigna, S | 1 |
| Assayag, F; Berniard, A; Beuzeboc, P; Dahmani, A; de Plater, L; Decaudin, D; Fontaine, JJ; Guyader, C; Marangoni, E; Némati, F; Oudard, S; Pasik, C; Poupon, MF | 1 |
| Dai, B; Shen, YJ; Shi, GH; Yang, LF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
| Bauer, J; Bolla, M; Bougnoux, A; Buffet-Miny, J; Colonna, M; Descotes, JL; Ferrero, JM; Fourneret, P; Hannoun-Levi, JM; Jover, F; Maingon, P | 1 |
| Baker, SD; Carducci, MA; Franke, RM; Rudek, MA; Sparreboom, A | 1 |
| Halabi, S; Kaplan, EB; Kelly, WK; Picus, J; Small, EJ; Stadler, WM; Vogelzang, NJ; Whang, YE | 1 |
| Chioni, A; Cianci, C; Crea, F; Danesi, R; Figg, WD; Giovannetti, E; Orlandini, C; Pastina, I; Price, DK; Ricci, S; Sissung, TM | 1 |
| Dence, C; Fujibayashi, Y; Hasegawa, Y; Kiyono, Y; Kobayashi, M; Oyama, N; Ponde, DE; Welch, MJ; Yokoyama, O | 1 |
| Armstrong, AJ; Berry, WR; de Wit, R; Eisenberger, MA; Pond, GR; Sonpavde, G; Tannock, IF | 1 |
| Dorff, TB; Quinn, DI | 2 |
| Bodrogi, I; de Bono, JS; Gravis, G; Gupta, S; Hansen, S; Kocak, I; Machiels, JP; Mackenzie, MJ; Oudard, S; Ozguroglu, M; Roessner, M; Sartor, AO; Shen, L | 1 |
| El Bary, NM; El Halim Mohamed Abu Hamar, A; El Shebiney, M; Mansour, S; Maria, A; Sadaka, E | 1 |
| Dhar, S; Farokhzad, OC; Karnik, R; Kolishetti, N; Langer, R; Lin, LQ; Lippard, SJ; Valencia, PM | 1 |
| Dreicer, R; Elson, P; Garcia, JA; Hutson, TE; Shepard, D | 1 |
| Hayashi, T; Kakuta, Y; Nakai, Y; Nakao, A; Nakayama, M; Nonomura, N; Okumi, M; Takayama, H | 1 |
| Maehana, T; Mizuno, T; Muto, M; Nishiyama, N; Yanase, M | 1 |
| Hwang, JJ; Jeong, IG; Kim, CS; Kim, DE; Kim, MJ; Kim, YS | 1 |
| Amin, P; Bassi, S; Dawson, N; Dibiase, SJ; Hussain, A; Kataria, R; Kwok, Y | 1 |
| Cormier, L; Eymard, JC; Ghiringhelli, F; Kermarrec, I; Ladoire, S; Martin, E; Michel, F; Mignot, G; Mourey, E; Zanetta, S | 1 |
| Allory, Y; Buttyan, R; Coppolani, E; Culine, S; de la Taille, A; Kheuang, L; Maillé, P; Nicolaiew, N; Paule, B; Ploussard, G; Salomon, L; Sirab, N; Soyeux, P; Terry, S; Vacherot, F | 1 |
| Carpinito, G; Desarnaud, F; Geck, P; Makarovskiy, AN; Parkin, C | 1 |
| Fujikawa, A; Moriyama, M; Mouri, S; Ota, J; Tajiri, T; Yokomizo, Y; Yumura, Y | 1 |
| Nabhan, C | 3 |
| Hori, A; Kami, M; Tanimoto, T | 1 |
| Aneja, R; Karna, P; Pannu, V; Sajja, HK; Shukla, D | 1 |
| Costa, J; Henderson, R; Hoppe, BS; Li, Z; Marcus, RB; Mendenhall, NP; Mendenhall, WM; Morris, CG; Nichols, RC; Williams, CR | 1 |
| Pal, SK; Sartor, O | 2 |
| Chen, L; Hachem, P; Ma, CM; Mu, Z; Pollack, A; Wallentine, A | 1 |
| Baum, CE; Danesi, R; Figg, WD; Kirkland, CT; Ockers, SB; Price, DK; Sissung, TM; Stein, EV; Venzon, D | 1 |
| Figg, WD | 2 |
| Bilusic, M; Dahut, WL | 1 |
| Pal, SK; Sartor, O; Twardowski, P | 1 |
| Feng, N; Hua, L; Li, P; Niu, X; Tao, J; Wang, X; Wang, Z; Wu, D; Wu, H; Xu, B; Zhang, W; Zhang, X | 1 |
| Halstead, M; Katz, L; Sartor, O | 1 |
| Fujisawa, M; Miyake, H; Sakai, I; Terakawa, T | 1 |
| Alberola, V; Casinello, J; Gasent, JM; Grande, E; Laforga, JB; Provencia, M | 1 |
| Alamanis, C; Anastasiou, I; Bamias, A; Bournakis, E; Chrisofos, M; Constantinides, C; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Karadimou, A; Mountzios, I; Papadimitriou, C; Tsiatas, M; Varkaris, A; Wen, S | 1 |
| Balko, JM; Black, EP | 1 |
| Burris, HA; de Bono, JS; Hubner, A; Miller, K; Morris, T; Nathan, F; Payne, H; Stephenson, J; Taboada, M; Trump, DL | 1 |
| Eary, JF; Hackenbracht, JA; Higano, CS; Link, JM; Mankoff, DA; Montgomery, RB; Muzi, M; Rezvani, BB; Yu, EY | 1 |
| Barbanti, G; Bargagli, G; Chiriacò, G; Conca, R; De Rubertis, G; Fiaschi, AI; Francini, E; Francini, G; Manganelli, A; Pascucci, A; Petrioli, R; Ponchietti, R | 1 |
| Faucz, FR | 1 |
| Ding, ST; Fujii, N; Inoue, T; Kobayashi, T; Lv, JJ; Nishiyama, H; Nishizawa, K; Ogawa, O; Oishi, S; Saito, R; Xing, ND | 1 |
| Canter, DJ; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Uzzo, RG | 1 |
| Angulo, JC | 1 |
| Mathew, P; Morita, S; Thall, PF; Wen, S | 1 |
| Checcaglini, F; Colloca, G; Venturino, A | 1 |
| Hasegawa, M; Ide, H; Kikuchi, E; Kosaka, T; Maeda, T; Miyajima, A; Oya, M; Shirotake, S; Tanaka, N; Yasumizu, Y | 1 |
| Goetz, D | 1 |
| Altieri, V; Buonerba, C; Cavaliere, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Ferro, M; Perdonà, S; Puglia, L; Rescigno, P | 1 |
| Bracarda, S; Logothetis, C; Oudard, S; Sternberg, CN | 1 |
| Enomoto, Y; Fujimura, T; Fukuhara, H; Homma, Y; Ishikawa, A; Kume, H; Nishimatsu, H; Suzuki, M | 1 |
| Fruehauf, J; Lilly, M; Parmakhtiar, B; Simoneau, AR; Tang, Y; Xie, J; Zi, X | 1 |
| Alhasso, A; Ansari, A; Ansari, J; Glaholm, J; Hussain, SA; Mahmood, R | 1 |
| Miller, K | 1 |
| Cetnar, J; Eickhoff, J; Liu, G; LoConte, NK; McFarland, TA; McNeel, D; Wilding, G | 1 |
| Bernaudin, JF; Fajac, A; Gligorov, J | 1 |
| Albers, P; Berry, WR; Chi, K; Chu, L; de Wit, R; Heidenreich, A; Heller, G; Henick, B; Jia, X; Meluch, AA; Nordquist, LT; Rosen, PJ; Ruether, DJ; Scher, HI; Venner, PM; Waterhouse, D | 1 |
| Bahl, A; Biernacka, KM; Gillatt, D; Holly, JM; Perks, CM; Persad, RA; Uzoh, CC | 1 |
| Barnett, CM; Beer, TM; Flamiatos, JF | 1 |
| Kikuchi, E; Kosaka, T; Miyajima, A; Oya, M; Shirotake, S; Suzuki, E | 1 |
| Sartor, AO | 1 |
| Aoki, K; Azuma, K; Kikugawa, T; Miura, N; Nishida, T; Sasaki, T; Sato, H; Shimamoto, K; Takeda, H; Tanji, N; Yanagihara, Y; Yokoyama, M | 1 |
| Cicero, G; De Luca, R | 1 |
| Joshi, S; Khatri, A; Russell, PJ; Singh, PP; Verma, ND; Wang, X | 1 |
| Alves, V; Freitas, M; Mota-Pinto, A; Sarmento-Ribeiro, AB | 1 |
| Biordi, L; Festuccia, C; Gravina, GL; Jannini, EA; Marampon, F; Petini, F; Sherris, D; Tombolini, V | 1 |
| Mirza, A; Mithal, N | 1 |
| Asmane, I; Barthélémy, P; Bergerat, JP; Céraline, J; Duclos, B; Dufour, P; Kurtz, JE; Litique, V; Rob, L | 1 |
| Antonarakis, ES; Armstrong, AJ | 1 |
| Kubo, A; Miyazawa, K; Moriyama, M; Motoo, Y; Nakajima, H; Nakaya, N; Sato, I; Shimasaki, T; Suzuki, K; Tanaka, T | 1 |
| Bauer, H; Ghandehari, H; Greish, K; Grüner, M; Larson, N; Malugin, A; Naik, S; Pike, DB; Ray, A | 1 |
| Forsey, S; Harris, V; Lloyd, K; Parker, C; Roche, M; Rogers, P | 1 |
| Efstathiou, E; Hoang, A; Karlou, M; Logothetis, CJ; Pagliaro, LC; Pettaway, CA; Pisters, LL; Troncoso, P; Tzelepi, V; Wen, S | 1 |
| Caffo, O; Comploj, E; Fariello, A; Galligioni, E; Sacco, C; Sava, T; Segati, R; Veccia, A; Zustovich, F | 1 |
| Boxall, A; Harrington, KJ; Heinemann, L; Kottke, T; Melcher, A; Morgan, R; Pandha, HS; Prestwich, R; Relph, KL; Simpson, GR; Vile, R | 1 |
| Iwaki, H; Kageyama, S; Masuda, Y; Narita, M; Okada, Y; Yoshida, T | 1 |
| Gan, L; Wang, J; Xu, H; Yang, X | 1 |
| Harrington, JA; Jones, RJ | 1 |
| Attard, G; de Bono, JS | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Maita, S; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H; Yuasa, T | 1 |
| Armstrong, AJ; Berry, WR; Brookes, M; de Wit, R; Eisenberger, MA; Leopold, L; Pond, GR; Sonpavde, G; Tannock, IF; Wood, BA | 1 |
| Arnaout, M; Beuzeboc, P; Lokiec, F; Moachon, L; Mongardon, N; Pène, F; Rezai, K; Vodovar, D | 1 |
| Culine, S; Drouet, L; Eymard, JC; Fizazi, K; Gravis, G; Hennequin, C; Oudard, S; Ravery, V; Zerbib, M | 1 |
| Beardsley, E; Chi, KN; Eigl, BJ; Hotte, SJ; Ko, YJ; Saad, F; Sridhar, SS; Venner, P; Weber, D; Winquist, E | 1 |
| Choi, J; Hwang, JJ; Jang, S; Jeong, IG; Kim, CS; Kim, MJ; Kim, T; Kim, YS; Lee, JH; Ro, S | 1 |
| Berry, S; Chi, K; Czaykowski, P; Eigl, B; Gleave, M; Hotte, S; Lattouf, JB; Mukherjee, SD; North, S; Pollak, M; Saad, F; Winquist, E; Wood, L | 1 |
| Holzbeierlein, JM; Nisbet, AA; Reed, GA; Thrasher, JB; VanVeldhuizen, PJ; Womble, PR | 1 |
| Agarwal, N | 1 |
| Bloemendal, HJ; de Haas, MJ; de Klerk, JM; O'Sullivan, JM; van Bezooijen, BP; van Dodewaard-de Jong, JM; Wilson, RH | 1 |
| Canter, D; Corlew, MM; Golovine, K; Kolenko, VM; Kutikov, A; Makhov, P; Simhan, J; Uzzo, RG | 1 |
| Awasthi, S; Fast, S; Nagaprashantha, LD; Roby, R; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
| Barbieri, R; Bernardo Bassan, F; Caffo, O; Fratino, L; Galligioni, E; Martini, T; Pappagallo, G; Perin, A; Sava, T; Segati, R; Vaccher, E; Veccia, A | 1 |
| Koroleva, IA; Mochalova, AS | 2 |
| Guancial, EA; Taplin, ME | 1 |
| Chen, I; Chow Maneval, E; George, DJ; Harmon, CS; Hutson, TE; Kozloff, M; Liu, G; Logothetis, CJ; Mathew, P; Shore, ND; Wang, SL; Wilding, G; Zurita, AJ | 1 |
| Shen, Y; Ye, D | 1 |
| Seruga, B; Tannock, IF | 1 |
| Gelpi, F; Gomella, LG; Kelly, WK | 1 |
| Hongo, F; Iwata, T; Kamoi, K; Kawauchi, A; Miki, T; Okihara, K; Takaha, N; Takeuchi, I; Ueda, T; Yamada, T; Yano, K | 1 |
| Del Giglio, A; Kaliks, R; Pompeo, AC; Serpa Neto, A; Tobias-Machado, M; Wroclawski, ML | 1 |
| Qi, WX; Shen, Z; Yao, Y | 1 |
| Arai, G; Itoh, K; Matsueda, S; Matsuoka, K; Moriya, F; Noguchi, M; Sasada, T; Suekane, S; Yamada, A | 1 |
| Higano, CS | 2 |
| Adams, M; Bartlett, JB; Dalgleish, AG; Galustian, C; Henry, JY; Lu, L; Meyer, B | 1 |
| Agrawal, S; Araujo, JC; Armstrong, AJ; Braud, EL; Gallick, GE; Logothetis, CJ; Lonberg, M; Mathew, P; Paliwal, P; Posadas, E; Trudel, GC | 1 |
| Corcoran, C; Devery, A; Dowling, C; Fan, Y; Fitzpatrick, JM; Gallagher, WM; Mulrane, L; O'Connor, D; O'Connor, R; O'Driscoll, L; O'Neill, AJ; Prencipe, M; Rani, S; Watson, RW | 1 |
| Amadio, P; Bortolus, R; Caffo, O; Cartenì, G; Facchini, G; Galligioni, E; Gernone, A; Ortega, C; Pagliarulo, V; Prati, V; Re, GL; Sava, T; Veccia, A | 1 |
| Bermudo, R; Buxo, E; Codony-Servat, J; Fernández, PL; Gascón, P; Kalko, SG; Marín-Aguilera, M; Mellado, B; Ribal, MJ | 1 |
| Alexandre, J; Bousquet, G; de Mont-Serrat, H; Faivre, S; Goldwasser, F; Kaiser, R; Le Tourneau, C; Misset, JL; Raymond, E | 1 |
| Garcia, JA; Rini, BI | 1 |
| de Bono, JS; Massard, C; Michels, RM; Sartor, O | 1 |
| Fukui, I; Ito, M; Kitsukawa, S; Kubo, Y; Numao, N; Saito, K; Sukegawa, G; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J; Yuasa, T | 1 |
| Borsellino, N; Gebbia, V; Serretta, V; Valerio, MR | 1 |
| Aoki, A; Baba, Y; Imoto, K; Kamiryo, Y; Kaneda, Y; Konishi, M; Matsuda, K; Matsuyama, H; Nasu, T; Sakano, S; Shimabukuro, T; Suga, A; Takai, K; Yamamoto, M; Yamamoto, N; Yoshihiro, S | 1 |
| Kawaguchi, K; Kinebuchi, Y; Suzuki, A; Tsuruta, T; Wajiki, M | 1 |
| Kobayashi, M; Nakamura, M; Ohmori, S; Yaguchi, T | 1 |
| Berry, WR; Brookes, M; Burke, JM; Caton, JR; Fleming, MT; Galsky, MD; Holmlund, JT; Hutson, TE; Karlov, P; Leopold, L; Matveev, V; Sonpavde, G; Wood, BA | 1 |
| Börgermann, C; Molitor, B | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Chinet-Charrot, P; Cojean-Zelek, I; Culine, S; Davin, JL; Delva, R; Deplanque, G; Ferrero, JM; Fizazi, K; Fléchon, A; Geneve, J; Gravis, G; Houedé, N; Krakowski, I; Labourey, JL; Lagrange, JL; Laguerre, B; Lesaunier, F; Linassier, C; Mourey, L; Oudard, S; Priou, F; Ravaud, A; Rolland, F; Theodore, C; Tournay, E | 1 |
| Cortesi, E; Gazzaniga, P; Iacovelli, R; Palazzo, A; Procopio, G | 1 |
| Lu, H; Martzen, MR; Slaton, JW; Verneris, MR; Wang, H; Wenner, CA | 1 |
| Fujisawa, M; Miyake, H; Muramaki, M | 1 |
| Igawa, M; Shiina, H; Urakami, S | 1 |
| Hara, I; Inagaki, T | 1 |
| Habuchi, T; Horikawa, Y; Inoue, T; Kumazawa, T; Maita, S; Nanjyo, H; Narita, S; Numakura, K; Obara, T; Saito, M; Satoh, S; Tsuchiya, N; Tsuruta, H | 1 |
| Chen, L; Chen, X; Cvetkovic, D; Ma, CM; Mu, Z; Pollack, A | 1 |
| Jeet, V; Khatri, A; Russell, PJ; Verma, ND | 1 |
| Dawson, N; Moul, JW | 1 |
| Dang, Q; He, D; Hsieh, JT; Jiao, M; Li, L; Li, X; Wang, X; Wu, D; Wu, K; Zhang, L; Zhu, G | 1 |
| Bahl, A; Bellmunt, J; Oudard, S | 1 |
| Barry, M; Bhatt, RS; Choueiri, TK; Febbo, P; Fennessy, FM; Galsky, MD; Hayes, J; Kantoff, PW; Oh, WK; Richie, JP; Ross, RW; Taplin, ME; Tempany, CM; Xie, W | 1 |
| Gallardo, HF; Gregor, P; Huang, QD; Morris, MJ; Rasalan, TS | 1 |
| Arranz, JÁ; Cassinello, J; Climent, MA; García-Donas, J; González del Alba, A; León-Mateos, L; Mellado, B; Méndez-Vidal, MJ; Pérez-Valderrama, B; Piulats, JM; Sánchez-Hernández, A | 1 |
| Braeckman, J; Decoster, L; Degrève, J; Fontaine, C; Schallier, D | 1 |
| Adams, L; Day, JR; Dhani, NC; Emmenegger, U; Groskopf, J; Jongstra, J; Joshua, AM; Knox, JJ; Sridhar, SS; Tannock, IF | 1 |
| Baran, Y; Bassoy, EY | 1 |
| Gschwend, JE; Heck, MM; Höppner, M; Horn, T; Retz, M; Thalgott, M | 1 |
| Brockow, K; Ring, J; Seifert, F; Zink, A; Zirbs, M | 1 |
| Asmar, L; Awasthi, S; Beer, TM; Berry, WR; Boehm, KA; Fleming, MT; Galsky, MD; Hutson, TE; Kolodziej, M; Martincic, D; Rastogi, A; Rauch, MA; Rousey, SR; Sonpavde, G; Wang, Y; Weinstein, RE | 1 |
| Esa, A; Hashimoto, K; Hatanaka, Y; Imanishi, M; Kajikawa, H; Ohzeki, T; Saitou, Y; Sugimoto, K; Uemura, H; Yamamoto, Y; Yasuda, M | 1 |
| Akaza, H; Arai, Y; Fujita, R; Hashine, K; Hoshi, S; Kakehi, Y; Kanayama, HO; Miki, T; Miura, T; Mizokami, A; Nishimura, K; Nonomura, K; Nonomura, N; Ogawa, O; Ozono, S | 1 |
| Kobayashi, M; Komatsu, K; Kubo, T; Kurokawa, S; Morita, T; Nakano, K; Nukui, A; Ohta, S; Suzuki, K | 1 |
| Bouchez, LC; Cho, CY; Dubrovska, A; Elliott, J; Kularatne, SA; Reddy, VA; Salamone, RJ; Schepotin, IB; Schultz, PG; Stakhovsky, AE; Telegeev, GD; Trussell, C; Wang, Y; Watson, J; Yan, F | 1 |
| Fujii, Y; Ishioka, J; Kawakami, S; Kihara, K; Kijima, T; Koga, F; Masuda, H; Matsuoka, Y; Numao, N; Saito, K; Yokoyama, M | 1 |
| Garnick, MB | 1 |
| Cheng, I; Kwee, S; Loo, L; Song, MA; Tiirikainen, M | 1 |
| Brugnara, S; Caffo, O; Caldara, A; di Pasquale, MC; Ferro, A; Frisinghelli, M; Galligioni, E; Murgia, V; Pappagallo, G; Russo, LM; Soini, B; Valduga, F; Veccia, A | 1 |
| Ito, K; Koike, H; Matsui, H; Morikawa, Y; Sekine, Y; Shibata, Y; Suzuki, K | 1 |
| Akseli, H; Claes, G; Ginman, C; Harmenberg, U; Heikkinen, M; Hemminki, A; Hervonen, P; Igor, Z; Ilari, L; Joensuu, H; Joensuu, T; Kellokumpu-Lehtinen, PL; Lehtinen, I; Luukkaa, M; Luukkaala, T; Marjaanai, L; McDermott, R; Mirja, H; Nilsson, S; Nyandoto, P; Paul, N; Pirkko-Liisa, KL; Ray, M; Sten, N; Tiina, L; Ulrika, H; Zaitsev, I | 1 |
| Moiseenko, BM; Nosov, AK; Vorob'ev, AV; Vorob'ev, NA | 1 |
| Perry, CJ; Sundar, S | 1 |
| Carducci, M; George, D; Halabi, S; Kantoff, P; Kaplan, E; Kelly, WK; Mahoney, JF; Monk, JP; Morris, M; Small, EJ; Stadler, WM; Vogelzang, NJ | 1 |
| Dhawan, R; Mehra, M; Wu, Y | 1 |
| Ding, DG; Du, GH; Hao, JW; Liu, ZH; Mao, XP | 1 |
| Bühler, P; Elsässer-Beile, U; Kopeček, J; Kopečková, P; Liu, J; Pan, H; Sima, M; Wolf, P | 1 |
| Akaza, H; Mera, T; Saijo, N | 1 |
| Beuzeboc, P; Goldwasser, F; Ropert, S; Zerbib, M | 1 |
| Abern, MR; Allott, EH; Freedland, SJ | 1 |
| Armstrong, AJ; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Gross-Goupil, M; Pasticier, G; Ravaud, A; Roca, S | 1 |
| Herchenhorn, D; Maluf, FC; Smaletz, O | 1 |
| Kim, W; Ryan, CJ | 1 |
| Åström, L; Franzen, L; Ginman, C; Hjälm-Eriksson, M; Kellokumpu-Lehtinen, PL; Marttila, T; Seke, M; Taalikka, M; Thellenberg-Karlsson, C | 1 |
| Bahl, A; Masson, S | 1 |
| Enomoto, Y; Fujimura, T; Fukuhara, H; Hirano, Y; Homma, Y; Igawa, Y; Ishikawa, A; Kume, H; Miyazaki, H; Nishimatsu, H; Suzuki, M | 1 |
| Adediran, S; Hussain, A; Khan, MA; Livak, F; Ning, Y; Suer, S; Vemula, A; Zhang, B | 1 |
| Berry, JE; Daignault, SD; Eber, MR; Koh, AJ; Li, X; Liao, J; McCauley, LK; Michalski, ME; Nemeth, JA; Park, SI; Pienta, KJ; Sadler, D; Snyder, LA; Soki, FN; Sud, S; Tisdelle, S; Wronski, TJ | 1 |
| Cristino, L; De Petrocellis, L; Di Marzo, V; Iappelli, M; Ligresti, A; Orlando, P; Schiano Moriello, A; Stott, CG; Verde, R | 1 |
| Brunstein, MC; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Guérin, O; Lattanzio, L; Lo Nigro, C; Maffi, M; Merlano, M; Milano, G; Monteverde, M; Ortholan, C; Pagès, G; Sudaka, A; Tonissi, F | 1 |
| Corcoran, C; Dowling, P; Henry, M; Meleady, P; O'Connell, K; O'Connor, R; O'Driscoll, L; O'Neill, A; Prencipe, M; Rani, S; Watson, W | 1 |
| Liu, F; Qin, W; Wang, F; Wang, Y; Yang, X; Yuan, J; Zhang, G; Zhang, Y | 1 |
| Antonarakis, ES; Carducci, MA; De Marzo, AM; Eisenberger, MA; Fedor, HL; Gurel, B; Hicks, JL; Keizman, D; Lotan, TL; Zhang, Z | 1 |
| Coenen, JL; Creemers, GJ; Dalesio, O; de Jong, PC; de Wit, R; Fosså, SD; Gerritsen, W; Loosveld, OJ; Meulenbeld, HJ; Polee, M; Ten Tije, AJ; van Werkhoven, ED | 1 |
| Antonarakis, ES; Carducci, MA; Eisenberger, MA; Goyal, J; Huang, P; Nuhn, P; Oh, D; Tyagi, P | 1 |
| Fujisawa, M; Harada, K; Miyake, H; Muramaki, M; Sakai, I | 1 |
| Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S | 1 |
| Bobek, V; Bouvet, M; Hassanein, MK; Hoffman, RM; Kolostova, K; Menen, R; Zhang, L; Zhao, M | 1 |
| Attard, G; Baikady, B; Bianchini, D; de Bono, J; Hunt, J; Maier, G; Mezynski, J; Mulick Cassidy, A; Olmos, D; Pezaro, C; Reid, AHM; Sandhu, S; Sarvadikar, A; Sheridan, E; Thompson, E; Zivi, A | 1 |
| Gottfried, M; Keizman, D; Maimon, N | 1 |
| Ader, I; Bocquet, M; Brizuela, L; Cuvillier, O; Malavaud, B; Mazerolles, C | 1 |
| McKeage, K | 1 |
| Alesini, D; Altavilla, A; Campennì, GM; Cortesi, E; Iacovelli, R; Palazzo, A; Procopio, G; Risi, E | 1 |
| Cornfeld, M; Eisenberger, M; Hudes, G; Puchalski, TA; Qi, M; Qin, X; Reddy, M; Tagawa, ST; Whang, YE | 1 |
| Adler, AI; George, E; Jilani, A | 1 |
| Hervonen, P; Kellokumpu-Lehtinen, P; Tulijoki, T | 1 |
| Aufderklamm, S; Fetisch, J; Feyerabend, S; Gerber, V; Hauch, S; Hennenlotter, J; Kühs, U; Mischinger, J; Schilling, D; Schwentner, C; Stenzl, A; Todenhöfer, T | 1 |
| Carrión, B; Ceña, V; Herrero, MA; Lucío, MI; Pérez-Martínez, FC; Rubio, N; Vázquez, E | 1 |
| Beretov, J; Chang, L; Cozzi, PJ; Graham, PH; Hao, J; Hung, TT; Kearsley, JH; Khatri, A; Li, Y; Madigan, MC; Power, CA; Xiao, W | 1 |
| Miyazaki, Y; Ogura, K; Sawazaki, H; Sengiku, A; Takahashi, T | 1 |
| Joly, F; Lheureux, S | 1 |
| Gschwend, JE; Hatzichristodoulou, G; Heck, MM; Kübler, H; Maurer, T; Nawroth, R; Retz, M; Thalgott, M; Wolf, P | 1 |
| Acunzo, J; Andrieu, C; Baylot, V; Fazli, L; Garrido, C; Giusiano, S; Gleave, M; Katsogiannou, M; Rocchi, P; Taieb, D | 1 |
| Armstrong, AJ; Chi, KN; de Bono, JS; de Wit, R; Fizazi, K; Flaig, TW; Fléchon, A; Fleming, M; Hainsworth, JD; Hirmand, M; Mainwaring, P; Miller, K; Mulders, P; Saad, F; Scher, HI; Seely, L; Selby, B; Shore, ND; Sternberg, CN; Taplin, ME | 1 |
| Bennett, HL; Fleming, JT; Leung, HY; Mandal, R; O'Prey, J; Robson, CN; Ryan, KM; Stockley, J | 1 |
| Bhowmick, NA; Chu, CY; Chung, LW; Fernandez, A; Fritz, G; Jackson, RS; Kitada, S; Pellecchia, M; Placzek, W; Reed, JC; Stebbins, J; Wei, J; Ziaee, S | 1 |
| Gerritsen, WR | 1 |
| Berardi, R; Bleuse, JP; Cappuzzo, F; de Wit, R; Dogliotti, L; Jannuzzo, MG; Mariani, M; Meulenbeld, HJ; Petroccione, A; Raymond, E; Santoro, A; Sternberg, CN; Tagawa, ST; Vinci, EM; Vitali, G | 1 |
| He, LY; Long, Z; Ming, YZ; Peng, XQ; Ye, QF; Zhang, YC | 1 |
| Meisel, A; Stenner, F | 1 |
| Deep, A; Dhingra, R; Malhotra, M; Narasimhan, B; Phogat, P; Sharma, PC; Sharma, T | 1 |
| Ananias, HJ; de Jong, IJ; De Vries, EG; Domanska, UM; Huls, G; Kliphuis, NM; Kruizinga, RC; Nagengast, WB; Oude Munnink, TH; Timmer-Bosscha, H; Walenkamp, AM | 1 |
| Armstrong, AJ; Bahnson, RR; Boston, B; Busby, JE; D'Amico, AV; Eastham, JA; Enke, CA; Farrington, T; Higano, CS; Ho, M; Horwitz, EM; Kantoff, PW; Kawachi, MH; Kuettel, M; Lee, RJ; MacVicar, GR; Malcolm, AW; Miller, D; Mohler, JL; Plimack, ER; Pow-Sang, JM; Roach, M; Rohren, E; Rosenfeld, S; Shead, DA; Srinivas, S; Strope, SA; Tward, J; Twardowski, P; Walsh, PC | 1 |
| Heidenreich, A; Pfister, D | 1 |
| Al-Azayzih, A; Al-Husein, B; Goc, A; Kochuparambil, ST; Mohammad, S; Somanath, PR | 1 |
| Benson, MC; Bonal, DM; Castillo-Martin, M; Charytonowicz, E; Cordon-Cardo, C; de la Iglesia-Vicente, J; Domingo-Domenech, J; Gladoun, N; Petrylak, DP; Quinn, SA; Rodriguez-Barrueco, R; Rodriguez-Bravo, V; Silva, JM; Vidal, SJ | 1 |
| Berthold, DR; Betticher, DC; Brauchli, P; Bubendorf, L; Cathomas, R; Cotting, D; Droege, C; Gillessen, S; Jaggi, R; Klingbiel, D; Pless, M; Rothermundt, C; Schiess, R; Siciliano, D; von Moos, R; Winterhalder, R | 1 |
| Albiges, L; Escudier, B; Fizazi, K; Loriot, Y; Massard, C | 1 |
| Lattanzio, L; Lo Nigro, C; Merlano, MC; Milano, G; Monteverde, M; Tonissi, F | 1 |
| Hayakawa, Y; Hirano, K; Iguchi, K; Ishii, K; Matsumoto, K; Sugimura, Y; Usui, S | 1 |
| Chen, X; deVere White, RW; Gao, AC; Liu, C; Lou, W; Nadiminty, N; Shi, XB; Zhou, Q; Zhu, Y | 1 |
| Berry, WR; Galsky, MD; Leopold, L; Pond, GR; Sonpavde, G; Wood, BA | 1 |
| Aapro, MS | 1 |
| Chen, RC; Chiu, WK; Crane, JM; Godley, PA; Hoffman, LG; Kim, WY; Pruthi, RS; Rathmell, WK; Rosenman, JG; Wallen, EM; Wang, AZ; Whang, YE | 1 |
| Blom, R; Bolstad, B; Bruland, ØS; Franzén, L; Johannessen, DC; Lennernäs, B; Nilsson, S; O'Bryan-Tear, CG; Parker, C; Petersson, U; Pigott, K; Sokal, M; Tennvall, J; Thuresson, M; Tyrrell, C | 1 |
| Adler, AI; Dyer, M; George, E; Rinaldi, F | 1 |
| Codony-Servat, J; Fernández, PL; Filella, X; García-Albéniz, X; Gascón, P; Marín-Aguilera, M; Mellado, B; Pineda, E; Visa, L | 1 |
| Culig, Z; Erb, HH; Heidegger, I; Hoefer, J; Klocker, H; Neuwirt, H; Oh, SJ; Puhr, M; Schäfer, G | 1 |
| Clarke, NW | 1 |
| Date, S; Hirayama, K; Mukaisho, K; Nagashima, T; Niiro, M; Okihara, K | 1 |
| Cherubini, G; Garate, Z; Halldén, G; Lemoine, NR; Maya Pineda, H; Miranda, E; Öberg, D | 1 |
| Suzuki, K | 1 |
| Iguchi, R; Imanaka, K; Ito, N; Kamiyama, Y; Kanamaru, S; Makino, Y | 1 |
| Farokhzad, OC | 1 |
| Browne, G; Lian, JB; McKeown, SR; Ming, L; Nesbitt, H; Stein, GS; Worthington, J | 1 |
| Chen, B; Li, H; Liu, C; Xu, A; Xu, K; Xu, Y; Zheng, S | 1 |
| Penson, DF; Resnick, MJ | 1 |
| Cheng, HH; Lin, DW; Yu, EY | 1 |
| Antonarakis, ES; Eisenberger, MA | 1 |
| Lewis, B; Pal, SK; Sartor, O | 1 |
| Bogdanova, N; Dawkins, F; de Boer, CJ; Dirix, L; Heidenreich, A; Rawal, SK; Schrijvers, D; Stenzl, A; Szkarlat, K; Wang, G; Welslau, M | 1 |
| Albers, P; Arsov, C; Bokemeyer, C; Ecstein-Fraisse, E; Gschwend, J; Heidenreich, A; Heinrich, E; Honecker, F; Keck, B; Miller, K; Müller, SC; Otremba, B; Pfister, D; Retz, M; Rogenhofer, S; Scholz, HJ; Steiner, U; Trojan, L; Volkmer, B; Wirth, M | 1 |
| Hayashi, N; Kawahara, T; Kubota, Y; Misaki, H; Miyoshi, Y; Noguchi, K; Sano, F; Sekiguchi, Z; Teranishi, J; Uemura, H | 1 |
| Bulbul, MA; Elias, E; Farhat, FS; Khauli, RB; Saleh, A; Shamseddine, A | 1 |
| Dai, B; Kong, YY; Ma, CG; Qu, YY; Yang, WY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL | 1 |
| Cleeland, C; de Bono, JS; Fizazi, K; Gagnon, DD; Hao, Y; Haqq, CM; Kheoh, T; Mainwaring, P; Molina, A; North, S; Rothman, M; Scher, HI; Sternberg, CN | 1 |
| Chen, YY; Essand, M; Hughes, R; Lewis, CE; Morrow, F; Muthana, M; Rodrigues, S; Tazzyman, S; Welford, A | 1 |
| Aldinucci, D; Borghese, C; Cattaruzza, L; Celegato, M; Colombatti, A; De Luca, A; Mazzucato, M; Normanno, N; Pivetta, E | 1 |
| Mukhtar, H; Sanna, V; Sechi, M; Siddiqui, IA | 1 |
| Caffo, O; Galligioni, E; Russo, L; Veccia, A | 1 |
| Attarian, H; Ghadyani, M; Haghighi, S; Rezvani, H | 1 |
| Petrányi, Á | 1 |
| Corcoran, C; Crown, J; McDermott, R; O'Brien, K; O'Driscoll, L; O'Neill, A; Prencipe, M; Rani, S; Sheikh, R; Watson, W; Webb, G | 1 |
| Birtle, A | 1 |
| Eidelman, O; Kallakury, BV; Kasid, UN; Kumar, D; Luta, G; Mewani, RR; Pollard, HB; Ross, JS; Sakabe, I; Sheehan, CE; Sreenath, TL; Srivastava, M; Srivastava, S; Starr, J; Yadavalli, S; Zhang, C | 1 |
| Agache, V; Chen, B; Goertz, DE; Hynynen, K; Karshafian, R; Mortazavi, O; Todorova, M | 1 |
| Nanus, DM; Tagawa, ST | 1 |
| Asola, R; Ginman, C; Harmenberg, U; Hemminki, A; Hervonen, P; Joensuu, H; Joensuu, T; Keane, M; Kellokumpu-Lehtinen, PL; Laestadius, F; Lehtinen, I; Luukkaa, M; Luukkaala, T; McCaffrey, J; McDermott, R; Nilsson, S; Nyandoto, P; Sandberg, K; Tasmuth, T; Turpeenniemi-Hujanen, T | 1 |
| Sweeney, C | 1 |
| Baciuchka, M; Berdah, JF; Beuzeboc, P; Bousquet, G; Dauba, J; Delva, R; Deplanque, G; El Kouri, C; Esterni, B; Eymard, JC; Ferrero, JM; Fizazi, K; Gravis, G; Habibian, M; Hasbini, A; Joly, F; Krakowski, I; Labourey, JL; Laguerre, B; Latorzeff, I; Linassier, C; Machiels, JP; Mourey, L; Oudard, S; Platini, C; Pouessel, D; Priou, F; Ravaud, A; Rolland, F; Soulie, M; Suc, E; Théodore, C; Zanetta, S | 1 |
| Kawai, N; Kobayashi, D; Kobayashi, T; Kohri, K; Naiki, T; Sato, S; Takahashi, S; Tozawa, K; Yamada, K; Yasui, T | 1 |
| Yu, EY; Zhao, S | 1 |
| Farsaci, B; Ferrone, S; Gameiro, SR; Garnett, CT; Hodge, JW; Palena, C; Tsang, KY | 1 |
| Araujo, JC; Chatterji, T; Dayyani, F; Gallick, GE; Logothetis, CJ; Song, JH; Trudel, GC; Varkaris, A | 1 |
| Saylor, PJ | 1 |
| Beer, TM; Chen, V; Geng, H; Harvey, CT; Liu, Q; Qian, DZ; Xue, C | 1 |
| Bijnsdorp, IV; Geldof, AA; Hoekstra, OS; Oprea-Lager, DE; VAN DEN Eertwegh, AJ; VAN Moorselaar, RJ | 1 |
| Krause, BJ; Nawroth, R; Sachs, D; Schuster, T; Schwaiger, M; Schwarzenböck, S; Senekowitsch-Schmidtke, R; Souvatzoglou, M; Treiber, U; Weirich, G; Wester, HJ; Ziegler, S | 1 |
| Logothetis, CJ | 1 |
| Ernst, DS | 1 |
| de Wit, R; Petrylak, DP | 1 |
| Akerley, W; Hixson, DC; Makarovskiy, AN; Siryaporn, E | 1 |
| Avancès, C; Culine, S; Jacot, W; Sénesse, P | 1 |
| Bucana, C; Dinney, CP; Fan, D; Fidler, IJ; Huang, SF; Karashima, T; Kedar, D; Killion, JJ; Kim, SJ; Lee, AT; Mian, B; Shepherd, D; Sweeney, P | 1 |
| Howard, A; Nicolopoulos, J | 1 |
| Kelly, K; Morris, MJ; Santamauro, J; Scher, H; Schwartz, L; Shia, J; Vander Els, N | 1 |
| Beer, TM; Egorin, MJ; Eilers, KM; Garzotto, M; Henner, WD; Lowe, BA | 1 |
| Naito, K | 1 |
| Nishimura, K; Nonomura, N; Okuyama, A; Takahara, S | 1 |
| Arlen, P; Dahut, WL; Figg, WD; Gulley, J; Horne, MK; Lakhani, N; Parker, C; Parnes, H | 1 |
| Apiou, F; Arvelo, F; Bara, J; Boye, K; de Pinieux, G; Dutrillaux, AM; Dutrillaux, B; Legrier, ME; Lidereau, R; Poirson-Bichat, F; Poupon, MF; Sihassen, A | 1 |
| Du, W; El-Rayes, BF; Fontana, J; Hussain, M; Sakr, W; Smith, DC; Vaishampayan, U; Wood, D | 1 |
| Boyé, K; Bras-Gonçalves, R; De Cremoux, P; De Pinieux, G; Legrier, ME; Oudard, S; Poupon, MF | 1 |
| Siderov, J | 1 |
| Correale, P; Di Palma, T; Francini, G; Manganelli, A; Marsili, S; Messinese, S; Petrioli, R; Pozzessere, D; Sabatino, M; Salvestrini, F | 1 |
| Bissery, MC; Bouquet, C; Galaup, A; Griscelli, F; Li, H; Opolon, D; Opolon, P; Perricaudet, M; Tursz, T | 1 |
| Morris, JC | 1 |
| Beer, TM; Eilers, KM; El-Geneidi, M | 1 |
| Widmark, A | 1 |
| Adinin, RB; Ahmadi, MA; Arbuckle, R; Coats, C; Esmaeli, B; Faustina, M; Hidaji, L; Rivera, E; Tu, SM; Valero, V | 1 |
| Beer, TM; Eilers, KM; Garzotto, M; Henner, WD; Wersinger, EM | 2 |
| Davis, TL; Hauke, R; Kakitelashvilli, V; Kellerman, M; Lee, MS; Lin, MF; Lugo, E; Spellman, M; Taylor, R; Zelivianski, S; Zhou, XW | 1 |
| Carducci, M; Khan, MA; Partin, AW | 1 |
| Bardou, VJ; Bladou, F; Camerlo, J; Genre, D; Gravis, G; Macquart-Moulin, G; Maraninchi, D; Salem, N; Serment, G; Viens, P | 1 |
| Bissery, MC; Dykes, DJ; Kraus, LA; Samuel, SK; Schmid, SM; Waud, WR | 1 |
| Aggarwal, A; Baranda, J; Reed, G; Van Veldhuizen, PJ; Williamson, S; Zulfiqar, M | 1 |
| Al-sisi, H; Ibraheim, I; Parvez, T | 1 |
| Oh, WK | 2 |
| Hervonen, P; Jekunen, A; Kellokumpu-Lehtinen, P; Lefebvre, P | 1 |
| Godley, PA; Halabi, S; Kelly, WK; Oh, WK; Small, EJ; Vogelzang, NJ; Werner, C | 1 |
| Wolff, JM | 1 |
| Moyer, P | 1 |
| Wang, Q; Wieder, R | 1 |
| Eastham, JA; Grossfeld, GD; Kelly, WK; Small, EJ | 1 |
| Dahut, WL; Gulley, J | 1 |
| Beer, TM; Eilers, KM; Garzotto, M; Hsieh, YC; Mori, M | 1 |
| Beer, TM; Ellis, WJ; Garzotto, M; Higano, CS; Lange, PH; Lowe, BA; Montalto, MA | 1 |
| Johannsen, M; Loening, SA; Schnorr, D; Wilke, K | 1 |
| MacDonald, JR; Van Laar, ES; Waters, SJ; Weitman, S | 1 |
| Peyromaure, M; Thiounn, N | 1 |
| Klem, J; Price, N; Reddy, K; Tyagi, P | 1 |
| Beer, TM; Berry, W; Bland, LB; Wersinger, EM | 1 |
| D'Orazio, A; Klem, J; Tyagi, P | 1 |
| DeGrendele, H | 1 |
| Briasoulis, E; Karavasilis, V; Pavlidis, N; Siarabi, O | 1 |
| Arlen, PM; Cox, MC; Dahut, W; Figg, WD; Gulley, J; Linehan, WM | 1 |
| Ferrero, JM | 2 |
| Hurtubise, A; Momparler, RL | 1 |
| Akaza, H; Hattori, K; Hinotsu, S; Kawai, K; Kojima, T; Miyanaga, N; Onozawa, M; Shimazui, T; Tsukamoto, S | 1 |
| Chee, KG; Doroshow, JH; Edwards, RG; Gandara, DR; Gray, CR; Gumerlock, PH; Lara, PN; Longmate, J; Meyers, FJ; Ruel, C; Twardowski, P | 1 |
| Cummings, K; DiPaola, RS; Goodin, S; Kumar, P; Perrotti, M; Todd, M; Weiss, R | 1 |
| Sorscher, SM | 1 |
| Itoh, S; Mitsuhata, N; Watanabe, Y | 1 |
| Fidler, IJ; Logothetis, CJ; Mathew, P | 1 |
| Dreicer, R; Fergany, A; Klein, EA; Magi-Galluzzi, C; Reuther, A; Rothaermel, J; Ulchaker, J; Zhou, M; Zippe, C | 1 |
| Kadota, M; Katoh, M; Nishimura, Y | 1 |
| Ayers, D; Chi, KN; Chia, S; Cripps, C; Fry, D; Gelmon, KA; Huan, S; Janke, S; McIntosh, L; Seymour, LK; Shabbits, JA; Stewart, D; Walsh, W | 1 |
| Amiel, J; Boublil, JL; Chevallier, D; Ferrero, JM; Foa, C; Garnier, G; Lesbats, G; Peyrade, F; Ronchin, P; Tchiknavorian, X; Thezenas, S; Valenza, B | 1 |
| Arlen, PM; Chen, CC; Dahut, WL; Fedenko, KM; Figg, WD; Gulley, JL; Jones, E; Linehan, WM; Liu, Y; Parker, CE; Parnes, H; Steinberg, SM; Wright, JJ | 1 |
| Heine, K; Wolff, JM | 1 |
| Price, N | 1 |
| Bushnell, D; Fingert, H; Hammond, LA; Izbicka, E; Kreisberg, J; Kuhn, J; Malik, S; Patnaik, A; Rowinsky, EK; Schwartz, G; Smetzer, L; Thompson, I; Tolcher, AW | 1 |
| Bucana, C; Fidler, IJ; Jones, D; Kim, SJ; Logothetis, C; Mathew, P; Perez, C; Thall, PF; Troncoso, P | 1 |
| Abbou, CC; Allory, Y; Chopin, D; de la Taille, A; Hoznek, A; Paule, B; Salomon, L; Vacherot, F; Vordos, D; Yiou, R | 1 |
| Bartsch, G; Berger, AP; Fischer-Colbrie, R; Horninger, W; Niescher, M; Pelzer, A | 1 |
| Debes, JD; Tindall, DJ | 1 |
| Berry, WR; Chi, KN; de Wit, R; Eisenberger, MA; Horti, J; James, ND; Oudard, S; Pluzanska, A; Rosenthal, MA; Tannock, IF; Théodore, C; Turesson, I | 1 |
| Benson, MC; Berry, D; Burch, PA; Crawford, ED; Hussain, MH; Jones, JA; Kohli, M; Lara, PN; Moinpour, C; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME | 1 |
| Kanno, T; Shibasaki, N; Takeuchi, H; Taki, Y; Tsuji, Y | 1 |
| Rosenberg, JE; Small, EJ | 1 |
| Hisatake, Y; Ikezoe, T; Koeffler, HP; Ohtsuki, Y; Said, JW; Taguchi, H; Takeuchi, T; Yang, Y | 1 |
| Joly, F; Tannock, IF | 1 |
| Altieri, V; Autorino, R; Bianco, AR; Cancello, G; D'Alessio, A; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Marano, O; Perdonà, S; Pizza, C; Tortora, G | 1 |
| Li, DJ; Li, H; Li, X; Lu, YP; Sun, M; Wei, Q; Yang, YR | 1 |
| Dandekar, DS; Lokeshwar, BL | 1 |
| Ahmad, K | 1 |
| Carducci, MA; Khan, MA; Partin, AW | 1 |
| Battistel, C; Hartung, R; Kübler, HR; Lehmer, A; Paul, R; Treiber, U; van Randenborgh, H; Wagenpfeil, S; Wutzler, S | 1 |
| Abraham, S; Dagher, R; Li, N; Pazdur, R; Rahman, A; Sridhara, R | 1 |
| Dreicer, R; Price, N | 1 |
| Eliason, J; Hussain, M; Li, R; Li, Y; Sarkar, FH; Sarkar, SH | 1 |
| Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, C; Dimopoulos, MA; Efstathiou, E; Kastritis, E; Kostakopoulos, A; Papadimitriou, C; Skarlos, D | 1 |
| Areal, J; Arroyo, FR; Constenla, M; Font, A; Martin, C; Murias, A; Rosell, R; Saladie, JM; Sanchez, JJ; Santiago, JA | 1 |
| George, DJ; Gilligan, TD; Hagmann, E; Jacobson, JO; Kantoff, PW; Kaufman, DS; Manola, J; Oh, WK; Smith, MR | 1 |
| Taniguchi, M; Watanabe, A | 1 |
| Carey, RI; Dandekar, DS; Lokeshwar, BL; Lopez, M | 1 |
| Hara, I; Kamidono, S; Miyake, H; Muramaki, M | 1 |
| Ciccolini, J; Ferrero, JM; Fischel, JL; Formento, JL; Formento, P; Milano, G; Renée, N | 1 |
| Itoh, N | 1 |
| Kubota, Y; Miyoshi, Y; Uemura, H | 1 |
| Hofer, MD; Rubin, MA | 1 |
| Fujinami, K; Miura, T; Osada, Y; Takizawa, A | 1 |
| de Wit, R | 2 |
| Abraham, S; Capanna, T; DiPaola, RS; Doyle-Lindrud, S; Goodin, S; Medina, P; Shih, WJ; Todd, M; Winnie, J | 1 |
| Andrieu, JM; Banu, A; Banu, E; Beuzeboc, P; Coscas, Y; Dourthe, LM; Guinet, F; Hardy-Bessard, AC; Linassier, C; Oudard, S; Poupon, MF; Scotté, F; Voog, E | 1 |
| Carducci, MA | 1 |
| Hong, X; Hussain, M; Li, R; Li, Y; Sarkar, FH; Sarkar, SH | 1 |
| Van Poppel, H | 1 |
| Honda, S; Igawa, M; Imai, S; Kikuno, N; Kishi, H; Shigeno, K; Shiina, H; Urakami, S; Yoneda, T; Yoshino, T | 1 |
| Asano, K; Egawa, S; Hayashi, N; Manome, Y; Suzuki, H; Tanigawa, N; Yamamoto, T | 1 |
| Bokemeyer, C; Lipp, HP | 1 |
| Birle, DC; Tannock, IF; Wu, L | 1 |
| Bhandari, MS; Hussain, M; Petrylak, DP | 1 |
| Fossella, F; Hortobagyi, G; Montero, A; Valero, V | 1 |
| George, DJ; Moore, CN | 1 |
| Ryan, CJ; Small, EJ | 1 |
| Amin, P; Dawson, N; Dorsey, B; Engstrom, C; Guo, C; Hussain, A; Siegel, E | 1 |
| Capanna, T; Dave, N; DiPaola, RS; Doyle-Lindrud, S; Engle, E; Goodin, S; Jin, L; Kane, M; Rao, KV; Todd, M | 1 |
| Ryan, CW; Stadler, WM; Vogelzang, NJ | 2 |
| Burt, HM; Gleave, ME; Jackson, JK; Springate, CM | 1 |
| Berg, K; Chi, K; D'Aloisio, S; Frankel, SR; Gleave, M; Izbicka, E; Kuhn, J; Murray, N; Patnaik, A; Rowinsky, E; Schwartz, G; Takimoto, C; Thompson, I; Tolcher, AW | 1 |
| Engels, FK; Verweij, J | 1 |
| Doggrell, SA | 1 |
| Berry, WR | 1 |
| Kibel, AS | 1 |
| Emberton, M; Parker, C | 1 |
| Hasumi, H; Kishida, T; Kubota, Y; Makiyama, K; Miyoshi, Y; Nakaigawa, N; Nakamura, M; Ogawa, T; Sugiura, S; Uemura, H; Yao, M | 1 |
| George, DJ; Oh, WK; Tay, MH | 1 |
| Arena, G; Bertelli, G; Botto, A; Colantonio, I; Fea, E; Garrone, O; Giubergia, S; Heouaine, A; Merlano, M; Occelli, M | 1 |
| Engels, FK; Mathot, RA; Sparreboom, A; Verweij, J | 1 |
| Allen, KO; Bolger, GB; Neidhart, J; Rinehart, JJ; Saleh, M; Sellers, S; Triozzi, PL; Waddell, MJ | 1 |
| Barnes, AS; Catalona, W; Febbo, PG; George, DJ; Kantoff, PW; Loda, M; Manola, J; Oh, WK; Richie, JP; Shankar, S; Tempany, C | 1 |
| Day, LL; John, LS; Loberg, RD; Mawocha, SC; Pienta, BA; Pienta, KJ; Rubin, MA; Tantivejkul, K | 1 |
| Ahmed, F; Ali, S; Kucuk, O; Li, Y; Philip, PA; Sarkar, FH | 1 |
| Beer, TM; Garzotto, M; Ryan, CW; Tiffany, NM; Wersinger, EM | 1 |
| Beer, TM | 1 |
| Bierer, S; Bögemann, M; Hertle, L; Piechota, H; Wülfing, C | 1 |
| Androulakis, N; Georgoulias, V; Kalykaki, A; Kentepozidis, N; Kouroussis, Ch; Saridaki, Z; Spiridonakou, S; Vamvakas, L; Xiropoulou, E | 1 |
| Alexandre, J | 1 |
| Mimata, H; Nomura, T; Nomura, Y; Yamasaki, M | 1 |
| Harmenberg, U; Hjelm-Eriksson, M; Kälkner, KM; Lennartsson, L; Lennernäs, B; Nilsson, S; Ullén, A | 1 |
| Armstrong, AJ; Carducci, MA | 1 |
| Boyer, MJ; Clarke, S; Joshua, AM; Nordman, I; Stockler, MR; Venkataswaran, R | 1 |
| Desotelle, JA; Fu, VX; Jarrard, DF; Kenowski, ML; Schwarze, SR | 1 |
| Allhoff, EP; Burandt, J; Filleur, S; Klatte, T; Lindenmeir, T; Nelius, T; Rau, O; Reiher, F | 1 |
| Protheroe, A | 1 |
| Sleijfer, S; Stoter, G | 1 |
| Keam, SJ; McKeage, K | 1 |
| Banu, E; Medioni, J; Oudard, S; Scotté, F | 1 |
| Scardino, P | 1 |
| De Lena, M; Leone, B; Lorusso, V; Numico, G; Silvestris, N | 1 |
| Batman, E; de Wit, R | 1 |
| Bonhoure, E; Calvet, C; Cuvillier, O; Doumerc, N; Garcia, V; Golzio, M; Malavaud, B; Mazerolles, C; Pchejetski, D; Rischmann, P; Teissié, J | 1 |
| Petrylak, D | 2 |
| Bird, BR; Breathnach, OS; Hussein, MA; Kalimuthu, SG; O'Reilly, S; O'Sullivan, GC; O'Sullivan, MJ | 1 |
| Brodie, AM; Goloubeva, O; Hussain, A; Jelovac, D; Khan, MA; Lee, DI; Tang, Y | 1 |
| Brown, LG; Brubaker, KD; Corey, E; Vessella, RL | 1 |
| Patel, AR; Pienta, KJ; Sandler, HM | 1 |
| Kovel, S; Sella, A; Yarom, N | 1 |
| Kollmannsberger, C; Michels, J; Montemurro, T; Murray, N; Nguyen Chi, K | 1 |
| Berry, WR; Hutson, TE; Sonpavde, G | 1 |
| Mackler, NJ; Pienta, KJ | 1 |
| Arlen, PM; Beetham, P; Chen, C; Dahut, W; Feldman, J; Grosenbach, DW; Gulley, JL; Jones, E; Marte, J; Panicali, D; Parker, C; Pazdur, M; Schlom, J; Skarupa, L; Steinberg, SM; Tsang, KY | 1 |
| Lehmer, A; Treiber, U; Wagenpfeil, S | 1 |
| Nakabayashi, M; Oh, WK | 1 |
| Arlen, PM; Gulley, JL | 1 |
| Gilbert, DC; Parker, C | 1 |
| Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G | 1 |
| Hutson, TE; Sonpavde, G | 1 |
| Cheng, J; Farokhzad, OC; Jon, S; Kantoff, PW; Langer, R; Richie, JP; Sherifi, I; Teply, BA | 1 |
| Ankerst, DP; Benson, MC; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, JA; Kohli, M; Lara, PN; Petrylak, DP; Raghavan, D; Small, EJ; Tangen, CM; Taplin, ME | 1 |
| Burgess, EF; Roth, BJ | 1 |
| Ghio, R; Mencoboni, M; Olivieri, R; Schettini, G; Vannozzi, MO; Viazzi, F | 1 |
| Bao, BY; Hsu, J; Lee, YF; Ting, HJ | 1 |
| Abrams, J; Cher, ML; Hussain, M; Kucuk, O; Li, Y; Sarkar, FH | 1 |
| Cole, A; Cooc, J; Danenberg, K; Danenberg, PV; Pinski, J; Quek, ML; Wang, Q | 1 |
| Hägg, M; Havelka, AM; Kramer, G; Linder, S; Schwarz, S | 1 |
| Fazli, L; Gleave, ME; Miyake, H; Rocchi, P; So, A; Yamanaka, K; Zangemeister-Wittke, U | 1 |
| Puhalla, S; Ramaswamy, B | 1 |
| Hoffman, TJ; Johnson, CV; Ma, L; Perry, MC; Shelton, T; Smith, CJ; Volkert, WA | 1 |
| Gallagher, E; Gapstur, R | 1 |
| Albers, P; Börgermann, C; Miller, K; Thüroff, J; Wirth, M | 1 |
| Sartor, O | 2 |
| Greco, FA; Hainsworth, JD; Meluch, AA; Meng, C; Spigel, DR; Yost, K | 1 |
| de Las Pozas, A; Gomez, LA; Perez-Stable, C | 1 |
| Becker, K; Finke, F; Geiges, G; Göckel-Beining, B; Hossfeld, DK; Miller, K; Osieka, R; Rüssel, C; Tesch, H; Weissbach, L; Wirth, M; Wolff, JM | 1 |
| Avcu, F; Ural, AU | 1 |
| Babcic, V; Harnam, N; Kantoff, PW; Manola, J; Oh, WK | 1 |
| Azuma, K; Hashine, K; Miura, N; Numata, K; Sumiyoshi, Y | 2 |
| Basler, JW | 1 |
| Ankerst, DP; Berry, DL; Burch, PA; Crawford, ED; Hussain, MH; Jiang, CS; Jones, S; Lara, PN; Moinpour, CM; Petrylak, DP; Taplin, ME; Vinson, LV | 1 |
| Chang, SS; Rumohr, JA | 1 |
| Bloomfield, D; James, ND; Luscombe, C | 1 |
| Cavaglione, G; Chamorey, E; Dides, S; Ferrero, JM; Foa, C; Kaphan, R; Lesbats, G; Nouyrigat, P; Oudard, S | 1 |
| Hoshinaga, K; Kuwahara, Y; Maruyama, T; Sakurai, T; Shiroki, R | 1 |
| Bernshausen, A; Bieler, A; Dravits, T; Gansbacher, B; Hartung, R; Holm, PS; Kaszubiak, A; Köhler-Vargas, N; Lage, H; Mantwill, K; Surowiak, P; Treiber, U | 1 |
| Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Riemsma, R; Trowman, R | 1 |
| Cervera, A; Glisson, SD; Goldsmith, G; Hargis, JB; Kosfeld, RE; La Rocca, RV; Laber, DA | 1 |
| Baker, SD; Carducci, MA; Denmeade, SR; Eisenberger, MA; Elza-Brown, K; Pili, R; Rosenbaum, E; Schmidt, J; Sinibaldi, VJ; Walczak, J; Zahurak, M | 1 |
| Moss, RA; Petrylak, DP | 1 |
| de las Pozas, A; Perez-Stable, C; Reiner, T | 1 |
| Bhat-Nakshatri, P; Cheng, L; DeGrado, T; Gokmen-Polar, Y; Hutchins, GD; Jayaprakasan, V; Kelich, S; Miller, KD; Miller, MA; Nakshatri, H; Shanmugam, R; Sledge, GW; Sweeney, CJ; Yip-Schneider, M; Zheng, QH | 1 |
| Allhoff, EP; Filleur, S; Kalinski, T; Klatte, T; Nelius, T; Röpke, A; Yap, R | 1 |
| Ciccolini, J; Ferrero, JM; Fischel, JL; Formento, P; Milano, G | 1 |
| Li, M; Rayburn, ER; Wang, H; Wang, W; Zhang, R; Zhang, Z | 1 |
| Canfield, SE; McConkey, DJ; Williams, SA; Zhu, K | 1 |
| Hegele, A; Heidenreich, A; Hofmann, R; Kraeuter, P; Olbert, PJ; Schrader, AJ | 1 |
| Beer, TM; Bellmunt, J; Borner, MM; Bracarda, S; Fitzpatrick, JM; Krainer, M; Oh, WK; Oudard, S; Ozen, H; Rauchenwald, M; Skoneczna, I; Sternberg, CN; Zlotta, A | 1 |
| Beer, TM; Chatta, G; Chi, KN; Curd, JG; Dean Ruether, J; DeLoughery, TG; Petrylak, DP; Ryan, CW; Venner, PM | 1 |
| Aoki, H; Arai, Y; Endoh, M; Ishidoya, S; Ito, A; Shimazui, T | 1 |
| Dogliotti, L | 1 |
| Albanell, J; Bosch, M; Campás, C; Codony-Servat, J; Dang, L; Domingo-Domenech, J; Filella, X; Gascon, P; Mellado, B; Montagut, C; Oliva, C; Rolfe, M; Ross, JS; Rovira, A; Tapia, M | 1 |
| Calabrò, F; Sternberg, CN | 1 |
| Asmar, L; Boehm, KA; Ilegbodu, D; Kolodziej, M; Mull, S; Neubauer, MA; Perrine, G; Pluenneke, RE; Rousey, SR | 1 |
| Azrak, RG; Foster, BA; Frank, CL; Li, F; Ling, X; Rustum, YM; Slocum, HK | 1 |
| Chung, JY; Kim, BG; Kim, JM; Kim, JY; Kim, YJ; Lee, SG; Park, JE; Park, YC; Yoo, KS; Yoo, YH | 1 |
| Browning, M; Fisher, W; Hahn, NM; Johnson, CS; Langdon, R; Li, L; Marsh, S; McLeod, HL; Scott-Horton, TJ; Sweeney, CJ; Zon, R | 1 |
| Baker, SD; Caravelli, J; Cutchall, K; D'Andrea, G; Fleming, MT; Gomez, J; Hudis, C; Hurria, A; Kelly, WK; Kris, MG; Miller, VA; Norton, L; Panageas, K; Scher, HI; Yeung, H | 1 |
| Coleman, I; Haugk, K; Ludwig, DL; Montgomery, RB; Nelson, P; Plymate, SR; Vessella, R; Woodke, L; Wu, JD | 1 |
| Mancuso, A; Oudard, S; Sternberg, CN | 1 |
| Fosså, SD; Hernes, E; Lilleby, W; Raabe, N; Waehre, H | 1 |
| Sweeney, CJ | 1 |
| Bubley, GJ; Ernstoff, MS; Morganstern, DE; Regan, MM; Taplin, ME; Walsh, W; Xie, W | 1 |
| Fukushima, M; Hattori, Y; Maitani, Y; Yoshizawa, T | 1 |
| Birtle, A; Collins, R; Fenwick, E; Light, K; Norman, G; Palmer, S; Perard, R; Riemsma, R; Trowman, R | 1 |
| Azzouzi, AR; Capron, F; Charlotte, F; Chartier-Kastler, E; Compérat, E; Ménégaux, F; Richard, F | 1 |
| Arichi, N; Hiraoka, T; Hyuga, T; Igawa, M; Kikuno, N; Kishi, H; Nakamura, S; Shigeno, K; Shiina, H; Sumura, M; Urakami, S; Wake, K; Yoneda, T | 1 |
| Boyé, K; de Cremoux, P; de Pinieux, G; Dutrillaux, B; Guyader, C; Judde, JG; Legrier, ME; Oudard, S; Poupon, MF | 1 |
| Tombal, B | 1 |
| Asmar, L; Berry, W; Boehm, KA; Chittoor, S; Fleagle, J; Loesch, D; Logie, K; Mull, S; Zhan, F | 1 |
| Genin, O; Iluz, M; Kawada, N; Leon, O; Mor, Y; Nagler, A; Pines, M; Pinthus, JH; Sheffer, Y; Yoshizato, K | 1 |
| Francini, E; Francini, G; Manganelli, A; Paolelli, L; Petrioli, R; Salvestrini, F | 1 |
| Dahl, AA; Fosså, SD; Ginman, C; Iversen, JR; Jacobsen, AB; Jacobsen, IN; Overn, S; Sandstad, B; Urnes, T; Veenstra, M | 1 |
| Bracarda, S | 2 |
| Ahmann, FR; Arroyo, A; Beer, TM; Carducci, MA; Chatta, GS; Chi, KN; Clow, FW; Dreicer, R; Fehrenbacher, L; Henner, WD; Higano, CS; Petrylak, DP; Redfern, CH; Ruether, JD; Ryan, CW; Saleh, MN; Venner, PM; Vicario, D; Waterhouse, DM | 1 |
| Agus, D; Dreicer, R; Petrylak, D; Roth, B; Webb, I | 1 |
| Arbiser, JL; Chung, LW; Fujisawa, M; Gotoh, A; Johnstone, PA; Shigemura, K; Sun, SY; Weksler, B; Zayzafoon, M; Zhau, HE | 1 |
| Autorino, R; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Forestieri, V; Giugliano, F; Imbimbo, C; Mirone, V; Prudente, A; Romano, C | 1 |
| Habuchi, T; Inoue, T; Kakinuma, H; Kanzaki, M; Kumazawa, T; Narita, S; Saito, M; Tsuchiya, N; Yuasa, T | 1 |
| Dorr, RT; Landowski, TH; Pourpak, A | 1 |
| Soga, N; Sugimura, Y | 1 |
| Betto, G; Cisternino, A; Gardiman, M; Pagano, F; Prayer-Galetti, T; Sacco, E; Sperandio, P | 1 |
| Altieri, V; Autorino, R; Cancello, G; D'Armiento, M; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Figg, WD; Imbimbo, C; Longo, N; Mirone, V; Perdonà, S; Tortora, G | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Vankatraman, G | 1 |
| Becker, RE; Dalrymple, SL; Isaacs, JT | 1 |
| Honda, J; Kai, N; Kikuchi, K; Kikukawa, H; Kuwahara, T; Matsumoto, K; Nakanishi, J; Takahashi, W; Ueda, S; Wada, Y | 1 |
| Salciccia, S; Sciarra, A | 1 |
| Gupta, S; Silliman, CG; Trump, DL | 1 |
| Autorino, R; Di Lorenzo, G | 1 |
| Ecstein-Fraïssé, E; Eymard, JC; Genet, D; Gomez, P; Hérait, P; Joly, F; Kerbrat, P; Lepillé, D; Paule, B; Priou, F; Ravaud, A; Zannetti, A | 1 |
| Arlen, P; Chen, C; Dahut, W; Fedenko, K; Figg, WD; Gulley, JL; Jones, E; Latham, L; Li, H; Parnes, H; Retter, A; Sissung, T; Steinberg, SM; Wright, JJ; Wu, S | 1 |
| Beer, TM; Benson, MC; Chatta, GS; Cookson, MS; DiPaola, RS; Dreicer, R; Eisenberger, MA; Garrett-Mayer, E; Jarrard, DF; Kattan, MW; Kibel, AS; Klein, EA; Nelson, JB; Partin, AW; Petrylak, DP; Picus, J; Rosenbaum, E; Roth, BJ; Ryan, CW; Wilding, G | 1 |
| Chenevert, TL; Lee, KC; Meyer, CR; Moffat, BA; Pienta, KJ; Rehemtulla, A; Ross, BD; Sud, S | 1 |
| Banerjee, S; Bonfil, D; Che, M; Cher, M; Hussain, M; Saliganan, A; Sarkar, FH; Wang, Z | 1 |
| Di Lorenzo, G | 2 |
| Alamanis, C; Alivizatos, G; Antoniou, N; Bamias, A; Bozas, G; Deliveliotis, H; Dimopoulos, MA; Katsifotis, H; Mitropoulos, D; Poulias, I; Skolarikos, A | 1 |
| Langner, C; Ott, A | 1 |
| Alexandre, I; Rixe, O | 1 |
| Beke, D; Kudlacek, S; Meran, JG | 1 |
| Albrecht, W; Eisenmenger, M; Elandt, K; Höltl, W; Horak, P; Krainer, M; Reibenwein, J; Schramek, P; Stackl, W; Tomek, S; Zielinski, C | 1 |
| Burnstein, K; de Las Pozas, A; Gomez, LA; Perez-Stable, C; Reiner, T | 1 |
| Calvo, A; de las Rivas, J; Gonzalez-Moreno, O; Nguewa, P; Segura, V; Serrano, D | 1 |
| Autorino, R; De Placido, S; Di Lorenzo, G; Figg, WD | 1 |
| Allona, A; Arias, F; Burgos, J; Fernández, E; González-Martín, A; Guillén, C; López García, M; Mayayo, T; Moyano, A; Rodríguez Patrón, R; Vaz, MA | 1 |
| Barbanti, G; De Rubertis, G; Francini, E; Francini, G; Manganelli, A; Marsili, S; Pascucci, A; Petrioli, R; Salvestrini, F; Sciandivasci, A | 1 |
| Barton, J; Gould, B; Greco, FA; Hainsworth, JD; Meluch, AA; Meng, C; Simons, L; Spigel, DR | 1 |
| Kovel, S; Sella, A; Skoneczna, I; Sternberg, C; Yarom, N | 1 |
| Bertelli, G; Jones, RM; Leonard, RC; Lewis, PD; Morgan, C; Thomas, GA | 1 |
| Engelmann, U; Heidenreich, A; Kohlmorgen, S; Ohlmann, CH; Sahi, D | 1 |
| Gross, M; Hussain, MH; Hutcheon, D; Kelly, WK; Michaelson, D; Rosenberg, JE; Small, EJ; Weinberg, VK; Wilding, G | 1 |
| Etienne-Grimaldi, MC; Ferrero, JM; Fischel, JL; Formento, P; Guérin, O; Hofman, P; Lo Nigro, C; Merlano, M; Milano, G | 1 |
| Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G | 1 |
| de Riese, W; Filleur, S; Klatte, T; Nelius, T | 1 |
| Beer, TM; Dreicer, R; Fehrenbacher, L; Hannah, AL; Higano, CS; Hudes, G; Picus, J; Rarick, M; Saleh, M | 1 |
| Engelmann, UH; Heidenreich, A; Ohlmann, CH; Ozgür, E; Pfister, D; Sahi, D; Thüer, D | 1 |
| Avancès, C; Culine, S; El Demery, M; Iborra, F; Lamy, PJ; Pinguet, F | 1 |
| Bubley, G; Derynck, MK; Lin, AM; Park, M; Rini, BI; Rosenberg, JE; Ryan, CJ; Small, EJ; Weinberg, V | 1 |
| Biroccio, A; D'Angelo, C; Leonetti, C; Scarsella, M; Semple, SC; Zupi, G | 1 |
| Dawson, NA | 1 |
| Agus, DB; Castellanos, O; Green, E; Gross, M; Higano, C; Nguyen, K; Pantuck, A | 1 |
| Akaza, H; Hinotsu, S; Joraku, A; Kawai, K; Kojima, T; Miyanaga, N; Oikawa, T; Sekido, N; Shimazui, T | 1 |
| Dreicer, R; Klein, EA; Magi-Galluzzi, C; Reuther, AM; Zhou, M | 1 |
| Hung, H | 1 |
| Bissery, A; Chapelon, JY; Chesnais, S; Curiel, L; Gelet, A; Paparel, P | 1 |
| Slovin, SF | 1 |
| Armstrong, AJ; Carducci, MA; de Wit, R; Eisenberger, M; Garrett-Mayer, E; Ou Yang, YC; Tannock, I | 1 |
| Albouy, B; Allain, P; Eschwege, P; Pfister, C; Rolland, F; Staerman, F; Tourani, JM | 1 |
| Becze, E | 1 |
| Fan, XR; Ji, ZG; Li, HZ; Shi, BB; Xia, M; Xiao, H; Yan, WG; Zhou, Y | 1 |
| Frenkel, E; Hsieh, JT; Kabbani, W; Stanfield, J; Zhang, Z | 1 |
| Bladou, F; Gravis, G; Salem, N; Viens, P | 1 |
| Banu, E; Beuzeboc, P; Guyader, C; Medioni, J; Oudard, S; Scotte, F | 1 |
| Chahine, GY; Farhat, FS; Ghosn, MG; Kattan, JG; Moukadem, WT; Nasr, FL; Yazbeck, NJ; Younes, FC | 1 |
| Arianayagam, M; Chang, J; Rashid, P | 1 |
| Tan, W | 1 |
| Daskivich, TJ; Oh, WK; Regan, MM | 1 |
| Bucana, CD; Cohen, L; Fidler, IJ; Johnson, MM; Jones, DM; Kim, SJ; Logothetis, CJ; Mathew, P; Meluch, AA; Morris, MJ; Oh, WK; Pagliaro, LC; Smith, L; Tannir, NM; Thall, PF; Troncoso, P; Tu, SM; Wen, S | 1 |
| Craig, M; Day, LL; Loberg, RD; Neeley, C; Pienta, KJ; Sargent, E; Snyder, LA; Wojno, K; Yan, L; Ying, C | 1 |
| Alfaro, J; Carles, J; Catalan, G; Domenech, M; Font, A; Gallardo, E; Gonzalez Del Alba, A; González-Larriba, JL; Lianes, P; Mellado, B; Nogué, M; Tello, JM | 1 |
| Beer, TM; Chatta, GS; Chi, KN; Henner, WD; Petrylak, DP; Ruether, JD; Ryan, CW; Venner, PM; Young, J | 1 |
| Börgermann, C; Jäger, T; Rübben, H | 1 |
| Armstrong, AJ; de Wit, R; Eisenberger, M; Garrett-Mayer, ES; Tannock, IF; Yang, YC | 1 |
| Alcaraz, A; Codony, J; Domingo-Domenech, J; Fernandez, E; Fernandez, PL; Filella, X; Gascon, P; Martinez-Fernandez, A; Mellado, B; Molina, R | 1 |
| Chung, LW; Fuji, K; Fujisawa, M; Gardner, TA; Gotoh, A; Hamada, K; Hara, I; Higashihara, E; Hinata, N; Kamidono, S; Kao, C; Matsuo, M; Okegawa, T; Shirakawa, T; Sugimura, K; Takenaka, A; Tanaka, K; Terao, S | 1 |
| Chen, X; Djeu, JY; Gilvary, DL; Sallman, DA; Wei, S; Zhong, B; Zhou, J | 1 |
| Dai, B; Shen, YJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhang, W; Zhu, Y | 1 |
| Aitini, E; Andreuccetti, M; Antonuzzo, A; Barbieri, R; Di Marsico, R; Falcone, A; Fontana, A; Fontana, E; Galli, C; Galli, L; Landi, L | 1 |
| Copeman, M; Gurney, H; Rosenthal, MA; Woo, H; Zingarelli, G | 1 |
| Burzykowski, T; Buyse, M; Collette, L | 1 |
| Bertolini, F; Figg, WD; Li, H; Price, DK; Raia, V | 1 |
| Beer, TM; Bubley, GJ; Huang, J; Jacobus, S; Oh, WK; Ross, RW; Ryan, CW; Taplin, ME | 1 |
| Fleshner, NE; Shahani, R; Zlotta, AR | 1 |
| Harzstark, AL; Ryan, CJ | 1 |
| McKeage, MJ | 1 |
| Banu, E; Beuzeboc, P; Dionysopoulos, D; Medioni, J; Oudard, S; Scotté, F | 1 |
| Miki, T; Okihara, K | 1 |
| Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Soban, F; Tannock, IF | 1 |
| Chiu, YT; Chua, CW; Howard, EW; Lee, DT; Wang, X; Wong, YC | 1 |
| Fujisawa, M; Kurahashi, T; Miyake, H; Soga, H; Takenaka, A; Yamada, Y | 1 |
| Jacobus, S; Kantoff, PW; McKearn, D; Nakabayashi, M; Oh, WK; Regan, MM; Ross, RW; Sartor, O; Taplin, ME | 1 |
| Cavalieri, E; Dahut, WL; Danesi, R; de Wit, R; Figg, WD; Gaikwad, N; Price, DK; Sackett, DL; Sissung, TM; Sparreboom, A; Steinberg, SM; Zahid, M | 1 |
| Bellezza, I; Bracarda, S; Conte, C; Culig, Z; Minelli, A; Tucci, A | 1 |
| Bradley, D; Dunn, RL; Friedman, J; Hussain, M; Montie, J; Sarkar, FH; Shah, RB; Vaishampayan, U; Wood, D; Wu, A | 1 |
| Sinibaldi, VJ | 1 |
| Andersen, RJ; Ettinger, S; Gleave, ME; Hadaschik, BA; Roberge, M; Sowery, RD; Zoubeidi, A | 1 |
| Chen, J; Fujiwara, T; Huang, P; Kaku, H; Kashiwakura, Y; Kumon, H; Nasu, Y; Saika, T; Urata, Y; Watanabe, M | 1 |
| Autorino, R; De Placido, S; Di Lorenzo, G; Figg, WD; Fossa, SD; Giordano, A; Giuliano, M; Imbimbo, C; Labianca, R; Longo, N; Mirone, V; Perdonà, S | 1 |
| Oudard, S | 1 |
| Hussain, M; Vaishampayan, U | 1 |
| Combs, GF; Hu, H; Li, GX; Lü, J; Wang, L; Watts, J | 1 |
| Fizazi, K | 1 |
| Chaladaj, A; Droz, JP | 1 |
| Kovel, S; Leibovici, D; Lindner, A; Sella, A; Yarom, N; Zisman, A | 1 |
| Dai, JL; Daignault, S; Day, ML; Dougall, W; Escara-Wilke, JF; Ignatoski, KM; Keller, ET; Lui, A; Sargent, EE; Yao, Z; Zhang, J | 1 |
| Fazli, L; Gleave, ME; Hadaschik, BA; Hurtado-Coll, A; So, AI; Sowery, RD; Zoubeidi, A | 1 |
| Chambers, C; Cusano, F; Howard, DN | 1 |
| Bossi, A; Chauchereau, A; de Crevoisier, R; Di Palma, M; Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Thuret, R | 1 |
| Corey, E; Gross, TS; Morgan, TM; Pitts, TE; Poliachik, SL; Vessella, RL | 1 |
| Ardine, M; Berruti, A; Dogliotti, L; Mosca, A; Poggio, M; Russo, L; Saini, A; Tucci, M; Vana, F | 1 |
| Bamias, A; Dimopoulos, MA; Gerassimos, A; Harilaos, K; Ioannis, V; Iraklis, M; Konstantinos, L; Lainakis, G; Michael, C; Nikos, A | 1 |
| Lee, YJ; Park, SS; Yoo, J | 1 |
| Basler, J; Brophy, M; Garzotto, M; Kelly, W; Lavori, P; Lee, K; Lin, DW; Montgomery, B; Ringer, R; Thaneemit-Chen, S; Whittemore, A; Yu, W | 1 |
| Ahuja, H; Alberti, D; Attia, S; Blank, J; Eastman, M; Eickhoff, J; Glode, M; Horvath, D; Jumonville, A; Liu, G; Marnocha, R; McNeel, D; Shevrin, D; Staab, MJ; Straus, J; Wilding, G | 1 |
| Akaza, H; Harabayashi, T; Hoshi, S; Koga, H; Naito, S; Sumiyoshi, Y; Tsukamoto, T | 1 |
| Bashkirova, S; Lilly, M; Sahakian, E; Zemskova, M | 1 |
| Beer, TM; Chi, KN; Curd, JG; Eilers, KM; Henner, WD; Lalani, AS; Lee, S; Mori, M; Ruether, JD; Ryan, CW; Venner, P | 1 |
| Armstrong, AJ; Eisenberger, M; Garrett-Mayer, EL | 1 |
| de Wit, R; Hamberg, P; Verhagen, PC | 1 |
| Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Roessner, M; Tannock, AI | 1 |
| Katz, JK; Sharma, R | 1 |
| Caffo, O; Cetto, G; Comploj, E; Fariello, A; Galligioni, E; Sacco, C; Sava, T; Segati, R; Valduga, F; Zustovich, F | 1 |
| Berthold, DR; de Wit, R; Eisenberger, M; Pond, GR; Tannock, IF | 1 |
| Li, TQ; Wang, JS | 1 |
| Fischel, JL; Formento, P; Lo Nigro, C; Maffi, M; Merlano, M; Milano, G | 1 |
| Basu, A; Croce, CM; Haldar, S | 1 |
| Orel, NF | 1 |
| Bagiella, E; Balog, J; Benson, M; Fine, R; Heitjan, D; Judge, T; Macarthur, RB; O'Connor, J; Olsson, CA; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Zuech, N | 1 |
| Barile, B; Budman, DR; Fetten, J; Gonzales, AL; Kreis, W; Vinciguerra, V | 1 |
| Stein, CA | 1 |
| Earhart, RH | 1 |
| Picus, J; Schultz, M | 1 |
| Cohen, J; Dimitt, B; Friedland, D; Gluckman, R; Keating, M; Lembersky, B; Miller, R; Reilly, N; Voloshin, M; Zidar, B | 1 |
| Bagiella, E; Benson, M; England-Owen, C; Hetjan, D; Judge, T; Macarthur, R; Newhouse, J; O'Connor, J; Olsson, C; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Weitzman, A; Zuech, N | 1 |
| Budman, D; Kreis, W | 1 |
| Halabi, S; Hars, V; Kreis, W; Savarese, D; Taplin, ME; Vogelzang, N | 1 |
| Carducci, M; Eisenberger, M; Laufer, M; Sinibaldi, VJ | 1 |
| Kantoff, PW; Oh, WK | 1 |
| Crawford, D; Fisher, E; Hussain, M; Petrylak, D; Tangen, C | 1 |
| Reese, DM; Small, EJ; Vogelzang, NJ | 1 |
| Hussain, M; Jasti, BR; Parchment, RE; Vaishampayan, U | 1 |
| Gleave, ME; Goldie, J; Miayake, H; Nelson, C; Tolcher, A | 1 |
| Bagiella, E; Benson, M; Judge, T; Katz, A; Newhouse, JH; Olsson, CA; Owen, CE; Petrylak, DP; Pfaff, C; Sawczuk, I; Shelton, G; Weitzman, AL; Zuech, N | 1 |
| Akaza, H; Hattori, K | 1 |
| Gagnon, GA; Sallah, S | 1 |
| Burris, HA | 1 |
| Alderson, PO; Cannon, P; Katz, J; Kline, RP; Petrylak, DP; Szabolcs, M; Weisfeldt, ML; Wu, EX | 1 |
| Budman, D; Kreis, W; Petrylak, D; Savarese, D | 1 |
| Kamradt, JM; Korenchuk, S; Muenchen, HJ; Pienta, KJ; Williams, JF | 1 |
| Ascherman, JA; Attkiss, K; Knowles, SL | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Muenchen, HJ; Pienta, KJ; Poncza, PJ | 1 |
| Culine, S; Droz, JP | 1 |
| Amin, P; Chen, Y; Dilley, J; Embry, M; Henderson, DR; Li, Y; Nguyen, N; Oh, J; Yu, DC; Zhang, H | 1 |
| Akerley, WL; Godley, PA; Halabi, S; Hars, V; Hussain, A; Savarese, DM; Small, EJ; Taplin, ME; Vogelzang, NJ | 1 |
| Small, EJ | 1 |
| Christen, RD; Gerhold, M; Lin, X; Nehmé, A; Niedner, H; Sellakumar, G; Varadarajan, P; Zhang, Q | 1 |
| Godley, PA; Herndon, JE; Kornblith, AB; Savarese, D; Vogelzang, NJ; Zuckerman, E | 1 |
| Hudes, GR; Obasaju, C | 1 |
| Haas, NB | 1 |
| Beer, TM; Bubalo, JS | 2 |
| Pienta, KJ | 1 |
| Asmar, L; Berry, W; Dakhil, S; Gregurich, MA | 1 |
| Bolton, M; Hake, L; Hauke, R; Ledakis, P; Lynch, J; Muhvic, J; Norvell, M; Sitka Copur, M; Tarantolo, S; Wendt, J | 1 |
| Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M | 1 |
| Bubley, GJ; Ko, YJ; Morganstern, DE; Rajeshkumar, B; Shuster, T; Taplin, ME | 1 |
| George, DJ; Kantoff, PW; Kaufman, DS; Moss, K; Oh, WK; Richie, JP; Smith, MR | 1 |
| Dreicer, R; Klein, EA | 1 |
| Beer, TM; Garzotto, M; Henner, WD; Hough, KM; Lowe, BA | 1 |
| Arlen, P; Dahut, WL; Fedenko, K; Fernandez, P; Figg, WD; Gulley, J; Hamilton, M; Kruger, EA; Noone, M; Parker, C; Pluda, J | 1 |
| Tolcher, AW | 1 |
| Senzer, NN | 1 |
| Bok, R; Frohlich, M; Reese, DM; Small, EJ; Sudilovsky, D | 1 |
| Beer, TM; Henner, WD; Lowe, BA; Pierce, WC | 1 |
| Frenkel, EP; Hsieh, JT; Li, Y; Lombardi, DP; Okegawa, T | 1 |
| DeNardo, GL; DeNardo, SJ; Kukis, DL; Lamborn, KR; Meyers, FJ; Miers, LA; O'Donnell, RT | 1 |
| Beer, TM; Hayes-Lattin, BM; Henner, WD; Kovach, PA | 1 |
| Heicappell, R | 1 |
| Mortimer, JE; Picus, J; Read, WL | 1 |
| Carducci, MA; Eisenberger, MA; Laufer, M; Moore-Cooper, S; Sinibaldi, VJ; Zahurak, M | 1 |
284 review(s) available for docetaxel anhydrous and Cancer of Prostate
| Article | Year |
|---|---|
FOXO3a and Its Regulators in Prostate Cancer.
Topics: Apoptosis; Cell Proliferation; Cisplatin; Docetaxel; Doxorubicin; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Male; Oxidative Stress; Paclitaxel; Prostatic Neoplasms | 2021 |
Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prospective Studies; Prostatic Neoplasms | 2022 |
Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Castration; Cost-Benefit Analysis; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms | 2022 |
Treatments for Metastatic Hormone-sensitive Prostate Cancer: Systematic Review, Network Meta-analysis, and Benefit-harm assessment.
Topics: Androgens; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms | 2022 |
Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review of Economic Evaluations.
Topics: Abiraterone Acetate; Cost-Benefit Analysis; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2022 |
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
Topics: Androgen Antagonists; Caregivers; Docetaxel; Hormones; Humans; Language; Male; Prostatic Neoplasms; Pyrazoles | 2022 |
Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms; Receptors, Androgen | 2022 |
Current status and future perspective on the management of metastatic castration-sensitive prostate cancer.
Topics: Androgen Antagonists; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2022 |
Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms | 2022 |
Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2022 |
Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Receptors, Androgen | 2022 |
Current status and future perspectives of the managements of metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Quality of Life | 2023 |
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms; Receptors, Androgen; Treatment Outcome | 2023 |
Addition of androgen receptor-targeted agents to androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Receptors, Androgen | 2022 |
The current role of local treatment in metastatic prostate cancer: systematic review and meta-analysis.
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Prostatectomy; Prostatic Neoplasms; Quality of Life | 2022 |
Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2023 |
Survival modelling and cost-effectiveness analysis of treatments for newly diagnosed metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Cost-Benefit Analysis; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2022 |
Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Castration; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms | 2023 |
What is the ideal combination therapy in de novo, oligometastatic, castration-sensitive prostate cancer?
Topics: Androgen Antagonists; Castration; Combined Modality Therapy; Docetaxel; Humans; Male; Prostatic Neoplasms | 2023 |
Combination treatment in metastatic prostate cancer: is the bar too high or have we fallen short?
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2023 |
Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change.
Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms | 2022 |
Addition of New Androgen Receptor Pathway Inhibitors to Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Metanalysis.
Topics: Androgen Receptor Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms | 2022 |
[Androgen deprivation therapy plus chemotherapy ± androgen receptor-targeting agents for metastatic hormone-sensitive prostate cancer].
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Receptors, Androgen | 2023 |
Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.
Topics: Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2023 |
[Androgen deprivation therapy ± new antihormonal therapy for the treatment of metastatic hormone-sensitive prostate cancer].
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2023 |
SYSTEMIC TRIPLE THERAPY IN METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC).
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2022 |
Treatments and challenges in advanced prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2023 |
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms | 2023 |
Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care.
Topics: Abiraterone Acetate; Androgen Antagonists; Docetaxel; Humans; Male; Prostatic Neoplasms; Standard of Care | 2023 |
Early Treatment Intensification in Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms | 2023 |
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Network Meta-Analysis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen | 2023 |
Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Progression-Free Survival; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2023 |
Cost-effectiveness analysis of 7 treatments in metastatic hormone-sensitive prostate cancer: a public-payer perspective.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Bayes Theorem; Cost-Effectiveness Analysis; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Novel Approaches in the Systemic Management of High-Risk Prostate Cancer.
Topics: Androgen Antagonists; Combined Modality Therapy; Docetaxel; Humans; Male; Prostatic Neoplasms | 2023 |
Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2023 |
Systemic therapies for high-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms; Treatment Outcome | 2023 |
Second-Line Systemic Therapy for Highly Aggressive Neuroendocrine Prostate Cancer.
Topics: Docetaxel; Humans; Male; Prospective Studies; Prostate; Prostatic Neoplasms; Retrospective Studies | 2023 |
Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis.
Topics: Docetaxel; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2023 |
Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Docetaxel; Humans; Male; Markov Chains; Network Meta-Analysis; Progression-Free Survival; Proportional Hazards Models; Prostatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Prostate radiotherapy in newly diagnosed metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients.
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Grading; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer.
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
Prostate Cancer: Biology, Incidence, Detection Methods, Treatment Methods, and Vaccines.
Topics: Age Factors; Antineoplastic Agents; Biomarkers, Tumor; Cancer Vaccines; Docetaxel; Drug Therapy, Combination; Estramustine; Humans; Incidence; Male; MicroRNAs; Mortality; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Treatment Outcome | 2020 |
Docetaxel Rechallenge in Patients with Metastatic Prostate Cancer: A Comprehensive Review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retreatment | 2020 |
Treatment in hormone-sensitive metastatic prostate cancer: factors to consider when personalizing therapy.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Precision Medicine; Prostatic Neoplasms; Survival Rate | 2020 |
Systemic treatment options for metastatic hormone-sensitive prostate cancer: making sense of the data.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Hormones; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2020 |
[mHSPC-Therapie mit Apalutamid/ADT].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Thiohydantoins | 2020 |
Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Treatment Outcome | 2020 |
Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?
Topics: Androgen Antagonists; Androgens; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Treatment Outcome | 2020 |
The evolving options in metastatic castration-sensitive prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2020 |
Management of Prostate Cancer with Systemic Therapy: A Prostate Cancer Unit Perspective.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Neoplasm Staging; Patient Care Management; Prostatic Neoplasms | 2021 |
Mechanisms of docetaxel resistance in prostate cancer: The key role played by miRNAs.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Prostatic Neoplasms; Taxoids | 2021 |
First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings.
Topics: Androgen Antagonists; Castration; Docetaxel; Humans; Male; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2021 |
Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions.
Topics: Androstenes; Animals; Benzamides; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, LHRH; Signal Transduction | 2020 |
Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design | 2021 |
Contemporary management of advanced prostate cancer: an evolving landscape.
Topics: Adenocarcinoma; Androstenes; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Disease Management; Docetaxel; Humans; Male; Multicenter Studies as Topic; Nitriles; Phenylthiohydantoin; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Radium; Taxoids; Therapies, Investigational | 2021 |
Recent trend of androgen deprivation therapy in newly diagnosed prostate cancer patients: Comparing between high- and middle-income Asian countries.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Asia; Docetaxel; Early Detection of Cancer; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2021 |
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
Topics: Androgen Antagonists; Docetaxel; Hormones; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms | 2022 |
Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Docetaxel; Hormones; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms | 2022 |
Use of docetaxel in low- and high-burden metastatic hormone-sensitive prostate cancer: A systematic review and assessment of subgroup analyses.
Topics: Androgen Antagonists; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2021 |
Targeting the mercapturic acid pathway and vicenin-2 for prevention of prostate cancer.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Apigenin; Docetaxel; Drug Resistance, Neoplasm; Glucosides; Humans; Male; Prostatic Neoplasms; Signal Transduction; Taxoids | 2017 |
The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report.
Topics: Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2017 |
[Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Early Medical Intervention; Evidence-Based Medicine; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2017 |
Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
Topics: Androgen Antagonists; Androstenes; Clinical Decision-Making; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Progression-Free Survival; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2018 |
Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Geriatric Assessment; Humans; Kaplan-Meier Estimate; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Physical Fitness; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2017 |
[Patients with metastatic prostate cancer : Recommendations for primary hormonal or chemohormonal therapy].
Topics: Androgen Antagonists; Combined Modality Therapy; Disease Progression; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2017 |
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Network Meta-Analysis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Survival Rate | 2018 |
The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
Topics: Abiraterone Acetate; Androgens; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Steroid Synthesis Inhibitors; Taxoids; Treatment Outcome | 2017 |
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2018 |
Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Tumor Burden | 2018 |
Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Network Meta-Analysis; Proportional Hazards Models; Prostatic Neoplasms; Quality of Life; Treatment Outcome | 2018 |
Recent advances in the management of metastatic prostate cancer: optimizing use of existing therapies, while searching for novel interventions.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
[The role of chemotherapy in the treatment of hormone sensitive metastatic prostate cancer.]
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Practice Guidelines as Topic; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2018 |
What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Network Meta-Analysis; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2018 |
Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Treatment Outcome | 2018 |
Treatment of hormone-naïve metastatic prostate cancer.
Topics: Androgen Antagonists; Androstenes; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy, Combination; Humans; Male; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2018 |
Management of patients with advanced prostate cancer in the Asia Pacific region: 'real-world' consideration of results from the Advanced Prostate Cancer Consensus Conference (APCCC) 2017.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Asia, Eastern; Asia, Southeastern; Combined Modality Therapy; Consensus; Developing Countries; Docetaxel; Humans; Lymph Node Excision; Male; Neoplasm Metastasis; Oceania; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Risk Factors | 2019 |
Contemporary Management of the Newly Diagnosed Prostate Cancer Patient with Metastatic Disease at Presentation.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2018 |
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis.
Topics: Abiraterone Acetate; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic | 2018 |
[DNA damage repair: An emerging strategy in metastatic prostate cancer].
Topics: Androstenes; Antineoplastic Agents; Benzamides; DNA Damage; DNA Repair; Docetaxel; Genomic Instability; Humans; Male; Nitriles; Phenylthiohydantoin; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
What Do the Guidelines Say for Metastatic Prostate Cancer Starting Androgen Deprivation Therapy? National Comprehensive Cancer Network, European Society for Medical Oncology, and European Association of Urology recommendations.
Topics: Abiraterone Acetate; Androgen Antagonists; Clinical Trials as Topic; Docetaxel; Humans; Infusions, Intravenous; Male; Medical Oncology; Neoplasm Metastasis; Practice Guidelines as Topic; Prostatic Neoplasms; Steroid Synthesis Inhibitors; Tubulin Modulators; Urology | 2019 |
Evidence Synthesis to Accelerate and Improve the Evaluation of Therapies for Metastatic Hormone-sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic | 2019 |
Zoledronic acid for the treatment of prostate cancer.
Topics: Androgen Antagonists; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2019 |
The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radiopharmaceuticals; Radium; Retrospective Studies; Taxoids; Thiohydantoins; Tissue Extracts | 2019 |
Estimating utilities/disutilities for high-risk metastatic hormone-sensitive prostate cancer (mHSPC) and treatment-related adverse events.
Topics: Adolescent; Adult; Aged; Androgen Antagonists; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Quality of Life; Young Adult | 2019 |
[New therapeutic options for hormone sensitive prostate cancers].
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Male; Prospective Studies; Prostatic Neoplasms; Survival Rate | 2019 |
Optimization of therapies for men with advanced prostate cancer: a review of recent developments with a look toward the future.
Topics: Androstenes; Docetaxel; Humans; Male; Medical Oncology; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic | 2019 |
Novel Insights into the Management of Oligometastatic Prostate Cancer: A Comprehensive Review.
Topics: Androgen Antagonists; Androstenes; Combined Modality Therapy; Docetaxel; Humans; Lymph Node Excision; Male; Metastasectomy; Neoplasm Metastasis; Prostatic Neoplasms; Standard of Care | 2019 |
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Treatment Outcome | 2019 |
Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
Topics: Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2019 |
[Metastatic prostate cancer: new insights and developments].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Denosumab; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Taxoids | 2013 |
Expert opinion on chemotherapy use in castration-resistant prostate cancer progressing after docetaxel.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Expert Testimony; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Taxoids | 2013 |
Are post-docetaxel treatments effective in patients with castration-resistant prostate cancer and performance of 2? A meta-analysis of published trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Orchiectomy; Proportional Hazards Models; Prostatic Neoplasms; Publication Bias; Taxoids; Treatment Outcome | 2013 |
[Integration of drug treatment in the management concept of prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids; Treatment Outcome | 2013 |
[Biomarker docetaxel-based chemotherapy].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Evidence-Based Medicine; Humans; Male; Neoplasm Proteins; Prevalence; Prognosis; Prostatic Neoplasms; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Taxoids | 2013 |
[The non-hormonal treatment of metastatic prostate cancer].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Cisplatin; Denosumab; Docetaxel; Etoposide; Humans; Male; Mitoxantrone; Organometallic Compounds; Organophosphorus Compounds; Osteoporosis; Prostatic Neoplasms; Radiation Protection; Radioisotopes; Radium; RANK Ligand; Strontium; Strontium Radioisotopes; Taxoids | 2013 |
The Utility of Chemotherapy in the Treatment of Metastatic Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate; Prostatic Neoplasms; Taxoids | 2016 |
Challenges in treating advanced disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Invasiveness; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2013 |
Chemotherapy plus estramustine for management of castration-resistant prostate cancer: meta-analysis of randomized controlled trials.
Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cardiovascular Diseases; Combined Modality Therapy; Docetaxel; Epirubicin; Epothilones; Estramustine; Fatigue; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Orchiectomy; Paclitaxel; Peripheral Nervous System Diseases; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine | 2014 |
Reconsideration of progression to CRPC during androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Dehydroepiandrosterone; Disease Progression; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Signal Transduction; Steroids; Taxoids | 2015 |
The efficacy and safety of docetaxel plus thalidomide vs. docetaxel alone in patients with androgen-independent prostate cancer: a systematic review.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2014 |
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Topics: Abiraterone Acetate; Androstadienes; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplastic Cells, Circulating; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids | 2014 |
Nanoways to overcome docetaxel resistance in prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Docetaxel; Drug Carriers; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Molecular Targeted Therapy; Nanoparticles; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2014 |
Prostate cancer in 2014: The year chemotherapy finally gets some respect!
Topics: Androstenes; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
[Metastatic hormone-sensitive prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Combined Modality Therapy; Docetaxel; Humans; Male; Orchiectomy; Prognosis; Prostatic Neoplasms; Taxoids | 2015 |
Managing advanced prostate cancer: the rapidly changing treatment landscape.
Topics: Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Cancer Vaccines; Diagnostic Imaging; Docetaxel; Humans; Male; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2014 |
[Posterior reversible encephalopathy syndrome after neurosurgery: A literature review].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Blindness, Cortical; Brain Neoplasms; Craniotomy; Docetaxel; Epilepsy, Tonic-Clonic; Frontal Lobe; Humans; Hypertension; Male; Middle Aged; Paresis; Posterior Leukoencephalopathy Syndrome; Postoperative Complications; Prednisone; Prostatic Neoplasms; Taxoids | 2015 |
Immunotherapy in prostate cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Humans; Immunotherapy; Ipilimumab; Male; Prostatic Neoplasms; Taxoids | 2015 |
Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Proportional Hazards Models; Prostatic Neoplasms; Standard of Care; Taxoids | 2015 |
Role of chemotherapy in combination with hormonal therapy in first-line treatment of metastatic hormone-sensitive prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Hormones; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2015 |
Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Odds Ratio; Prostatic Neoplasms; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Tumor Burden | 2016 |
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Survival Rate; Taxoids; Zoledronic Acid | 2016 |
Chemotherapy for metastatic castrate-sensitive prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2016 |
A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Efficacy and Safety of Combined Androgen Deprivation Therapy (ADT) and Docetaxel Compared with ADT Alone for Metastatic Hormone-Naive Prostate Cancer: A Systematic Review and Meta-Analysis.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Patient Safety; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; Tubulin Modulators | 2016 |
Early Docetaxel and Androgen Deprivation in the Treatment of Metastatic, Hormone-sensitive Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.
Topics: Age Factors; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Evidence-Based Medicine; Health Status; Humans; Male; Neoplasm Grading; Neoplasm Metastasis; Patient Selection; Population Surveillance; Prednisone; Prostatic Neoplasms; Taxoids; Tumor Burden; Uncertainty | 2017 |
Understanding the role of new systemic agents in the treatment of prostate cancer.
Topics: Abiraterone Acetate; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Precision Medicine; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radium; Randomized Controlled Trials as Topic; Taxoids; Tissue Extracts | 2016 |
Systemic nonhormonal management of advanced prostate cancer and its likely impact on patients' survival and quality of life.
Topics: Atrasentan; Cisplatin; Diphosphonates; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Pyrrolidines; Quality of Life; Receptors, Calcitriol; Taxoids | 2008 |
Docetaxel in the management of prostate cancer: current standard of care and future directions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Controlled Clinical Trials as Topic; Docetaxel; Drug Delivery Systems; Humans; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Prostatic Neoplasms; Survival Rate; Taxoids | 2008 |
Systemic therapy after first-line docetaxel in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Epothilones; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Organoplatinum Compounds; Prostatic Neoplasms; Receptors, Vascular Endothelial Growth Factor; Taxoids; Testosterone; Thionucleotides | 2008 |
Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer.
Topics: Androgen Antagonists; Animals; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2009 |
[Therapy related leukemia with 11q23 abnormality induced by chemotherapy consisted of docetaxel for advanced prostatic carcinoma: case report].
Topics: Aged; Antineoplastic Agents; Carcinoma; Chromosomes, Human, Pair 11; Combined Modality Therapy; Docetaxel; Humans; Leukemia, Myelomonocytic, Acute; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Prostatectomy; Prostatic Neoplasms; Taxoids; Translocation, Genetic | 2009 |
PSA surge/flare-up in patients with castration-refractory prostate cancer during the initial phase of chemotherapy.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Taxoids | 2009 |
Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Genetic Therapy; Humans; Male; Mitoxantrone; Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids; Virus Replication | 2009 |
[Palliative systemic therapy of castration-resistant prostate cancer: current developments].
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Epothilones; Evidence-Based Medicine; Humans; Immunotherapy; Male; Neoplasm Staging; Orchiectomy; Palliative Care; Practice Guidelines as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Tubulin Modulators | 2009 |
[What comes after docetaxel?].
Topics: Castration; Docetaxel; Drug Therapy; Forecasting; Humans; Male; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Substance Withdrawal Syndrome; Taxoids; Treatment Outcome | 2010 |
Angiogenesis inhibitors in the treatment of prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Genetic Therapy; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prednisone; Prostatic Neoplasms; Protein Kinase Inhibitors; Signal Transduction; Taxoids; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2010 |
The role of docetaxel based therapy for prostate cancer in the era of targeted medicine.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Precision Medicine; Prostatic Neoplasms; Taxoids | 2010 |
Molecular and traditional chemotherapy: a united front against prostate cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Genetic Therapy; Humans; Male; Prostatic Neoplasms; Taxoids | 2010 |
Neoadjuvant therapy preceding prostatectomy for prostate cancer: rationale and current trials.
Topics: Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Humans; Male; Neoadjuvant Therapy; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2010 |
Docetaxel-based combination therapy for castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids | 2010 |
[Scleroderma-like skin sclerosis induced by docetaxel chemotherapy for hormone refractory prostate cancer: a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prednisolone; Prostatic Neoplasms; Scleroderma, Diffuse; Taxoids | 2010 |
Critical appraisal of cabazitaxel in the management of advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Neutropenia; Prednisone; Prostatic Neoplasms; Rats; Taxoids | 2010 |
Improving outcomes with recent advances in chemotherapy for castrate-resistant prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Second-line chemotherapy in metastatic docetaxel-resistant prostate cancer: a review.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Salvage Therapy; Taxoids | 2012 |
New options for the management of castration-resistant prostate cancer: a case perspective.
Topics: Aged; Androgen Antagonists; Androgens; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Immunotherapy; Male; Prostatectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
Role of second-line systemic treatment post-docetaxel in metastatic castrate resistant prostate cancer- current strategies and future directions.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Forecasting; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2011 |
[Castration resistant prostate cancer 2011].
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Tissue Extracts | 2011 |
Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Treatment Outcome | 2011 |
Current clinical trials in castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Neovascularization, Pathologic; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Tissue Extracts; Treatment Outcome | 2011 |
New strategies for medical management of castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids | 2011 |
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Standard of Care; Taxoids; Treatment Failure; Tumor Microenvironment | 2011 |
Management of metastatic castration-resistant prostate cancer after first-line docetaxel.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Docetaxel; Hormones; Humans; Immunotherapy; Male; Neoplasm Metastasis; Neovascularization, Pathologic; Orchiectomy; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids | 2011 |
Translating scientific advancement into clinical benefit for castration-resistant prostate cancer patients.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Taxoids; Translational Research, Biomedical | 2011 |
The use of estramustine phosphate in the modern management of advanced prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Nausea; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids; Thromboembolism; Treatment Outcome; Vomiting | 2011 |
Chemotherapy-based treatment for castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2011 |
New treatment options for castrate-resistant prostate cancer: a urology perspective.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
Ten years of docetaxel-based therapies in prostate adenocarcinoma: a systematic review and meta-analysis of 2244 patients in 12 randomized clinical trials.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2011 |
Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2011 |
Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Immunotherapy; Male; Mitoxantrone; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2012 |
Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Radioisotopes; Taxoids; Tissue Extracts | 2011 |
[Second line therapy for castration-resistant prostate cancer (CRPC)].
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Survival Rate; Taxoids; Tissue Extracts | 2012 |
Abiraterone acetate in castration-resistant prostate cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Clinical Trials as Topic; Docetaxel; Humans; Male; Orchiectomy; Prednisolone; Prostatic Neoplasms; Taxoids | 2012 |
[Antisense oligonucleotide therapy for patients with castration-resistant prostate cancer].
Topics: Castration; Docetaxel; Humans; Male; Oligonucleotides, Antisense; Prednisolone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2011 |
Quality of life associated with treatment of castration-resistant prostate cancer: a review of the literature.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Survival; Taxoids | 2012 |
[Management of metastatic castration-resistant prostate cancer following docetaxel].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prognosis; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Treatment Failure | 2012 |
[Strategy in advanced castration-resistant prostate cancer].
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cancer Vaccines; Denosumab; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
Castration-resistant prostate cancer: systemic therapy in 2012.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
Androgen receptor directed therapies in castration-resistant metastatic prostate cancer.
Topics: Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Thiohydantoins | 2012 |
Metastatic castrate-resistant prostate cancer: dawn of a new age of management.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Taxoids | 2012 |
Metastatic hormone refractory prostate cancer: recent advances in standard treatment paradigm, and future directions.
Topics: Androgen Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; Cathepsin K; Dendritic Cells; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Radiopharmaceuticals; RANK Ligand; Receptors, Endothelin; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; src-Family Kinases; Taxoids; Tissue Extracts | 2014 |
Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Male; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2012 |
Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Male; Orchiectomy; Prostatic Neoplasms; Taxoids | 2012 |
The evolving role of immunotherapy in prostate cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Cell Line, Tumor; CTLA-4 Antigen; Docetaxel; Humans; Immunotherapy; Intercellular Adhesion Molecule-1; Ipilimumab; Male; Prostatic Neoplasms; Survival Rate; Taxoids; Tissue Extracts; Treatment Outcome | 2012 |
[New drug treatment possibilities in castration resistant prostate carcinoma].
Topics: Aged; Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunotherapy; Lung Neoplasms; Male; Orchiectomy; Palliative Care; Prognosis; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids | 2012 |
Cabazitaxel: a novel drug for hormone-refractory prostate cancer.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Approval; Drug Resistance, Neoplasm; Humans; Male; Prostate; Prostatic Neoplasms; Taxoids; Tubulin Modulators | 2013 |
Management of advanced prostate cancer in senior adults: the new landscape.
Topics: Aged; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Castration; Clinical Trials as Topic; Disease Management; Docetaxel; Drug Resistance, Neoplasm; Humans; Life Expectancy; Male; Prostate; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Design; Endothelin Receptor Antagonists; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Research; Taxoids; Treatment Outcome | 2012 |
Quality of life with advanced metastatic prostate cancer.
Topics: Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Neoplasms; Denosumab; Diphosphonates; Disease Progression; Docetaxel; Health Status Indicators; Humans; Imidazoles; Male; Mitoxantrone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome; Zoledronic Acid | 2012 |
Advanced clinical states in prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Cancer Vaccines; Disease Progression; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
Management of docetaxel failures in metastatic castrate-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Radium; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Failure | 2012 |
Nanoformulation of natural products for prevention and therapy of prostate cancer.
Topics: Animals; Anticarcinogenic Agents; Antigens, Surface; Antineoplastic Agents; Biological Products; Docetaxel; Glutamate Carboxypeptidase II; Humans; Male; Molecular Targeted Therapy; Nanoparticles; Nanotechnology; Prostatic Neoplasms; Taxoids | 2013 |
Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2012 |
[The treatment of castration-resistant prostate cancer].
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androstenes; Androstenols; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cancer Vaccines; Docetaxel; Humans; Immunotherapy; Male; Molecular Targeted Therapy; Oligonucleotides, Antisense; Orchiectomy; Prostatic Neoplasms; Protein-Tyrosine Kinases; RANK Ligand; Receptors, Vascular Endothelial Growth Factor; Taxoids; Tissue Extracts; Treatment Failure | 2012 |
Maximizing survival in metastatic castrate-resistant prostate cancer: a clinical viewpoint.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
Prostate cancer: The androgen receptor remains front and centre.
Topics: Abiraterone Acetate; Adenocarcinoma; Androgen Antagonists; Androgens; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Enzyme Inhibitors; Humans; Male; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Survival Rate; Taxoids | 2013 |
Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Forecasting; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Prostatic Neoplasms; Recurrence; Taxoids | 2002 |
The role of chemotherapy in advanced prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2002 |
Chemotherapy for androgen-independent prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Palliative Care; Prostatic Neoplasms; Taxoids | 2002 |
Docetaxel-induced nail dystrophy.
Topics: Acute Disease; Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Nail Diseases; Paclitaxel; Prostatic Neoplasms; Taxoids | 2002 |
Fatal respiratory failure associated with treatment of prostate cancer using docetaxel and estramustine.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Fatal Outcome; Humans; Male; Paclitaxel; Prostatic Neoplasms; Radiography; Respiratory Insufficiency; Taxoids | 2002 |
[Chemotherapy for prostate cancers].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Etoposide; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
[Therapy for hormone-refractory prostate cancer].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Clodronic Acid; Cyclophosphamide; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids; Tegafur; Treatment Outcome | 2002 |
[A new model of human prostate cancer, the PAC120 xenograft].
Topics: Adenocarcinoma; Animals; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous | 2003 |
Docetaxel (taxotere) in the treatment of prostate cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
New principles in the treatment of prostate cancer--the oncologist's view.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Radiotherapy, High-Energy; Taxoids | 2003 |
The evolving role of docetaxel in the management of androgen independent prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Palliative Care; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2003 |
What next after hormonotherapy in cancer prostate?
Topics: Antineoplastic Agents, Hormonal; Docetaxel; Estramustine; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2003 |
The evolving role of chemotherapy and other systemic therapies for managing localized prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Estramustine; Humans; Male; Neoadjuvant Therapy; Prostatic Neoplasms; Taxoids | 2003 |
[Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2003 |
Novel approaches to treating the asymptomatic hormone-refractory prostate cancer patient.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Estramustine; Forecasting; Genetic Therapy; Humans; Immunotherapy, Active; Male; Oligonucleotides, Antisense; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2003 |
[Taxanes in the chemotherapy of hormone-refractory prostate carcinoma].
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Pain; Palliative Care; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2004 |
Current studies with docetaxel in hormone-refractory prostate cancer: selected presentations from the 27th European Society for Medical Oncology Congress, 2002.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2003 |
[Docetaxel and prostate cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomedical Research; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Prostatic Neoplasms; Taxoids | 2004 |
Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Delivery Systems; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids | 2004 |
[Chemotherapy of the hormone-refractory prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Neoplasm Staging; Palliative Care; Prednisone; Prostatic Neoplasms; Taxoids | 2004 |
Second-line chemotherapy for hormone-refractory prostate cancer: has the time come?
Topics: Aged; Androgen Antagonists; Clinical Trials, Phase III as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
[Chemotherapy for prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Bridged-Ring Compounds; Docetaxel; Drug Resistance; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2005 |
[Treatment of androgen-independent hormone refractory prostate cancer using docetaxel].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Dexamethasone; Docetaxel; Estramustine; Gene Silencing; Genes, bcl-2; Humans; Male; Microtubules; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Shifting paradigms in prostate cancer; docetaxel plus low-dose prednisone - finally an effective chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2005 |
Recent docetaxel studies establish a new standard of care in hormone refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
[The action and toxicity of taxanes].
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Taxoids | 2005 |
Clinical trials in metastatic prostate cancer--has there been real progress in the past decade?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Male; Prostatic Neoplasms; Suramin; Taxoids; Treatment Outcome | 2005 |
Docetaxel for treatment of solid tumours: a systematic review of clinical data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2005 |
Update in the management of patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agonists; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Epothilones; Estramustine; Humans; Male; Mitoxantrone; Multicenter Studies as Topic; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Progress in detection and treatment of prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Medical Oncology; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Taxoids | 2005 |
The current role of chemotherapy in metastatic hormone-refractory prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Taxoids | 2005 |
Docetaxel administration schedule: from fever to tears? A review of randomised studies.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
[Hormonoresistant metastatic prostate cancer: analysis of two phase III clinical studies].
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Which drug combination for hormone-refractory prostate cancer?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids | 2005 |
The evolving role of chemotherapy in androgen-independent (hormone-refractory) prostate cancer.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
An interdisciplinary approach to treating prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Nitriles; Prednisone; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tosyl Compounds | 2005 |
Future directions in the treatment of androgen-independent prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Estramustine; Forecasting; Humans; Male; Mitoxantrone; Organoplatinum Compounds; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2005 |
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Taxoids | 2005 |
Current status of treatment for patients with metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Creatinine; Diphosphonates; Docetaxel; Drug Monitoring; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2005 |
[Therapy of hormone refractory prostate cancer: new standards, new trends].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Humans; Male; Meta-Analysis as Topic; Mitoxantrone; Mutation; Oligonucleotides, Antisense; Patient Selection; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Randomized Controlled Trials as Topic; Receptors, Androgen; Taxoids; Time Factors; Trastuzumab | 2005 |
Novel therapeutic approaches to advanced prostate cancer.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cancer Vaccines; Cell Differentiation; Cell Division; Child, Preschool; Clinical Trials as Topic; Disease Management; Docetaxel; Drug Delivery Systems; Enzyme Inhibitors; Humans; Immunotherapy; Male; Neoplasm Proteins; Neovascularization, Pathologic; Prostatic Neoplasms; Signal Transduction; Taxoids | 2005 |
Docetaxel in hormone-refractory metastatic prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids | 2005 |
[Prostate cancer: update].
Topics: Androgen Antagonists; Antineoplastic Agents; Cancer Vaccines; Clinical Trials, Phase III as Topic; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Humans; Male; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Radiotherapy; Receptor, ErbB-2; Taxoids | 2005 |
Present status and perspectives in the treatment of hormone-refractory prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Diphosphonates; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
[Therapy of hormone-refractory prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Diphosphonates; Docetaxel; Germany; Humans; Male; Mitoxantrone; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
Therapeutic options in androgen-independent prostate cancer: building on docetaxel.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids | 2005 |
Hormone refractory prostate cancer: Management and advances.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cancer Vaccines; Docetaxel; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Male; Oligonucleotides, Antisense; Prognosis; Prostatic Neoplasms; Survival Analysis; Taxoids | 2006 |
Drug insight: Use of docetaxel in prostate and urothelial cancers.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Transitional Cell; Clinical Trials as Topic; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; Urologic Neoplasms | 2005 |
Chemotherapy for high-risk localized prostate cancer.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Mitoxantrone; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2006 |
Docetaxel for the treatment of prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2005 |
New approaches in hormone refractory prostate cancer.
Topics: Androgen Antagonists; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Cancer Vaccines; Docetaxel; Drug Resistance, Neoplasm; Enzyme Inhibitors; Growth Inhibitors; Humans; Male; Oligonucleotides, Antisense; Prostatic Neoplasms; Proteasome Inhibitors; Taxoids | 2006 |
Changing perspectives of the role of chemotherapy in advanced prostate cancer.
Topics: Androgens; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Taxoids | 2006 |
Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Metastasis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators | 2006 |
Hormone-refractory prostate cancer: a shifting paradigm in treatment.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drugs, Investigational; Humans; Male; Patient Education as Topic; Prognosis; Prostatic Neoplasms; Risk Factors; Taxoids | 2006 |
[Therapeutic options for hormone-refractory prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Practice Patterns, Physicians'; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
Current chemotherapeutic approaches for androgen-independent prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bevacizumab; Cancer Vaccines; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Endothelin-1; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Taxoids; Tubulin Modulators; Vascular Endothelial Growth Factor A | 2006 |
The changing pattern of management for hormone-refractory, metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Palliative Care; Prednisolone; Prostatic Neoplasms; Spinal Cord Compression; Taxoids; Urologic Diseases | 2006 |
A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Cytotoxic chemotherapy for prostate cancer: Who and when?
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Survival Rate; Taxoids | 2006 |
The medical management of prostate cancer: a multidisciplinary team approach.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Patient Care Team; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2007 |
Current indications for chemotherapy in prostate cancer patients.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2007 |
Effective chemotherapy for hormone-refractory prostate cancer (HRPC): present status and perspectives with taxane-based treatments.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Epothilones; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 2007 |
[Treatment of hormone-resistant prostate cancer].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Decompression, Surgical; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
A systematic review and economic model of the clinical effectiveness and cost-effectiveness of docetaxel in combination with prednisone or prednisolone for the treatment of hormone-refractory metastatic prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Male; Models, Economic; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Treatment Outcome; United Kingdom | 2007 |
[Optimal treatment for elderly high-risk prostate cancer patients].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Dexamethasone; Diphosphonates; Docetaxel; Drug Administration Schedule; Estramustine; Gonadotropin-Releasing Hormone; Humans; Male; Orchiectomy; Prostatic Neoplasms; Quality of Life; Risk; Taxoids | 2007 |
[Hormone-refractory prostate cancer].
Topics: Adult; Aged; Androgen Antagonists; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Calcitriol; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Diphosphonates; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Taxoids; Time Factors; Vitamins | 2007 |
[The hormone refractory prostate cancer - a challenge for the internal specialist].
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Internal Medicine; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2007 |
Hormone-refractory prostate cancer: where are we going?
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Docetaxel; Drug Resistance; Humans; Immunotherapy; Male; Prostatic Neoplasms; Taxoids | 2007 |
Epothilones in prostate cancer: review of clinical experience.
Topics: Animals; Antineoplastic Agents; Docetaxel; Epothilones; Humans; In Vitro Techniques; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tubulin Modulators | 2007 |
[Prostate cancer and chemotherapy].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2007 |
[New targeted therapies in hormone-refractory prostate cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Boronic Acids; Bortezomib; Calcitriol; Cancer Vaccines; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Endothelin-1; Epothilones; Humans; Male; Oligonucleotides, Antisense; Organoplatinum Compounds; Prostatic Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Taxoids | 2007 |
Chemotherapy in the treatment of prostate cancer--is there a role?
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Family Practice; Humans; Male; Neoadjuvant Therapy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2007 |
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides | 2007 |
[Differential therapy of prostate cancer].
Topics: Aged; Androgen Antagonists; Biomarkers, Tumor; Biopsy; Combined Modality Therapy; Docetaxel; Early Diagnosis; Endosonography; Humans; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Palliative Care; Prognosis; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids | 2007 |
Novel therapeutic strategies in development for prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Drug Design; Humans; Male; Neoadjuvant Therapy; Organoplatinum Compounds; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2008 |
The potential of DMXAA (ASA404) in combination with docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Invasiveness; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Xanthones | 2008 |
[Chemotherapy for prostate cancer].
Topics: Antineoplastic Agents; Calcitriol; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Neoadjuvant Therapy; Prostatic Neoplasms; Taxoids; Vitamins | 2008 |
[Therapeutic guidelines in prostate cancer and role for bisphosphonates in bone metastasis].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Osteoporosis; Practice Guidelines as Topic; Prognosis; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Salvage Therapy; Taxoids; Zoledronic Acid | 2007 |
Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; United States | 2007 |
Update in systemic therapy of prostate cancer: improvement in quality and duration of life.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Immunotherapy; Infusions, Intravenous; Male; Neoplasm Invasiveness; Neoplasm Staging; Palliative Care; Prednisone; Prognosis; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Time Factors | 2008 |
[Prostate cancer: future strategies for chemotherapy management].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Prostatic Neoplasms; Taxoids | 2007 |
Chemotherapy in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Humans; Male; Multivariate Analysis; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nomograms; Predictive Value of Tests; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids | 2008 |
Management of metastatic prostate cancer: the crucial role of geriatric assessment.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Geriatric Assessment; Humans; Lymphatic Metastasis; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Palliative Care; Prednisone; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2008 |
Veterans Affairs Cooperative Studies Program study 553: Chemotherapy after prostatectomy, a phase III randomized study of prostatectomy versus prostatectomy with adjuvant docetaxel for patients with high-risk, localized prostate cancer.
Topics: Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Hospitals, Veterans; Humans; Male; Prostatectomy; Prostatic Neoplasms; Radiography; Radiotherapy; Randomized Controlled Trials as Topic; Recurrence; Risk; Taxoids; Treatment Outcome | 2008 |
When to start cytotoxic therapy in asymptomatic patients with hormone refractory prostate cancer?
Topics: Antineoplastic Agents, Hormonal; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Nomograms; Prostatic Neoplasms; Taxoids | 2008 |
[Update of combined therapies with docetaxel for hormone-independent prostate cancer].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biological Products; Combined Modality Therapy; Docetaxel; Drug Therapy, Combination; Humans; Male; Prostatic Neoplasms; Taxoids; Vaccines | 2008 |
[Taxotere in various solid tumors].
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Melanoma; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Prostatic Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Taxoids; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms | 1998 |
Mechanisms of action of taxanes in prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Microtubules; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Suppressor Protein p53 | 1999 |
Docetaxel (Taxotere): preclinical and general clinical information.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Evaluation, Preclinical; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Daily oral estramustine and intermittent intravenous docetaxel (Taxotere) as chemotherapeutic treatment for metastatic, hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Hormone-refractory prostate cancer: an evolving standard of care.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Taxanes: an overview of the pharmacokinetics and pharmacodynamics.
Topics: Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Docetaxel; Drug Interactions; Humans; Male; Mitosis; Molecular Structure; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
[New combination chemotherapy in urological cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Humans; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Methotrexate; Paclitaxel; Prostatic Neoplasms; Taxoids; Testicular Neoplasms; Urinary Bladder Neoplasms; Vinblastine | 2000 |
Docetaxel (Taxotere) in the treatment of cancer.
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Humans; Lung Neoplasms; Male; Paclitaxel; Prognosis; Prostatic Neoplasms; Taxoids | 2000 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2000 |
Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: a decade of progress?
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Paclitaxel; Palliative Care; Prednisolone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids | 2000 |
Docetaxel in prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Paclitaxel and docetaxel in prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enzyme Inhibitors; Estramustine; Etoposide; Genes, bcl-2; Humans; Hydrocortisone; Male; Microtubules; Mitosis; Mitoxantrone; Multicenter Studies as Topic; Neoplasm Proteins; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Palliative Care; Prostatic Neoplasms; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survival Analysis; Taxoids; Treatment Outcome; Tubulin | 2001 |
Can chemotherapy alter the course of prostate cancer?
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasm Staging; Paclitaxel; Prostatic Neoplasms; Quality of Life; Taxoids | 2001 |
Complications of chemotherapy for prostate cancer.
Topics: Adenocarcinoma; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Docetaxel; Gastrointestinal Diseases; Humans; Male; Mitoxantrone; Nervous System Diseases; Paclitaxel; Prednisone; Prostatic Neoplasms; Taxoids | 2001 |
Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Cycle; Docetaxel; Drug Evaluation, Preclinical; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Male; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tubulin; Tumor Cells, Cultured | 2001 |
Prostate cancer: multimodality approaches with docetaxel.
Topics: Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids | 2001 |
Controversies in chemotherapy of prostate cancer.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Clinical Trials as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Suramin; Taxoids; Testosterone; Treatment Outcome | 2002 |
Effects of docetaxel on pain due to metastatic androgen-independent prostate cancer.
Topics: Aged; Androgens; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Male; Paclitaxel; Pain; Prostatic Neoplasms; Taxoids | 2002 |
332 trial(s) available for docetaxel anhydrous and Cancer of Prostate
| Article | Year |
|---|---|
Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Quality of Life | 2022 |
A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anemia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Fatigue; Follow-Up Studies; Humans; Male; Middle Aged; Nail Diseases; Neutropenia; Pneumonia; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Stomatitis | 2021 |
Health-related Quality of Life in Intermediate- or High-risk Patients Treated With Radical External Radiotherapy and Adjuvant Docetaxel for Localized Prostate Cancer: A Randomized, Phase III SPCG-13 Study.
Topics: Adolescent; Adult; Aged; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Young Adult | 2022 |
Efficacy of Plinabulin vs Pegfilgrastim for Prevention of Docetaxel-Induced Neutropenia in Patients With Solid Tumors: A Randomized Clinical Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Diketopiperazines; Docetaxel; Double-Blind Method; Female; Filgrastim; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Polyethylene Glycols; Prostatic Neoplasms; Treatment Outcome | 2022 |
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Proportional Hazards Models; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrazoles | 2022 |
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Female; Humans; Hypertension; Male; Prednisone; Prostatic Neoplasms | 2022 |
Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial.
Topics: Docetaxel; Humans; Male; Prostate; Prostatic Neoplasms; Quality of Life; Switzerland | 2022 |
The impact of enzalutamide on quality of life in men with metastatic hormone-sensitive prostate cancer based on prior therapy, risk, and symptom subgroups.
Topics: Androgen Antagonists; Benzamides; Docetaxel; Hormones; Humans; Male; Nitriles; Pain; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life | 2022 |
Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial.
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2022 |
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer.
Topics: Antineoplastic Agents, Hormonal; Docetaxel; Humans; Leuprolide; Male; Prostatic Neoplasms; Testosterone | 2023 |
Effect of docetaxel added to bicalutamide in Hormone-Naïve non-metastatic prostate cancer with rising PSA, a randomized clinical trial (SPCG-14).
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chronic Disease; Disease-Free Survival; Docetaxel; Hormones; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2023 |
Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
Topics: Abiraterone Acetate; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Meta-Analysis as Topic; Prednisolone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic | 2023 |
Androgen Deprivation and Radiotherapy with or Without Docetaxel for Localized High-risk Prostate Cancer: Long-term Follow-up from the Randomized NRG Oncology RTOG 0521 Trial.
Topics: Androgen Antagonists; Androgens; Docetaxel; Follow-Up Studies; Humans; Male; Prospective Studies; Prostatic Neoplasms | 2023 |
Re: Darolutamide plus Androgen-deprivation Therapy and Docetaxel in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Very Long-Term Complete Remission Can Be Achieved in Men With High-Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial.
Topics: Androgen Antagonists; Docetaxel; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2023 |
Risk of Short-Term Prostate-Specific Antigen Recurrence and Failure in Patients With Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Docetaxel; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms | 2023 |
Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer-Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Risk Assessment; Watchful Waiting | 2019 |
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies | 2019 |
Long-term Castration-related Outcomes in Patients With High-risk Localized Prostate Cancer Treated With Androgen Deprivation Therapy With or Without Docetaxel and Estramustine in the UNICANCER GETUG-12 Trial.
Topics: Androgen Antagonists; Androgens; Docetaxel; Estramustine; Humans; Male; Neoplasm Recurrence, Local; Orchiectomy; Prostatic Neoplasms | 2020 |
Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Progression-Free Survival; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors; United States | 2020 |
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Kallikreins; Male; Middle Aged; Neoplasm Grading; Prognosis; Progression-Free Survival; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Testosterone; Tumor Burden | 2020 |
Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Androgen Antagonists; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate; Prostatic Neoplasms | 2021 |
Impact of therapy on cancer metabolism in high-risk localized prostate cancer treated with neoadjuvant docetaxel and androgen deprivation therapy.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Immunohistochemistry; Male; Neoadjuvant Therapy; Outcome Assessment, Health Care; Preoperative Period; Prostate; Prostatectomy; Prostatic Neoplasms; Protein Array Analysis; Risk Assessment; Signal Transduction | 2021 |
Efficacy and Adverse Events of Docetaxel for Metastatic, Hormone-sensitive Prostate Cancer Among Elderly Men: A Post Hoc Analysis of the CHAARTED Trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Middle Aged; Progression-Free Survival; Prostatic Neoplasms | 2021 |
Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Analysis | 2021 |
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503).
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Male; Prostatic Neoplasms; Quality of Life | 2021 |
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2021 |
Toxicity and Efficacy of Concurrent Androgen Deprivation Therapy, Pelvic Radiotherapy, and Radium-223 in Patients with
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prospective Studies; Prostatic Neoplasms; Radium; Treatment Outcome | 2021 |
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk.
Topics: Androgen Antagonists; Benzamides; Docetaxel; Hormones; Humans; Male; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome | 2022 |
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Regression Analysis; Taxoids; Treatment Outcome | 2017 |
Docetaxel-related fatigue in men with metastatic prostate cancer: a descriptive analysis.
Topics: Aged; Aged, 80 and over; Benzhydryl Compounds; Docetaxel; Double-Blind Method; Fatigue; Humans; Male; Middle Aged; Modafinil; Neoplasm Metastasis; Prostatic Neoplasms; Surveys and Questionnaires; Taxoids | 2017 |
Differences in Trial and Real-world Populations in the Dutch Castration-resistant Prostate Cancer Registry.
Topics: Aged; Aged, 80 and over; Disease-Free Survival; Docetaxel; Humans; Incidence; Male; Middle Aged; Neoplasm Metastasis; Netherlands; Pragmatic Clinical Trials as Topic; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Treatment Outcome; Tubulin Modulators | 2018 |
Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; France; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prostatic Neoplasms; Quality-Adjusted Life Years; Risk Factors; Taxoids; Time Factors; Treatment Outcome; Tumor Burden | 2017 |
'Thursday's child has far to go'-interpreting subgroups and the STAMPEDE trial.
Topics: Androstenes; Antineoplastic Agents; Data Interpretation, Statistical; Docetaxel; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2017 |
Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Databases, Factual; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Time Factors; Treatment Outcome | 2018 |
External validation of the prostascore model in patients with metastatic hormone-sensitive prostate cancer recruited to the CHAARTED study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Treatment Outcome | 2018 |
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Time Factors; Treatment Outcome | 2018 |
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm, Residual; Postoperative Period; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Factors; Survival Rate; Watchful Waiting | 2018 |
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Pain Measurement; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2018 |
Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol.
Topics: Abiraterone Acetate; Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Network Meta-Analysis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Standard of Care | 2018 |
Impact of Prior Local Treatment on the Outcomes of Metastatic Hormone-Sensitive Prostate Cancer: Secondary Analysis of a Randomized Controlled Trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Neoplasm Staging; Progression-Free Survival; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Retrospective Studies | 2018 |
Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Grading; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy Dosage; Treatment Outcome | 2019 |
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Radiotherapy; Standard of Care; Survival Analysis; Treatment Outcome | 2018 |
Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naïve Prostate Cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Goserelin; Humans; Longitudinal Studies; Male; Middle Aged; Patient Reported Outcome Measures; Progression-Free Survival; Prospective Studies; Prostatic Neoplasms; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Time Factors | 2018 |
Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nitriles; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk; Tosyl Compounds; Triptorelin Pamoate | 2019 |
Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Disease-Free Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Radiotherapy; Taxoids; Treatment Outcome; Tubulin Modulators | 2019 |
Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cost-Benefit Analysis; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Prostatic Neoplasms; Quality-Adjusted Life Years; Standard of Care; United Kingdom | 2018 |
Phase II trial assessing granulocyte-macrophage-colony stimulating factor, ketoconazole plus mitoxantrone in metastatic castration-resistant prostate cancer progressing after docetaxel treatments.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Ketoconazole; Male; Middle Aged; Mitoxantrone; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2013 |
Long-term follow-up of a phase II trial of chemotherapy plus hormone therapy for biochemical relapse after definitive local therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Estramustine; Follow-Up Studies; Goserelin; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors; Tosyl Compounds; Treatment Outcome | 2013 |
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Kaplan-Meier Estimate; Male; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Failure | 2013 |
Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cancer Vaccines; Cell Line, Tumor; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Male; Neoadjuvant Therapy; Neoplasm Grading; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Europe; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Male; Middle Aged; North America; Orchiectomy; Prednisone; Proportional Hazards Models; Prostatic Neoplasms; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; South America; Taxoids; Time Factors; Treatment Outcome | 2013 |
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Survival Rate; Taxoids | 2013 |
The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (
Topics: Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; International Agencies; Ketoconazole; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Orchiectomy; Prednisone; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2013 |
Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Follow-Up Studies; Humans; International Agencies; Leuprolide; Male; Middle Aged; Neoplasm Staging; Prognosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
Intermittent tri-weekly docetaxel plus bicalutamide in patients with castration-resistant prostate cancer: a single-arm prospective study using a historical control for comparison.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Nitriles; Orchiectomy; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Tosyl Compounds | 2013 |
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy.
Topics: Abiraterone Acetate; Adenocarcinoma; Androstadienes; Antineoplastic Agents; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Placebos; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Taxoids; Treatment Failure | 2013 |
Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: a phase 2 study of the Department Of Defense Prostate Cancer Clinical Trials Consortium.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Disease Progression; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Humans; Indoles; Kaplan-Meier Estimate; Lymphopenia; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Outcome | 2014 |
Phase III, randomized, double-blind, placebo-controlled study of modafinil for fatigue in patients treated with docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzhydryl Compounds; Breast Neoplasms; Docetaxel; Double-Blind Method; Fatigue; Female; Humans; Male; Middle Aged; Modafinil; Nausea; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Vomiting; Wakefulness-Promoting Agents | 2014 |
Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Docetaxel; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nitriles; Prostatic Neoplasms; Radiotherapy, Image-Guided; Radiotherapy, Intensity-Modulated; Taxoids; Tosyl Compounds; Treatment Outcome | 2014 |
Multimodal treatment for high-risk prostate cancer with high-dose intensity-modulated radiation therapy preceded or not by radical prostatectomy, concurrent intensified-dose docetaxel and long-term androgen deprivation therapy: results of a prospective ph
Topics: Aged; Androgen Antagonists; Carcinoma; Chemoradiotherapy; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prostatectomy; Prostatic Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Radiotherapy, Intensity-Modulated; Risk; Taxoids | 2014 |
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Arthralgia; Docetaxel; Fatigue; Hot Flashes; Humans; Male; Middle Aged; Neoplasm Metastasis; Outcome Assessment, Health Care; Physician-Patient Relations; Prostatic Neoplasms; Self-Assessment; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Taxoids; Weight Gain; Weight Loss | 2014 |
Long-term results of a phase II study with neoadjuvant docetaxel chemotherapy and complete androgen blockade in locally advanced and high-risk prostate cancer.
Topics: Aged; Androgen Antagonists; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2014 |
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Atrasentan; Biomarkers, Tumor; Castration; Cell Count; Disease Progression; Docetaxel; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Grading; Neoplastic Cells, Circulating; Prognosis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2014 |
Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gemcitabine; Humans; Infusions, Intravenous; Inhibitory Concentration 50; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Thrombocytopenia; Treatment Outcome | 2014 |
Chemotherapy-induced monoamine oxidase expression in prostate carcinoma functions as a cytoprotective resistance enzyme and associates with clinical outcomes.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice; Mice, SCID; Middle Aged; Mitoxantrone; Monoamine Oxidase; Neoplasm Proteins; Prostatectomy; Prostatic Neoplasms; Taxoids | 2014 |
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Decision Support Techniques; Docetaxel; France; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Nomograms; Orchiectomy; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Prostatic Neoplasms; Reproducibility of Results; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2015 |
Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Androgen Antagonists; Cohort Studies; Disease-Free Survival; Docetaxel; Early Detection of Cancer; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Physical Fitness; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome | 2015 |
Bevacizumab and the risk of arterial and venous thromboembolism in patients with metastatic, castration-resistant prostate cancer treated on Cancer and Leukemia Group B (CALGB) 90401 (Alliance).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arteries; Bevacizumab; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prognosis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Survival Rate; Taxoids; Thromboembolism; Venous Thromboembolism | 2015 |
Long-term survival of patients with locally advanced prostate cancer managed with neoadjuvant docetaxel and radical prostatectomy.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
[Study and therapy of metastatic castration-resistant prostate cancer: A randomized, double blind, multicenter, parallel-group, phase III study to evaluate efficacy and safety of DCVAC/PCa versus placebo in men with metastatic castration resistant prostat
Topics: Antineoplastic Agents; Cancer Vaccines; Carcinoma; Castration; Combined Modality Therapy; Dendritic Cells; Docetaxel; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Humans; Male; Placebo Effect; Prevalence; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Failure; Treatment Outcome | 2015 |
Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; Dendritic Cells; Docetaxel; Humans; Hypersensitivity, Delayed; Inhibitor of Apoptosis Proteins; Male; Middle Aged; Neoplasm Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Survivin; Taxoids; Vaccination | 2015 |
Molecular profiling of prostate cancer derived exosomes may reveal a predictive signature for response to docetaxel.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biomarkers, Tumor; Blood Proteins; Cell Death; Cell Line, Tumor; Cohort Studies; Computational Biology; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Extracellular Matrix; Humans; Intracellular Signaling Peptides and Proteins; Male; Nanoparticles; Poly(A)-Binding Proteins; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proteome; Taxoids | 2015 |
Integrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.
Topics: Animals; Antineoplastic Agents; Bone Density; Bone Neoplasms; Diffusion Magnetic Resonance Imaging; Diphosphonates; Disease Models, Animal; Docetaxel; Humans; Male; Mice; Multimodal Imaging; Osteoblasts; Osteolysis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Tumor Burden | 2015 |
Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
Topics: Adenocarcinoma; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; France; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2015 |
Feasibility study of a randomized controlled trial comparing docetaxel chemotherapy and androgen deprivation therapy with sequential prostatic biopsies from patients with advanced non-castration-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Biopsy; Docetaxel; Feasibility Studies; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids | 2015 |
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2015 |
Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.
Topics: Aged; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Confidence Intervals; Disease-Free Survival; Docetaxel; Estramustine; Goserelin; Humans; Lymph Node Excision; Lymphatic Irradiation; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2016 |
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Outcome and Process Assessment, Health Care; Prostate; Prostatic Neoplasms; Radiography; Taxoids; Tumor Burden | 2016 |
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2016 |
A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy.
Topics: Adult; Aged; Disease-Free Survival; Docetaxel; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Pyrroles; Quality of Life; Salvage Therapy; Sunitinib; Taxoids | 2016 |
Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Strontium; Taxoids; Zoledronic Acid | 2016 |
Docetaxel and mitoxantrone before radical prostatectomy in men with high-risk prostate cancer: 10-year follow-up and immune correlates.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cohort Studies; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Prostatectomy; Prostatic Neoplasms; Risk Factors; Taxoids | 2017 |
The Canadian Uro-Oncology Group multicentre phase II study of docetaxel administered every 3 weeks with prednisone in men with metastatic hormone-refractory prostate cancer progressing after mitoxantrone/prednisone.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
A randomized phase II trial comparing weekly taxotere plus prednisolone versus prednisolone alone in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2008 |
Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer.
Topics: Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Biopsy, Needle; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Docetaxel; Humans; Leuprolide; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Testosterone | 2008 |
Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Belgium; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2008 |
A phase II study of estramustine, docetaxel, and exisulind in patients with hormone- refractory prostate cancer: results of cancer and leukemia group B trial 90004.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Sulindac; Survival Analysis; Taxoids; Thromboembolism | 2008 |
A phase I-II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2008 |
Systemic therapy for advancing or metastatic prostate cancer (STAMPEDE): a multi-arm, multistage randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrazoles; Risk Factors; Sulfonamides; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Interleukin-6; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2009 |
Chemotherapeutic impact on pain and global health-related quality of life in hormone-refractory prostate cancer: Dynamically Modified Outcomes (DYNAMO) analysis of a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Models, Statistical; Neoplasms, Hormone-Dependent; Pain; Pain Measurement; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Follow-Up Studies; Gefitinib; Humans; Immunoenzyme Techniques; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2009 |
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Pain; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Severity of Illness Index; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thionucleotides; Treatment Outcome | 2009 |
Combination chemotherapy with docetaxel, vinorelbine and estramustine phosphate in metastatic androgen-resistant prostate cancer: a single institution experience.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2009 |
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids | 2009 |
Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.
Topics: Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Organometallic Compounds; Organophosphorus Compounds; Pain; Pain Measurement; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids | 2009 |
[Toxicity and efficacy of intermittent docetaxel chemotherapy for hormone refractory prostate cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Survival Rate; Taxoids | 2009 |
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Goserelin; Humans; Male; Middle Aged; Mitoxantrone; Nitriles; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2009 |
Phase II study of sunitinib in men with advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Angiogenic Proteins; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Radiography; Sunitinib; Taxoids; Time Factors; Treatment Outcome | 2009 |
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Piperidines; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids; Treatment Outcome | 2009 |
Phase I study of concurrent weekly docetaxel and repeated samarium-153 lexidronam in patients with castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Constipation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Feasibility Studies; Humans; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Neutrophils; Orchiectomy; Organometallic Compounds; Organophosphorus Compounds; Pain; Platelet Count; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Taxoids | 2009 |
Phase II trial of capecitabine and weekly docetaxel for metastatic castrate resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Confidence Intervals; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Probability; Prognosis; Prostatectomy; Prostatic Neoplasms; Statistics, Nonparametric; Survival Analysis; Taxoids; Treatment Failure; Treatment Outcome | 2009 |
A phase I trial of imexon, a pro-oxidant, in combination with docetaxel for the treatment of patients with advanced breast, non-small cell lung and prostate cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Demography; Docetaxel; Female; Hexanones; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Reactive Oxygen Species; Taxoids; Treatment Outcome | 2010 |
[Patients with metastatic hormone-refractory prostate cancer. Second-line chemotherapy with mitoxantrone plus prednisone].
Topics: Aged; Antineoplastic Agents; Docetaxel; Hormone Replacement Therapy; Humans; Male; Middle Aged; Mitoxantrone; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2009 |
Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
Topics: Androgen Antagonists; Antineoplastic Agents; Data Interpretation, Statistical; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Software; Taxoids; Zoledronic Acid | 2009 |
Evaluation of docetaxel plus estramustine in the treatment of patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Estramustine; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Taxoids; Treatment Failure | 2009 |
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Prostatic Neoplasms; Sulfonamides; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Castration; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Pyrroles; Quality of Life; Sunitinib; Taxoids; Time Factors; Treatment Failure | 2010 |
Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostatic Neoplasms; Taxoids | 2009 |
Docetaxel-based chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: factors predicting response and survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Karnofsky Performance Status; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Endpoint Determination; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Pain; Palliative Care; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids | 2010 |
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer.
Topics: Aged; Androgen Antagonists; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; Docetaxel; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Kaplan-Meier Estimate; Male; Poxviridae; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Transgenes | 2010 |
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Glucuronidase; Humans; Male; Middle Aged; Neoplasm Metastasis; Oligosaccharides; Prostatic Neoplasms; Taxoids; Treatment Failure | 2010 |
[Combined treatment of metastatic hormone-resistant prostate cancer].
Topics: Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasms, Hormone-Dependent; Palliative Care; Prednisolone; Prostatic Neoplasms; Radiotherapy, Adjuvant; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Nomograms; Orchiectomy; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
A phase II study of paclitaxel poliglumex in combination with transdermal estradiol for the treatment of metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estradiol; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Paclitaxel; Polyglutamic Acid; Prostatic Neoplasms; Taxoids | 2010 |
A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.
Topics: Adult; Aged; Carbohydrate Sulfotransferases; Docetaxel; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Orchiectomy; Pharmacogenetics; Polymorphism, Single Nucleotide; PPAR delta; Prostatic Neoplasms; Sulfotransferases; Taxoids; Thalidomide | 2010 |
Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Recurrence; Risk; Taxoids; Testosterone | 2010 |
A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human α(v) integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Integrin alphaV; Male; Middle Aged; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Glucocorticoids; Humans; Hyperaldosteronism; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids | 2010 |
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Topics: Acetylation; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Fluorodeoxyglucose F18; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Panobinostat; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2010 |
Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer.
Topics: Aged; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Predictive Value of Tests; Prostate; Prostatectomy; Prostatic Neoplasms; Regression Analysis; Taxoids; Treatment Outcome | 2010 |
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Disease-Free Survival; Docetaxel; Down-Regulation; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Mice; Mice, SCID; Middle Aged; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; Time Factors; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
A phase I clinical study of high dose ketoconazole plus weekly docetaxel for metastatic castration resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Humans; Ketoconazole; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Treatment Failure | 2010 |
Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Electrocardiography; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Xanthones | 2010 |
Docetaxel-prednisolone combination therapy for Japanese patients with hormone-refractory prostate cancer: a single institution experience.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Neoplasms, Hormone-Dependent; Prednisolone; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Epidemiologic Methods; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Taxoids; Treatment Outcome | 2011 |
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Follow-Up Studies; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Oligodeoxyribonucleotides; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cellulitis; Docetaxel; Dose-Response Relationship, Drug; Female; Humans; Immunoglobulins, Intravenous; Lymphopenia; Male; Middle Aged; Neoplasms; Neutropenia; Prostatic Neoplasms; Receptor, IGF Type 1; Taxoids | 2010 |
Metronomic administration of zoledronic acid and taxotere combination in castration resistant prostate cancer patients: phase I ZANTE trial.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Feasibility Studies; Fever; Humans; Imidazoles; Infusions, Intravenous; Interleukin-8; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Neutropenia; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2010 |
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tubulin Modulators; Urologic Neoplasms; Vorinostat | 2012 |
Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Canada; Clusterin; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Orchiectomy; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Risk Factors; Taxoids; Thionucleotides; Time Factors; Treatment Failure; Washington | 2010 |
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Microarray Analysis; Mitoxantrone; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reference Values; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Taxoids; Tubulin | 2010 |
Concurrent and adjuvant docetaxel with three-dimensional conformal radiation therapy plus androgen deprivation for high-risk prostate cancer: preliminary results of a multicentre phase II trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Radiotherapy, Adjuvant; Radiotherapy, Conformal; Risk Factors; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer.
Topics: Animals; Antineoplastic Agents; Baltimore; Biological Transport; Biotransformation; Breath Tests; Cell Line; Cytochrome P-450 CYP3A; Docetaxel; Hepatocytes; Humans; Liver; Male; Neutropenia; Orchiectomy; Organic Anion Transporters, Sodium-Independent; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Taxoids; Transfection; Treatment Outcome | 2010 |
A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Castration; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Vascular Endothelial Growth Factor A | 2011 |
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
Topics: Administration, Oral; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Neutropenia; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
Poor survival outcome of docetaxel every three weeks plus prednisone for treatment of patients with hormone-refractory metastatic prostate cancer.
Topics: Aged; Alopecia; Anemia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Prednisone; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer: results from a phase 2 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Brachytherapy; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Pelvis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Taxoids | 2011 |
Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Humans; Male; Middle Aged; Prednisolone; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2010 |
[Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Compassionate Use Trials; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Prospective Studies; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Failure | 2011 |
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Humans; Leukopenia; Male; Middle Aged; Neutropenia; Orchiectomy; Pain; Prostatic Neoplasms; Pyrrolidines; Taxoids; Treatment Outcome | 2011 |
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Topics: Acetates; Bone Neoplasms; Carbon; Docetaxel; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Feasibility Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Failure | 2011 |
Placental growth factor and soluble c-kit receptor dynamics characterize the cytokine signature of imatinib in prostate cancer and bone metastases.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Pharmacological; Bone Neoplasms; Disease-Free Survival; Docetaxel; Female; Humans; Imatinib Mesylate; Male; Piperazines; Placenta Growth Factor; Pregnancy Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Taxoids | 2011 |
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Cisplatin; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Failure | 2011 |
A phase 1/1b study of satraplatin (JM-216) in combination with docetaxel in patients with advanced solid tumors and metastatic castrate-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms; Organoplatinum Compounds; Prognosis; Prostatic Neoplasms; Taxoids | 2013 |
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Docetaxel; Drug Resistance, Neoplasm; Early Termination of Clinical Trials; Humans; Male; Prednisone; Prostatic Neoplasms; Salvage Therapy; Taxoids | 2011 |
[AUO study AP 59/10: first-line therapy of castration-resistant prostate cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Docetaxel; Germany; Humans; Male; Oligonucleotides, Antisense; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids; Thionucleotides | 2011 |
Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Topics: Adenocarcinoma; Adult; Aged; Androgens; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Adhesion Molecules; Combined Modality Therapy; Cystectomy; Disease Progression; Docetaxel; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Neoplastic Stem Cells; Neovascularization, Physiologic; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Signal Transduction; Taxoids; Time Factors | 2011 |
Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chronic Disease; Docetaxel; Estramustine; Humans; Male; Middle Aged; Orchiectomy; Pain; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2011 |
Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
A phase 2 study of patupilone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: Canadian Urologic Oncology Group study P07a.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Canada; Castration; Disease-Free Survival; Docetaxel; Epothilones; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids | 2012 |
Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clusterin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostatic Neoplasms; Taxoids; Thionucleotides; Treatment Outcome | 2011 |
A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Prostatectomy; Prostatic Neoplasms; Risk Factors; Taxoids | 2011 |
A phase I study of combined docetaxel and repeated high activity 186Re-HEDP in castration-resistant prostate cancer (CRPC) metastatic to bone (the TAXIUM trial).
Topics: Aged; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Orchiectomy; Organometallic Compounds; Prostatic Neoplasms; Radiotherapy Dosage; Taxoids; Treatment Outcome | 2011 |
Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study.
Topics: Adult; Aged; Androgen Antagonists; Antineoplastic Agents; Castration; Docetaxel; Drug Resistance, Neoplasm; Glutamates; Guanine; History, 17th Century; Humans; Kaplan-Meier Estimate; Male; Pemetrexed; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids | 2013 |
Sunitinib in combination with docetaxel and prednisone in chemotherapy-naive patients with metastatic, castration-resistant prostate cancer: a phase 1/2 clinical trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids | 2012 |
Phase II study of personalized peptide vaccination for castration-resistant prostate cancer patients who failed in docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Cancer Vaccines; Cytokines; Disease Progression; Docetaxel; Humans; Immunity, Humoral; Interleukin-6; Kaplan-Meier Estimate; Male; Middle Aged; Orchiectomy; Precision Medicine; Prospective Studies; Prostatic Neoplasms; Taxoids; Treatment Failure; Treatment Outcome | 2012 |
Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Castration; Dasatinib; Docetaxel; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Taxoids; Thiazoles | 2012 |
Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients.
Topics: Administration, Oral; Aged; Antigens; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids | 2011 |
Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Orchiectomy; Placebos; Prednisone; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Treatment Outcome | 2012 |
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Estramustine; Humans; Logistic Models; Male; Middle Aged; Prostatic Neoplasms; Quality of Life; Taxoids | 2012 |
Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Docetaxel; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neutropenia; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome | 2012 |
Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers; Carrier Proteins; Castration; Cytarabine; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostatic Neoplasms; RNA, Messenger; Serine Endopeptidases; Taxoids; Trans-Activators; Transcriptional Regulator ERG; Trypsin Inhibitor, Kazal Pancreatic | 2012 |
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; Exanthema; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Orchiectomy; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Prolonged treatment with three-weekly docetaxel plus daily prednisolone for metastatic castration-resistant prostate cancer: a multicenter, phase II, open-label, non-comparative, extension study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Orchiectomy; Prednisolone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Biweekly docetaxel is better tolerated than conventional three-weekly dosing for advanced hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids | 2012 |
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chi-Square Distribution; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Odds Ratio; Placebos; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome; United States | 2012 |
Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids | 2012 |
Toxicity in patients receiving adjuvant docetaxel + hormonal treatment after radical radiotherapy for intermediate or high-risk prostate cancer: a preplanned safety report of the SPCG-13 trial.
Topics: Aged; Antineoplastic Agents; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Taxoids | 2012 |
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Castration; Disease Progression; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Norway; Pain; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risedronic Acid; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Germany; Humans; Male; Neoplasm Metastasis; Orchiectomy; Patient Compliance; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Sensitizing Agents; Survival Rate; Taxoids; United States | 2012 |
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Niacinamide; Orchiectomy; Phenylurea Compounds; Pilot Projects; Prednisone; Prospective Studies; Prostatic Neoplasms; Pyridines; Sorafenib; Taxoids; Testosterone | 2012 |
Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?
Topics: Aged; Aged, 80 and over; Androgen Receptor Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Interactions; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Taxoids; Testosterone | 2012 |
A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; C-Reactive Protein; Docetaxel; Humans; Interleukin-6; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2013 |
No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
Increased survival with enzalutamide in prostate cancer after chemotherapy.
Topics: Aged; Androgen Receptor Antagonists; Antineoplastic Agents; Benzamides; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Seizures; Signal Transduction; Taxoids | 2012 |
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aurora Kinases; Benzamides; Bone Neoplasms; Castration; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Middle Aged; Neutropenia; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyrazoles; Taxoids; Treatment Failure | 2013 |
Efficacy of cetuximab in metastatic castration-resistant prostate cancer might depend on EGFR and PTEN expression: results from a phase II trial (SAKK 08/07).
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Docetaxel; ErbB Receptors; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Taxoids; Translational Research, Biomedical; Treatment Outcome | 2012 |
Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Gossypol; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Neutropenia; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids | 2012 |
Phase I study of concurrent weekly docetaxel, high-dose intensity-modulated radiation therapy (IMRT) and androgen-deprivation therapy (ADT) for high-risk prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Taxoids; Treatment Outcome | 2012 |
A randomized, double-blind, multicenter, phase 2 study of a human monoclonal antibody to human αν integrins (intetumumab) in combination with docetaxel and prednisone for the first-line treatment of patients with metastatic castration-resistant prostate c
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Double-Blind Method; Humans; Integrin alphaV; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Placebos; Prednisone; Prostatic Neoplasms; Survival; Taxoids | 2013 |
Risk factors for metastatic castration-resistant prostate cancer (CRPC) predict long-term treatment with docetaxel.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Humans; Kaplan-Meier Estimate; Long-Term Care; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome | 2012 |
High-dose calcitriol, docetaxel and zoledronic acid in patients with castration-resistant prostate cancer: a phase II study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Infusions, Intravenous; Kallikreins; Kaplan-Meier Estimate; Lebanon; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Zoledronic Acid | 2013 |
Effect of abiraterone acetate on fatigue in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy.
Topics: Abiraterone Acetate; Androstadienes; Castration; Docetaxel; Fatigue; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Surveys and Questionnaires; Taxoids | 2013 |
Efficacy of taxotere, thalidomide, and prednisolone in patients with hormone-resistant metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Kaplan-Meier Estimate; Male; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids; Thalidomide | 2012 |
2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Administration Routes; Humans; Male; Middle Aged; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Failure | 2013 |
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Taxoids | 2013 |
Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Docetaxel; Estramustine; Feasibility Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Paclitaxel; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Testosterone; Treatment Outcome | 2003 |
Weekly low-dose docetaxel in advanced hormone-resistant prostate cancer patients previously exposed to chemotherapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Palliative Care; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2003 |
Intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Dexamethasone; Disease-Free Survival; Docetaxel; Humans; Lymphatic Metastasis; Male; Middle Aged; Paclitaxel; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Docetaxel and ketoconazole in advanced hormone-refractory prostate carcinoma: a phase I and pharmacokinetic study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2003 |
Docetaxel-ifosfamide combination chemotherapy in patients with metastatic hormone-refractory prostate cancer: a phase I pharmacokinetic study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Humans; Ifosfamide; Male; Metabolic Clearance Rate; Prostatic Neoplasms; Taxoids | 2003 |
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Estramustine; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2003 |
Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease.
Topics: Adenocarcinoma; Anticoagulants; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Estramustine; Feasibility Studies; Humans; Lymph Node Excision; Male; Multicenter Studies as Topic; Neoadjuvant Therapy; Patient Selection; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Taxoids; Thromboembolism; Treatment Outcome; Warfarin | 2003 |
Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents, Phytogenic; Calcitriol; Calcium Channel Agonists; Docetaxel; Health Status; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2004 |
Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Testosterone; Treatment Outcome | 2004 |
Weekly docetaxel in elderly patients with prostate cancer: efficacy and toxicity in patients at least 70 years of age compared with patients younger than 70 years.
Topics: Age Factors; Aged; Antineoplastic Agents, Phytogenic; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2003 |
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Prostatic Neoplasms; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Up-Regulation | 2004 |
Phase I trial of weekly docetaxel with concurrent three-dimensional conformal radiation therapy in the treatment of unfavorable localized adenocarcinoma of the prostate.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Radiation Dosage; Radiotherapy, Conformal; Taxoids; Treatment Outcome | 2004 |
Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dexamethasone; Docetaxel; Humans; Lymph Node Excision; Male; Middle Aged; Premedication; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2004 |
A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cohort Studies; Diarrhea; Docetaxel; Female; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neoplasms, Squamous Cell; Neutropenia; Organoplatinum Compounds; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2004 |
A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2004 |
Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Infusions, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2004 |
A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Biopsy; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Infusions, Intravenous; Leukocytes, Mononuclear; Male; Middle Aged; Oligonucleotides, Antisense; Phosphorylation; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids; Thionucleotides; Time Factors | 2004 |
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Taxoids | 2004 |
Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2004 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2004 |
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2004 |
[Combination therapy with estramustine and docetaxel for hormone refractory prostate cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Leukopenia; Male; Middle Aged; Prostatic Neoplasms; Taxoids | 2004 |
Weekly docetaxel and vinorelbine (VIN-DOX) as first line treatment in patients with hormone refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Treatment Failure; Vinblastine; Vinorelbine | 2004 |
Approval summary: Docetaxel in combination with prednisone for the treatment of androgen-independent hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Approval; Drug Interactions; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; United States; United States Food and Drug Administration | 2004 |
Phase I/II trial of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Maximum Tolerated Dose; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids | 2004 |
Sequential mitoxantrone/prednisone followed by docetaxel/estramustine in patients with hormone refractory metastatic prostate cancer: results of a phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2005 |
A phase I study of estramustine, weekly docetaxel, and carboplatin chemotherapy in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Humans; Ketoconazole; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2005 |
Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Hormonal; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Taxoids; Treatment Outcome | 2005 |
Docetaxel followed by hormone therapy in men experiencing increasing prostate-specific antigen after primary local treatments for prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Goserelin; Humans; Infusions, Intravenous; Injections, Intramuscular; Injections, Subcutaneous; Leuprolide; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2005 |
A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2005 |
A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Male; Middle Aged; Prostatic Neoplasms; Sulindac; Taxoids | 2005 |
A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Oligonucleotides, Antisense; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survival Analysis; Taxoids; Thionucleotides; Treatment Outcome | 2005 |
Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2005 |
Weekly docetaxel and zoledronic acid every 4 weeks in hormone-refractory prostate cancer patients.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Imidazoles; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
Effect of docetaxel chemotherapy on the activity of a gonadotropin releasing hormone vaccine in patients with advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Cancer Vaccines; Cohort Studies; Combined Modality Therapy; Dexamethasone; Diphtheria-Tetanus Vaccine; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Male; Middle Aged; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Testosterone | 2005 |
Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer.
Topics: Adult; Androgens; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Assessment; RNA, Messenger; Taxoids; Treatment Outcome | 2005 |
High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
Topics: Administration, Oral; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2005 |
ASCENT: the androgen-independent prostate cancer study of calcitriol enhancing taxotere.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Calcitriol; Canada; Disease-Free Survival; Docetaxel; Double-Blind Method; Drug Administration Schedule; Humans; Male; Middle Aged; Placebos; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; United States | 2005 |
Phase I study of weekly docetaxel and liposomal doxorubicin in patients with advanced solid tumors.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Docetaxel; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liposomes; Male; Middle Aged; Neoplasms; Neoplasms, Unknown Primary; Polyethylene Glycols; Prostatic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2005 |
Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Characterization of prognostic factors and efficacy in a phase-II study with docetaxel and estramustine for advanced hormone refractory prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Germany; Humans; Male; Middle Aged; Prevalence; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Risk Factors; Severity of Illness Index; Survival Analysis; Survival Rate; Taxoids; Treatment Failure; Treatment Outcome | 2005 |
Does docetaxel plus prednisone prolong the survival of men with metastatic hormone-refractory prostate cancer?
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Can docetaxel plus estramustine prolong survival of men with metastatic hormone-refractory prostate cancer?
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Mitoxantrone; Prednisone; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer
Topics: Adrenal Cortex Hormones; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Humans; Male; Neoplasm Staging; Prednisone; Prostatic Neoplasms; Radiotherapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer.
Topics: Acid Phosphatase; Aged; Aged, 80 and over; Androgens; Antigens; Antigens, Neoplasm; Antigens, Surface; Antineoplastic Agents, Phytogenic; Cancer Vaccines; Combined Modality Therapy; Cross-Over Studies; Disease-Free Survival; Docetaxel; Glutamate Carboxypeptidase II; Glycoproteins; Humans; Leukocytes, Mononuclear; Male; Middle Aged; Mucin-1; Mucins; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Vaccination | 2006 |
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Estramustine; Gefitinib; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids | 2006 |
Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Caspases; Docetaxel; Drug Administration Schedule; Humans; Keratins; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2006 |
Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Taxoids; Treatment Outcome | 2006 |
[Start of a new Working Group on Urological Oncology (AUO) study of prostate cancer].
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Disease Progression; Docetaxel; Drug Administration Schedule; Germany; Humans; Male; Middle Aged; Prostatic Neoplasms; Retreatment; Taxoids | 2005 |
Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Pain; Pain Measurement; Palliative Care; Prednisone; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2006 |
A phase II study of higher dose docetaxel in androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Analysis; Taxoids | 2006 |
Phase II evaluation of docetaxel plus exisulind in patients with androgen independent prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Sulindac; Survival Analysis; Taxoids | 2006 |
A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Analysis of Variance; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Disease-Free Survival; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2006 |
High dose calcitriol may reduce thrombosis in cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Arteries; Calcitriol; Docetaxel; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Thrombosis; Treatment Outcome; Venous Thrombosis | 2006 |
Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cell Survival; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; Heterocyclic Compounds, 3-Ring; Humans; Interleukin-6; Lymph Nodes; Male; Middle Aged; Neoplasm Metastasis; NF-kappa B; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Statistics as Topic; Survival Analysis; Taxoids; Tumor Cells, Cultured | 2006 |
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Hoosier Oncology Group randomized phase II study of docetaxel, vinorelbine, and estramustine in combination in hormone-refractory prostate cancer with pharmacogenetic survival analysis.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Patient Selection; Prostatic Neoplasms; Survival Analysis; Taxoids; Vinblastine; Vinorelbine | 2006 |
ECOG: CHAARTED--ChemoHormonal therapy versus androgen ablation randomized trial for extensive disease in prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Male; Middle Aged; Multivariate Analysis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Remission Induction; Salvage Therapy; Taxoids | 2006 |
Phase-II study of docetaxel, estramustine phosphate, and carboplatin in patients with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2007 |
Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2006 |
Weekly docetaxel and epirubicin in treatment of advanced hormone-refractory prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Administration Schedule; Epirubicin; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Treatment Failure | 2007 |
Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prednisolone; Prostatic Neoplasms; Quality of Life; Taxoids | 2007 |
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
Topics: Age Factors; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Calcitriol; Docetaxel; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Placebos; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Docetaxel; Dose-Response Relationship, Drug; Humans; Interleukin-6; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazines; Taxoids | 2007 |
Thalidomide in combination with oral daily cyclophosphamide in patients with pretreated hormone refractory prostate cancer: a phase I clinical trial.
Topics: Administration, Oral; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome | 2007 |
Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Feasibility Studies; Follow-Up Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome; Triptorelin Pamoate | 2007 |
Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
Topics: Adenocarcinoma; Aged; Biomarkers, Tumor; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Survivors; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Floxuridine; Granulocyte Colony-Stimulating Factor; Humans; Japan; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids | 2008 |
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Patient Selection; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids | 2007 |
Pre-clinical and clinical evaluation of estramustine, docetaxel and thalidomide combination in androgen-independent prostate cancer.
Topics: Aged; Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1B1; Cytochrome P-450 Enzyme System; Docetaxel; Estramustine; Genotype; Humans; Male; Mice; Mice, Nude; Middle Aged; Prostatic Neoplasms; Survival Analysis; Taxoids; Thalidomide; Treatment Outcome | 2007 |
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2007 |
A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2007 |
Long-term outcome of a phase II study of weekly docetaxel with a short course of estramustine and enoxaparine in hormone-resistant prostate cancer patients.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Enoxaparin; Estramustine; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2007 |
Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrazines; Taxoids; Treatment Outcome | 2007 |
[Lethal course after chemotherapy with docetaxel. Acute liver failure with accompanying erythema multiforme major].
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Chemical and Drug Induced Liver Injury; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Fatal Outcome; Humans; Liver Failure; Liver Function Tests; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Stevens-Johnson Syndrome; Taxoids | 2007 |
Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Resistance, Neoplasm; Epothilones; Humans; Male; Middle Aged; Mitoxantrone; Neoplasms, Hormone-Dependent; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Taxoids; Treatment Outcome | 2007 |
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Epothilones; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Atropine; Biomarkers, Tumor; Chromogranin A; Cisplatin; Docetaxel; Humans; Male; Phosphopyruvate Hydratase; Prostatic Neoplasms; Taxoids | 2007 |
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrimidines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Erlotinib Hydrochloride; Humans; Male; Prostatic Neoplasms; Quality of Life; Quinazolines; Survival Rate; Taxoids | 2007 |
Three-weekly docetaxel with prednisone is feasible for Japanese patients with hormone-refractory prostate cancer: a retrospective comparative study with weekly docetaxel alone.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Drug Administration Schedule; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2007 |
Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Humans; Immunohistochemistry; Male; Microarray Analysis; Middle Aged; Neoadjuvant Therapy; Patient Selection; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2007 |
Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Comorbidity; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Pain; Pain Measurement; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
Preliminary results of the Prostacox phase II trial in hormonal refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrazoles; Quality of Life; Sulfonamides; Taxoids; Treatment Outcome | 2007 |
Weekly docetaxel, zoledronic acid and estramustine in hormone-refractory prostate cancer (HRPC).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alopecia; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Fatigue; Humans; Hypocalcemia; Imidazoles; Infusions, Intravenous; Injections, Intravenous; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome; Zoledronic Acid | 2008 |
Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Castration; Cohort Studies; Disease-Free Survival; Docetaxel; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Metastasis; Piperazines; Placebos; Prostatic Neoplasms; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor; Taxoids | 2007 |
Weekly administration of docetaxel in combination with estramustine and celecoxib in patients with advanced hormone-refractory prostate cancer: final results from a phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Celecoxib; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Neoplasms; Pyrazoles; Soft Tissue Neoplasms; Sulfonamides; Survival Rate; Taxoids | 2007 |
Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Docetaxel; Double-Blind Method; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2008 |
A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Humans; Kinetics; Male; Mitoxantrone; Neoplasm Metastasis; Nomograms; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer.
Topics: Acyclovir; Adenoviridae; Aged; Androgen Antagonists; Antineoplastic Agents; Antiviral Agents; Bone and Bones; Bone Neoplasms; Docetaxel; Genetic Therapy; Genetic Vectors; Humans; Male; Middle Aged; Osteocalcin; Promoter Regions, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Thymidine Kinase; Valacyclovir; Valine | 2007 |
Phase II study of sequential chemotherapy with docetaxel-estramustine followed by mitoxantrone-prednisone in patients with advanced hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Chromogranin A; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Male; Middle Aged; Phosphopyruvate Hydratase; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2008 |
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Combination chemotherapy with weekly docetaxel and estramustine for hormone refractory prostate cancer in Japanese patients.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2008 |
Targeting prostate cancer with HTI-286, a synthetic analog of the marine sponge product hemiasterlin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Proliferation; Docetaxel; Flow Cytometry; Gene Expression Profiling; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Oligopeptides; Prostatic Neoplasms; Radiation-Sensitizing Agents; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
Combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Hormones; Humans; Injections, Intravenous; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoadjuvant Therapy; Preoperative Care; Prognosis; Prostatectomy; Prostatic Neoplasms; Risk Factors; Taxoids | 2008 |
Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
Topics: Androgens; Cell Line, Tumor; Clusterin; Cohort Studies; Docetaxel; Dose-Response Relationship, Drug; Humans; Immunohistochemistry; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Prostatectomy; Prostatic Neoplasms; Taxoids; Thionucleotides | 2008 |
Randomized, double-blinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Calcium; Docetaxel; Double-Blind Method; Ergocalciferols; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2008 |
Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
Topics: Aged; Alopecia; Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Feasibility Studies; Humans; Japan; Leukopenia; Male; Middle Aged; Neutropenia; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2008 |
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Calcitriol; Calcium Channel Agonists; Docetaxel; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Placebos; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2008 |
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Humans; Male; Mitoxantrone; Pain; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2008 |
Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cross-Over Studies; Docetaxel; Drug Administration Schedule; Humans; Male; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2008 |
Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Estramustine; Gastrointestinal Diseases; Hematologic Diseases; Humans; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Estramustine; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 1999 |
Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 1999 |
A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Gene Expression; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids | 1999 |
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 1999 |
Preliminary evaluation of a short course of estramustine phosphate and docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Dexamethasone; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2000 |
Reversion of primary hyperfibrinogenolysis in patients with hormone-refractory prostate cancer using docetaxel.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Fibrinogen; Fibrinolysis; Hemorrhage; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Urokinase-Type Plasminogen Activator | 2000 |
Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Survival Rate; Taxoids | 2001 |
The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anxiety; Docetaxel; Drug Resistance, Neoplasm; Emotions; Estramustine; Feasibility Studies; Female; Health Status; Humans; Hydrocortisone; Infusions, Intravenous; Male; Mental Health; Middle Aged; Paclitaxel; Pain; Prostatic Neoplasms; Quality of Life; Sexual Behavior; Spouses; Taxoids | 2001 |
Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Paclitaxel; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2001 |
Weekly docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Survival Analysis; Taxoids | 2001 |
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results.
Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds | 2001 |
Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Pilot Projects; Prostatectomy; Prostatic Neoplasms; Taxoids | 2001 |
Preliminary observations of single-agent docetaxel as neoadjuvant therapy for locally advanced prostate cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Prostatectomy; Prostatic Neoplasms; Taxoids | 2001 |
Weekly high-dose calcitriol and docetaxel in advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Calcitriol; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2001 |
Docetaxel and exisulind in hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Sulindac; Survival Analysis; Taxoids | 2001 |
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Thalidomide | 2001 |
Preliminary phase I results of G3139 (bcl-2 antisense oligonucleotide) therapy in combination with docetaxel in hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Genes, bcl-2; Humans; Male; Middle Aged; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Taxoids; Thionucleotides | 2001 |
Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Genes, erbB-2; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Trastuzumab | 2001 |
Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Analgesics; Antineoplastic Agents, Phytogenic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Pain; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2001 |
Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Estramustine; Humans; Infusions, Intravenous; Male; Middle Aged; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
1083 other study(ies) available for docetaxel anhydrous and Cancer of Prostate
| Article | Year |
|---|---|
Synthesis and pharmacological screening of a large library of 1,3,4-thiadiazolines as innovative therapeutic tools for the treatment of prostate cancer and melanoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Humans; Kinesins; Male; Melanoma; Mice; Molecular Structure; Neoplasms, Experimental; Prostatic Neoplasms; Small Molecule Libraries; Structure-Activity Relationship; Thiadiazoles | 2015 |
Brefeldin A enhances docetaxel-induced growth inhibition and apoptosis in prostate cancer cells in monolayer and 3D cultures.
Topics: Apoptosis; Brefeldin A; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2017 |
Heterocyclic-Fused Pyrimidines as Novel Tubulin Polymerization Inhibitors Targeting the Colchicine Binding Site: Structural Basis and Antitumor Efficacy.
Topics: Animals; Apoptosis; Binding Sites; Colchicine; Crystallography, X-Ray; Drug Design; Drug Resistance, Multiple; Heterografts; Humans; Male; Melanoma; Polymerization; Prostatic Neoplasms; Pyrimidines; Tubulin | 2018 |
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF
Topics: Anilides; Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Ether-A-Go-Go Potassium Channels; Humans; Hydrocarbons, Fluorinated; Male; Mice; Mice, Nude; Molecular Structure; Neoplasms, Experimental; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Structure-Activity Relationship; Sulfhydryl Compounds; Tosyl Compounds | 2019 |
Synthesis, Characterization, and Preclinical Evaluation of a Small-Molecule Prostate-Specific Membrane Antigen-Targeted Monomethyl Auristatin E Conjugate.
Topics: Antigens, Surface; Cell Line, Tumor; Coordination Complexes; Glutamate Carboxypeptidase II; Humans; Male; Microsomes, Liver; Oligopeptides; Prostatic Neoplasms; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2021 |
Survival trends for patients with primary metastatic prostate cancer before and after the introduction of new antitumor drugs.
Topics: Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Nitriles; Norway; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
High expression of ladinin-1 (LAD1) predicts adverse outcomes: a new candidate docetaxel resistance gene for prostatic cancer (PCa).
Topics: Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Membrane Glycoproteins; Prostatic Neoplasms | 2021 |
Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy.
Topics: Anilides; Aniline Compounds; Animals; Antineoplastic Agents; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Cellular Senescence; Docetaxel; Humans; Male; Mice; Nitriles; Orchiectomy; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Sulfonamides; Tosyl Compounds; Xenograft Model Antitumor Assays | 2021 |
Oncolytic adenovirus carrying SPAG9-shRNA enhanced the efficacy of docetaxel for advanced prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Adenoviridae; Animals; Antineoplastic Agents; Docetaxel; Drug Combinations; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Oncolytic Virotherapy; Prostatic Neoplasms; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2022 |
SPOP mutation induces DNA methylation via stabilizing GLP/G9a.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; DNA (Cytosine-5-)-Methyltransferases; DNA Methylation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Male; Mice; Mutation; Nuclear Proteins; Prostatic Neoplasms; Protein Stability; Proteolysis; Repressor Proteins; Xenograft Model Antitumor Assays | 2021 |
Aptamer-conjugated mesoporous polydopamine for docetaxel targeted delivery and synergistic photothermal therapy of prostate cancer.
Topics: Cell Line, Tumor; Docetaxel; Doxorubicin; Drug Delivery Systems; Humans; Indoles; Male; Nanoparticles; Photothermal Therapy; Polymers; Porosity; Prostatic Neoplasms | 2021 |
Characterization of a castrate-resistant prostate cancer xenograft derived from a patient of West African ancestry.
Topics: Animals; Black People; Docetaxel; Heterografts; Humans; Male; Mice; Orchiectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2022 |
Induction of Endoplasmic Reticulum Stress-Mediated Apoptosis by Aminosteroid RM-581 Efficiently Blocks the Growth of PC-3 Cancer Cells and Tumors Resistant or Not to Docetaxel.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Endoplasmic Reticulum Stress; Estranes; Humans; Male; Mice; Mice, Nude; PC-3 Cells; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2021 |
The LEDGF/p75 Integrase Binding Domain Interactome Contributes to the Survival, Clonogenicity, and Tumorsphere Formation of Docetaxel-Resistant Prostate Cancer Cells.
Topics: Antibody Specificity; Apoptosis; Autoantibodies; Biomarkers, Tumor; Cell Line, Tumor; Cell Lineage; Cell Nucleus; Cell Survival; Clone Cells; Docetaxel; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Male; Neoplastic Stem Cells; Prostatic Neoplasms; Protein Binding; Protein Domains; Protein Transport; Proto-Oncogene Proteins; Repressor Proteins; Spheroids, Cellular | 2021 |
Treatment of patients with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) in Belgium: a real world data analysis.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Belgium; Data Analysis; Docetaxel; Hormones; Humans; Male; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Transcription factor network analysis based on single cell RNA-seq identifies that Trichostatin-a reverses docetaxel resistance in prostate Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Hydroxamic Acids; Male; Mice; Prostatic Neoplasms; Protein Interaction Maps; RNA-Seq; Single-Cell Analysis; Transcription Factors | 2021 |
LncRNA LINC00184 promotes docetaxel resistance and immune escape via miR-105-5p/PD-L1 axis in prostate cancer.
Topics: B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Prostatic Neoplasms; RNA, Long Noncoding; RNA, Small Interfering | 2022 |
Silencing of circDPP4 suppresses cell progression of human prostate cancer and enhances docetaxel cytotoxicity through regulating the miR-564/ZIC2 axis.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Nuclear Proteins; Prostatic Neoplasms; RNA, Circular; Transcription Factors | 2022 |
[Effects of silencing HMGB1 combined with docetaxel chemotherapy on the proliferation and apoptosis of prostate cancer cells and its action mechanism].
Topics: Apoptosis; Cell Proliferation; Docetaxel; HMGB1 Protein; Humans; Male; Prostatic Neoplasms | 2021 |
EIF4A3-Induced circARHGAP29 Promotes Aerobic Glycolysis in Docetaxel-Resistant Prostate Cancer through IGF2BP2/c-Myc/LDHA Signaling.
Topics: Cell Line, Tumor; Cell Proliferation; DEAD-box RNA Helicases; Docetaxel; Eukaryotic Initiation Factor-4A; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Lactate Dehydrogenase 5; Male; Prostatic Neoplasms; RNA-Binding Proteins; RNA, Circular; RNA, Messenger | 2022 |
Inhibitory effect of roburic acid in combination with docetaxel on human prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Esomeprazole; Humans; Male; Molecular Structure; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2022 |
Elevating the Patient Voice in Metastatic Hormone-Sensitive Prostate Cancer Clinical Trials.
Topics: Androstenes; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Quality of Life | 2022 |
Silencing of LINC01963 enhances the chemosensitivity of prostate cancer cells to docetaxel by targeting the miR-216b-5p/TrkB axis.
Topics: 3' Untranslated Regions; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Prostatic Neoplasms; Receptor, trkB; RNA, Long Noncoding | 2022 |
A Novel Docetaxel-Biotin Chemical Conjugate for Prostate Cancer Treatment.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biotin; Cell Proliferation; Docetaxel; Female; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostatic Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2022 |
Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Feasibility Studies; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Rural Health; Treatment Outcome | 2022 |
Combination treatment of docetaxel with caffeic acid phenethyl ester suppresses the survival and the proliferation of docetaxel-resistant prostate cancer cells via induction of apoptosis and metabolism interference.
Topics: Androgen Antagonists; Animals; Apoptosis; Caffeic Acids; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Mice; Mice, Nude; Phenylethyl Alcohol; Prostatic Neoplasms; Quality of Life | 2022 |
Real-world survival outcomes of adding docetaxel or abiraterone in patients with high-volume metastatic castration-sensitive prostate cancer: historically controlled, propensity score matched comparison with androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Propensity Score; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2022 |
Prostate arterial chemoembolization for treatment of refractory hematuria and urinary retention in patients with localized advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Docetaxel; Epirubicin; Hematuria; Humans; Liver Neoplasms; Male; Middle Aged; Prostate; Prostatic Neoplasms; Quality of Life; Treatment Outcome; Urinary Retention | 2023 |
Inflammatory molecules facilitate the development of docetaxel-resistant prostate cancer cells in vitro and in vivo.
Topics: Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Interleukin-6; Male; NF-kappa B; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt | 2022 |
Bone-targeted nanoplatform enables efficient modulation of bone tumor microenvironment for prostate cancer bone metastasis treatment.
Topics: Bone Neoplasms; Docetaxel; Humans; Male; Prostate; Prostatic Neoplasms; Tumor Microenvironment | 2022 |
Baseline Modified Glasgow Prognostic Score (mGPS) Predicts Radiologic Response and Overall Survival in Metastatic Hormone-sensitive Prostate Cancer Treated With Docetaxel Chemotherapy.
Topics: Docetaxel; Hormones; Humans; Lymphocytes; Male; Prognosis; Prostatic Neoplasms | 2022 |
Decreased Expression of HN1 Sensitizes Prostate Cancer Cells to Apoptosis Induced by Docetaxel and 2-Methoxyestradiol.
Topics: 2-Methoxyestradiol; Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cyclin B1; Docetaxel; Humans; Male; Mammals; Prostatic Neoplasms | 2022 |
Baseline basophil and basophil-to-lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer.
Topics: Basophils; Docetaxel; Hormones; Humans; Lymphocytes; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2022 |
A novel survivin dimerization inhibitor without a labile hydrazone linker induces spontaneous apoptosis and synergizes with docetaxel in prostate cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Dimerization; Docetaxel; Humans; Hydrazones; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Oxadiazoles; Prodrugs; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Survivin | 2022 |
Co-delivery of Docetaxel and Resveratrol by liposomes synergistically boosts antitumor efficiency against prostate cancer.
Topics: Animals; Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Humans; Liposomes; Male; Mice; Mice, Nude; Prostatic Neoplasms; Resveratrol | 2022 |
Combination of docetaxel versus nonsteroidal antiandrogen with androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer: a propensity score-matched analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Nonsteroidal Anti-Androgens; Propensity Score; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism.
Topics: Docetaxel; Drug Resistance, Neoplasm; Endonucleases; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Mitosis; Prostatic Neoplasms; RNA, Circular | 2022 |
IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms | 2022 |
Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-κB-IL6-STAT3 axis.
Topics: Animals; Anti-Bacterial Agents; Docetaxel; Dysbiosis; Feces; Humans; Interleukin-6; Lipopolysaccharides; Male; Mice; NF-kappa B; Prostatic Neoplasms; Proteobacteria; RNA, Ribosomal, 16S; STAT3 Transcription Factor | 2022 |
Management of Metastatic Hormone-Sensitive Prostate Cancer: Is Docetaxel Needed?
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2022 |
Continuous liquid interface production of 3D printed drug-loaded spacers to improve prostate cancer brachytherapy treatment.
Topics: Animals; Brachytherapy; Dexamethasone; Docetaxel; Humans; Male; Mice; Pharmaceutical Preparations; Printing, Three-Dimensional; Prostate; Prostatic Neoplasms | 2022 |
Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Tumor Burden | 2022 |
Synergistic Benefit of Adoptive T Cells in Combination With Chemoradiotherapy Against Metastatic Prostate Cancer Cells.
Topics: Chemoradiotherapy; Cytokine-Induced Killer Cells; Docetaxel; Humans; Lymphocyte Count; Male; Neoplasms, Second Primary; Prostatic Neoplasms | 2022 |
Role of multidisciplinary team meetings in implementation of chemohormonal therapy in metastatic prostate cancer in daily practice.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Patient Care Team; Prostatic Neoplasms | 2023 |
Docetaxel resistance-derived LINC01085 contributes to the immunotherapy of hormone-independent prostate cancer by activating the STING/MAVS signaling pathway.
Topics: Docetaxel; Glycogen Synthase Kinase 3 beta; Hormones; Humans; Immunotherapy; Interferon Type I; Male; Prostatic Neoplasms; RNA; Signal Transduction | 2022 |
Cases in the management of prostate cancer: the addition of darolutamide to androgen deprivation therapy and docetaxel in a 55-year-old man with metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyrazoles | 2022 |
The Treatment of Metastatic, Hormone-Sensitive Prostatic Carcinoma.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2022 |
Enhancing nanoparticle accumulation in two dimensional, three dimensional, and xenograft mouse cancer cell models in the presence of docetaxel.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Gold; Heterografts; Humans; Male; Metal Nanoparticles; Mice; Nanoparticles; Prostatic Neoplasms; Taxoids | 2022 |
Comparison of Weekly Low Dose Docetaxel with the Standard Protocol in Hormone-resistant Metastatic Prostate Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prednisolone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2022 |
New diterpenes from the marine sponge Spongionella sp. overcome drug resistance in prostate cancer by inhibition of P-glycoprotein.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Diterpenes; Docetaxel; Drug Resistance; Humans; Male; Molecular Structure; Porifera; Prostatic Neoplasms | 2022 |
Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; China; Docetaxel; Humans; Male; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2022 |
Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs.
Topics: Animals; Cell Line, Tumor; Cytokines; Docetaxel; Humans; Immunotherapy, Adoptive; Male; Mice; Myeloid-Derived Suppressor Cells; Prostate; Prostatic Neoplasms; Receptors, Chimeric Antigen; T-Lymphocytes; Xenograft Model Antitumor Assays | 2022 |
Prostate-specific membrane antigen targeted, glutathione-sensitive nanoparticles loaded with docetaxel and enzalutamide for the delivery to prostate cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cystamine; Docetaxel; Glutathione; Humans; Ligands; Male; Mice; Nanoparticles; Nitriles; Phenylthiohydantoin; Polyethylene Glycols; Prostate; Prostatic Neoplasms | 2022 |
Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; ErbB Receptors; Humans; Hyaluronic Acid; Isoflavones; Ligands; Male; Mice; Nanoparticles; Peptides; Prostate; Prostatic Neoplasms; Taxoids | 2022 |
Nimbolide enhances the antitumor effect of docetaxel via abrogation of the NF-κB signaling pathway in prostate cancer preclinical models.
Topics: Cell Line, Tumor; DNA; Docetaxel; Humans; Limonins; Male; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Survivin | 2022 |
Future directions in systemic treatment of metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2023 |
Effect of Bicalutamide Combined with Docetaxel on Serum PSA and VEGF Levels in Patients with Advanced Prostate Carcinoma.
Topics: Anilides; Carcinoma; Docetaxel; Humans; Male; Nitriles; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Tosyl Compounds; Vascular Endothelial Growth Factor A | 2022 |
Increased MYBL2 expression in aggressive hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Cell Cycle Proteins; Docetaxel; Histone Demethylases; Humans; Lysine; Male; Minor Histocompatibility Antigens; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Taxoids; Trans-Activators | 2022 |
SPOP Mutations as a Predictive Biomarker for Androgen Receptor Axis-Targeted Therapy in De Novo Metastatic Castration-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Biomarkers; Castration; Disease-Free Survival; Docetaxel; Humans; Male; Mutation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Treatment Outcome | 2022 |
Exosomal circRNA Scm-like with four malignant brain tumor domains 2 (circ-SFMBT2) enhances the docetaxel resistance of prostate cancer via the microRNA-136-5p/tribbles homolog 1 pathway.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Male; Mice; MicroRNAs; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Repressor Proteins; RNA, Circular | 2022 |
Identification of Calcium Channel-Related Gene P2RX2 for Prognosis and Immune Infiltration in Prostate Cancer.
Topics: Calcium Channels; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms; Receptors, Purinergic P2X2 | 2022 |
Cytotoxic N-Methylpretrichodermamide B Reveals Anticancer Activity and Inhibits P-Glycoprotein in Drug-Resistant Prostate Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caspase 3; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Hormones; Humans; Male; Phosphatidylserines; Prostatic Neoplasms | 2022 |
Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Treatment Outcome | 2023 |
Docosahexaenoic Acid Reverses Epithelial-Mesenchymal Transition and Drug Resistance by Impairing the PI3K/AKT/ Nrf2/GPX4 Signalling Pathway in Docetaxel-Resistant PC3 Prostate Cancer Cells.
Topics: Docetaxel; Docosahexaenoic Acids; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Male; NF-E2-Related Factor 2; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species | 2022 |
Acquired drug resistance interferes with the susceptibility of prostate cancer cells to metabolic stress.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cytostatic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Metformin; Prostatic Neoplasms; Stress, Physiological; Taxoids | 2022 |
Saikosaponin A enhances Docetaxel efficacy by selectively inducing death of dormant prostate cancer cells through excessive autophagy.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt | 2023 |
Comparison of efficacy and medical costs between upfront docetaxel and abiraterone treatments of metastatic hormone-sensitive prostate cancer patients in real-world practice: a multicenter retrospective study.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
The Changing Landscape of Systemic Therapy in the Treatment of Synchronous Metastatic Hormone-sensitive Prostate Cancer.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2023 |
Docetaxel suppressed cell proliferation through Smad3/HIF-1α-mediated glycolysis in prostate cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Luciferases; Male; Prostatic Neoplasms; Smad3 Protein | 2022 |
New Guanidine Alkaloids Batzelladines O and P from the Marine Sponge
Topics: Alkaloids; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Docetaxel; Guanidine; Guanidines; Humans; Male; Porifera; Prostatic Neoplasms | 2022 |
Comprehensive Evaluation of Multiple Approaches Targeting ABCB1 to Resensitize Docetaxel-Resistant Prostate Cancer Cell Lines.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; RNA, Small Interfering; Taxoids | 2022 |
Sonosensitive Phase-Changeable Nanoparticle Mediated Enhanced Chemotherapy in Prostate Cancer by Low-Intensity Focused Ultrasound.
Topics: Cell Line, Tumor; Docetaxel; Humans; Liposomes; Male; Nanoparticles; Prostatic Neoplasms | 2023 |
Evaluation of Trends in Treatment of Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Across Canada During the COVID-19 Pandemic.
Topics: Androgen Antagonists; Androgens; Canada; COVID-19; Docetaxel; Humans; Male; Pandemics; Prostatic Neoplasms; Treatment Outcome | 2023 |
Docetaxel versus abiraterone for metastatic hormone-sensitive prostate cancer with focus on efficacy of sequential therapy.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2023 |
Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Retrospective Studies; Treatment Outcome | 2023 |
A multidisciplinary consensus statement on the optimal pharmacological treatment for metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2023 |
4-Nerolidylcatechol (4-NC) and Docetaxel Synergize in Controlling Androgen- independent Prostate Cancer Cells.
Topics: Androgens; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2023 |
Exosomal lincROR Promotes Docetaxel Resistance in Prostate Cancer through a β-catenin/HIF1α Positive Feedback Loop.
Topics: beta Catenin; Cell Line, Tumor; Docetaxel; Feedback; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Prostatic Neoplasms; RNA, Long Noncoding; Signal Transduction | 2023 |
Utilizing mixture design response surface methodology to determine effective combinations of plant derived compounds as prostate cancer treatments.
Topics: Androgens; Berberine; Cell Line, Tumor; Docetaxel; Emodin; Humans; Male; Phytochemicals; Prostatic Neoplasms; Silybin | 2023 |
Construction and validation of a fatty acid metabolism-related gene signature for predicting prognosis and therapeutic response in patients with prostate cancer.
Topics: Docetaxel; Fatty Acids; Humans; Lipid Metabolism; Male; Prognosis; Prostatic Neoplasms | 2023 |
The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer.
Topics: Adult; Androgen Antagonists; Androgens; Castration; Docetaxel; Humans; Male; Physicians; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies | 2023 |
Identification of a novel senescence-associated signature to predict biochemical recurrence and immune microenvironment for prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis Regulatory Proteins; Cisplatin; Docetaxel; Genes, cdc; Histones; Humans; Male; Prostatic Neoplasms; Tumor Microenvironment | 2023 |
Necroptosis Induced by Delta-Tocotrienol Overcomes Docetaxel Chemoresistance in Prostate Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Necroptosis; Prostatic Neoplasms | 2023 |
Upfront Androgen Receptor-Axis-Targeted Therapies in Men with De Novo High-Volume Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Retrospective Studies | 2023 |
The Past, Present, and Future of Treatment Intensification for Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2023 |
Systemic treatment of metastatic hormone-sensitive prostate cancer-upfront triplet versus doublet combination therapy.
Topics: Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2023 |
Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Lactoferrin; Male; Nanoparticles; Prostatic Neoplasms; Rats | 2023 |
Integrated analysis of single-cell and bulk RNA sequencing identifies a signature based on macrophage marker genes involved in prostate cancer prognosis and treatment responsiveness.
Topics: Base Sequence; Docetaxel; Humans; Macrophages; Male; Prostatic Neoplasms; RNA-Seq; Tumor Microenvironment | 2023 |
The Management of Metastatic Castrate-Sensitive Prostate Cancer: From Guidelines to Real-World Practice.
Topics: Docetaxel; Humans; Male; Prostatic Neoplasms | 2023 |
STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Oxidoreductases; Paclitaxel; Prostate; Prostatic Neoplasms; Taxoids | 2023 |
A novel prostate cancer subtyping classifier based on luminal and basal phenotypes.
Topics: Androgen Antagonists; Biomarkers, Tumor; Docetaxel; Gene Expression Profiling; Humans; Male; Phenotype; Prognosis; Prostatic Neoplasms; Receptors, Androgen | 2023 |
Glucocorticoid Receptor and β-Catenin Interact in Prostate Cancer Cells and Their Co-Inhibition Attenuates Tumorsphere Formation, Stemness, and Docetaxel Resistance.
Topics: beta Catenin; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Receptors, Glucocorticoid | 2023 |
Personalizing approaches to the management of metastatic hormone sensitive prostate cancer: role of advanced imaging, genetics and therapeutics.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Treatment Outcome | 2023 |
Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.
Topics: Castration; Docetaxel; Genomics; Humans; Male; Molecular Imaging; Prostatic Neoplasms | 2023 |
A CXCR4 inhibitor (balixafortide) enhances docetaxel-mediated antitumor activity in a murine model of prostate cancer bone metastasis.
Topics: Animals; Bone Neoplasms; Caspase 3; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Humans; Interleukin-2; Ki-67 Antigen; Male; Mice; Prostatic Neoplasms; Receptors, CXCR4; Tartrate-Resistant Acid Phosphatase | 2023 |
The CCL2-CCR2 Axis Contributes to Migration of Cabazitaxel-resistant Prostate Cancer Cells.
Topics: Cell Line, Tumor; Chemokine CCL2; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Receptors, CCR2; RNA, Small Interfering | 2023 |
The utility of the [-2]pro-prostate-specific antigen level as a prognostic marker in patients with castration-resistant prostate cancer treated with enzalutamide.
Topics: Docetaxel; Humans; Male; Nitriles; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2023 |
Triplet Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms | 2023 |
rRNA-Derived Small RNA rsRNA-28S Regulates the Chemoresistance of Prostate Cancer Cells by Targeting PTGIS.
Topics: Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme System; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Prostatic Neoplasms; RNA, Messenger | 2023 |
Design, development, and in-vitro/in-vivo evaluation of docetaxel-loaded PEGylated solid lipid nanoparticles in prostate cancer therapy.
Topics: Docetaxel; Humans; Lipids; Male; Nanoparticles; Particle Size; Polyethylene Glycols; Prostatic Neoplasms; Tumor Microenvironment | 2023 |
Adjuvant Docetaxel in Nonmetastatic Prostate Cancer: The King Is Dead, Long Live the King!
Topics: Adjuvants, Immunologic; Chronic Disease; Docetaxel; Humans; Male; Prostatic Neoplasms | 2023 |
Improving the Antitumor Effect of Chemotherapy with Ocoxin as a Novel Adjuvant Agent to Treat Prostate Cancer.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Mice; Prostatic Neoplasms; Taxoids | 2023 |
Androgen receptor knockdown enhances prostate cancer chemosensitivity by down-regulating FEN1 through the ERK/ELK1 signalling pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Docetaxel; ets-Domain Protein Elk-1; Flap Endonucleases; Humans; Male; MAP Kinase Signaling System; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering | 2023 |
Impact of prostate radiotherapy on survival outcomes in clinically node-positive prostate cancer: A multicentre retrospective analysis.
Topics: Androgen Antagonists; Disease-Free Survival; Docetaxel; Humans; Male; Prostate; Prostatic Neoplasms; Retrospective Studies | 2023 |
How reliable is the high-volume definition in prostate cancer patients: the potential game-changing role of PSMA.
Topics: Docetaxel; Gallium Isotopes; Gallium Radioisotopes; Humans; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms; Retrospective Studies | 2023 |
Polysaccharides from Lentinus edodes prevent acquired drug resistance to docetaxel in prostate cancer cells by decreasing the TGF-β1 secretion of cancer-associated fibroblasts.
Topics: Cancer-Associated Fibroblasts; Cell Line, Tumor; Docetaxel; Fibroblasts; Humans; Male; Polysaccharides; Prostatic Neoplasms; Shiitake Mushrooms; Transforming Growth Factor beta1 | 2023 |
RGD-directed 24 nm micellar docetaxel enables elevated tumor-liver ratio, deep tumor penetration and potent suppression of solid tumors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Disulfides; Docetaxel; Humans; Liver Neoplasms; Male; Micelles; Oligopeptides; Prostatic Neoplasms | 2023 |
Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced Prostate Cancer.
Topics: Aged; Androgen Antagonists; Androgens; Docetaxel; Health Expenditures; Humans; Male; Medicare Part B; Prostatic Neoplasms; United States | 2023 |
Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models.
Topics: Animals; Apoptosis; Cell Line, Tumor; Docetaxel; Humans; Male; Mice; Nicardipine; Polycomb Repressive Complex 2; Prostatic Neoplasms | 2023 |
Predictors of outcomes of docetaxel treatment in de novo metastatic hormone-sensitive prostate cancer: A single-center cohort study.
Topics: Androgen Antagonists; Cohort Studies; Docetaxel; Hormones; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies | 2023 |
Inhibition of Ribonucleotide Reductase Induces Endoplasmic Reticulum Stress and Apoptosis, Leading to the Death of Docetaxel-resistant Prostate Cancer Cells.
Topics: Apoptosis; Cell Line, Tumor; Docetaxel; Endoplasmic Reticulum Stress; Humans; Male; Prostatic Neoplasms; Ribonucleotide Reductases | 2023 |
Cuproptosis enhances docetaxel chemosensitivity by inhibiting autophagy via the DLAT/mTOR pathway in prostate cancer.
Topics: Apoptosis; Autophagy; Cell Line, Tumor; Copper; Dihydrolipoyllysine-Residue Acetyltransferase; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; TOR Serine-Threonine Kinases | 2023 |
Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells.
Topics: Docetaxel; Glucocorticoids; Humans; Intercellular Signaling Peptides and Proteins; Male; Prostatic Neoplasms; Receptors, Glucocorticoid | 2023 |
Integrin-targeting disulfide-crosslinked micellar docetaxel eradicates lung and prostate cancer patient-derived xenografts.
Topics: Animals; Cell Line, Tumor; Disulfides; Docetaxel; Heterografts; Humans; Integrins; Lung; Lung Neoplasms; Male; Mice; Micelles; Peptides, Cyclic; Prostatic Neoplasms | 2023 |
Ki67 and prostate specific antigen are prognostic in metastatic hormone naïve prostate cancer.
Topics: Androgen Antagonists; Androgens; Docetaxel; Humans; Ki-67 Antigen; Male; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms | 2023 |
Time trends in systemic treatment for patients with metastatic prostate cancer: a national cohort study.
Topics: Androgen Antagonists; Cohort Studies; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2023 |
Fatty acid binding protein 5 regulates docetaxel sensitivity in taxane-resistant prostate cancer cells.
Topics: ATP Binding Cassette Transporter, Subfamily B; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Fatty Acid-Binding Proteins; Humans; Male; Prostatic Neoplasms; Taxoids | 2023 |
Combination of Kaempferol and Docetaxel Induces Autophagy in Prostate Cancer Cells In Vitro and In Vivo.
Topics: Animals; Apoptosis; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Docetaxel; Humans; Kaempferols; Male; Mice; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2023 |
Ultrasound targeted microbubble destruction using docetaxel and Rose Bengal loaded Microbubbles for targeted Chemo-Sonodynamic therapy treatment of prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Animals; Disease Models, Animal; Docetaxel; Humans; Male; Mice; Microbubbles; Prostatic Neoplasms; Rose Bengal | 2023 |
Use of nanoparticles in animal models for prostate cancer treatment: a systematic review.
Topics: Animals; Docetaxel; Humans; Male; Models, Animal; Nanoparticles; Prostatic Neoplasms; Systematic Reviews as Topic | 2023 |
The effect of Ganoderma lucidum polysaccharide extract on sensitizing prostate cancer cells to flutamide and docetaxel: an in vitro study.
Topics: Cell Line, Tumor; Docetaxel; Flutamide; Humans; Male; Polysaccharides; Prostate; Prostatic Neoplasms; Reishi | 2023 |
Effect of Upfront Docetaxel in De Novo Metastatic Castration-Sensitive Prostate Cancer Patients with Gleason Grade Group 5.
Topics: Androgen Antagonists; Androgens; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Retrospective Studies | 2023 |
Synergistic effect of docetaxel combined with a novel multi-target inhibitor CUDC-101 on inhibiting human prostate cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Hydroxamic Acids; Male; Mice; Prostatic Neoplasms | 2023 |
Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer.
Topics: Androstenes; Cost-Benefit Analysis; Docetaxel; Humans; Male; Prostatic Neoplasms | 2019 |
TUBB3 Reverses Resistance to Docetaxel and Cabazitaxel in Prostate Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chromones; Docetaxel; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Knockdown Techniques; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Binding; PTEN Phosphohydrolase; Taxoids; Tubulin | 2019 |
Treatment options for patients with prostate cancer who develop metastatic disease after hormonal therapy.
Topics: Abiraterone Acetate; Absorptiometry, Photon; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisolone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Zoledronic Acid | 2019 |
Neoadjuvant chemohormonal therapy combined with radical prostatectomy and extended PLND for very high risk locally advanced prostate cancer: A retrospective comparative study.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Follow-Up Studies; Humans; Kallikreins; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Pelvis; Progression-Free Survival; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Retrospective Studies | 2019 |
Activated Wnt/β-Catenin signaling contributes to E3 ubiquitin ligase EDD-conferred docetaxel resistance in prostate cancer.
Topics: Animals; Antineoplastic Agents; beta Catenin; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Prostatic Neoplasms; Ubiquitin-Protein Ligases; Up-Regulation; Wnt Signaling Pathway | 2020 |
Blockade of γ-Glutamylcyclotransferase Enhances Docetaxel Growth Inhibition of Prostate Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Docetaxel; Enzyme Inhibitors; gamma-Glutamylcyclotransferase; Gene Expression; Humans; Immunohistochemistry; Male; Prostatic Neoplasms; RNA, Small Interfering | 2019 |
Metastatic Prostate Cancer Presenting With Bilateral Inguinal Lymphadenopathy.
Topics: Biopsy; Bone Neoplasms; Docetaxel; Humans; Inguinal Canal; Lymph Nodes; Lymphadenopathy; Lymphatic Metastasis; Male; Middle Aged; Multiparametric Magnetic Resonance Imaging; Neoplasm Grading; Prostate; Prostatic Neoplasms; Radionuclide Imaging | 2019 |
Upregulation of GRIM-19 augments the sensitivity of prostate cancer cells to docetaxel by targeting Rad23b.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; DNA Damage; DNA Repair; DNA Repair Enzymes; DNA-Binding Proteins; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; NADH, NADPH Oxidoreductases; PC-3 Cells; Prostatic Neoplasms; Up-Regulation | 2020 |
Low-dose Docetaxel Enhanced the Anticancer Effect of Temsirolimus by Overcoming Autophagy in Prostate Cancer Cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Docetaxel; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; PC-3 Cells; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Sirolimus | 2019 |
Reduction of circular RNA Foxo3 promotes prostate cancer progression and chemoresistance to docetaxel.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Prostate; Prostatic Neoplasms; RNA Interference; RNA, Circular; Xenograft Model Antitumor Assays | 2020 |
Validation and development of the CHAARTED criteria in patients with hormone-naïve metastatic prostate cancer: A multi-institutional retrospective study in Japan.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Japan; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies | 2020 |
Synergistic combination treatment to break cross talk between cancer cells and bone cells to inhibit progression of bone metastasis.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Docetaxel; Humans; Male; Mice; Neoplasm Recurrence, Local; Prostatic Neoplasms; RANK Ligand; Tissue Distribution; Tumor Microenvironment | 2020 |
LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
Topics: Animals; Base Sequence; Cell Line, Tumor; Coenzyme A Ligases; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Prostatic Neoplasms; RNA, Long Noncoding; Up-Regulation | 2020 |
PEG-PLA nanoparticles decorated with small-molecule PSMA ligand for targeted delivery of galbanic acid and docetaxel to prostate cancer cells.
Topics: Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Cell Survival; Coumarins; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Glutamate Carboxypeptidase II; Glutarates; Humans; Ligands; Male; Nanoparticles; PC-3 Cells; Polyethylene Glycols; Prostatic Neoplasms | 2020 |
Hyperpolarized
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carbon Isotopes; Carboplatin; Docetaxel; Feasibility Studies; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Pilot Projects; Prognosis; Prostatic Neoplasms; Pyruvic Acid; Survival Rate | 2020 |
New Antiandrogen Compounds Compared to Docetaxel for Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Disease Progression; Docetaxel; Humans; Male; Network Meta-Analysis; Nitriles; Phenylthiohydantoin; Progression-Free Survival; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Standard of Care; Thiohydantoins | 2020 |
USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.
Topics: Apoptosis; Cell Cycle Proteins; Chromosomes; Chromosomes, Human; Docetaxel; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; HEK293 Cells; Humans; M Phase Cell Cycle Checkpoints; Male; Mitosis; Nasopharyngeal Neoplasms; Polo-Like Kinase 1; Prostatic Neoplasms; Protease Inhibitors; Protein Serine-Threonine Kinases; Protein Stability; Proto-Oncogene Proteins; Signal Transduction; Thiophenes; Transfection; Ubiquitin-Specific Peptidase 7 | 2019 |
Pigs in a blanket: an unusual presentation of malignant ascites in prostatic adenocarcinoma.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Ascites; Benzamides; Docetaxel; Humans; Male; Nitriles; Peritoneal Neoplasms; Phenylthiohydantoin; Prostatic Neoplasms; Treatment Outcome | 2019 |
A novel adjuvant drug-device combination tissue scaffold for radical prostatectomy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Chemotherapy, Adjuvant; Docetaxel; Humans; Male; PC-3 Cells; Prostate; Prostatectomy; Prostatic Neoplasms; Tissue Scaffolds | 2019 |
Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Proliferation; Class II Phosphatidylinositol 3-Kinases; Docetaxel; Down-Regulation; Female; HeLa Cells; Humans; Male; Mice, Nude; PC-3 Cells; Prostatic Neoplasms; Random Allocation; Transfection; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2019 |
A polymeric paste-drug formulation for intratumoral treatment of prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Docetaxel; Drug Compounding; Humans; Male; Mice; Nitriles; Polymers; Prostatic Neoplasms; Rats; Tissue Distribution; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly.
Topics: Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cytoplasmic Granules; Docetaxel; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Humans; Male; Models, Biological; Mutation; Nuclear Proteins; Prostatic Neoplasms; Protein Binding; Proteolysis; Repressor Proteins; Stress, Physiological; Ubiquitin-Protein Ligases; Ubiquitination | 2019 |
Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Repositioning; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Mebendazole; Mice; PC-3 Cells; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2020 |
Improving radio-chemotherapy efficacy of prostate cancer by co-deliverying docetaxel and dbait with biodegradable nanoparticles.
Topics: Antineoplastic Agents; Chemoradiotherapy; DNA Damage; Docetaxel; Humans; Male; Nanoparticles; PC-3 Cells; Prostatic Neoplasms | 2020 |
MiR-129-5p promotes docetaxel resistance in prostate cancer by down-regulating CAMK2N1 expression.
Topics: Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; MicroRNAs; PC-3 Cells; Prostate; Prostatic Neoplasms; Proteins; Up-Regulation | 2020 |
Expression profile-based screening for critical genes reveals S100A4, ACKR3 and CDH1 in docetaxel-resistant prostate cancer cells.
Topics: Antigens, CD; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Deletion; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Prostatic Neoplasms; Receptors, CXCR; S100 Calcium-Binding Protein A4; Transcriptome | 2019 |
Editorial Comment.
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Network Meta-Analysis; Prostatic Neoplasms | 2020 |
New Zampanolide Mimics: Design, Synthesis, and Antiproliferative Evaluation.
Topics: Antineoplastic Agents; Biomimetics; Cell Proliferation; Docetaxel; Drug Design; Drug Resistance, Neoplasm; Humans; Macrolides; Male; Prostatic Neoplasms; Tumor Cells, Cultured | 2020 |
CD44 variant 6 is associated with prostate cancer growth and chemo-/radiotherapy response in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Chemoradiotherapy; Docetaxel; Gamma Rays; Genetic Variation; Humans; Hyaluronan Receptors; Male; Mice; Mice, Inbred NOD; Mice, SCID; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Radiation Tolerance; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
γ-Tocotrienol and α-Tocopherol Ether Acetate Enhance Docetaxel Activity in Drug-Resistant Prostate Cancer Cells.
Topics: alpha-Tocopherol; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chromans; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Ether; Humans; Male; Prostatic Neoplasms; Vitamin E | 2020 |
Design and Characterization of Injectable Poly(Lactic-Co-Glycolic Acid) Pastes for Sustained and Local Drug Release.
Topics: Anilides; Animals; Antineoplastic Agents; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Stability; Humans; Injections; Lidocaine; Male; Mice; Mice, Nude; Neoplasms, Experimental; Nitriles; Ointments; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms; Rats; Tosyl Compounds; Viscosity | 2020 |
Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.
Topics: Androgens; Animals; Apoptosis; Cell Movement; Disease Progression; Docetaxel; Endoplasmic Reticulum Stress; Humans; Male; Mice; Neoplasm Metastasis; Proscillaridin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2020 |
Docetaxel for Early Prostate Cancer: What Have We Learned?
Topics: Docetaxel; Humans; Male; Prostatectomy; Prostatic Neoplasms; Veterans | 2020 |
Combined targeting of EGFR and HER2 against prostate cancer stem cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Docetaxel; ErbB Receptors; Humans; Male; Mice; Mice, SCID; Neoplastic Stem Cells; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2020 |
Establishment and characterization of patient-derived xenografts for hormone-naïve and castrate-resistant prostate cancers to improve treatment modality evaluation.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Castration; Disease Models, Animal; Docetaxel; Heterografts; Humans; Male; Mice; Prostatic Neoplasms | 2020 |
Immune Checkpoint Inhibition in Prostate Cancer.
Topics: Adenocarcinoma; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Humans; Immune Checkpoint Inhibitors; Immunotherapy; Male; Molecular Targeted Therapy; Neoplasm Proteins; Nitriles; Phenylthiohydantoin; Phthalazines; Piperazines; Prednisone; Programmed Cell Death 1 Receptor; Prostatic Neoplasms | 2020 |
Cancer epithelia-derived mitochondrial DNA is a targetable initiator of a paracrine signaling loop that confers taxane resistance.
Topics: Anaphylatoxins; Animals; Antineoplastic Agents; Apoptosis; Cancer-Associated Fibroblasts; DNA, Mitochondrial; Docetaxel; Drug Resistance, Neoplasm; Epithelium; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Paracrine Communication; Prostatic Neoplasms; Toll-Like Receptor 9; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
[Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial].
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
Docetaxel dose-intensity effect on overall survival in patients with metastatic castrate-sensitive prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Dose-Response Relationship, Drug; Drug Monitoring; Granulocyte Colony-Stimulating Factor; Humans; Male; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Time-to-Treatment; Treatment Outcome | 2020 |
Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer.
Topics: Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Computational Biology; Databases, Genetic; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; GABA Plasma Membrane Transport Proteins; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Prognosis; Prostatic Neoplasms; Survival Rate; Xenograft Model Antitumor Assays | 2020 |
Prostate-specific antigen dynamics predict individual responses to intermittent androgen deprivation.
Topics: Algorithms; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Administration Schedule; Humans; Kinetics; Male; Models, Theoretical; Neoplastic Stem Cells; Nitriles; Phenylthiohydantoin; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Thiohydantoins; Treatment Outcome | 2020 |
Synergistic anti-tumor effects of Liraglutide, a glucagon-like peptide-1 receptor agonist, along with Docetaxel on LNCaP prostate cancer cell line.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Gene Expression Regulation; Glucagon-Like Peptide-1 Receptor; Humans; Liraglutide; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 3; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger | 2020 |
FAM46C inhibits cell proliferation and cell cycle progression and promotes apoptosis through PTEN/AKT signaling pathway and is associated with chemosensitivity in prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nucleotidyltransferases; Polynucleotide Adenylyltransferase; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Xenograft Model Antitumor Assays | 2020 |
Impact of nuclear YAP1 expression in residual cancer after neoadjuvant chemohormonal therapy with docetaxel for high-risk localized prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Docetaxel; Gene Knockdown Techniques; Humans; Male; Neoadjuvant Therapy; Neoplasm, Residual; Prostatic Neoplasms; Survival Analysis; Tissue Array Analysis; Transcription Factors; Up-Regulation; YAP-Signaling Proteins | 2020 |
Surrogate endpoints for overall survival for patients with metastatic hormone-sensitive prostate cancer in the CHAARTED trial.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Disease Progression; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Multicenter Studies as Topic; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; United States | 2020 |
The Role of Crosstalk between AR3 and E2F1 in Drug Resistance in Prostate Cancer Cells.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; E2F1 Transcription Factor; Humans; Male; Mice; Mice, Nude; Nitriles; Phenylthiohydantoin; Prostate; Prostatic Neoplasms; Receptor Cross-Talk; Receptors, Androgen; Xenograft Model Antitumor Assays | 2020 |
Efficacy of Upfront Docetaxel With Androgen Deprivation Therapy for Castration-Sensitive Metastatic Prostate Cancer Among Minority Patients.
Topics: Androgen Antagonists; Androgens; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Retrospective Studies | 2020 |
Wnt/β-catenin signaling contributes to prostate cancer heterogeneity through reciprocal suppression of H3K27 trimethylation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Methylation; PC-3 Cells; Prostatic Neoplasms; Structure-Activity Relationship; Wnt Signaling Pathway | 2020 |
Chemotherapy, not androgen receptor-targeted therapy should be used upfront for metastatic hormone-sensitive prostate cancer. PRO: docetaxel chemotherapy should be the default consideration in metastatic hormone-sensitive prostate cancer.
Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms | 2020 |
Editorial Comment to Association of tumor burden with the eligibility of upfront intensification therapy in metastatic castration-sensitive prostate cancer: A multicenter retrospective study.
Topics: Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Retrospective Studies; Tumor Burden | 2020 |
Taxane resistance in prostate cancer is mediated by decreased drug-target engagement.
Topics: Animals; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Microtubules; Prostatic Neoplasms; Taxoids | 2020 |
Can docetaxel combined prednisone effectively treat hormone refractory prostate cancer?: A protocol of systematic review and meta-analysis.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Meta-Analysis as Topic; Prednisone; Prostatic Neoplasms; Systematic Review as Topic | 2020 |
Single-Cell Transcriptomics Analysis Identifies Nuclear Protein 1 as a Regulator of Docetaxel Resistance in Prostate Cancer Cells.
Topics: Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms; Single-Cell Analysis; Transcriptome; Transfection | 2020 |
Cost-Effectiveness of Metastasis-Directed Therapy in Oligorecurrent Hormone-Sensitive Prostate Cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Confidence Intervals; Cost-Benefit Analysis; Docetaxel; Humans; Male; Markov Chains; Monte Carlo Method; Prednisone; Prostatic Neoplasms; Quality-Adjusted Life Years; Radiosurgery; Salvage Therapy; Time Factors | 2020 |
EGFR-targeted immunoliposomes efficiently deliver docetaxel to prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; ErbB Receptors; Humans; Liposomes; Male; Prostatic Neoplasms | 2020 |
The CHK1 inhibitor MU380 significantly increases the sensitivity of human docetaxel-resistant prostate cancer cells to gemcitabine through the induction of mitotic catastrophe.
Topics: Animals; Cell Death; Cell Line, Tumor; Cell Proliferation; Checkpoint Kinase 1; Deoxycytidine; Docetaxel; Drug Resistance, Neoplasm; Gemcitabine; Humans; Male; Mice, SCID; Mitosis; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyrimidines; S Phase; Xenograft Model Antitumor Assays | 2020 |
Inhibition of Notch pathway enhances the anti-tumor effect of docetaxel in prostate cancer stem-like cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Prostatic Neoplasms; Receptors, Notch | 2020 |
Cediranib, an inhibitor of vascular endothelial growth factor receptor kinases, inhibits proliferation and invasion of prostate adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Docetaxel; Gamma Rays; Gene Expression Regulation; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor | 2020 |
HOTAIR expands the population of prostatic cancer stem-like cells and causes Docetaxel resistance via activating STAT3 signaling.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Docetaxel; Drug Resistance, Neoplasm; Heterografts; Humans; Male; Mice; Mice, Nude; Neoplastic Stem Cells; Prostatic Neoplasms; RNA, Long Noncoding; STAT3 Transcription Factor | 2020 |
Combination of NDRG2 overexpression, X-ray radiation and docetaxel enhances apoptosis and inhibits invasiveness properties of LNCaP cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Tumor Suppressor Proteins; X-Rays | 2020 |
Preparation and Evaluation of Cabazitaxel-Loaded Bovine Serum Albumin Nanoparticles for Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chromatography, Liquid; Contrast Media; Docetaxel; Drug Carriers; Humans; Magnetic Resonance Imaging; Male; Mice, Inbred BALB C; Nanoparticles; Prostatic Neoplasms; Rats, Sprague-Dawley; Serum Albumin, Bovine; Tandem Mass Spectrometry; Taxoids; Tissue Distribution | 2020 |
Retronychia Triggered by Docetaxel.
Topics: Aged; Docetaxel; Humans; Male; Nails; Nails, Ingrown; Prostatic Neoplasms; Toes; Treatment Outcome; Tubulin Modulators | 2021 |
Re: Is There a Benefit of Additional Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years with Hormone-Sensitive Advanced Prostate Cancer? A Meta-Analysis.
Topics: Androstenes; Celecoxib; Docetaxel; Humans; Male; Prostatic Neoplasms; Zoledronic Acid | 2020 |
Synthesis of PEGylated nanographene oxide as a nanocarrier for docetaxel drugs and anticancer activity on prostate cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Graphite; Humans; Male; Oxides; Particle Size; Polyethylene Glycols; Prostate; Prostatic Neoplasms | 2021 |
Phosphoinositide-dependent Kinase-1 (PDPK1) regulates serum/glucocorticoid-regulated Kinase 3 (SGK3) for prostate cancer cell survival.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Cell Death; Cell Line, Tumor; Cell Survival; Docetaxel; Gene Library; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyrimidines; RNA, Small Interfering; Signal Transduction; Thiophenes | 2020 |
Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805).
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Interleukin-8; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2020 |
LHRH-conjugated, PEGylated, poly-lactide-co-glycolide nanocapsules for targeted delivery of combinational chemotherapeutic drugs Docetaxel and Quercetin for prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dioxanes; Docetaxel; Drug Carriers; Gonadotropin-Releasing Hormone; Humans; Male; Nanocapsules; Nanoparticles; Polyethylene Glycols; Prostatic Neoplasms; Quercetin | 2020 |
Synergistic antitumor interaction of valproic acid and simvastatin sensitizes prostate cancer to docetaxel by targeting CSCs compartment via YAP inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle Proteins; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Prostatic Neoplasms; Simvastatin; Transcription Factors; Tumor Cells, Cultured; Valproic Acid; Xenograft Model Antitumor Assays | 2020 |
In vivo CRISPR/Cas9 knockout screen: TCEAL1 silencing enhances docetaxel efficacy in prostate cancer.
Topics: Animals; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; CRISPR-Cas Systems; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genetic Engineering; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids; Transcription Factors; Xenograft Model Antitumor Assays | 2020 |
Exploitation of the chick embryo chorioallantoic membrane (CAM) as a platform for anti-metastatic drug testing.
Topics: Animals; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; Chick Embryo; Chorioallantoic Membrane; Cisplatin; Crizotinib; Docetaxel; Drug Screening Assays, Antitumor; Gefitinib; Male; Neoplasm Metastasis; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms | 2020 |
Local and metastatic curative radiotherapy in patients with de novo oligometastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Recurrence; Retrospective Studies; Tumor Burden | 2020 |
Multifunctional nanoparticles for targeting the tumor microenvironment to improve synergistic drug combinations and cancer treatment effects.
Topics: Animals; Antineoplastic Agents; Catechin; Docetaxel; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Synergism; Humans; Male; Mice, SCID; Multifunctional Nanoparticles; Prostatic Neoplasms; Tumor Microenvironment | 2020 |
Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Repair-Deficiency Disorders; Docetaxel; Drug Therapy; Humans; Male; Middle Aged; Paclitaxel; Platinum Compounds; Prostatic Neoplasms; Retrospective Studies | 2020 |
Bone-Targeted Calcium Phosphate-Polymer Hybrid Nanoparticle Co-Deliver Zoledronate and Docetaxel to Treat Bone Metastasis of Prostate Cancer.
Topics: Antineoplastic Agents; Calcium Phosphates; Cell Line, Tumor; Docetaxel; Humans; Male; Nanoparticles; Polymers; Prostatic Neoplasms; Zoledronic Acid | 2021 |
Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.
Topics: Animals; Cellular Senescence; Docetaxel; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Male; Matrix Metalloproteinases; Mice; Neoplasm Metastasis; Neoplasm Transplantation; PC-3 Cells; Prostatic Neoplasms; PTEN Phosphohydrolase; Tissue Inhibitor of Metalloproteinase-1 | 2021 |
Protein Disulfide Isomerase 4 Drives Docetaxel Resistance in Prostate Cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Disulfide-Isomerases; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Signal Transduction | 2020 |
Chondroitin sulfate-hybridized zein nanoparticles for tumor-targeted delivery of docetaxel.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Chondroitin Sulfates; Docetaxel; Drug Carriers; Half-Life; Humans; Hyaluronan Receptors; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Nanoparticles; NIH 3T3 Cells; Particle Size; PC-3 Cells; Prostatic Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays; Zein | 2021 |
Selective cytotoxic and anti-metastatic activity in DU-145 prostate cancer cells induced by Annona muricata L. bark extract and phytochemical, annonacin.
Topics: Annona; Antineoplastic Agents; Carcinoma; Caspases; Cell Line, Tumor; Cell Movement; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Furans; Humans; Lactones; Male; Membrane Potential, Mitochondrial; Phytotherapy; Plant Bark; Plant Extracts; Plant Leaves; Prostatic Neoplasms; Reactive Oxygen Species | 2020 |
Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT.
Topics: Aged; Docetaxel; Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Lung Diseases, Interstitial; Male; Oligopeptides; Positron Emission Tomography Computed Tomography; Prostatic Neoplasms | 2021 |
Targeted micelles with chemotherapeutics and gene drugs to inhibit the G1/S and G2/M mitotic cycle of prostate cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Delivery Systems; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Micelles; Particle Size; Polyesters; Prostatic Neoplasms; RNA, Small Interfering | 2021 |
Toxicity profile of taxanes in Tunisian cancer patients: A retrospective study of 90 cases.
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Breast Neoplasms; Cisplatin; Digestive System Diseases; Docetaxel; Fatigue; Female; Fluorouracil; Hematologic Diseases; Humans; Male; Middle Aged; Nail Diseases; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Stomach Neoplasms; Taxoids; Tunisia | 2021 |
Antiandrogen abiraterone and docetaxel treatments affect Notch1, Jagged1 and Hes1 expressions in metastatic prostate cancer cells.
Topics: Androgen Antagonists; Androstenes; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Male; Neoplasm Metastasis; Prostatic Neoplasms; Receptor, Notch1; RNA, Messenger; Transcription Factor HES-1 | 2021 |
Body composition and metastatic prostate cancer survivorship.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Body Composition; Cancer Survivors; Disease Progression; Docetaxel; Humans; Male; Progression-Free Survival; Prostate; Prostatic Neoplasms; Survivorship | 2021 |
Mesenchymal stem cell-derived interleukin-28 drives the selection of apoptosis resistant bone metastatic prostate cancer.
Topics: Adenocarcinoma; Aminosalicylic Acids; Animals; Apoptosis; Benzenesulfonates; Bone Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Culture Media, Conditioned; Disease Models, Animal; Docetaxel; Humans; Interferons; Male; Mesenchymal Stem Cells; Mice, Knockout; Osteoblasts; Primary Cell Culture; Prostatic Neoplasms; Receptors, Interferon; Recombinant Proteins; RNA, Small Interfering; STAT1 Transcription Factor; STAT3 Transcription Factor; Tibia | 2021 |
An effective strategy for development of docetaxel encapsulated gold nanoformulations for treatment of prostate cancer.
Topics: Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Compounding; Drug Liberation; Drug Screening Assays, Antitumor; Gold; Humans; Male; Metal Nanoparticles; Particle Size; Polyethylene Glycols; Prostatic Neoplasms | 2021 |
Glutamate-urea-based PSMA-targeted PLGA nanoparticles for prostate cancer delivery of docetaxel.
Topics: Antigens, Surface; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Delivery Systems; Glutamate Carboxypeptidase II; Glutamic Acid; Humans; Inhibitory Concentration 50; Male; Nanoparticles; Particle Size; Polyethylene Glycols; Polyglactin 910; Prostatic Neoplasms; Time Factors; Urea | 2021 |
Docetaxel chemotherapy response in PC3 prostate cancer mouse model detected by rotating frame relaxations and water diffusion.
Topics: Animals; Diffusion; Disease Models, Animal; Docetaxel; Humans; Magnetic Resonance Imaging; Male; Prostatic Neoplasms; Tumor Burden; Water | 2021 |
PSMA-targeted therapy in prostate cancer.
Topics: Adenocarcinoma; Antibodies, Bispecific; Antibodies, Neoplasm; Antigens, Surface; Biomarkers, Tumor; Clinical Trials as Topic; Dipeptides; Docetaxel; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lutetium; Male; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Randomized Controlled Trials as Topic | 2021 |
Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Ferroptosis; Gene Expression Regulation, Neoplastic; Humans; Lipid Metabolism; Lipidomics; Lipids; Male; Middle Aged; Neoplasm Metastasis; Nuclear Proteins; Phosphatidate Phosphatase; Prostatic Neoplasms; Signal Transduction | 2021 |
SEOM clinical guidelines for the treatment of advanced prostate cancer (2020).
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Benzamides; Combined Modality Therapy; Docetaxel; Genes, BRCA1; Genes, BRCA2; Genetic Testing; Humans; Male; Medical Oncology; Nitriles; Orchiectomy; Phenylthiohydantoin; Phthalazines; Piperazines; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy; Randomized Controlled Trials as Topic; Societies, Medical; Spain; Thiohydantoins | 2021 |
Use of miR‑145 and testicular nuclear receptor 4 inhibition to reduce chemoresistance to docetaxel in prostate cancer.
Topics: Animals; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; MicroRNAs; Neoplasm Transplantation; Octamer Transcription Factor-3; Prostatic Neoplasms; Receptors, Steroid; Receptors, Thyroid Hormone; RNA, Small Interfering; Signal Transduction | 2021 |
Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Treatment Outcome; Victoria | 2022 |
Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; PC-3 Cells; Pentoxifylline; Phosphodiesterase Inhibitors; Prostatic Neoplasms | 2021 |
Short-term outcomes of risk-adapted upfront docetaxel administration in patients with metastatic hormone-sensitive prostate cancer: a multicenter prospective study in Japan.
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Japan; Male; Middle Aged; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Treatment Outcome | 2021 |
Periprostatic adipose tissue promotes prostate cancer resistance to docetaxel by paracrine IGF-1 upregulation of TUBB2B beta-tubulin isoform.
Topics: Adipose Tissue; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor I; Male; Paracrine Communication; Prostatic Neoplasms; Tubulin; Up-Regulation | 2021 |
SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cysteine Endopeptidases; Docetaxel; Hexokinase; Humans; Male; Mice; Mitochondria; Prostatic Neoplasms; Protein Binding; Sumoylation; Xenograft Model Antitumor Assays | 2021 |
Skp2 and Slug Are Coexpressed in Aggressive Prostate Cancer and Inhibited by Neddylation Blockade.
Topics: Antigens, CD; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Cyclopentanes; Docetaxel; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Lymphatic Metastasis; Male; NEDD8 Protein; Neoplasm Grading; PC-3 Cells; Prostate; Prostatic Neoplasms; Protein Processing, Post-Translational; Pyrimidines; Receptors, Androgen; RNA, Small Interfering; S-Phase Kinase-Associated Proteins; Snail Family Transcription Factors | 2021 |
Tau oligomers accumulation sensitizes prostate cancer cells to docetaxel treatment.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Protein Multimerization; tau Proteins; Tumor Cells, Cultured | 2021 |
Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Topics: Acid Phosphatase; Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Epithelial Cells; Gene Expression Profiling; Genomics; Humans; Male; Neoplasm Grading; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Sequence Analysis, RNA; Transcriptome | 2021 |
Proteomic analysis of extracellular vesicles identified PI3K pathway as a potential therapeutic target for cabazitaxel-resistant prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Discovery; Drug Resistance, Neoplasm; Extracellular Vesicles; Humans; Male; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Proteomics; Signal Transduction; Taxoids | 2021 |
Neoadjuvant Chemohormonal Therapy before Radical Prostatectomy for Japanese Patients with High-Risk Localized Prostate Cancer.
Topics: Docetaxel; Humans; Japan; Male; Neoadjuvant Therapy; Prospective Studies; Prostatectomy; Prostatic Neoplasms | 2021 |
Deficiency of NEIL3 Enhances the Chemotherapy Resistance of Prostate Cancer.
Topics: Androgen Antagonists; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Checkpoints; Cell Line, Tumor; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; N-Glycosyl Hydrolases; Neoplasm Invasiveness; Neurosecretory Systems; Prostatic Neoplasms; S Phase | 2021 |
Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer.
Topics: Abiraterone Acetate; Cost-Benefit Analysis; Docetaxel; Hormones; Humans; Male; Markov Chains; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Therapies, Investigational; Treatment Outcome | 2021 |
Exosomal Circ-XIAP Promotes Docetaxel Resistance in Prostate Cancer by Regulating miR-1182/TPD52 Axis.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Humans; Male; MicroRNAs; Neoplasm Proteins; Prostatic Neoplasms; RNA, Circular; Tumor Cells, Cultured | 2021 |
Identification of docetaxel-related biomarkers for prostate cancer.
Topics: APOBEC-3G Deaminase; Biomarkers, Tumor; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms; Tumor Microenvironment | 2021 |
Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Databases, Genetic; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Male; Prostatic Neoplasms; Protein Interaction Maps; Signal Transduction; Transcriptome | 2021 |
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Bone Neoplasms; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Discovery; Drug Resistance, Neoplasm; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; Humans; Inhibitory Concentration 50; Male; Mice; Polycomb Repressive Complex 2; Prostatic Neoplasms; S-Phase Kinase-Associated Proteins; Signal Transduction; STAT3 Transcription Factor; Survivin; Xenograft Model Antitumor Assays | 2021 |
Clinical Outcomes and Racial Disparities in Metastatic Hormone-Sensitive Prostate Cancer in the Era of Novel Treatment Options.
Topics: Androstenes; Black or African American; Docetaxel; Georgia; Health Status Disparities; Hormones; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies | 2021 |
ADME gene polymorphisms do not influence the pharmacokinetics of docetaxel: Results from a population pharmacokinetic study in Indian cancer patients.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents; Docetaxel; Female; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Pharmacogenomic Variants; Polymorphism, Genetic; Prostatic Neoplasms; Reference Values; Young Adult | 2021 |
Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Aged; Datasets as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Kallikreins; Kaplan-Meier Estimate; Male; Neoplasm Grading; Neoplasm Recurrence, Local; PC-3 Cells; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Up-Regulation | 2021 |
Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro.
Topics: Antineoplastic Agents; Biflavonoids; Breast Neoplasms; Catechin; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Female; Humans; In Vitro Techniques; Male; MCF-7 Cells; Proanthocyanidins; Prostatic Neoplasms | 2021 |
Molecular Mechanism Mediating Cytotoxic Activity of Cabazitaxel in Docetaxel-resistant Human Prostate Cancer Cells.
Topics: Animals; Antineoplastic Agents; Chromones; Docetaxel; Drug Resistance, Neoplasm; Humans; Ki-67 Antigen; Male; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Morpholines; PC-3 Cells; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Taxoids; Xenograft Model Antitumor Assays | 2021 |
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer.
Topics: Androgen Antagonists; Docetaxel; Genes, Tumor Suppressor; Hormones; Humans; Male; Prostatic Neoplasms; PTEN Phosphohydrolase; Retinoblastoma Binding Proteins; Retrospective Studies; Treatment Outcome; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases | 2022 |
DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Chromones; DNA Damage; DNA-Activated Protein Kinase; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Humans; Male; Morpholines; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridazines; Quinazolines; Taxoids | 2021 |
ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Docetaxel; Humans; Immunotherapy; Intracellular Signaling Peptides and Proteins; Male; Mice; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Signal Transduction | 2021 |
Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Azetidines; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Janus Kinase 1; Male; Nitriles; Prostatic Neoplasms; Purines; Pyrazoles; Pyrimidines; Sulfonamides | 2021 |
Prognostic role of docetaxel-induced suppression of free testosterone serum levels in metastatic prostate cancer patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Limit of Detection; Male; Neoplasm Metastasis; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone | 2021 |
Suppressed PLIN3 frequently occurs in prostate cancer, promoting docetaxel resistance via intensified autophagy, an event reversed by chloroquine.
Topics: Antineoplastic Agents; Autophagy; Cell Line, Tumor; Chloroquine; Docetaxel; Drug Resistance, Neoplasm; Gene Silencing; Humans; Male; Perilipin-3; Prostatic Neoplasms | 2021 |
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Androstenes; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Progression-Free Survival; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Treatment Outcome | 2021 |
Adjuvant radiation therapy, androgen deprivation, and docetaxel for high-risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Chemoradiotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Kallikreins; Male; Middle Aged; Multivariate Analysis; Neoplasm Grading; Neoplasm Staging; Nitriles; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Taxoids; Tosyl Compounds | 2017 |
Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Docetaxel; HSP90 Heat-Shock Proteins; Immunoblotting; Lactams, Macrocyclic; Male; Mice, Knockout; Mice, Transgenic; Micelles; Molecular Targeted Therapy; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2017 |
Prostate cancer: Custirsen fails to improve outcomes.
Topics: Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Thionucleotides | 2017 |
Systematic Trial for Evaluating Docetaxel in a Human Prostate Cancer Cell DU145 Xenograft Model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Docetaxel; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Phase II study of cabazitaxel with or without abiraterone acetate and prednisone in patients with metastatic castrate resistant prostate cancer after prior docetaxel and abiraterone acetate.
Topics: Abiraterone Acetate; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2017 |
Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Nude; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; RNA Interference; Taxoids; Thiourea; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Combination of Nexrutine and docetaxel suppresses NFκB-mediated activation of c-FLIP.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Metastasis; NF-kappa B; Plant Extracts; Prostatic Neoplasms; Signal Transduction; Taxoids | 2017 |
Taxane-Grafted Metal-Oxide Nanoparticles as a New Theranostic Tool against Cancer: The Promising Example of Docetaxel-Functionalized Titanate Nanotubes on Prostate Tumors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Stability; Humans; Male; Metal Nanoparticles; Mice; Mice, Nude; Oxides; Particle Size; Prostatic Neoplasms; Taxoids; Theranostic Nanomedicine; Tissue Distribution; Titanium; Xenograft Model Antitumor Assays | 2017 |
Hypoxia-induced angiopoietin-like protein 4 as a clinical biomarker and treatment target for human prostate cancer.
Topics: Aged; Angiopoietin-Like Protein 4; Antineoplastic Agents; Apoptosis; Biomarkers; Case-Control Studies; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Humans; Hypoxia; Male; Middle Aged; Prognosis; Prostatic Neoplasms; RNA, Small Interfering; Signal Transduction; Taxoids; Tumor Cells, Cultured | 2017 |
Combination of RAD001 (everolimus) and docetaxel reduces prostate and breast cancer cell VEGF production and tumour vascularisation independently of sphingosine-kinase-1.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Docetaxel; Everolimus; Female; Humans; Male; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred BALB C; Mice, Nude; PC-3 Cells; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Vascular Endothelial Growth Factor A | 2017 |
Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
Topics: Androgen Antagonists; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2017 |
ABCB1 Mediates Cabazitaxel-Docetaxel Cross-Resistance in Advanced Prostate Cancer.
Topics: Androgen Antagonists; ATP Binding Cassette Transporter, Subfamily B; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2017 |
Metabolic reprogramming is associated with flavopiridol resistance in prostate cancer DU145 cells.
Topics: Apoptosis; Biomarkers, Tumor; Cell Division; Cell Line, Tumor; Cell Movement; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Flavonoids; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Potential, Mitochondrial; Mitochondria; Neoplastic Stem Cells; Piperidines; Prostatic Neoplasms; Pseudopodia; Up-Regulation | 2017 |
Core shell lipid-polymer hybrid nanoparticles with combined docetaxel and molecular targeted therapy for the treatment of metastatic prostate cancer.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Drug Liberation; Humans; Lipids; Male; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Nanoparticles; Neoplasm Metastasis; Particle Size; Polylactic Acid-Polyglycolic Acid Copolymer; Prostatic Neoplasms | 2017 |
Magnetically-actuated drug delivery device (MADDD) for minimally invasive treatment of prostate cancer: An in vivo animal pilot study.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Drug Monitoring; Magnets; Male; Mice; Mice, Nude; Minimally Invasive Surgical Procedures; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome; Tumor Burden | 2017 |
Prostate cancer: A new standard-of-care for advanced-stage disease.
Topics: Docetaxel; Humans; Male; Prostatectomy; Prostatic Neoplasms; Zoledronic Acid | 2017 |
Identification of simvastatin-regulated targets associated with JNK activation in DU145 human prostate cancer cell death signaling.
Topics: Anthracenes; Apoptosis; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; JNK Mitogen-Activated Protein Kinases; Male; Phosphorylation; Prostatic Neoplasms; Proteomics; Signal Transduction; Simvastatin; Taxoids | 2017 |
Prostate cancer: Localized docetaxel delivery is feasible.
Topics: Animals; Docetaxel; Humans; Male; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms | 2017 |
Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.
Topics: Androgen Receptor Antagonists; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy, Needle; Combined Modality Therapy; Docetaxel; Gene Expression Regulation, Neoplastic; Genomics; Humans; Male; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms; Taxoids; Transcriptome | 2017 |
Plasma Level of hsa-miR-619-5p microRNA Is Associated with Prostatic Cancer Dissemination beyond the Capsule.
Topics: Biomarkers, Tumor; Cisplatin; Docetaxel; Granulocytes; Humans; Male; MicroRNAs; Neutrophils; Prostatic Neoplasms; Stem Cells; Taxoids | 2017 |
Ginger Phytochemicals Inhibit Cell Growth and Modulate Drug Resistance Factors in Docetaxel Resistant Prostate Cancer Cell.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Phytochemicals; Plant Extracts; Prostatic Neoplasms; Taxoids; Zingiber officinale | 2017 |
Docetaxel-titanate nanotubes enhance radiosensitivity in an androgen-independent prostate cancer model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Humans; Male; Mice, Inbred BALB C; Nanotubes; Prostatic Neoplasms; Radiation Tolerance; Radiation-Sensitizing Agents; Taxoids; Tissue Distribution; Titanium; Xenograft Model Antitumor Assays | 2017 |
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel.
Topics: Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Taxoids | 2017 |
Real-world uptake, safety profile and outcomes of docetaxel in newly diagnosed metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Febrile Neutropenia; Gonadotropin-Releasing Hormone; Hospitalization; Humans; Male; Middle Aged; Neoplasm Metastasis; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Time Factors | 2018 |
Pharmacokinetic/Pharmacodynamic Modeling of Schedule-Dependent Interaction between Docetaxel and Cabozantinib in Human Prostate Cancer Xenograft Models.
Topics: Anilides; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Administration Schedule; Drug Synergism; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Pyridines; Taxoids | 2018 |
microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; MicroRNAs; Prostatic Neoplasms; Taxoids; Tumor Protein p73; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Additive naftopidil treatment synergizes docetaxel-induced apoptosis in human prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Naphthalenes; Piperazines; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2018 |
miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; Mice; Mice, Nude; MicroRNAs; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2018 |
Multifunctional gold nanorods and docetaxel-encapsulated liposomes for combined thermo- and chemotherapy.
Topics: Animals; Antineoplastic Agents; Docetaxel; Drug Delivery Systems; Gold; Humans; Hyperthermia, Induced; Liposomes; Male; Mice, Nude; Nanomedicine; Nanotubes; Peptides; Polyethylene Glycols; Prostatic Neoplasms; Receptors, LDL; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2018 |
A standardized herbal extract mitigates tumor inflammation and augments chemotherapy effect of docetaxel in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Macrophages; Male; Mice; Neovascularization, Pathologic; NF-kappa B; Phosphorylation; Plant Extracts; Prostatic Neoplasms; Wedelia; Xenograft Model Antitumor Assays | 2017 |
Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Humans; Male; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Testosterone | 2018 |
Rare incidence of tumor lysis syndrome in metastatic prostate cancer following treatment with docetaxel.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Tumor Lysis Syndrome | 2018 |
The Microwell-mesh: A high-throughput 3D prostate cancer spheroid and drug-testing platform.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Screening Assays, Antitumor; High-Throughput Screening Assays; Humans; Male; Prostatic Neoplasms; Spheroids, Cellular; Taxoids; Tumor Cells, Cultured | 2018 |
Hyper-acetylation contributes to the sensitivity of chemo-resistant prostate cancer cells to histone deacetylase inhibitor Trichostatin A.
Topics: Acetyl Coenzyme A; Adaptor Proteins, Signal Transducing; Allografts; Animals; Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Eukaryotic Initiation Factors; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Male; Mice; Mice, Inbred C57BL; Phosphoproteins; Prostatic Neoplasms; Protein Isoforms; Proto-Oncogene Proteins c-akt; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Burden | 2018 |
Posttranscriptional Regulation of Human Antigen R by miR-133b Enhances Docetaxel Cytotoxicity Through the Inhibition of ATP-Binding Cassette Subfamily G Member 2 in Prostate Cancer Cells.
Topics: 3' Untranslated Regions; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Base Sequence; Binding Sites; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ELAV-Like Protein 1; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Proteins; Prostatic Neoplasms; RNA Interference; Taxoids | 2018 |
Safety and Efficacy of Prostatic Artery Chemoembolization for Prostate Cancer-Initial Experience.
Topics: Aged; Antineoplastic Agents; Chemoembolization, Therapeutic; Docetaxel; Humans; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2018 |
Long non-coding RNA CASC2 regulates Sprouty2 via functioning as a competing endogenous RNA for miR-183 to modulate the sensitivity of prostate cancer cells to docetaxel.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; MicroRNAs; Prostatic Neoplasms; RNA; RNA, Long Noncoding; Tumor Suppressor Proteins | 2019 |
Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Movement; Cell Proliferation; Docetaxel; Drug Synergism; Drugs, Chinese Herbal; Forkhead Box Protein M1; Humans; Lung Neoplasms; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Targeting prostate cancer cells with hybrid elastin-like polypeptide/liposome nanoparticles.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Delivery Systems; Elastin; Humans; Hydrophobic and Hydrophilic Interactions; Liposomes; Male; Micelles; Molecular Targeted Therapy; Nanoparticles; Peptides; Prostatic Neoplasms; Receptors, Bombesin; Taxoids | 2018 |
PARP1-siRNA suppresses human prostate cancer cell growth and progression.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Mice; Phthalazines; Piperazines; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Prostatic Neoplasms; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays | 2018 |
[Two Cases of Non-Occlusive Mesenteric Ischemia That Developed after Chemotherapy].
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Intestinal Diseases; Male; Mesenteric Ischemia; Oropharyngeal Neoplasms; Prostatic Neoplasms; Taxoids | 2017 |
Tricin isolated from
Topics: Allium; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Flavonoids; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Prostatic Neoplasms | 2019 |
MicroRNA-223-3p regulates cell chemo-sensitivity by targeting FOXO3 in prostatic cancer.
Topics: Animals; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Forkhead Box Protein O3; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Prostatic Neoplasms; Taxoids | 2018 |
Propofol Reversed Hypoxia-Induced Docetaxel Resistance in Prostate Cancer Cells by Preventing Epithelial-Mesenchymal Transition by Inhibiting Hypoxia-Inducible Factor 1
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Propofol; Prostate; Prostatic Neoplasms; Signal Transduction; Taxoids; Vimentin | 2018 |
Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Glucocorticoids; Humans; Male; Prostatic Neoplasms; Survival Analysis; United States | 2018 |
Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12.
Topics: A Kinase Anchor Proteins; Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; MicroRNAs; Prostate; Prostatic Neoplasms; RNA, Long Noncoding; Xenograft Model Antitumor Assays | 2018 |
Oleic acid promotes prostate cancer malignant phenotype via the G protein-coupled receptor FFA1/GPR40.
Topics: Aged; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; Middle Aged; Oleic Acid; Phenotype; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptors, G-Protein-Coupled; RNA, Messenger; Signal Transduction | 2018 |
Preliminary efficacy and tolerability of chemohormonal therapy in metastatic hormone-naïve prostate cancer: The first real-life experience in Asia.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Granulocyte Colony-Stimulating Factor; Hong Kong; Humans; Kallikreins; Male; Middle Aged; Neutropenia; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2018 |
MicroRNA-195 regulates docetaxel resistance by targeting clusterin in prostate cancer.
Topics: Base Sequence; Cell Line, Tumor; Clusterin; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Male; MicroRNAs; Prostatic Neoplasms; Taxoids; Up-Regulation | 2018 |
Zinc-ion-mediated self-assembly of forky peptides for prostate cancer-specific drug delivery.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Carriers; Drug Liberation; Humans; Hydrogels; Male; Nanofibers; Oligopeptides; Prostatic Neoplasms; Protein Multimerization; Taxoids; Viscoelastic Substances; Zinc | 2018 |
Reversal of drug resistance by planetary ball milled (PBM) nanoparticle loaded with resveratrol and docetaxel in prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Folic Acid; Humans; Male; Nanoparticles; Prostatic Neoplasms; Resveratrol | 2018 |
The case for 'successfully' treating hormone naïve metastatic prostate cancer.
Topics: Androstenes; Docetaxel; Humans; Male; Prostatic Neoplasms | 2018 |
Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC).
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Pain; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Registries; Retrospective Studies; Survival Rate; Time Factors | 2018 |
[Expression of AXL enhances docetaxel-resistance of prostate cancer cells].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Axl Receptor Tyrosine Kinase; Cell Count; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Humans; Intercellular Signaling Peptides and Proteins; Male; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins; Pyrimidines; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Taxoids; Thiourea | 2017 |
FOXM1 contributes to taxane resistance by regulating UHRF1-controlled cancer cell stemness.
Topics: Animals; Bridged-Ring Compounds; CCAAT-Enhancer-Binding Proteins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Forkhead Box Protein M1; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Phenotype; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Binding; Signal Transduction; Taxoids; Ubiquitin-Protein Ligases | 2018 |
Acquisition of tumorigenic potential and therapeutic resistance in CD133+ subpopulation of prostate cancer cells exhibiting stem-cell like characteristics.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinogenesis; Cell Line, Tumor; Core Binding Factor Alpha 1 Subunit; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Prostatic Neoplasms; Radiation Tolerance; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Using high throughput microtissue culture to study the difference in prostate cancer cell behavior and drug response in 2D and 3D co-cultures.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Cell Proliferation; Coculture Techniques; Docetaxel; Drug Screening Assays, Antitumor; Feasibility Studies; High-Throughput Screening Assays; Humans; Male; Prostate; Prostatic Neoplasms; Stromal Cells; Tumor Microenvironment | 2018 |
Counterpoint: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Abiraterone.
Topics: Abiraterone Acetate; Antineoplastic Agents; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Prostatic Neoplasms; Risk Factors; Steroid Synthesis Inhibitors; Taxoids; Time Factors; Treatment Outcome | 2018 |
Point: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer: The Case for Chemotherapy.
Topics: Abiraterone Acetate; Antineoplastic Agents; Clinical Decision-Making; Docetaxel; Humans; Male; Neoplasm Metastasis; Patient Selection; Prostatic Neoplasms; Risk Factors; Steroid Synthesis Inhibitors; Taxoids; Time Factors; Treatment Outcome | 2018 |
Application of Mixture Design Response Surface Methodology for Combination Chemotherapy in PC-3 Human Prostate Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dioxolanes; Docetaxel; Drug Synergism; Flavonoids; Humans; Male; Mitoxantrone; Models, Statistical; Piperidines; Prostatic Neoplasms; Resveratrol; Taxoids | 2018 |
Intra versus Inter Cross-resistance Determines Treatment Sequence between Taxane and AR-Targeting Therapies in Advanced Prostate Cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Staging; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2018 |
Repositioning Dopamine D2 Receptor Agonist Bromocriptine to Enhance Docetaxel Chemotherapy and Treat Bone Metastatic Prostate Cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Bromocriptine; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Docetaxel; Dopamine Agonists; Drug Repositioning; Drug Synergism; Humans; Male; Mice, Nude; Prostatic Neoplasms; Receptors, Dopamine D2; Xenograft Model Antitumor Assays | 2018 |
Reversal of docetaxel resistance in prostate cancer by Notch signaling inhibition.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Female; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Receptors, Notch; Signal Transduction; Survival Rate; Xenograft Model Antitumor Assays | 2018 |
The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Chitinase-3-Like Protein 1; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant | 2018 |
[Infiltrating mast cells promote neuroendocrine differentiation and increase docetaxel resistance of prostate cancer cells by up-regulating p21].
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mast Cells; Neuroendocrine Cells; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Up-Regulation | 2018 |
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Re: Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial.
Topics: Docetaxel; Humans; Male; Prospective Studies; Prostatectomy; Prostatic Neoplasms | 2018 |
[Integrated podiatrist care for prostate cancer patients treated with docetaxel: Feasibility and results].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Feasibility Studies; Hematoma; Humans; Male; Middle Aged; Nail Diseases; Onycholysis; Photography; Podiatry; Prostatic Neoplasms; Retrospective Studies | 2018 |
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Black or African American; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Polycomb Repressive Complex 1; Prostatic Neoplasms; White People; Zebrafish | 2018 |
Acetyl-11-keto-β-boswellic acid suppresses docetaxel-resistant prostate cancer cells in vitro and in vivo by blocking Akt and Stat3 signaling, thus suppressing chemoresistant stem cell-like properties.
Topics: Animals; Apoptosis; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred C57BL; Neoplastic Stem Cells; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; STAT3 Transcription Factor; Triterpenes | 2019 |
Docetaxel-induced radiation recall dermatitis with atypical features: A case report.
Topics: Antineoplastic Agents; Diagnosis, Differential; Docetaxel; Humans; Male; Prostatic Neoplasms; Radiodermatitis; Taxoids | 2018 |
Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Cyclobutanes; Disease Progression; Docetaxel; Down-Regulation; Humans; Male; Mice; Neoplasm Recurrence, Local; Organoplatinum Compounds; Prostate; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Transcriptional Regulator ERG | 2018 |
Effects of 3-butenyl isothiocyanate on phenotypically different prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Isothiocyanates; Male; Prostatic Neoplasms | 2018 |
Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
Topics: Antineoplastic Agents; Apoptosis; Cell Proliferation; Curcumin; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Proteolysis; Receptors, Androgen; Tumor Cells, Cultured | 2019 |
A functional genomics screen reveals a strong synergistic effect between docetaxel and the mitotic gene DLGAP5 that is mediated by the androgen receptor.
Topics: Benzamides; Cdc20 Proteins; Cell Cycle Proteins; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Genomics; Humans; Male; Metaphase; Microtubule-Associated Proteins; Neoplasm Proteins; Nitriles; PC-3 Cells; Phenylthiohydantoin; Prostatic Neoplasms; Receptors, Androgen; Transfection | 2018 |
Clinical effectiveness of docetaxel for castration-sensitive prostate cancer in a real-world population-based analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome | 2019 |
Radical Prostatectomy With and Without Neoadjuvant Chemohormonal Pretreatment for High-Risk Localized Prostate Cancer: A Comparative Propensity Score Matched Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Combined Modality Therapy; Docetaxel; Estramustine; Follow-Up Studies; Humans; Male; Neoadjuvant Therapy; Propensity Score; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Treatment Outcome | 2019 |
Suppression of Taxanes Cytotoxicity by Citrus Flavonoid Hesperetin in PPC-1 Human Prostate Cancer Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Dietary Supplements; Docetaxel; Drug Antagonism; Hesperidin; Humans; Male; Prostatic Neoplasms; Taxoids | 2018 |
Qualitative and Quantitative Assessment of Patient and Carer Experience of Chemotherapy (Docetaxel) in Combination with Androgen Deprivation Therapy (ADT) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC).
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Caregivers; Cross-Sectional Studies; Disease-Free Survival; Docetaxel; Europe; Humans; Male; Middle Aged; Neoplasm Metastasis; Patient Satisfaction; Prostatic Neoplasms; Quality of Life; Self Report | 2018 |
Evidence for L-Dopa Decarboxylase Involvement in Cancer Cell Cytotoxicity Induced by Docetaxel and Mitoxantrone.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Survival; CHO Cells; Cricetinae; Cricetulus; Docetaxel; Dopa Decarboxylase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; MCF-7 Cells; Mitoxantrone; Prostatic Neoplasms; Protein Isoforms | 2018 |
Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer.
Topics: Antineoplastic Agents; Bridged-Ring Compounds; Chalcones; Delayed-Action Preparations; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Micelles; MicroRNAs; Neoplastic Stem Cells; PC-3 Cells; Prostatic Neoplasms; Taxoids | 2019 |
Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
Topics: Aged; Androgen Antagonists; Androstenes; Antineoplastic Agents; Biopsy, Large-Core Needle; Clinical Trials as Topic; Disease Progression; Docetaxel; Humans; Japan; Male; Neoplasm Recurrence, Local; Orchiectomy; Prognosis; Progression-Free Survival; Prostate; Prostatic Neoplasms; Retrospective Studies; Risk Assessment | 2019 |
Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Tubulin Modulators | 2019 |
Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Grading; Prostatic Neoplasms; Retrospective Studies; Survival Analysis | 2019 |
Sarcomatoid Carcinoma of the Prostate Presenting in a 44 Year Old
Topics: Adult; Biopsy; Carcinosarcoma; Combined Modality Therapy; Docetaxel; Heart Neoplasms; Heart Ventricles; Humans; Magnetic Resonance Imaging; Male; Palliative Care; Pleural Effusion, Malignant; Prostatic Neoplasms; Radiotherapy; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2018 |
Development of PSMA-targeted and core-crosslinked glycol chitosan micelles for docetaxel delivery in prostate cancer therapy.
Topics: Animals; Cell Line, Tumor; Chitosan; Docetaxel; Drug Delivery Systems; Humans; Kallikreins; Male; Mice, Inbred BALB C; Micelles; Prostate-Specific Antigen; Prostatic Neoplasms; Xenograft Model Antitumor Assays | 2019 |
Patient Preferences for Metastatic Hormone-Sensitive Prostate Cancer Treatments: A Discrete Choice Experiment Among Men in Three European Countries.
Topics: Abiraterone Acetate; Adult; Aged; Antineoplastic Agents; Decision Making; Docetaxel; Germany; Humans; Male; Middle Aged; Neoplasm Staging; Patient Preference; Prostatic Neoplasms; Severity of Illness Index; Spain; Surveys and Questionnaires; Treatment Outcome; United Kingdom | 2019 |
Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Prostate; Prostatic Neoplasms | 2019 |
Small molecule BKM1972 inhibits human prostate cancer growth and overcomes docetaxel resistance in intraosseous models.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Bone Neoplasms; Bradykinin Receptor Antagonists; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; Molecular Targeted Therapy; Organophosphonates; Phosphorylation; Prostatic Neoplasms; Signal Transduction; STAT3 Transcription Factor; Survivin; Tumor Burden; Xenograft Model Antitumor Assays | 2019 |
The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity.
Topics: Aged; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Humans; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Retrospective Studies | 2019 |
Engineered bone for probing organotypic growth and therapy response of prostate cancer tumoroids in vitro.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Culture Techniques; Cell Proliferation; Docetaxel; Drug Screening Assays, Antitumor; Humans; Male; Mice, SCID; PC-3 Cells; Prostatic Neoplasms; Radium; Spheroids, Cellular; Tumor Cells, Cultured; Tumor Microenvironment | 2019 |
Adjuvant Androgen-Deprivation Therapy for Prostate Cancer: Should Docetaxel Be Added?
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2019 |
Secreted frizzled-related protein 5 suppresses aggressive phenotype and reverses docetaxel resistance in prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; beta Catenin; Carcinogenesis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; G1 Phase; Humans; Male; Mice, Nude; Neoplasm Invasiveness; Phenotype; Prostatic Neoplasms; Resting Phase, Cell Cycle; Signal Transduction | 2019 |
Oligometastatic Prostate Cancer Should Be Studied and Treated Differently to High-volume Disease. Con: The Underlying Biology is the Same, So They Should Not Be Treated Differently.
Topics: Androstenes; Cost of Illness; Docetaxel; Humans; Male; Molecular Biology; Neoplasm Metastasis; Phenotype; Positron-Emission Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy; Tubulin Modulators; Whole Body Imaging | 2019 |
The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells.
Topics: Antineoplastic Agents; Cell Culture Techniques; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Male; Neoplastic Stem Cells; PC-3 Cells; Prostatic Neoplasms; Tumor Microenvironment | 2019 |
Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Brazil; Cost-Benefit Analysis; Docetaxel; Humans; Male; Placebos; Progression-Free Survival; Prostatic Neoplasms; Quality-Adjusted Life Years; Reference Values; Reproducibility of Results; Time Factors; Treatment Outcome | 2019 |
Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Docetaxel; Humans; Male; Prostatic Neoplasms; Tumor Cells, Cultured | 2019 |
Multidisciplinary Care in High-Risk Prostate Cancer Is the New Standard of Care.
Topics: Docetaxel; Humans; Male; Medical Oncology; Prostatic Neoplasms; Standard of Care | 2019 |
The impact of Catechol-O-methyl transferase knockdown on the cell proliferation of hormone-responsive cancers.
Topics: 2-Methoxyestradiol; Aromatase; Breast Neoplasms; Catechol O-Methyltransferase; Catechols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Hormones; Humans; Male; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Estrogen; RNA, Small Interfering; Transcription Factor RelA | 2019 |
Raddeanin A down-regulates androgen receptor and its splice variants in prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; PC-3 Cells; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Isoforms; Receptors, Androgen; RNA Splicing; Saponins | 2019 |
CD44 Promotes Migration and Invasion of Docetaxel-Resistant Prostate Cancer Cells Likely via Induction of Hippo-Yap Signaling.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Movement; Docetaxel; Drug Resistance, Neoplasm; Hippo Signaling Pathway; Humans; Hyaluronan Receptors; Male; Neoplasm Invasiveness; Neoplasm Proteins; Phosphoproteins; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Signal Transduction; Transcription Factors; Wound Healing; YAP-Signaling Proteins | 2019 |
Multimodal treatment for high-risk locally-advanced prostate cancer following radical prostatectomy and extended lymphadenectomy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Chemoradiotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymph Node Excision; Male; Middle Aged; Neoplasm Grading; Progression-Free Survival; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Intensity-Modulated; Survival Analysis; Treatment Outcome | 2019 |
Prostate cancer cells hyper-activate CXCR6 signaling by cleaving CXCL16 to overcome effect of docetaxel.
Topics: ADAM10 Protein; Amyloid Precursor Protein Secretases; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Chemokine CXCL16; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Membrane Proteins; NF-kappa B; PC-3 Cells; Prostatic Neoplasms; Receptors, CXCR6; Signal Transduction | 2019 |
AICAR Induces Apoptosis and Inhibits Migration and Invasion in Prostate Cancer Cells Through an AMPK/mTOR-Dependent Pathway.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases; Transforming Growth Factor beta | 2019 |
Re: Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients with High-risk Prostate Cancer with Rising Prostate-specific Antigen Levels After Primary Local Therapy A Randomized Clinical Trial.
Topics: Androgen Antagonists; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 2019 |
Midkine silencing enhances the anti-prostate cancer stem cell activity of the flavone apigenin: cooperation on signaling pathways regulated by ERK, p38, PTEN, PARP, and NF-κB.
Topics: Antineoplastic Agents; Apigenin; Apoptosis; Cell Line, Tumor; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Gene Silencing; Humans; Male; Midkine; Neoplastic Stem Cells; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; PTEN Phosphohydrolase; RNA, Small Interfering; Signal Transduction | 2020 |
Pomolic acid exhibits anticancer potential against a docetaxel‑resistant PC3 prostate cell line.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Male; Multidrug Resistance-Associated Proteins; Oleanolic Acid; Prostatic Neoplasms | 2019 |
Use of docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in Korean patients: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Republic of Korea; Retrospective Studies; Treatment Outcome | 2019 |
Targeted Notch1 inhibition with a Notch1 antibody, OMP-A2G1, decreases tumor growth in two murine models of prostate cancer in association with differing patterns of DNA damage response gene expression.
Topics: Amyloid Precursor Protein Secretases; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; DNA Damage; DNA Repair; Docetaxel; Humans; Male; Mice; Prostatic Neoplasms; Receptor, Notch1; Xenograft Model Antitumor Assays | 2019 |
Exosome-derived miR-27a produced by PSC-27 cells contributes to prostate cancer chemoresistance through p53.
Topics: Cell Line, Tumor; Cells, Cultured; Cisplatin; Coculture Techniques; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Exosomes; Fibroblasts; Gene Expression; Genes, p53; Humans; Male; MicroRNAs; Prostate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Tumor Microenvironment | 2019 |
Building an Understanding of the Value of Docetaxel Plus Hormone Therapy in Prostate Cancer: An Ever-growing Evidence Base.
Topics: Androgen Antagonists; Cost-Benefit Analysis; Docetaxel; Humans; Male; Prostatic Neoplasms | 2018 |
Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Prostate; Prostatic Neoplasms; Proteasome Endopeptidase Complex; RNA Interference; Trans-Activators | 2019 |
Treatment of the Primary Tumor in Metastatic Hormone-sensitive Prostate Cancer: Not Yet Ready for Prime Time as the Standard of Care.
Topics: Androgen Antagonists; Androstenes; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Patient Selection; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Standard of Care; Tumor Burden | 2019 |
Adjuvant Chemotherapy for High-Risk Localized Prostate Cancer: Time for Change or Need More Time to Change?
Topics: Chemotherapy, Adjuvant; Docetaxel; Humans; Male; Prostatectomy; Prostatic Neoplasms | 2019 |
Reply to J.B. Aragon-Ching.
Topics: Docetaxel; Humans; Male; Medical Oncology; Prostatic Neoplasms | 2019 |
A Novel FGFR3 Splice Variant Preferentially Expressed in African American Prostate Cancer Drives Aggressive Phenotypes and Docetaxel Resistance.
Topics: Alternative Splicing; Animals; Black or African American; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; PC-3 Cells; Phenotype; Prostatic Neoplasms; Rabbits; Receptor, Fibroblast Growth Factor, Type 3; RNA Splicing; Signal Transduction; Survival Analysis; Transfection | 2019 |
Management of patients with high-risk and advanced prostate cancer in the Middle East: resource-stratified consensus recommendations.
Topics: Abiraterone Acetate; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Biopsy, Large-Core Needle; Bone Neoplasms; Docetaxel; Endosonography; Health Resources; Health Services Accessibility; Humans; Iraq; Kallikreins; Kuwait; Lebanon; Lymph Node Excision; Magnetic Resonance Imaging; Male; Margins of Excision; Middle East; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Risk; Salvage Therapy; Saudi Arabia; Syria | 2020 |
Eya2 Is Overexpressed in Human Prostate Cancer and Regulates Docetaxel Sensitivity and Mitochondrial Membrane Potential through AKT/Bcl-2 Signaling.
Topics: Aged; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Male; Membrane Potential, Mitochondrial; Middle Aged; Nuclear Proteins; Prostatic Neoplasms; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2 | 2019 |
Marked improvement of cytotoxic effects induced by docetaxel on highly metastatic and androgen-independent prostate cancer cells by downregulating macrophage inhibitory cytokine-1.
Topics: Androgen Antagonists; Androgens; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Growth Differentiation Factor 15; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2013 |
Predictive and prognostic values of Tau and BubR1 protein in prostate cancer and their relationship to the Gleason score.
Topics: Biomarkers, Tumor; Docetaxel; Down-Regulation; Humans; Male; Neoplasm Grading; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Retrospective Studies; tau Proteins; Taxoids | 2013 |
Targeting the Vav3 oncogene enhances docetaxel-induced apoptosis through the inhibition of androgen receptor phosphorylation in LNCaP prostate cancer cells under chronic hypoxia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Line, Tumor; Docetaxel; Gene Expression; Humans; Male; MAP Kinase Signaling System; Mice; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-vav; Receptors, Androgen; RNA Interference; Signal Transduction; Taxoids; Tumor Burden | 2013 |
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).
Topics: Aged; Aged, 80 and over; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Kallikreins; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
Restoration of IGFBP-rP1 increases radiosensitivity and chemosensitivity in hormone-refractory human prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Humans; Insulin-Like Growth Factor Binding Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostatic Neoplasms; Taxoids; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Humans; Interleukin 1 Receptor Antagonist Protein; Male; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Prostatic Neoplasms; Receptors, Steroid; Receptors, Thyroid Hormone; Taxoids | 2013 |
[Recrudescent prostate cancer with a low serum PSA level and a high serum CEA level treated with docetaxel : a case report].
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoembryonic Antigen; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Recurrence; Taxoids | 2013 |
Is there an optimal treatment sequencing strategy for metastatic castration-resistant prostate cancer?
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Taxoids | 2013 |
BMI1 polycomb group protein acts as a master switch for growth and death of tumor cells: regulates TCF4-transcriptional factor-induced BCL2 signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cell Proliferation; Cellular Senescence; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Male; Metribolone; Mice; Mice, Nude; Neoplasm Transplantation; Polycomb Repressive Complex 1; Promoter Regions, Genetic; Prostate; Prostatic Neoplasms; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Taxoids; Testosterone Congeners; Transcription Factor 4; Transcription Factors | 2013 |
Large-cell neuroendocrine carcinoma of prostate. Case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carboplatin; Carcinoma, Neuroendocrine; Combined Modality Therapy; Docetaxel; Fatal Outcome; Humans; Immunohistochemistry; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2013 |
Safety of megestrol acetate in palliating anorexia-cachexia syndrome in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cachexia; Castration; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Megestrol Acetate; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Taxoids | 2013 |
Inhibition of CCL2 signaling in combination with docetaxel treatment has profound inhibitory effects on prostate cancer growth in bone.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Density; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemokine CCL2; Docetaxel; Humans; Immunohistochemistry; Male; Mice, SCID; Prostate-Specific Antigen; Prostatic Neoplasms; Signal Transduction; Survival Analysis; Taxoids; Time Factors; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Analysis of the correlation between endorectal MRI response to neoadjuvant chemotherapy and biochemical recurrence in patients with high-risk localized prostate cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Docetaxel; Humans; Kallikreins; Magnetic Resonance Imaging; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prospective Studies; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Therapeutic options in docetaxel-refractory metastatic castration-resistant prostate cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Agents; Cost-Benefit Analysis; Docetaxel; Humans; Male; Neoplasm Metastasis; Orchiectomy; Probability; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Treatment Outcome | 2013 |
Serum sarcosine is a risk factor for progression and survival in patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Castration; Disease-Free Survival; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms; Risk Factors; Sarcosine; Taxoids | 2013 |
[Successful treatment with docetaxel and prednisolone for paxlitaxel and carboplatin-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Paclitaxel; Prednisolone; Prostatic Neoplasms; Taxoids | 2013 |
Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy.
Topics: Administration, Metronomic; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fecal Impaction; Gene Expression Regulation, Neoplastic; Gene Ontology; Humans; Male; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Taxoids; Topotecan; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Bone Neoplasms; Disease Progression; Disease-Free Survival; Docetaxel; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Staging; Neutropenia; Orchiectomy; Organometallic Compounds; Organophosphorus Compounds; Platelet Count; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Severity of Illness Index; Taxoids; Thrombocytopenia; Treatment Outcome | 2013 |
Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Nuclear Proteins; Orchiectomy; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Twist-Related Protein 1; Y-Box-Binding Protein 1 | 2013 |
Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Cell Culture Techniques; Chemoradiotherapy; Culture Media, Serum-Free; Docetaxel; Flow Cytometry; Glycoproteins; Humans; Hyaluronan Receptors; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Peptides; Prostatic Neoplasms; Taxoids; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
Residual prostate cancer cells after docetaxel therapy increase the tumorigenic potential via constitutive signaling of CXCR4, ERK1/2 and c-Myc.
Topics: Animals; Antineoplastic Agents; Benzylamines; Carcinogenesis; Cell Line, Tumor; Cyclams; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds; Humans; Male; MAP Kinase Signaling System; Mice, Nude; Mice, SCID; Neoplasm, Residual; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, CXCR4; Signal Transduction; Taxoids | 2013 |
Therapeutic windows and opportunity cost cast upon prostate cancer's fatal shore.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids | 2013 |
The effectiveness of the TAX 327 nomogram in predicting overall survival in Chinese patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Castration; China; Docetaxel; Humans; Male; Mitoxantrone; Nomograms; Predictive Value of Tests; Prostatic Neoplasms; Survival Rate; Taxoids | 2013 |
Paraneoplastic palmar fasciitis and polyarthritis syndrome in a patient with advanced prostate cancer.
Topics: Adrenal Cortex Hormones; Androgen Antagonists; Anilides; Antineoplastic Agents; Arthritis; Docetaxel; Fasciitis; Humans; Male; Middle Aged; Nitriles; Paraneoplastic Syndromes; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2013 |
Repression of NR4A1 by a chromatin modifier promotes docetaxel resistance in PC-3 human prostate cancer cells.
Topics: Animals; Apoptosis; Cell Death; Cell Line, Tumor; Cell Survival; Chromatin; Docetaxel; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase 2; Histone Deacetylases; Humans; Male; Mi-2 Nucleosome Remodeling and Deacetylase Complex; Mice; Mice, Nude; Neoplasm Transplantation; Nuclear Receptor Subfamily 4, Group A, Member 1; Prostatic Neoplasms; Protein Binding; Repressor Proteins; Taxoids; Trans-Activators; Transcription, Genetic | 2013 |
The mechanism of DAB2IP in chemoresistance of prostate cancer cells.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Clusterin; Docetaxel; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Knockout; Prostatic Neoplasms; ras GTPase-Activating Proteins; Taxoids; Wnt Signaling Pathway | 2013 |
Caffeic acid phenethyl ester synergistically enhances docetaxel and paclitaxel cytotoxicity in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caffeic Acids; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Estrogen Receptor alpha; Estrogen Receptor beta; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Inhibitory Concentration 50; Male; Paclitaxel; Phenylethyl Alcohol; Prostatic Neoplasms; Taxoids | 2013 |
Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Diethylstilbestrol; Disease Progression; Docetaxel; Estrogens, Non-Steroidal; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Taxoids; Treatment Outcome | 2013 |
Prevalence of pain and analgesic use in men with metastatic prostate cancer using a patient-reported outcome measure.
Topics: Adult; Aged; Analgesics; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Middle Aged; Pain; Patient Outcome Assessment; Prevalence; Prostatic Neoplasms; Self Report; Taxoids | 2013 |
Hyperglycaemia-induced chemoresistance of prostate cancer cells due to IGFBP2.
Topics: Acetylation; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Hyperglycemia; Insulin-Like Growth Factor Binding Protein 2; Male; Naphthols; Promoter Regions, Genetic; Prostatic Neoplasms; RNA, Small Interfering; Sirtuin 1; Sirtuin 2; Taxoids | 2013 |
Magnetic nanoparticles of Fe3O4 enhance docetaxel-induced prostate cancer cell death.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Deoxyguanosine; DNA; Docetaxel; Humans; Magnetite Nanoparticles; Male; NF-kappa B; Prostatic Neoplasms; Reactive Oxygen Species; Taxoids | 2013 |
Time to prostate specific antigen (PSA) nadir may predict rapid relapse in men with metastatic castration-resistant prostate cancer (CRPC) receiving docetaxel chemotherapy.
Topics: Aged; Aged, 80 and over; Castration; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2013 |
HPMA copolymer-based combination therapy toxic to both prostate cancer stem/progenitor cells and differentiated cells induces durable anti-tumor effects.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Humans; Male; Methacrylates; Mice; Mice, Nude; Neoplastic Stem Cells; Prostate; Prostatic Neoplasms; Taxoids; Veratrum Alkaloids | 2013 |
[A case on hemodialysis with castration-resistant prostate cancer which responded to combination chemotherapy with docetaxel and prednisolone].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Kidney Failure, Chronic; Male; Prednisolone; Prostatic Neoplasms; Renal Dialysis; Taxoids | 2013 |
The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Mice; Microtubules; Prostatic Neoplasms; Random Allocation; Sulfonamides; Taxoids; Toluidines; Tubulin; Xenograft Model Antitumor Assays | 2013 |
Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling.
Topics: Acid Ceramidase; Active Transport, Cell Nucleus; Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cytoplasm; Docetaxel; Drug Resistance, Neoplasm; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Humans; Karyopherins; Lysophospholipids; Male; Mice; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Sphingosine; Taxoids | 2013 |
Concurrent chemoradiotherapy with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Proliferation; Chemoradiotherapy; Docetaxel; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
[Polyneuropathic pain therapy with a patient suffering from generalized castrate- resistant prostate cancer - clinical case report].
Topics: Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Pain Management; Phenols; Polyneuropathies; Prostate-Specific Antigen; Prostatic Neoplasms; Tapentadol; Taxoids | 2013 |
[Case of prostate cancer associated with bisphosphonate-related osteonecrosis of the jaw followed by retropharyngeal abscess].
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drainage; Fatal Outcome; Humans; Imidazoles; Jaw; Male; Prostatic Neoplasms; Retropharyngeal Abscess; Taxoids; Tomography, X-Ray Computed; Zoledronic Acid | 2013 |
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Spacer length impacts the efficacy of targeted docetaxel conjugates in prostate-specific membrane antigen expressing prostate cancer.
Topics: Acrylamides; Adenocarcinoma; Animals; Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Delayed-Action Preparations; Docetaxel; Drug Delivery Systems; Glutamate Carboxypeptidase II; Glutarates; Humans; Male; Mice; Mice, Nude; Molecular Weight; Oligopeptides; Polymers; Prostatic Neoplasms; Taxoids; Urea; Xenograft Model Antitumor Assays | 2013 |
Context-dependent role of ATG4B as target for autophagy inhibition in prostate cancer therapy.
Topics: Animals; Autophagy; Autophagy-Related Proteins; Cell Line, Tumor; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Transplantation; Prostatic Neoplasms; Radiation Tolerance; Taxoids; Topotecan | 2013 |
Poor survival in prostate cancer patients with primary refractoriness to docetaxel.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Multivariate Analysis; Prognosis; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Time Factors | 2014 |
Inhibition of PARP1 by small interfering RNA enhances docetaxel activity against human prostate cancer PC3 cells.
Topics: Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cellular Senescence; Docetaxel; Drug Resistance, Neoplasm; Epidermal Growth Factor; Forkhead Box Protein O1; Forkhead Transcription Factors; Gene Knockdown Techniques; Humans; Male; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA, Small Interfering; Signal Transduction; Taxoids | 2013 |
miR-200b suppresses cell proliferation, migration and enhances chemosensitivity in prostate cancer by regulating Bmi-1.
Topics: Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Male; MicroRNAs; Octamer Transcription Factor-3; Polycomb Repressive Complex 1; Prostate; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Taxoids; Tumor Suppressor Proteins; Vimentin | 2014 |
Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cell Hypoxia; Docetaxel; Doxorubicin; Female; Humans; Male; Mice; Mice, Nude; Nitroimidazoles; Phosphoramide Mustards; Prodrugs; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Comparison of abiraterone acetate versus ketoconazole in patients with metastatic castration resistant prostate cancer refractory to docetaxel.
Topics: Abiraterone Acetate; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Combined Modality Therapy; Databases, Factual; Disease Progression; Disease-Free Survival; Docetaxel; Humans; Ketoconazole; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; Retreatment; Retrospective Studies; Taxoids; Treatment Outcome | 2014 |
US Food and Drug Administration approval of drugs for the treatment of prostate cancer: a new era has begun.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Denosumab; Diphosphonates; Docetaxel; Drug Approval; Drugs, Investigational; Estramustine; Goserelin; Humans; Imidazoles; Male; Mitoxantrone; Nitriles; Oligopeptides; Phenylthiohydantoin; Prostatic Neoplasms; Radioisotopes; Radium; Taxoids; Tissue Extracts; United States; United States Food and Drug Administration; Zoledronic Acid | 2014 |
Highly specific PET imaging of prostate tumors in mice with an iodine-124-labeled antibody fragment that targets phosphatidylserine.
Topics: Animals; beta 2-Glycoprotein I; Docetaxel; Immunoglobulin Fab Fragments; Iodine Radioisotopes; Male; Mice; Mice, Nude; Phosphatidylserines; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids | 2013 |
Enhanced anticancer activity of a combination of docetaxel and Aneustat (OMN54) in a patient-derived, advanced prostate cancer tissue xenograft model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Inbred NOD; Neoplasms, Experimental; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2014 |
[2-deoxyglucose enhances chemosensitivity of androgen-independent prostate cancer cells to docetaxel].
Topics: Androgens; Cell Line, Tumor; Deoxyglucose; Docetaxel; Drug Resistance, Neoplasm; HSP70 Heat-Shock Proteins; Humans; Male; Prostatic Neoplasms; Taxoids; Ubiquitinated Proteins | 2013 |
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Docetaxel; Germany; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Nomograms; Orchiectomy; Predictive Value of Tests; Prednisone; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Random Allocation; Reproducibility of Results; Risk Assessment; Risk Factors; Taxoids | 2014 |
A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Back Pain; Biopsy, Needle; Bone Neoplasms; Diagnostic Imaging; Disseminated Intravascular Coagulation; Docetaxel; Drug Resistance, Neoplasm; False Negative Reactions; Fatal Outcome; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Unknown Primary; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Transurethral Resection of Prostate | 2014 |
Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Guinea Pigs; Hemolysis; Humans; Male; Mice; Mice, Nude; Micelles; Particle Size; Polyesters; Polyethylene Glycols; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Taxoids; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Re: docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Bone Neoplasms; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Pyrrolidines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2014 |
α-Tocopheryl succinate pre-treatment attenuates quinone toxicity in prostate cancer PC3 cells.
Topics: Active Transport, Cell Nucleus; alpha-Tocopherol; Antioxidants; Apoptosis; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Inhibitors; Glutathione; Heme Oxygenase-1; Humans; Hydrogen Peroxide; Hydroquinones; Male; NAD(P)H Dehydrogenase (Quinone); NF-E2-Related Factor 2; Oxidative Stress; Paraquat; Prostatic Neoplasms; Protoporphyrins; RNA Interference; RNA, Small Interfering; Taxoids | 2014 |
Syndecan-1 (CD138) contributes to prostate cancer progression by stabilizing tumour-initiating cells.
Topics: Aged; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Transformation, Neoplastic; Combined Modality Therapy; Disease Progression; Docetaxel; Gene Knockdown Techniques; Gene Silencing; Genetic Therapy; Heterografts; Humans; Male; Mice; Mice, SCID; Mice, Transgenic; NADPH Oxidases; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Prostatectomy; Prostatic Neoplasms; Reactive Oxygen Species; Recurrence; Syndecan-1; Taxoids; Tumor Cells, Cultured | 2013 |
Radiation recall dermatitis after docetaxel chemotherapy. Treatment by antioxidant ointment.
Topics: Antineoplastic Agents; Antioxidants; Bone Neoplasms; Chemoradiotherapy; Docetaxel; Humans; Male; Middle Aged; Neoplasm Staging; Ointments; Prostatic Neoplasms; Radiodermatitis; Taxoids | 2014 |
The end of the beginning: circulating tumor cells as a biomarker in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Atrasentan; Docetaxel; Humans; Male; Neoplastic Cells, Circulating; Prostatic Neoplasms; Pyrrolidines; Taxoids | 2014 |
Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrasentan; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Pyrrolidines; Taxoids | 2014 |
Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Topics: Aged; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Hyaluronan Receptors; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prostatic Neoplasms; Taxoids; Transcription Factors; Treatment Outcome; Zinc Finger E-box-Binding Homeobox 1 | 2014 |
Beau's lines of the fingernails.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Nail Diseases; Nails; Prednisone; Prostatic Neoplasms; Taxoids | 2015 |
Anti-inflammatory effect of Marchantin M contributes to sensitization of prostate cancer cells to docetaxel.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Cell Survival; Chemokine CCL2; Docetaxel; Dose-Response Relationship, Drug; HT29 Cells; Human Umbilical Vein Endothelial Cells; Humans; I-kappa B Proteins; Inflammation Mediators; Interleukin-1beta; Interleukin-6; K562 Cells; Leukocytes, Mononuclear; Lipopolysaccharides; Male; NF-KappaB Inhibitor alpha; Phenyl Ethers; Phosphorylation; Prostatic Neoplasms; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Taxoids; Time Factors; Transcription Factor RelA; Transfection; Tumor Necrosis Factor-alpha | 2014 |
Circulating microRNAs are associated with docetaxel chemotherapy outcome in castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Kaplan-Meier Estimate; Male; MicroRNAs; Middle Aged; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; RNA, Neoplasm; ROC Curve; Taxoids; Treatment Outcome | 2014 |
Metastatic castrate-resistant prostate cancer with a late, complete and durable response to docetaxel chemotherapy: a case report.
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Goserelin; Humans; Lymphatic Metastasis; Male; Nitriles; Prostate; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Treatment Failure; Treatment Outcome | 2014 |
Gonadotropin-releasing hormone agonists sensitize, and resensitize, prostate cancer cells to docetaxel in a p53-dependent manner.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Drug Synergism; Gonadotropin-Releasing Hormone; Humans; Male; Oligonucleotide Array Sequence Analysis; Phosphorylation; Prostatic Neoplasms; Signal Transduction; Taxoids; Tumor Suppressor Protein p53 | 2014 |
Phosphatidylserine-targeting antibody induces M1 macrophage polarization and promotes myeloid-derived suppressor cell differentiation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cytokines; Dendritic Cells; Docetaxel; Humans; Lymphocyte Activation; Macrophages; Male; Mice; Mice, SCID; Neoplasm Transplantation; Phosphatidylserines; Prostatic Neoplasms; Signal Transduction; Taxoids; Tumor Microenvironment | 2013 |
Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Evaluation, Preclinical; Humans; Hyaluronic Acid; Hydrogel, Polyethylene Glycol Dimethacrylate; Male; Mice; Mice, SCID; Prostate; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Xenograft Model Antitumor Assays | 2014 |
NOTCH1 signaling promotes chemoresistance via regulating ABCC1 expression in prostate cancer stem cells.
Topics: Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Multidrug Resistance-Associated Proteins; Neoplastic Stem Cells; Prostatic Neoplasms; Receptor, Notch1; Signal Transduction; Taxoids | 2014 |
Relaxin receptor antagonist AT-001 synergizes with docetaxel in androgen-independent prostate xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Binding, Competitive; Blotting, Western; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Immunoenzyme Techniques; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Receptors, G-Protein-Coupled; Receptors, Peptide; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
A one-two punch against prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Prostatic Neoplasms; Survival Rate; Taxoids | 2014 |
Regulation of SOD2 and β-arrestin1 by interleukin-6 contributes to the increase of IGF-1R expression in docetaxel resistant prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Arrestins; beta-Arrestins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Interleukin-6; Male; Prostatic Neoplasms; Reactive Oxygen Species; Receptor, IGF Type 1; Receptors, CXCR4; STAT3 Transcription Factor; Superoxide Dismutase; Taxoids; Up-Regulation | 2014 |
Poly(styrene)-b-poly(DL-lactide) copolymer-based nanoparticles for anticancer drug delivery.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Diffusion; Docetaxel; Humans; Male; Nanocapsules; Particle Size; Polyesters; Polystyrenes; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Taxoids; Treatment Outcome | 2014 |
The oncological outcomes and risk stratification in docetaxel chemotherapy for castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease-Free Survival; Docetaxel; Humans; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Risk Assessment; Risk Factors; Taxoids; Treatment Outcome | 2014 |
EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205.
Topics: Antigens, Neoplasm; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Epithelial Cell Adhesion Molecule; Epithelial-Mesenchymal Transition; Humans; Male; MicroRNAs; Prostatic Neoplasms; RNA, Messenger; Taxoids | 2014 |
Effect of mitochondrial metabolism-interfering agents on cancer cell mitochondrial function and radio/chemosensitivity.
Topics: Amiodarone; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Lung Neoplasms; Male; Metformin; Mitochondria; Prostatic Neoplasms; Radiation Tolerance; Taxoids | 2014 |
Targeted enzyme prodrug therapy for metastatic prostate cancer - a comparative study of L-methioninase, purine nucleoside phosphorylase, and cytosine deaminase.
Topics: Antimetabolites, Antineoplastic; Carbon-Sulfur Lyases; Cell Line, Tumor; Cytosine Deaminase; Docetaxel; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Male; Prodrugs; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Taxoids; Tubulin Modulators | 2014 |
miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
Topics: Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Prognosis; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Blotting, Western; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Male; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Signal Transduction; Taxoids; Tumor Cells, Cultured | 2015 |
Prostate cancer cell malignancy via modulation of HIF-1α pathway with isoflurane and propofol alone and in combination.
Topics: Anesthetics, Inhalation; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoflurane; Male; Neoplasm Invasiveness; Phosphorylation; Propofol; Prostatic Neoplasms; Protein Processing, Post-Translational; Protein Transport; Taxoids; Up-Regulation; Vascular Endothelial Growth Factor A | 2014 |
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
Topics: Animals; Cell Movement; Cellular Senescence; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunity, Innate; Interleukin 1 Receptor Antagonist Protein; Interleukin-1alpha; Male; Mice; Myeloid Cells; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Chemokine; Receptors, Interleukin-8B; Taxoids; Tumor Escape; Tumor Microenvironment | 2014 |
The pluripotency factor Nanog is directly upregulated by the androgen receptor in prostate cancer cells.
Topics: Antineoplastic Agents; Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation; Homeodomain Proteins; Humans; Immunoprecipitation; Male; Nanog Homeobox Protein; Nitriles; Phenylthiohydantoin; Polymorphism, Restriction Fragment Length; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Taxoids; Up-Regulation | 2014 |
Targeting Btk/Etk of prostate cancer cells by a novel dual inhibitor.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Antineoplastic Agents; Autophagy; Binding Sites; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Imidazoles; Male; Mice; Mice, Nude; Molecular Docking Simulation; Phospholipase C gamma; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinoxalines; RNA Interference; RNA, Small Interfering; STAT3 Transcription Factor; Taxoids; Transplantation, Heterologous | 2014 |
Immediate and transient phosphorylation of the heat shock protein 27 initiates chemoresistance in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; HSP27 Heat-Shock Proteins; Humans; Male; Phosphorylation; Prostatic Neoplasms; Protein Processing, Post-Translational; Taxoids | 2014 |
Enhancing chemotherapy efficacy in Pten-deficient prostate tumors by activating the senescence-associated antitumor immunity.
Topics: Animals; Antineoplastic Agents; Cellular Senescence; Cytokines; Docetaxel; Female; Gene Expression Profiling; Humans; Male; Mice; Mice, Transgenic; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Taxoids; Tumor Microenvironment | 2014 |
The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Male; Mice; Orchiectomy; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Proteolysis; Receptor, IGF Type 1; Signal Transduction; Taxoids; Tumor Burden; Tyrphostins; Xenograft Model Antitumor Assays | 2014 |
Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Nucleus; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kinesins; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2014 |
Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2015 |
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? Yes; we must beware of drawing conclusions from a subset analysis.
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Patient Selection; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids | 2014 |
In hormone-naive metastatic prostate cancer, should all patients now receive docetaxel? No, not yet.
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Patient Selection; Prognosis; Prostatic Neoplasms; Survival Rate; Taxoids | 2014 |
Interferon inducible antiviral MxA is inversely associated with prostate cancer and regulates cell cycle, invasion and Docetaxel induced apoptosis.
Topics: Apoptosis; Cell Cycle; Cell Division; Cell Line, Tumor; Docetaxel; Humans; Male; Myxovirus Resistance Proteins; Neoplasm Invasiveness; Prostatic Neoplasms; Taxoids; Tubulin | 2015 |
Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Caspase 9; Caspase Inhibitors; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nitrophenols; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Taxoids; Transfection; Xenograft Model Antitumor Assays | 2014 |
Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31.
Topics: Apoptosis; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enhancer of Zeste Homolog 2 Protein; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Histones; Humans; Male; Methylation; MicroRNAs; Models, Biological; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Prostatic Neoplasms; RNA, Small Interfering; Taxoids | 2014 |
'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Rate; Taxoids | 2014 |
Evaluation of histopathological findings at the injection site following degarelix administration.
Topics: Aged; Aged, 80 and over; Docetaxel; Drug Therapy, Combination; Erythema; Gonadotropin-Releasing Hormone; Hematologic Diseases; Humans; Hypersensitivity; Injections, Subcutaneous; Male; Middle Aged; Oligopeptides; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Risk Factors; Skin; Taxoids | 2015 |
CXCL12/CXCR4 signaling counteracts docetaxel-induced microtubule stabilization via p21-activated kinase 4-dependent activation of LIM domain kinase 1.
Topics: Anticarcinogenic Agents; Cell Cycle; Cell Division; Cell Line, Tumor; Chemokine CXCL12; Docetaxel; Drug Resistance, Neoplasm; G2 Phase; Gene Expression Regulation, Neoplastic; Humans; Lim Kinases; Male; Microscopy, Fluorescence; Microtubules; p21-Activated Kinases; Phosphorylation; Prostatic Neoplasms; Receptors, CXCR4; RNA Interference; Signal Transduction; Taxoids | 2014 |
Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling.
Topics: Animals; Antineoplastic Agents; Arsenicals; Cell Cycle; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutathione; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Male; Mice; Neoplastic Stem Cells; Nuclear Proteins; Prostatic Neoplasms; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays; Zinc Finger Protein Gli2 | 2015 |
Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Chromones; Docetaxel; Drug Synergism; Female; Humans; Male; Mice; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Taxoids; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2015 |
[18F]fluoromethylcholine as a chemotherapy response read-out in prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Choline; Docetaxel; Drug Screening Assays, Antitumor; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Rhodamines; Taxoids | 2015 |
PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Heterografts; Humans; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Protein Inhibitors of Activated STAT; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Small Ubiquitin-Related Modifier Proteins; Taxoids; Tissue Array Analysis; Transfection | 2014 |
Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Docetaxel; Drug Therapy, Combination; Humans; Male; Methacrylates; Mice; Mice, Nude; Phosphoinositide-3 Kinase Inhibitors; Polymers; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Stem Cells; Taxoids; TOR Serine-Threonine Kinases | 2015 |
Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment.
Topics: Bridged-Ring Compounds; Cell Line, Tumor; Cyclic AMP-Dependent Protein Kinases; Docetaxel; Humans; Male; Paclitaxel; Prostatic Neoplasms; Protein Kinase Inhibitors; Taxoids | 2014 |
The diffusion of docetaxel in patients with metastatic prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Comorbidity; Docetaxel; Drug Approval; Humans; Male; Medicare; Middle Aged; Practice Patterns, Physicians'; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; SEER Program; Taxoids; United States | 2015 |
Differential expression of the multidrug resistance 1 (MDR1) protein in prostate cancer cells is independent from anticancer drug treatment and Y box binding protein 1 (YB-1) activity.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromatography, Liquid; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Prostate; Prostatic Neoplasms; Tandem Mass Spectrometry; Taxoids; Y-Box-Binding Protein 1 | 2015 |
Ipilimumab in the treatment of prostate cancer.
Topics: Antibodies, Monoclonal; Antigens, Surface; Antigens, Tumor-Associated, Carbohydrate; CTLA-4 Antigen; Docetaxel; Glutamate Carboxypeptidase II; Humans; Immunotherapy; Ipilimumab; Male; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2015 |
DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Damage; Docetaxel; Drug Resistance, Neoplasm; Fibroblasts; Gene Expression Regulation, Neoplastic; Glial Cell Line-Derived Neurotrophic Factor; Glial Cell Line-Derived Neurotrophic Factor Receptors; Humans; Male; Mitoxantrone; Oligonucleotide Array Sequence Analysis; Prostate; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Taxoids; Transcriptome; Tumor Microenvironment | 2015 |
[Docetaxel for small cell carcinoma of the prostate with a metastatic pelvic tumor: a case report].
Topics: Aged; Carcinoma, Small Cell; Docetaxel; Humans; Male; Pelvic Neoplasms; Prostatic Neoplasms; Taxoids | 2014 |
Effects of zoledronic acid and docetaxel on small GTP-binding proteins in prostate cancer.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Diphosphonates; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; Prostatic Neoplasms; ras Proteins; rhoA GTP-Binding Protein; Taxoids; Zoledronic Acid | 2015 |
Sensitization to docetaxel in prostate cancer cells by green tea and quercetin.
Topics: Apoptosis; Catechin; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Docetaxel; Down-Regulation; Drug Synergism; Humans; Male; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Quercetin; Taxoids; Tea | 2015 |
Inhibition of hedgehog signaling improves the anti-carcinogenic effects of docetaxel in prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Docetaxel; Drug Synergism; Hedgehog Proteins; Humans; Male; Mice; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Pyridines; Random Allocation; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2015 |
Paradoxical effects of the autophagy inhibitor 3-methyladenine on docetaxel-induced toxicity in PC-3 and LNCaP prostate cancer cells.
Topics: Adenine; Antineoplastic Agents; Apoptosis; Autophagy; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2015 |
Analysis of Side Effect Profile of Alopecia, Nail Changes, Peripheral Neuropathy, and Dysgeusia in Prostate Cancer Patients Treated With Docetaxel and Cabazitaxel.
Topics: Alopecia; Clinical Trials as Topic; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Dysgeusia; Humans; Male; Nail Diseases; Peripheral Nervous System Diseases; Prospective Studies; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
Effective photothermal chemotherapy with docetaxel-loaded gold nanospheres in advanced prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Liberation; Drug Stability; Gold; Humans; Male; Mice; Nanospheres; Photochemotherapy; Prostatic Neoplasms; Radioligand Assay; Taxoids; Technetium; Tissue Distribution; Xenograft Model Antitumor Assays | 2015 |
Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials, Phase III as Topic; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2015 |
The presence and clinical implication of intraductal carcinoma of prostate in metastatic castration resistant prostate cancer.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Ductal; Disease Progression; Docetaxel; Humans; Incidence; Kallikreins; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Long-term Efficacy and Safety Results: Can Enzalutamide Challenge the Dogma of Androgen Deprivation Therapy in Hormone-naïve Prostate Cancer?
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Phenylthiohydantoin; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids | 2015 |
Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; bcl-X Protein; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cytochromes c; Docetaxel; Drug Synergism; Female; Humans; Inhibitor of Apoptosis Proteins; Male; Octreotide; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Somatostatin; Taxoids | 2015 |
Cyclic-RGDfK peptide conjugated succinoyl-TPGS nanomicelles for targeted delivery of docetaxel to integrin receptor over-expressing angiogenic tumours.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Human Umbilical Vein Endothelial Cells; Humans; Integrins; Male; Micelles; Nanostructures; Neovascularization, Pathologic; Peptides, Cyclic; Polyethylene Glycols; Prostatic Neoplasms; Receptors, Cell Surface; Taxoids; Vitamin E | 2015 |
Retrospective review of the incidence of monitoring blood glucose levels in patients receiving corticosteroids with systemic anticancer therapy.
Topics: Aged; Antineoplastic Agents; Blood Glucose; Comorbidity; Dexamethasone; Diabetes Complications; Diabetes Mellitus; Docetaxel; Drug Therapy, Combination; Glucocorticoids; Humans; Hyperglycemia; Male; Monitoring, Physiologic; Ontario; Prednisone; Prostatic Neoplasms; Retrospective Studies; Taxoids; Urinary Bladder Neoplasms; Urogenital Neoplasms | 2015 |
Why Chemotherapy Should be Given Early for Men with Metastatic Prostate Cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2015 |
Antiandrogens Inhibit ABCB1 Efflux and ATPase Activity and Reverse Docetaxel Resistance in Advanced Prostate Cancer.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Androgen Antagonists; Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Benzamides; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; Rhodamines; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2015 |
Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model.
Topics: Animals; Cancer Vaccines; Disease Models, Animal; Docetaxel; Humans; Immunotherapy; Interleukin-11; Interleukin-6; Killer Cells, Natural; Male; Mice; Neoplastic Stem Cells; Prostatic Neoplasms; Recombinant Fusion Proteins; Taxoids | 2015 |
Axl receptor tyrosine kinase is up-regulated in metformin resistant prostate cancer cells.
Topics: Adenylate Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Benzocycloheptenes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cyclin D1; Docetaxel; Drug Resistance, Neoplasm; Enzyme Activation; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Humans; Male; Metformin; Neoplasm Invasiveness; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Receptor Protein-Tyrosine Kinases; Taxoids; Triazoles; Up-Regulation | 2015 |
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Bone Density Conservation Agents; Docetaxel; Humans; Male; Orchiectomy; Practice Guidelines as Topic; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiotherapy, Adjuvant; Taxoids | 2015 |
E10A, an adenovirus carrying human endostatin gene, in combination with docetaxel treatment inhibits prostate cancer growth and metastases.
Topics: Adenoviridae; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Docetaxel; Endostatins; Genetic Therapy; Genetic Vectors; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Nude; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2010 |
GLIPR1-ΔTM synergizes with docetaxel in cell death and suppresses resistance to docetaxel in prostate cancer cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Humans; Male; MAP Kinase Signaling System; Membrane Proteins; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Nerve Tissue Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Receptors, CXCR4; Sequence Deletion; Taxoids; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Tissue Chromogranin A Expression during Prostate Cancer Progression: Prediction of Chemosensitivity.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chromogranin A; Disease Progression; Disease-Free Survival; Docetaxel; Estramustine; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2015 |
A combination of desmopressin and docetaxel inhibit cell proliferation and invasion mediated by urokinase-type plasminogen activator (uPA) in human prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Deamino Arginine Vasopressin; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice, Nude; Prostatic Neoplasms; Taxoids; Urokinase-Type Plasminogen Activator; Xenograft Model Antitumor Assays | 2015 |
Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Inbred NOD; NF-kappa B; Prostatic Neoplasms; Signal Transduction; Taxoids; Tetrahydronaphthalenes; Valine; Xenograft Model Antitumor Assays | 2015 |
Targeted nanomedicine for prostate cancer therapy: docetaxel and curcumin co-encapsulated lipid-polymer hybrid nanoparticles for the enhanced anti-tumor activity in vitro and in vivo.
Topics: Animals; Cell Line, Tumor; Curcumin; Docetaxel; Drug Carriers; Drug Delivery Systems; Heterografts; Humans; Lipids; Male; Mice; Nanomedicine; Particle Size; Polymers; Prostatic Neoplasms; Taxoids | 2016 |
Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzamides; Cell Adhesion; Cell Culture Techniques; Cell Dedifferentiation; Cell Line, Tumor; Cell Plasticity; Cell Self Renewal; Cellular Senescence; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Heterografts; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplastic Stem Cells; Phenotype; Prostatic Neoplasms; Pyrans; Pyridines; Serpins; Suspensions; Taxoids; Tumor Microenvironment | 2015 |
Should docetaxel be administered earlier in prostate cancer therapy?
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Time Factors | 2015 |
Docetaxel for hormone-sensitive metastatic prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2015 |
Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Calpain; Cell Line, Tumor; Cell Proliferation; Cell-Derived Microparticles; Dipeptides; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
Bombesin-conjugated nanoparticles improve the cytotoxic efficacy of docetaxel against gastrin-releasing but androgen-independent prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents; Bombesin; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Gastrins; Humans; Male; Mice, Inbred BALB C; Nanoparticles; Prostate; Prostatic Neoplasms; Taxoids | 2015 |
[Chemotherapy of prostate cancer].
Topics: Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Docetaxel; Drug Therapy; Evidence-Based Medicine; Humans; Male; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2015 |
Osteopontin splice variants expression is involved on docetaxel resistance in PC3 prostate cancer cells.
Topics: Alternative Splicing; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Male; Osteopontin; Prostate; Prostatic Neoplasms; RNA Splicing; Signal Transduction; Taxoids; Up-Regulation | 2016 |
Advances in advanced prostate cancer - the continuing journey.
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials as Topic; Disease Progression; Docetaxel; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Male; Practice Patterns, Physicians'; Prostatic Neoplasms; Taxoids | 2016 |
MicroRNA‑328 directly targets p21‑activated protein kinase 6 inhibiting prostate cancer proliferation and enhancing docetaxel sensitivity.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Inbred BALB C; MicroRNAs; p21-Activated Kinases; Prostatic Neoplasms; Taxoids | 2015 |
Glucocorticoid receptor antagonism reverts docetaxel resistance in human prostate cancer.
Topics: Apoptosis; Cyproterone Acetate; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Hormone Antagonists; Humans; Male; Mifepristone; Prostatic Neoplasms; Receptors, Glucocorticoid; Taxoids; Tumor Cells, Cultured | 2016 |
Dramatic PSA Increase With Tumor Shrinkage After Initiating Degarelix in Advanced Prostate Cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Kallikreins; Male; Oligopeptides; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Treatment Outcome; Tumor Burden | 2016 |
Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice, Nude; Mutation; Prostatic Neoplasms; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sterol Regulatory Element Binding Proteins; Taxoids; Thiazoles; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
New developments in metastatic prostate cancer therapy.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Bone Neoplasms; Docetaxel; Humans; Male; Neoplasm Staging; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiotherapy; Radium; Risk Assessment; Taxoids; Therapies, Investigational; United Kingdom | 2015 |
Infiltrating mast cells increase prostate cancer chemotherapy and radiotherapy resistances via modulation of p38/p53/p21 and ATM signals.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Cell Movement; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Male; Mast Cells; Mice, Nude; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Radiation Tolerance; RNA Interference; Signal Transduction; Taxoids; Time Factors; Transfection; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Prostatic Neoplasms; Taxoids | 2016 |
Will chemotherapy change the management of prostate cancer?
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Risk Assessment; Taxoids; Treatment Outcome | 2016 |
Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cancer Vaccines; Cell Line, Tumor; Cytotoxicity, Immunologic; Dendritic Cells; Docetaxel; Humans; Hydrostatic Pressure; Immune System; Immunotherapy; Interferon-gamma; Interleukin-12; Male; Mice; Mice, Inbred C57BL; Neoplasms, Experimental; Papillomavirus Infections; Prostatic Neoplasms; Spleen; Taxoids; Toll-Like Receptor 9 | 2016 |
Metastatic prostate cancer in 2015: The new and the old that is new again.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids | 2016 |
Role of DNA Methylation in Cabazitaxel Resistance in Prostate Cancer.
Topics: Antineoplastic Agents; Azacitidine; Cell Line, Tumor; Cell Survival; DNA Methylation; DNA Modification Methylases; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Prostatic Neoplasms; Taxoids; Time Factors | 2016 |
Ad5/35E1aPSESE4: A novel approach to marking circulating prostate tumor cells with a replication competent adenovirus controlled by PSA/PSMA transcription regulatory elements.
Topics: Adenoviridae; Adult; Animals; Antigens, Surface; Antineoplastic Agents; Case-Control Studies; Cell Line, Tumor; Disease Progression; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Viral; Genes, Reporter; Glutamate Carboxypeptidase II; Green Fluorescent Proteins; Humans; Kallikreins; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Staging; Neoplastic Cells, Circulating; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Regulatory Elements, Transcriptional; Reproducibility of Results; Taxoids; Time Factors; Transcription, Genetic; Tumor Cells, Cultured; Virus Replication; Young Adult | 2016 |
Translating Clinical Evidence-Based Medicine into the Real World: Single-Center Experience with Cabazitaxel in Metastatic Prostate Cancer Patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Evidence-Based Medicine; Humans; Kaplan-Meier Estimate; Male; Neoplasm Metastasis; Prednisolone; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2016 |
Abhydrolase domain containing 2, an androgen target gene, promotes prostate cancer cell proliferation and migration.
Topics: Aged; Aged, 80 and over; Androgens; Animals; Antineoplastic Agents; Apoptosis; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Hydrolases; Immunohistochemistry; Male; Mice, Nude; Middle Aged; Neoplasm Grading; Neoplasm Transplantation; Prostatic Neoplasms; Receptors, Androgen; RNA, Small Interfering; Survival Analysis; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 2016 |
Activation of the PD-1/PD-L1 immune checkpoint confers tumor cell chemoresistance associated with increased metastasis.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Jurkat Cells; Male; Mice; Mice, Inbred BALB C; Programmed Cell Death 1 Receptor; Prostatic Neoplasms; T-Lymphocytes, Cytotoxic; Taxoids; Tumor Escape | 2016 |
Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostatectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2016 |
Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate
Topics: Androgen Antagonists; Docetaxel; Drug Therapy, Combination; Humans; Male; Medical Oncology; Neoplasm Metastasis; Oncologists; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms; Standard of Care; Surveys and Questionnaires; Taxoids | 2016 |
Prognostic value of the bone scan index using a computer-aided diagnosis system for bone scans in hormone-naive prostate cancer patients with bone metastases.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Diagnosis, Computer-Assisted; Docetaxel; Humans; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids | 2016 |
Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Survival; Disease Models, Animal; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice; Neoplastic Stem Cells; Prostatic Neoplasms; STAT3 Transcription Factor; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Cluster Analysis; Docetaxel; Estramustine; Humans; Male; Middle Aged; Mitoxantrone; National Cancer Institute (U.S.); Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; United States | 2016 |
[I. Docetaxel must be reconsidered in light of high cost-effectiveness in the treatment of prostate cancer].
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Docetaxel; Humans; Male; Meta-Analysis as Topic; Prostatic Neoplasms; Taxoids | 2016 |
In vitro and in vivo effects of a recombinant anti-PSMA immunotoxin in combination with docetaxel against prostate cancer.
Topics: Animals; Antigens, Surface; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Glutamate Carboxypeptidase II; Humans; Immunotoxins; Male; Mice; Mice, SCID; Prostatic Neoplasms; Single-Chain Antibodies; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Humans; Male; Mice, Nude; Nuclear Proteins; Nucleophosmin; Nucleoproteins; Peptides; Phosphorylation; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Protein Binding; Receptors, Androgen; Taxoids; Threonine; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Graphene oxide-wrapped PEGylated liquid crystalline nanoparticles for effective chemo-photothermal therapy of metastatic prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Docetaxel; Drug Liberation; Graphite; Humans; Liquid Crystals; Male; Microscopy, Electron, Transmission; Nanoparticles; Neoplasm Metastasis; Oxides; Photochemotherapy; Polyethylene Glycols; Prostatic Neoplasms; Spectroscopy, Fourier Transform Infrared; Taxoids | 2016 |
Defining new standards of care for men with prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2016 |
Anticancer effect of docetaxel induces apoptosis of prostate cancer via the cofilin-1 and paxillin signaling pathway.
Topics: Apoptosis; Cell Line, Tumor; Cofilin 1; Docetaxel; Humans; Male; Neoplasm Proteins; Paxillin; Prostatic Neoplasms; Signal Transduction; Taxoids | 2016 |
Inhibition of skeletal growth of human prostate cancer by the combination of docetaxel and BKM1644: an aminobisphosphonate derivative.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Drug Interactions; Humans; Male; Mice; Mice, Nude; Neoplasm Metastasis; Prostatic Neoplasms; Random Allocation; Taxoids; Xenograft Model Antitumor Assays | 2016 |
PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cytosol; Dextrans; Docetaxel; Endocytosis; Humans; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Mice; Molecular Targeted Therapy; Nanoparticles; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tubulin | 2016 |
Docetaxel induces Bcl-2- and pro-apoptotic caspase-independent death of human prostate cancer DU145 cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Docetaxel; Drug Screening Assays, Antitumor; Humans; Male; Mice; Mice, Inbred C3H; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transfection; Xenograft Model Antitumor Assays | 2016 |
Comparison of two kinds of docetaxel-vitamin E prodrugs: In vitro evaluation and in vivo antitumor activity.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Line, Tumor; Chemistry, Pharmaceutical; Docetaxel; Female; Half-Life; Humans; Inhibitory Concentration 50; Liposomes; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prodrugs; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Taxoids; Vitamin E; Xenograft Model Antitumor Assays | 2016 |
Copy number variations in urine cell free DNA as biomarkers in advanced prostate cancer.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Cell-Free Nucleic Acids; Chromosome Aberrations; DNA Copy Number Variations; DNA, Neoplasm; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Outcome Assessment, Health Care; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptor, Notch1; Receptors, Androgen; Taxoids | 2016 |
High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neutropenia; Prostatic Neoplasms; Taxoids | 2016 |
Cost-effectiveness analysis of additional docetaxel for metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy from a Chinese perspective.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Decision Support Techniques; Dexamethasone; Disease-Free Survival; Docetaxel; Drug Costs; Humans; Male; Markov Chains; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Treatment Outcome | 2017 |
Green tea and quercetin sensitize PC-3 xenograft prostate tumors to docetaxel chemotherapy.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; Plant Extracts; Polyphenols; Prostatic Neoplasms; Quercetin; Taxoids; Tea; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Growth Arrest-Specific 6 (GAS6) Promotes Prostate Cancer Survival by G
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Bone Marrow; Cell Cycle Proteins; Cell Proliferation; Cells, Cultured; Docetaxel; G1 Phase; Humans; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Knockout; Osteoblasts; Prostatic Neoplasms; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; S Phase; Taxoids | 2016 |
Upfront Chemohormonal Therapy for Prostate Cancer: Neutropenia and G-CSF Use.
Topics: Aged; Androgen Antagonists; Docetaxel; Granulocyte Colony-Stimulating Factor; Humans; Male; Middle Aged; Neutropenia; Prostatic Neoplasms; Taxoids | 2016 |
Targeting IκB Kinase β/NF-κB Signaling in Human Prostate Cancer by a Novel IκB Kinase β Inhibitor CmpdA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; Disease Models, Animal; Docetaxel; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Knockdown Techniques; Humans; I-kappa B Kinase; Male; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Neoplastic Stem Cells; NF-kappa B; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Cabazitaxel for metastatic hormone-relapsed prostate cancer treated with docetaxel.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2016 |
High expression of TROP2 characterizes different cell subpopulations in androgen-sensitive and androgen-independent prostate cancer cells.
Topics: Androgen Antagonists; Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Adhesion Molecules; Cell Survival; Docetaxel; Flutamide; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Kaplan-Meier Estimate; Male; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2016 |
INPP4B reverses docetaxel resistance and epithelial-to-mesenchymal transition via the PI3K/Akt signaling pathway in prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Male; Phosphatidylinositol 3-Kinases; Phosphoric Monoester Hydrolases; Prostatic Neoplasms; Protein Kinases; Signal Transduction; Taxoids | 2016 |
[Primary Squamous Cell Carcinoma of the Prostate in which Docetaxel Therapy was Effective : A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Docetaxel; Fluorodeoxyglucose F18; Humans; Male; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids | 2016 |
Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Drug Delivery Systems; Female; Humans; Hyperthermia, Induced; Liposomes; Male; Mice; Mice, Nude; Prostatic Neoplasms; Random Allocation; Survival Rate; Taxoids; Temperature; Tissue Distribution; Xenograft Model Antitumor Assays | 2016 |
Influence of Matrices on 3D-Cultured Prostate Cancer Cells' Drug Response and Expression of Drug-Action Associated Proteins.
Topics: Antineoplastic Agents; Biocompatible Materials; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Collagen; Docetaxel; Drug Combinations; ErbB Receptors; Humans; Laminin; Male; Prostatic Neoplasms; Proteoglycans; Sirolimus; Taxoids; Tubulin; Tubulin Modulators; Tumor Suppressor Protein p53 | 2016 |
Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals.
Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; HSP27 Heat-Shock Proteins; Humans; Male; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Kinase Inhibitors; Receptor, Parathyroid Hormone, Type 1; Receptors, Androgen; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2016 |
Aptamer-mediated delivery of docetaxel to prostate cancer through polymeric nanoparticles for enhancement of antitumor efficacy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Aptamers, Nucleotide; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Carriers; Male; Prostatic Neoplasms; Rats; Spectrophotometry, Ultraviolet; Taxoids; Tissue Distribution | 2016 |
Docetaxel for Metastatic Hormone-sensitive Prostate Cancer: Urgent Need to Minimize the Risk of Neutropenic Fever.
Topics: Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Docetaxel; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Taxoids | 2016 |
[Drug therapy of hormone-sensitive metastatic prostate cancer : Consensus paper of the AKO/AUO].
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Castration; Combined Modality Therapy; Docetaxel; Evidence-Based Medicine; Germany; Humans; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Practice Guidelines as Topic; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Outcome; Urology | 2016 |
Human SRMAtlas: A Resource of Targeted Assays to Quantify the Complete Human Proteome.
Topics: Access to Information; Antineoplastic Agents; Cell Line, Tumor; Cholesterol; Databases, Protein; Docetaxel; Female; Humans; Internet; Liver; Male; Mutation; Prostatic Neoplasms; Proteome; RNA Splicing; Taxoids | 2016 |
Response to 'High Risk of Neutropenia for Hormone-naive Prostate Cancer Patients Receiving STAMPEDE-style Upfront Docetaxel Chemotherapy in Usual Clinical Practice', by Tanguay et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neutropenia; Prostatic Neoplasms; Taxoids | 2016 |
Overcoming chemoresistance in prostate cancer with Chinese medicine Tripterygium wilfordii via multiple mechanisms.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Cell Cycle; Cell Line, Tumor; Cell Survival; Daunorubicin; Docetaxel; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Male; Mice; Mice, SCID; Neoplasm Transplantation; Neovascularization, Pathologic; Plant Extracts; Prostatic Neoplasms; Taxoids; Tripterygium | 2016 |
Intra-tumoral delivery of functional ID4 protein via PCL/maltodextrin nano-particle inhibits prostate cancer growth.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Carriers; Humans; Inhibitor of Differentiation Proteins; Male; Mice, SCID; Nanoparticles; Polyesters; Polysaccharides; Prostatic Neoplasms; RNA Interference; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis.
Topics: Abiraterone Acetate; Aged, 80 and over; Antineoplastic Agents; Benzamides; Docetaxel; Electronic Health Records; Humans; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2016 |
S6Ks isoforms contribute to viability, migration, docetaxel resistance and tumor formation of prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Knockdown Techniques; Heterografts; Humans; Isoenzymes; Male; Mice; Mice, Nude; Prostatic Neoplasms; Ribosomal Protein S6 Kinases; Taxoids | 2016 |
Docetaxel-Related Toxic Optic Neuropathy in Management of Prostate Adenocarcinoma.
Topics: Adrenal Cortex Hormones; Docetaxel; Humans; Male; Middle Aged; Optic Nerve Diseases; Prostatic Neoplasms; Taxoids; Treatment Outcome; Visual Fields | 2017 |
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
Topics: Adenocarcinoma; Androgens; Androstenes; Animals; Antineoplastic Agents, Phytogenic; Benzamides; Biological Transport; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Heterografts; Humans; Male; Mice, Nude; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Nitriles; Organic Anion Transporters, Sodium-Independent; Phenylthiohydantoin; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Solute Carrier Organic Anion Transporter Family Member 1B3; Taxoids | 2016 |
Metabolic shift toward oxidative phosphorylation in docetaxel resistant prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Fibroblasts; Glucose; Glutamine; Glycolysis; Humans; Male; Mitochondria; NADP; Oxidative Phosphorylation; Phenotype; Prostate; Prostatic Neoplasms; Reactive Oxygen Species; Taxoids | 2016 |
Nephrotoxicity of epigenetic inhibitors used for the treatment of cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Azacitidine; Cell Death; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Epigenesis, Genetic; HEK293 Cells; Histones; Humans; Hydroxamic Acids; Kidney; Male; Methylation; Neoplasms; Oligopeptides; Prostatic Neoplasms; Rats; Taxoids | 2016 |
Anti-CD24 nano-targeted delivery of docetaxel for the treatment of prostate cancer.
Topics: Animals; CD24 Antigen; Docetaxel; Drug Delivery Systems; Lactic Acid; Male; Mice; Mice, Nude; Nanoparticles; Polyglycolic Acid; Prostatic Neoplasms; Taxoids | 2017 |
A biodistribution study of solid lipid-polyethyleneimine hybrid nanocarrier for cancer RNAi therapy.
Topics: Animals; Cell Line, Tumor; Docetaxel; Epidermal Growth Factor; Genetic Therapy; Humans; Lipids; Liver Neoplasms; Male; Mice; Nanomedicine; Nanoparticles; Neoplasm Metastasis; Neoplasm Transplantation; Polyethyleneimine; Prostatic Neoplasms; Random Allocation; RNA Interference; RNA, Small Interfering; Taxoids; Transfection | 2016 |
Ecotropic viral integration site 1, a novel oncogene in prostate cancer.
Topics: Antineoplastic Agents; Cell Proliferation; DNA-Binding Proteins; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Gene Knockdown Techniques; Humans; Immunohistochemistry; Male; MDS1 and EVI1 Complex Locus Protein; Models, Biological; Neoplasm Grading; Neoplasm Metastasis; Oncogenes; Prostatic Neoplasms; Proto-Oncogenes; Spheroids, Cellular; Taxoids; Transcription Factors; Tumor Cells, Cultured | 2017 |
Re: Addition of Docetaxel, Zoledronic Acid, or Both to First-Line Long-Term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Diphosphonates; Disease-Free Survival; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2016 |
The Utility of Serum CA9 for Prognostication in Prostate Cancer.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carbonic Anhydrase IX; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Phenotype; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2016 |
The UCA1/miR-204/Sirt1 axis modulates docetaxel sensitivity of prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Caspase 3; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Male; MicroRNAs; Prostatic Neoplasms; RNA, Long Noncoding; RNA, Small Interfering; Sirtuin 1; Taxoids | 2016 |
Molecular complexity of taxane-induced cytotoxicity in prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Prostatic Neoplasms; Protein Translocation Systems; Proto-Oncogene Proteins p21(ras); raf Kinases; Receptors, Androgen; Taxoids; Xenograft Model Antitumor Assays | 2017 |
Fractionated radiation exposure amplifies the radioresistant nature of prostate cancer cells.
Topics: Cell Line, Tumor; Cell Survival; Docetaxel; Dose Fractionation, Radiation; Humans; Male; Prostatic Neoplasms; Radiation Tolerance; Reactive Oxygen Species; S Phase; Taxoids | 2016 |
Reply to Che-Kai Tsao, Matthew D. Galsky, and William K. Oh's Platinum Opinion. Docetaxel for Metastatic Hormone-Sensitive Prostate Cancer: Urgent Need To Minimize The Risk Of Neutropenic Fever. Eur Urol 2016;70:707-708.
Topics: Attitude; Docetaxel; Humans; Male; Platinum; Prostatic Neoplasms; Taxoids | 2017 |
Hyperglycaemia-induced resistance to Docetaxel is negated by metformin: a role for IGFBP-2.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 2; Male; Metformin; Prostatic Neoplasms; Protein Serine-Threonine Kinases; RNA, Small Interfering; Taxoids | 2017 |
Avoiding Undertreatment of Aggressive Prostate Cancer by Early Use of Chemotherapy.
Topics: Docetaxel; Humans; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2017 |
Should Chemotherapy Be Used in Nonmetastatic Prostate Cancer?
Topics: Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Drug Therapy; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2017 |
Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Cobalt; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Mice, Inbred BALB C; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; RNA Interference; Signal Transduction; Taxoids; Time Factors; TOR Serine-Threonine Kinases; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Amplification of MUC1 in prostate cancer metastasis and CRPC development.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Computational Biology; Databases, Genetic; Disease Progression; Disease-Free Survival; Docetaxel; Gene Amplification; Gene Dosage; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mucin-1; Neoplastic Stem Cells; Neuroendocrine Tumors; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Receptors, Androgen; RNA, Messenger; Signal Transduction; Survival Analysis; Taxoids; Time Factors; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
miR-375 induces docetaxel resistance in prostate cancer by targeting SEC23A and YAP1.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; MicroRNAs; Phosphoproteins; Prostatic Neoplasms; RNA Interference; Taxoids; Transcription Factors; Vesicular Transport Proteins; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |
Enhanced efficacy of combination heat shock targeted polymer therapeutics with high intensity focused ultrasound.
Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Endoplasmic Reticulum Chaperone BiP; High-Intensity Focused Ultrasound Ablation; Humans; Hyperthermia, Induced; Male; Mice, Nude; Peptides; Prostate; Prostatic Neoplasms; Taxoids | 2017 |
Re: Resistance to Docetaxel in Prostate Cancer is Associated with Androgen Receptor Activation and Loss of KDM5D Expression.
Topics: Androgens; Docetaxel; Histone Demethylases; Humans; Male; Minor Histocompatibility Antigens; Prostatic Neoplasms; Receptors, Androgen | 2017 |
Addition of docetaxel and/or zoledronic acid to standard of care for hormone-naive prostate cancer: a cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; China; Cost-Benefit Analysis; Diphosphonates; Disease Progression; Docetaxel; Humans; Imidazoles; Male; Markov Chains; Prostatic Neoplasms; Standard of Care; Taxoids; Zoledronic Acid | 2017 |
Low density lipoprotein peptide conjugated submicron emulsions for combating prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Cations; Cell Line, Tumor; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Emulsions; Humans; Lipoproteins, LDL; Male; Particle Size; Peptides; Prostatic Neoplasms; Receptors, LDL; Taxoids | 2017 |
Androgen-induced lncRNA POTEF-AS1 regulates apoptosis-related pathway to facilitate cell survival in prostate cancer cells.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Humans; Male; Prostatic Neoplasms; Receptors, Androgen; RNA Interference; RNA, Long Noncoding; RNA, Small Interfering; Signal Transduction; Taxoids; Toll-Like Receptors | 2017 |
Impact of ethnicity on the outcome of men with metastatic, hormone-sensitive prostate cancer.
Topics: Aged; Alaskan Natives; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Asian; Black or African American; Disease-Free Survival; Docetaxel; Ethnicity; Hispanic or Latino; Humans; Indians, North American; Male; Native Hawaiian or Other Pacific Islander; Neoplasm Metastasis; Neoplasm Staging; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; SEER Program; Survival Rate; Taxoids; Treatment Outcome; White People | 2017 |
Bone Microenvironment Changes in Latexin Expression Promote Chemoresistance.
Topics: Animals; Bone and Bones; Cell Line, Tumor; DNA Methylation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Nerve Tissue Proteins; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Stromal Cells; Taxoids; Tumor Microenvironment; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
Regulation of Docetaxel Sensitivity in Prostate Cancer Cells by hsa-miR-125a-3p via Modulation of Metastasis-Associated Protein 1 Signaling.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Line, Tumor; Docetaxel; Gene Expression Regulation, Neoplastic; Histone Deacetylases; Humans; Male; MicroRNAs; Prostatic Neoplasms; Repressor Proteins; Trans-Activators | 2017 |
Cytotoxic Effects of the Therapeutic Radionuclide Rhenium-188 Combined with Taxanes in Human Prostate Carcinoma Cell Lines.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Chemoradiotherapy; Chemotherapy, Adjuvant; DNA Repair; Docetaxel; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Male; Organometallic Compounds; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radiopharmaceuticals; Taxoids | 2017 |
Co-delivery of docetaxel and curcumin prodrug via dual-targeted nanoparticles with synergistic antitumor activity against prostate cancer.
Topics: Aconitic Acid; Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Coumarins; Curcumin; Docetaxel; Drug Delivery Systems; Drug Liberation; Drug Stability; Drug Synergism; Endocytosis; Humans; Inhibitory Concentration 50; Lactic Acid; Male; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Particle Size; Peptides; Polyethylene Glycols; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Prodrugs; Prostatic Neoplasms; Proton Magnetic Resonance Spectroscopy; Taxoids; Thiazoles | 2017 |
The role of epithelial-mesenchymal transition drivers ZEB1 and ZEB2 in mediating docetaxel-resistant prostate cancer.
Topics: Antineoplastic Agents; Cadherins; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Male; Prostate; Prostatic Neoplasms; Repressor Proteins; RNA Interference; RNA, Small Interfering; Taxoids; Up-Regulation; Zinc Finger E-box Binding Homeobox 2; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Radiosensitizing Silica Nanoparticles Encapsulating Docetaxel for Treatment of Prostate Cancer.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Dialysis; Docetaxel; Drug Compounding; Drug Delivery Systems; Humans; Male; Nanoparticles; Prostatic Neoplasms; Radiation-Sensitizing Agents; Silicon Dioxide; Taxoids | 2017 |
Application of sequential factorial design and orthogonal array composite design (OACD) to study combination of 5 prostate cancer drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Artemisinins; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Drug Interactions; Humans; Male; Models, Statistical; Paclitaxel; Prostatic Neoplasms; Regression Analysis; Taxoids | 2017 |
Combinatorial effect of curcumin with docetaxel modulates apoptotic and cell survival molecules in prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Curcumin; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2017 |
Resveratrol induces cell cycle arrest and apoptosis with docetaxel in prostate cancer cells via a p53/ p21WAF1/CIP1 and p27KIP1 pathway.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Drug Synergism; Humans; Immunoblotting; Male; Microscopy, Fluorescence; Prostatic Neoplasms; Resveratrol; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stilbenes; Taxoids; Tumor Suppressor Protein p53 | 2017 |
The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Topics: Bone Neoplasms; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Oligonucleotide Array Sequence Analysis; Prognosis; Prostatic Neoplasms; Serum Response Factor; Survival Analysis; Taxoids; Transcription Factors; Transcriptional Activation | 2017 |
The effects of 1,4-dimethylpyridine in metastatic prostate cancer in mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Models, Animal; Docetaxel; Humans; Male; Mice; Neoplasm Metastasis; Niacinamide; Prostatic Neoplasms; Pyridines; Taxoids | 2017 |
Contrasting roles of the ABCG2 Q141K variant in prostate cancer.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Docetaxel; Folic Acid; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasm Proteins; Neoplasm Recurrence, Local; Polymorphism, Single Nucleotide; Prostatic Neoplasms; Taxoids | 2017 |
Soluble ErbB3 levels in bone marrow and plasma of men with prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Bone Marrow; Bone Neoplasms; Disease Progression; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Male; Middle Aged; Neoplasm Staging; Prostatic Neoplasms; Receptor, ErbB-3; Solubility; Survival Analysis; Taxoids | 2008 |
Genistein combined polysaccharide enhances activity of docetaxel, bicalutamide and Src kinase inhibition in androgen-dependent and independent prostate cancer cell lines.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Genistein; Humans; Male; Neoplasms, Hormone-Dependent; Nitriles; Prostatic Neoplasms; Pyrimidines; src-Family Kinases; Taxoids; Tosyl Compounds | 2008 |
Rapid testosterone cycling and chemotherapy for prostate cancer: a way forward or return to the past?
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Prostatic Neoplasms; Rats; Taxoids; Testosterone | 2008 |
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
Topics: Aged; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Obesity; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Testosterone; Treatment Outcome | 2009 |
Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Blood Platelets; Cell-Derived Microparticles; Docetaxel; Humans; Male; Middle Aged; Orchiectomy; Prognosis; Prospective Studies; Prostatic Neoplasms; Survival Rate; Taxoids; Treatment Failure | 2009 |
Editorial comment on: Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy.
Topics: Antineoplastic Agents; Blood Platelets; Cell-Derived Microparticles; Docetaxel; Humans; Male; Prostatic Neoplasms; Survival Rate; Taxoids | 2009 |
Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Infusions, Intravenous; Male; Mice; Mice, Nude; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Docetaxel and bortezomib downregulate Bcl-2 and sensitize PC-3-Bcl-2 expressing prostate cancer cells to irradiation.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Docetaxel; Down-Regulation; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Radiation-Sensitizing Agents; Taxoids; Tumor Cells, Cultured | 2008 |
RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Male; Mice; Mice, Nude; Osteolysis; Osteoprotegerin; Prostatic Neoplasms; RANK Ligand; Receptors, Fc; Survival Analysis; Taxoids; Tumor Burden; Whole Body Imaging; Xenograft Model Antitumor Assays | 2008 |
Mitotic catastrophe and apoptosis induced by docetaxel in hormone-refractory prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Caspase 2; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Shape; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cysteine Endopeptidases; Docetaxel; Dose-Response Relationship, Drug; Enzyme Activation; Humans; Male; Mitosis; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Time Factors | 2008 |
ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel.
Topics: Androgens; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Drug Resistance, Neoplasm; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Male; Polymerase Chain Reaction; Polymorphism, Genetic; Prostatic Neoplasms; Taxoids; Thalidomide | 2008 |
[A case of hormone/docetaxel-refractory prostate cancer in which PSA level decreased after docetaxel+zoledronic acid treatment].
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2008 |
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Dimerization; Docetaxel; Dose-Response Relationship, Drug; Gossypol; Humans; Interleukin-3; Male; Mice; Mice, Nude; Mitochondria; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays | 2008 |
Durable complete response to frontline docetaxel in an advanced prostate cancer patient with favourable CYP1B1 isoforms: suggestion for changing paradigms?
Topics: Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1B1; Disease Progression; Docetaxel; Humans; Isoenzymes; Male; Middle Aged; Prostatic Neoplasms; Remission Induction; Taxoids; Time Factors | 2008 |
Docosahexaenoic acid enhances the efficacy of docetaxel in prostate cancer cells by modulation of apoptosis: the role of genes associated with the NF-kappaB pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Docetaxel; Docosahexaenoic Acids; Drug Synergism; Gene Expression; Humans; Male; Membrane Potential, Mitochondrial; NF-kappa B; Prostatic Neoplasms; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Taxoids | 2008 |
[Feasibility of targeted therapy based on immunohistochemical expression analysis in androgen-independent prostate cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Biomarkers, Tumor; Biopsy; Cetuximab; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Imatinib Mesylate; Lymph Nodes; Male; Neoplasms, Hormone-Dependent; Piperazines; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Receptors, Androgen; Taxoids; Trastuzumab | 2008 |
Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Caspase 3; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Diphosphonates; Docetaxel; Drug Synergism; Enzyme Activation; Fluorescent Dyes; Humans; Imidazoles; In Situ Nick-End Labeling; Male; MAP Kinase Kinase 1; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Rhodamines; Taxoids; Time Factors; Zoledronic Acid | 2008 |
Editorial comment on: Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Frail Elderly; Geriatric Assessment; Humans; Male; Prognosis; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cohort Studies; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Geriatric Assessment; Humans; Infusions, Intravenous; Male; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2009 |
[Chemotherapy for prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Disease Progression; Docetaxel; Evidence-Based Medicine; Humans; Male; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Palliative Care; Patient Care Team; Prostatic Neoplasms; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Taxoids | 2008 |
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer--a multi-arm multi-stage randomised controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Neoplasm Metastasis; Pilot Projects; Prostatic Neoplasms; Pyrazoles; Randomized Controlled Trials as Topic; Sulfonamides; Taxoids; Zoledronic Acid | 2008 |
Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Lymphotoxin beta Receptor; Male; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin; Taxoids; Tretinoin | 2008 |
Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells.
Topics: Androgens; Apoptosis; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Tumor; Docetaxel; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Interleukin-8; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Recombinant Proteins; RNA, Small Interfering; Signal Transduction; Taxoids; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic | 2008 |
Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Fas Ligand Protein; fas Receptor; Humans; Male; Mice; Mitoxantrone; Prostate; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Up-Regulation | 2008 |
Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Delivery Systems; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2008 |
Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2008 |
Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leukocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer.
Topics: Antineoplastic Agents; Dimerization; Docetaxel; Humans; Leukocytes; Male; Multivariate Analysis; Phosphorylation; Platelet-Derived Growth Factor; Prostatic Neoplasms; Receptors, Platelet-Derived Growth Factor; Taxoids | 2008 |
Therapeutic efficacy of 177Lu-CHX-A''-DTPA-hu3S193 radioimmunotherapy in prostate cancer is enhanced by EGFR inhibition or docetaxel chemotherapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Humans; Isothiocyanates; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Pentetic Acid; Phosphorylation; Prostatic Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; Taxoids; Tyrphostins; Xenograft Model Antitumor Assays | 2009 |
Docetaxel for hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2008 |
Docetaxel chemotherapy of Korean patients with hormone- refractory prostate cancer:comparative analysis between 1st-line and 2nd-line docetaxel.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2008 |
Prostate-specific antigen flare phenomenon with docetaxel-based chemotherapy in patients with androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Androgens; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2008 |
A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes.
Topics: Algorithms; Antineoplastic Agents; Breast Neoplasms; Cluster Analysis; Computer Simulation; Docetaxel; Environment; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Likelihood Functions; Logistic Models; Male; Models, Genetic; Models, Statistical; Monte Carlo Method; Pharmacogenetics; Phenotype; Prostatic Neoplasms; Reproducibility of Results; Tamoxifen; Taxoids; Treatment Outcome | 2008 |
Combining 153Sm-lexidronam and docetaxel for the treatment of patients with hormone-refractory prostate cancer: first experience.
Topics: Aged; Analgesics, Non-Narcotic; Antineoplastic Agents; Body Weight; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Organophosphorus Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Taxoids; Time Factors; Treatment Outcome | 2008 |
Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Gonadotropin-Releasing Hormone; Humans; Imatinib Mesylate; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Risk Factors; Survival Rate; Taxoids | 2009 |
Adenoviral-mediated pHyde gene transfer and cisplatin additively inhibit human prostate cancer growth by enhancing apoptosis.
Topics: Adenoviridae; Amino Acid Sequence; Animals; Antineoplastic Agents; Apoptosis; Base Sequence; Caspase 3; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Membrane; Cisplatin; Combined Modality Therapy; DNA, Complementary; Docetaxel; Gene Transfer Techniques; Genetic Therapy; Humans; Male; Oncogene Proteins; Oxidoreductases; Prostatic Neoplasms; Protein Structure, Tertiary; Rats; RNA, Messenger; Sequence Homology; Taxoids | 2009 |
Low dose combinations of 2-methoxyestradiol and docetaxel block prostate cancer cells in mitosis and increase apoptosis.
Topics: 2-Methoxyestradiol; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Docetaxel; Estradiol; Flow Cytometry; Humans; Immunohistochemistry; Male; Mice; Mice, Transgenic; Mitosis; Prostatic Neoplasms; RNA, Small Interfering; Taxoids; Transfection; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Dexamethasone; Docetaxel; Endothelial Cells; Humans; Interleukin-8; Male; Mice; NF-kappa B; Orchiectomy; Prostatic Neoplasms; Taxoids; Transcription Factor AP-1; Xenograft Model Antitumor Assays | 2008 |
[Chemotherapy of hormonorefractory and hormonoresistant metastatic prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2008 |
Retrovirally transduced murine T lymphocytes expressing FasL mediate effective killing of prostate cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cells, Cultured; Docetaxel; Fas Ligand Protein; Gene Expression Regulation; Humans; Immunotherapy; Male; Mice; Mice, Inbred C57BL; Mitoxantrone; Phenotype; Prostatic Neoplasms; Retroviridae; T-Lymphocytes; Taxoids; Transduction, Genetic | 2009 |
Editorial and introduction to Asian Journal of Andrology Prostate Cancer special issue.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Biopsy, Fine-Needle; Brachytherapy; Docetaxel; Global Health; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Taxoids; Ultrasonography | 2009 |
Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; Diphosphonates; DNA Fragmentation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Imidazoles; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Zoledronic Acid | 2009 |
Ciprofloxacin sensitizes hormone-refractory prostate cancer cell lines to doxorubicin and docetaxel treatment on a schedule-dependent manner.
Topics: Anti-Infective Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Ciprofloxacin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Antagonism; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Male; Prostatic Neoplasms; Taxoids; Time Factors | 2009 |
Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Argininosuccinate Synthase; Autophagy; Caspase 3; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Hydrolases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Polyethylene Glycols; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Nevirapine restores androgen signaling in hormone-refractory human prostate carcinoma cells both in vitro and in vivo.
Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Animals; Cell Differentiation; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Dihydrotestosterone; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nevirapine; Nitriles; Prostatic Neoplasms; Random Allocation; Receptors, Androgen; Reverse Transcriptase Inhibitors; RNA, Neoplasm; Signal Transduction; Taxoids; Tosyl Compounds; Xenograft Model Antitumor Assays | 2009 |
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Blotting, Western; Caspase 3; Cell Proliferation; Cisplatin; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Disease Models, Animal; Docetaxel; Drug Synergism; Drug Therapy, Combination; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Docetaxel-induced skin toxicity.
Topics: Antineoplastic Agents; Docetaxel; Foot Dermatoses; Hand Dermatoses; Humans; Male; Prostatic Neoplasms; Risk Factors; Taxoids | 2009 |
Combining docetaxel with estramustine: back to the future?
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Prostatic Neoplasms; Taxoids | 2009 |
Chemotherapeutic sensitization by endoplasmic reticulum stress: increasing the efficacy of taxane against prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Death; Cell Line, Tumor; Docetaxel; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme-Linked Immunosorbent Assay; Formazans; Heat-Shock Proteins; Humans; Male; Molecular Chaperones; Organoselenium Compounds; Paclitaxel; Prostatic Neoplasms; RNA, Small Interfering; Taxoids; Tetrazolium Salts; Thapsigargin; Time Factors; Transcription Factor CHOP; Transfection | 2009 |
Methylation-mediated repression of GADD45alpha in prostate cancer and its role as a potential therapeutic target.
Topics: Antineoplastic Agents; Azacitidine; Cell Cycle Proteins; Cell Line, Tumor; DNA Methylation; DNA Primers; DNA, Neoplasm; Docetaxel; Gene Expression Regulation, Neoplastic; Genome; Humans; Male; Methylation; Nuclear Proteins; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Up-Regulation | 2009 |
Regulation of growth factors in hormone- and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Intercellular Signaling Peptides and Proteins; Male; Neoplasms, Hormone-Dependent; Octreotide; Prostate; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2009 |
Predictive modelling in hormone-refractory prostate cancer (HRPC).
Topics: Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Kinetics; Male; Predictive Value of Tests; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Synergy between anti-CCL2 and docetaxel as determined by DW-MRI in a metastatic bone cancer model.
Topics: Animals; Antibodies; Antineoplastic Agents; Bone Neoplasms; Chemokine CCL2; Diffusion Magnetic Resonance Imaging; Docetaxel; Drug Synergism; Humans; Male; Mice; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Overcoming drug resistance in hormone- and drug-refractory prostate cancer cell line, PC-3 by docetaxel and gossypol combination.
Topics: Apoptosis; Cell Line, Tumor; DNA, Complementary; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gossypol; Humans; Male; Prostatic Neoplasms; Taxoids; Time Factors | 2010 |
Pre-clinical evaluation of Rh2 in PC-3 human xenograft model for prostate cancer in vivo: formulation, pharmacokinetics, biodistribution and efficacy.
Topics: Administration, Oral; Alanine Transaminase; Animal Structures; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Aspartate Aminotransferases; Body Weight; Cell Line, Tumor; Creatinine; Docetaxel; Drug Stability; Ginsenosides; Humans; Ki-67 Antigen; Male; Mice; Mice, Nude; Prostatic Neoplasms; Solubility; Solvents; Taxoids; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |
Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Chemotaxis; Docetaxel; Heterogeneous-Nuclear Ribonucleoprotein K; Humans; Immunoenzyme Techniques; Male; Neoplasm Invasiveness; Neovascularization, Pathologic; Phenotype; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Taxoids; Thrombospondin 1; Tumor Cells, Cultured | 2009 |
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Epothilones; Humans; Infusions, Subcutaneous; Male; Middle Aged; Military Personnel; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2009 |
Characterization of choline uptake in prostate cancer cells following bicalutamide and docetaxel treatment.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Choline; Diffusion; Docetaxel; Hemicholinium 3; Humans; Male; Nitriles; Organic Cation Transport Proteins; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids; Tosyl Compounds; Tritium | 2009 |
Knockdown of p21-activated kinase 6 inhibits prostate cancer growth and enhances chemosensitivity to docetaxel.
Topics: Antineoplastic Agents; Cells, Cultured; Combined Modality Therapy; Docetaxel; Gene Knockdown Techniques; Humans; Male; p21-Activated Kinases; Prostatic Neoplasms; Taxoids | 2009 |
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quality of Life; Taxoids | 2009 |
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Ketoconazole; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors; Treatment Outcome | 2009 |
Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Diethylstilbestrol; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Time Factors; Treatment Outcome | 2009 |
Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2009 |
3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Cell Division; Cell Line, Tumor; Cell Survival; Docetaxel; Down-Regulation; Drug Therapy, Combination; Female; Humans; Indoles; Inhibitor of Apoptosis Proteins; Luciferases; Male; Mice; Microtubule-Associated Proteins; Neoplasm Metastasis; Plasmids; Prostatic Neoplasms; Survivin; Taxoids | 2009 |
[Comment to P. J. Olbert et al., page 164].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Controlled Clinical Trials as Topic; Disease Progression; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Retreatment; Survival Rate; Taxoids; Treatment Outcome | 2009 |
Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Methotrexate; Mitoxantrone; Multidrug Resistance-Associated Proteins; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2009 |
Luteinizing hormone-releasing hormone receptor-targeted deslorelin-docetaxel conjugate enhances efficacy of docetaxel in prostate cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, Liquid; Docetaxel; Dose-Response Relationship, Drug; Flow Cytometry; Humans; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Structure; Prostatic Neoplasms; Receptors, LHRH; Spectroscopy, Fourier Transform Infrared; Taxoids; Triptorelin Pamoate; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
Sphingosine kinase 1 inhibition sensitizes hormone-resistant prostate cancer to docetaxel.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Male; Neoplasms, Hormone-Dependent; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Taxoids | 2009 |
Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Piperidines; Prostatic Neoplasms; Pyridines; Taxoids; Xenograft Model Antitumor Assays | 2009 |
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy.
Topics: Antigens, Surface; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Gene Expression Regulation, Neoplastic; Glutamate Carboxypeptidase II; Humans; Male; Microtubules; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Transfection | 2009 |
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Neoplasms; Cell Line, Tumor; Dasatinib; Docetaxel; Humans; Male; Mice; Mice, SCID; Osteolysis; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrimidines; src-Family Kinases; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2009 |
The relationship of neuroendocrine carcinomas to anti-tumor therapies in TRAMP mice.
Topics: Adenocarcinoma; Androgen Antagonists; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Neuroendocrine; Cell Proliferation; Docetaxel; Drug Therapy, Combination; Incidence; Male; Mice; Mice, Transgenic; Neoplasm Proteins; Prostatic Neoplasms; Survival Analysis; Taxoids | 2009 |
Reversal of docetaxel resistance with bevacizumab and thalidomide.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Taxoids; Thalidomide | 2009 |
Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Female; Fluorouracil; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; Caspase 2; Caspase 3; Caspase Inhibitors; Caspases; Cathepsin B; Cell Cycle; Cell Line, Tumor; Cell Survival; Cysteine Proteinase Inhibitors; Docetaxel; Dose-Response Relationship, Drug; Enzyme Activation; Flow Cytometry; Humans; Immunoblotting; Intercellular Signaling Peptides and Proteins; Lysosomes; Male; Membrane Potential, Mitochondrial; Prostatic Neoplasms; Taxoids; Time Factors; TNF-Related Apoptosis-Inducing Ligand; Transfection | 2009 |
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Administration Schedule; Humans; Imidazoles; Male; Neoplasms, Hormone-Dependent; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome; Zoledronic Acid | 2009 |
Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profiling.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Growth Differentiation Factor 15; Humans; Male; Mucoproteins; Oncogene Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Proteins; Proteomics; Recombinant Proteins; RNA, Small Interfering; Taxoids; Transfection | 2009 |
Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression.
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids | 2010 |
Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Epirubicin; Humans; Male; Prostatic Neoplasms; Taxoids | 2009 |
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.
Topics: Androgen Receptor Antagonists; Androgens; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Chromatin Immunoprecipitation; Chromones; Docetaxel; Enzyme Inhibitors; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Immunoblotting; Immunoenzyme Techniques; Luciferases; Male; Mice; Mice, Inbred NOD; Mice, SCID; Morpholines; Orchiectomy; Paclitaxel; Phosphoinositide-3 Kinase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Taxoids | 2009 |
Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Biphenyl Compounds; Cell Death; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Colonic Neoplasms; Docetaxel; Drug Synergism; Fluorescent Dyes; HCT116 Cells; Humans; In Situ Nick-End Labeling; Indoles; Inhibitory Concentration 50; Magnolia; Male; Molecular Structure; NF-kappa B; Phenyl Ethers; Plant Leaves; Prostatic Neoplasms; Taxoids | 2009 |
Docetaxel in combination with prednisolone for hormone refractory prostate cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Humans; Male; Neoplasms, Hormone-Dependent; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2010 |
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Chemokine CCL2; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Gene Expression; Gene Expression Profiling; Gene Silencing; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Recombinant Proteins; RNA, Messenger; RNA, Small Interfering; Taxoids; Up-Regulation | 2010 |
Suppressed tumour growth and enhanced chemosensitivity by RNA interference targeting Aurora-A in the PC3 human prostate cancer model.
Topics: Aged; Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinases; Docetaxel; Humans; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; RNA Interference; Taxoids; Tumor Burden; Tumor Cells, Cultured | 2010 |
Decrease in prostate specific antigen secretion correlated with docetaxel-induced growth inhibition and apoptosis in human prostate tumor cells.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Division; Chromatin; DNA Fragmentation; Docetaxel; Dose-Response Relationship, Drug; Humans; In Situ Nick-End Labeling; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2009 |
Downmodulation of Bcl-2 sensitizes metastatic LNCaP-LN3 cells to undergo apoptosis via the intrinsic pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Docetaxel; Down-Regulation; Humans; Male; Neoplasm Metastasis; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Taxoids | 2010 |
A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line.
Topics: Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mutation; Prostatic Neoplasms; Receptors, Androgen; RNA Interference; RNA, Small Interfering; Signal Transduction; Taxoids; Tubulin | 2010 |
Telomerase enzyme inhibition (TEI) and cytolytic therapy in the management of androgen independent osseous metastatic prostate cancer.
Topics: Androgens; Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Enzyme Inhibitors; Humans; Male; Mice; Mice, Nude; Oligoribonucleotides, Antisense; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Telomerase; Xenograft Model Antitumor Assays | 2010 |
Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells.
Topics: Androgens; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azacitidine; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Docetaxel; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; Humans; Male; Neoplasm Proteins; Polymerase Chain Reaction; Promoter Regions, Genetic; Prostatic Neoplasms; RNA, Messenger; Taxoids | 2010 |
Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Topics: Adjuvants, Pharmaceutic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Shape; Cell Survival; Cisplatin; DNA-Binding Proteins; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Synergism; Ginsenosides; Humans; Male; NF-kappa B; Prostatic Neoplasms; Taxoids; Time Factors | 2010 |
Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.
Topics: Animals; Antineoplastic Agents; Cell Adhesion; Cell Movement; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Ligands; Male; Mice; Neoplasm Invasiveness; Neoplasm Transplantation; Phosphorylation; Prostatic Neoplasms; Protein Isoforms; Protein Structure, Tertiary; RNA Interference; Taxoids | 2010 |
[Chemotherapy with low-dose docetaxel and estramustine phosphate in patient with liver dysfunction due to liver metastases of hormone-refractory prostate cancer : a case report].
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Liver Diseases; Liver Neoplasms; Male; Prostatic Neoplasms; Taxoids | 2010 |
KLK5 gene expression is severely upregulated in androgen-independent prostate cancer cells after treatment with the chemotherapeutic agents docetaxel and mitoxantrone.
Topics: Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cytostatic Agents; Docetaxel; Gene Expression Regulation, Neoplastic; Humans; Kallikreins; Male; Mitoxantrone; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Up-Regulation | 2010 |
A new therapy paradigm for prostate cancer founded on clinical observations.
Topics: Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Models, Biological; Prostatic Neoplasms; Taxoids | 2010 |
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
Topics: Adenocarcinoma; Apoptosis; Cell Fractionation; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatic Neoplasms; Quinazolines; Taxoids; Transcription Factors; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2010 |
Phenethyl isothiocyanate sensitizes androgen-independent human prostate cancer cells to docetaxel-induced apoptosis in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Docetaxel; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids | 2010 |
Rapamycin enhances the susceptibility of both androgen-dependent and -independent prostate carcinoma cells to docetaxel.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Synergism; Flow Cytometry; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Random Allocation; Sirolimus; Taxoids; Xenograft Model Antitumor Assays | 2010 |
Combination chemotherapy with weekly paclitaxel or docetaxel, carboplatin, and estramustine for hormone-refractory prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2010 |
Carboplatin plus weekly docetaxel as salvage chemotherapy in docetaxel-resistant and castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cohort Studies; Confidence Intervals; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Patient Selection; Probability; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2010 |
ID1 enhances docetaxel cytotoxicity in prostate cancer cells through inhibition of p21.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chromatin; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; G1 Phase; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Differentiation Protein 1; Male; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; Taxoids | 2010 |
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Docetaxel; Humans; Indium Radioisotopes; Male; Nanoparticles; Prostatic Neoplasms; Taxoids; Yttrium Radioisotopes | 2010 |
Circulating endothelial cells, circulating tumour cells, tissue factor, endothelin-1 and overall survival in prostate cancer patients treated with docetaxel.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Biomarkers, Tumor; Docetaxel; Endothelin-1; Enzyme-Linked Immunosorbent Assay; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Orchiectomy; Prospective Studies; Prostatic Neoplasms; Survival Analysis; Taxoids; Thromboplastin; Treatment Outcome | 2010 |
Differential effects of ibandronate, docetaxel and farnesol treatment alone and in combination on the growth of prostate cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Diphosphonates; Docetaxel; Drug Synergism; Farnesol; Humans; Ibandronic Acid; Male; Mevalonic Acid; Prenylation; Prostatic Neoplasms; Signal Transduction; Taxoids | 2011 |
Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Therapy, Combination; Estramustine; Humans; Hydrocortisone; Male; Middle Aged; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2010 |
[Low-dose docetaxel, estramustine and dexamethasone combination chemotherapy for hormone-refractory prostate cancer].
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Docetaxel; Drug Administration Schedule; Estramustine; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2010 |
The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2010 |
[Chemotherapy with docetaxel in prostate cancer. A case report].
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2010 |
Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Topics: Adenovirus E1A Proteins; Adenovirus E1B Proteins; Adenoviruses, Human; Animals; Antineoplastic Agents; Cell Cycle; Cell Death; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Flow Cytometry; Gene Expression; Genes, p53; Humans; Immunoblotting; Male; Mice; Mice, Nude; Mitoxantrone; Neoplasm Transplantation; Oncolytic Virotherapy; Oncolytic Viruses; Polymerase Chain Reaction; Prostatic Neoplasms; Retinoblastoma Protein; Taxoids; Transplantation, Heterologous; Tumor Suppressor Protein p53; Virus Replication | 2010 |
Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Clusterin; Cytoprotection; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; Male; Phenotype; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; STAT1 Transcription Factor; Taxoids; Up-Regulation | 2010 |
[11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.
Topics: Animals; Biomarkers, Tumor; Carbon Radioisotopes; Cell Line, Tumor; Choline; Docetaxel; Humans; Male; Mice; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Docetaxel-resistant prostate cancer cells remain sensitive to S-trityl-L-cysteine-mediated Eg5 inhibition.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cysteine; Docetaxel; Drug Screening Assays, Antitumor; Humans; Kinesins; Male; Propidium; Prostatic Neoplasms; Taxoids; Up-Regulation | 2010 |
Docetaxel increases antitumor efficacy of oncolytic prostate-restricted replicative adenovirus by enhancing cell killing and virus distribution.
Topics: Adenoviridae; Animals; Cell Death; Cell Line, Tumor; Docetaxel; Enzyme Activation; Gene Expression Regulation, Neoplastic; Genes, Reporter; Genetic Therapy; Genetic Vectors; Humans; Integrin beta1; Integrin beta3; Male; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Promoter Regions, Genetic; Prostatic Neoplasms; Taxoids; Transgenes; Virus Replication | 2010 |
Resolution of thrombocytopenia secondary to disseminated intravascular coagulation with docetaxel chemotherapy in prostate cancer.
Topics: Aged, 80 and over; Antineoplastic Agents; Disseminated Intravascular Coagulation; Docetaxel; Hematuria; Humans; Male; Platelet Count; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Treatment Outcome | 2012 |
Anaemia and thrombocytopenia in patients with prostate cancer and bone metastases.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Docetaxel; Erythrocyte Transfusion; Hemoglobins; Humans; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Norway; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Taxoids; Thrombocytopenia; Time Factors; Treatment Outcome | 2010 |
Ductal variant of adenocarcinoma prostate responding to docetaxel--a case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Docetaxel; Fatal Outcome; Humans; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Taxoids | 2010 |
Poxviral-based prostate-specific antigen vaccine in prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Genetic Vectors; Humans; Male; Nomograms; Poxviridae; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids | 2010 |
BMI1 silencing enhances docetaxel activity and impairs antioxidant response in prostate cancer.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Profiling; Humans; Male; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Polycomb Repressive Complex 1; Prostatic Neoplasms; Proto-Oncogene Proteins; Repressor Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Tumor Cells, Cultured | 2011 |
Docetaxel rechallenge in castration-resistant prostate cancer: scientific legitimacy of common clinical practice.
Topics: Antineoplastic Agents; Docetaxel; Evidence-Based Medicine; Humans; Male; Prostatic Neoplasms; Taxoids; Treatment Failure | 2010 |
Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents; Castration; Docetaxel; Humans; Male; Mutation; Neoplastic Cells, Circulating; Nitriles; Prostatic Neoplasms; Receptors, Androgen; Taxoids; Tosyl Compounds | 2010 |
Involvement of microRNA-21 in mediating chemo-resistance to docetaxel in androgen-independent prostate cancer PC3 cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitory Concentration 50; Lipids; Male; MicroRNAs; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; RNA-Binding Proteins; Taxoids | 2010 |
Docetaxel-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome-related complex in a patient with metastatic prostate cancer?
Topics: Antineoplastic Agents; Docetaxel; Hemolytic-Uremic Syndrome; Humans; Male; Middle Aged; Plasma; Prostatic Neoplasms; Purpura, Thrombotic Thrombocytopenic; Renal Dialysis; Taxoids | 2011 |
NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Apoptosis; Base Sequence; Betulinic Acid; Blotting, Western; Cell Line, Tumor; DNA Primers; Docetaxel; Estradiol; Flow Cytometry; Humans; Immunohistochemistry; Male; Mitosis; NF-kappa B; Pentacyclic Triterpenes; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Triterpenes | 2010 |
[Chemotherapy in early stage of hormone-resistant metastatic prostate cancer: what are the indications?].
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Neoplasm Staging; Prostatic Neoplasms; Taxoids | 2010 |
Hyperglycemia during chemotherapy for hematologic and solid tumors is correlated with increased toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Blood Glucose; Cyclophosphamide; Docetaxel; Doxorubicin; Female; Florida; Humans; Hyperglycemia; Kaplan-Meier Estimate; Linear Models; Lymphoma, Non-Hodgkin; Male; Medical Records; Middle Aged; Neoplasm Staging; Prednisone; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Rituximab; Taxoids; Treatment Outcome; Vincristine | 2011 |
The disintegrin contortrostatin in combination with docetaxel is a potent inhibitor of prostate cancer in vitro and in vivo.
Topics: Animals; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Disintegrins; Docetaxel; Humans; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 2010 |
Properties and effects of a novel liquid crystal nanoparticle formulation of docetaxel in a prostate cancer mouse model.
Topics: Animals; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Mice; Mice, SCID; Nanoparticles; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous | 2010 |
Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Blotting, Western; Caspase 2; Cell Cycle; Cell Line, Tumor; Cell Survival; Cysteine Endopeptidases; Docetaxel; Drug Carriers; Drug Compounding; Durapatite; Enzyme Activation; Flow Cytometry; Humans; Male; Membrane Potential, Mitochondrial; Nanoparticles; Oleic Acid; Particle Size; Prostatic Neoplasms; RNA, Small Interfering; Taxoids | 2010 |
Role of androgen deprivation treatment in patients with castration-resistant prostate cancer, receiving docetaxel-based chemotherapy.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Middle Aged; Prostatic Neoplasms; Republic of Korea; Retrospective Studies; Survival Analysis; Taxoids; Testosterone | 2011 |
Rh2 or its aglycone aPPD in combination with docetaxel for treatment of prostate cancer.
Topics: Analysis of Variance; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drugs, Chinese Herbal; Ginsenosides; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids | 2010 |
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs.
Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dehydroascorbic Acid; Docetaxel; Drug Synergism; Epirubicin; Humans; Irinotecan; Male; Organoplatinum Compounds; Oxaliplatin; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2011 |
[Expert consensus for the diagnosis and treatment of bone metastasis from prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2010 |
Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: a new paradigm for understanding the therapeutic effect of combined treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Cell Division; Cell Survival; Cytoplasm; Docetaxel; Female; Humans; Male; Phosphorylation; Prostatic Neoplasms; Sp1 Transcription Factor; Taxoids; Transcription, Genetic; Treatment Outcome; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression.
Topics: Adult; Aged; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Basigin; Biomarkers, Tumor; Cell Line, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Male; Middle Aged; Monocarboxylic Acid Transporters; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids; Up-Regulation | 2010 |
[Effects of bioactive molecules of Beta vulgaris L. ssp. esculenta var. rubra on metastatic prostate cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Beta vulgaris; Chromatography, High Pressure Liquid; Docetaxel; Humans; Luminescent Measurements; Male; Middle Aged; Phytotherapy; Plant Extracts; Prostatic Neoplasms; Taxoids; Trace Elements; Treatment Outcome | 2010 |
In vitro anticancer activity of docetaxel-loaded micelles based on poly(ethylene oxide)-poly(epsilon-caprolactone) block copolymers: Do nanocarrier properties have a role?
Topics: Antineoplastic Agents; Biological Transport; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemistry, Pharmaceutical; Delayed-Action Preparations; Docetaxel; Dose-Response Relationship, Drug; Drug Carriers; Drug Compounding; Drug Stability; Female; Humans; Inhibitory Concentration 50; Kinetics; Male; Micelles; Nanoparticles; Polyesters; Prostatic Neoplasms; Solubility; Taxoids | 2010 |
A preclinical therapeutic schedule optimizing docetaxel plus estramustine administration in prostate cancer.
Topics: Aged; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Comorbidity; Docetaxel; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Estramustine; Gastrointestinal Diseases; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Vascular Diseases; Venous Thrombosis; Xenograft Model Antitumor Assays | 2010 |
Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; MicroRNAs; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
Cytochrome 450 1B1 (CYP1B1) polymorphisms associated with response to docetaxel in Castration-Resistant Prostate Cancer (CRPC) patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1B1; Docetaxel; Drug Resistance, Neoplasm; Genotype; Humans; Male; Middle Aged; Multivariate Analysis; Polymorphism, Genetic; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2010 |
Early response assessment in prostate carcinoma by ¹⁸F-fluorothymidine following anticancer therapy with docetaxel using preclinical tumour models.
Topics: Animals; Antineoplastic Agents; Biological Transport; Cell Line, Tumor; Cell Proliferation; Dideoxynucleosides; Disease Models, Animal; Docetaxel; Drug Evaluation, Preclinical; Flow Cytometry; Humans; Immunohistochemistry; Male; Mice; Positron-Emission Tomography; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2011 |
Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mitoxantrone; Orchiectomy; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors | 2012 |
Cabazitaxel in prostate cancer: stretching a string.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Drug Approval; Drug Resistance, Neoplasm; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Quality of Life; Taxoids; Tissue Extracts | 2010 |
Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy.
Topics: Antineoplastic Agents; Cisplatin; Docetaxel; Drug Therapy, Combination; Electrochemistry; Endocytosis; Humans; Male; Nanoparticles; Prostatic Neoplasms; Taxoids | 2010 |
[A case of leiomyosarcoma of prostate: multimodality therapy suppressed disease progression for long term].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Leiomyosarcoma; Male; Prostatic Neoplasms; Taxoids | 2010 |
Histone deacetylase inhibitor potentiates anticancer effect of docetaxel via modulation of Bcl-2 family proteins and tubulin in hormone refractory prostate cancer cells.
Topics: Animals; Apoptosis; Docetaxel; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tubulin; Tumor Cells, Cultured | 2010 |
Class III beta-tubulin expression predicts prostate tumor aggressiveness and patient response to docetaxel-based chemotherapy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Orchiectomy; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms; RNA Interference; Survival Analysis; Taxoids; Tubulin | 2010 |
Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel.
Topics: Androgens; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Death; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Male; Microarray Analysis; Prostatic Neoplasms; Taxoids; Up-Regulation | 2011 |
[Two cases of pellagra associated with chemotherapy of docetaxel, estramustine, dexamethasone].
Topics: Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Pellagra; Prostatic Neoplasms; Taxoids | 2010 |
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Cost-Benefit Analysis; Disease Progression; Docetaxel; Humans; Immunotherapy; Male; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2010 |
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Cancer Vaccines; Combined Modality Therapy; Docetaxel; Glucocorticoids; Humans; Immunotherapy; Male; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2010 |
Synergistic antimicrotubule therapy for prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dioxoles; Docetaxel; Humans; Isoquinolines; Male; Prostatic Neoplasms; Taxoids; Tubulin Modulators | 2011 |
Early outcomes from three prospective trials of image-guided proton therapy for prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Androgen Antagonists; Disease Progression; Docetaxel; Dose Fractionation, Radiation; Fiducial Markers; Gastrointestinal Hemorrhage; Gastrointestinal Tract; Humans; Male; Middle Aged; Multivariate Analysis; Prospective Studies; Prostatic Neoplasms; Prostatitis; Proton Therapy; Radiation-Sensitizing Agents; Radiotherapy, Image-Guided; Rectum; Taxoids; Treatment Outcome; Urinary Incontinence; Urogenital System | 2012 |
Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2011 |
MR-guided focused ultrasound: enhancement of intratumoral uptake of [³H]-docetaxel in vivo.
Topics: Animals; Antineoplastic Agents; Biological Transport; Capillary Permeability; Cell Line, Tumor; Docetaxel; Humans; Magnetic Resonance Imaging; Male; Mice; Prostatic Neoplasms; Taxoids; Temperature; Thermometers; Time Factors; Tritium; Ultrasonic Therapy; Xenograft Model Antitumor Assays | 2010 |
Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Aromatase; Disease-Free Survival; Docetaxel; Estrogen Receptor alpha; Genotype; Humans; Male; Orchiectomy; Polymorphism, Genetic; Prognosis; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Risk Assessment; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Cabazitaxel: filling one of the gaps in the treatment of prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids; Tubulin | 2010 |
Cabazitaxel: a new drug for metastatic prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Drug Approval; Humans; Male; Mitoxantrone; Orchiectomy; Prostatic Neoplasms; Taxoids | 2011 |
miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma; Cell Movement; Cell Proliferation; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Genes, bcl-1; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Prostatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Taxoids; Tumor Cells, Cultured | 2011 |
Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-6; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazines; RNA, Small Interfering; Taxoids; Tumor Cells, Cultured | 2011 |
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Drug Administration Schedule; Humans; Infusions, Intravenous; Male; Middle Aged; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Taxoids | 2011 |
Do the genes tell us the path of most resistance?
Topics: Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Taxoids | 2011 |
Docetaxel treatment in castration-resistant prostate cancer: the triad gene-drug-disease.
Topics: Antineoplastic Agents, Phytogenic; Aromatase Inhibitors; Docetaxel; Estrogens; Humans; Male; Orchiectomy; Prostatic Neoplasms; Receptors, Estrogen; Risk Factors; Taxoids | 2011 |
A potent chemotherapeutic strategy in prostate cancer: S-(methoxytrityl)-L-cysteine, a novel Eg5 inhibitor.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Survival; Cysteine; Docetaxel; Drug Resistance, Neoplasm; Humans; Kinesins; Male; Mice; Mice, Nude; Prostatic Neoplasms; Protein Array Analysis; Taxoids; Trityl Compounds; Xenograft Model Antitumor Assays | 2011 |
Docetaxel-mediated apoptosis in myeloid progenitor TF-1 cells is mitigated by zinc: potential implication for prostate cancer therapy.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Docetaxel; Humans; Male; Myeloid Progenitor Cells; Prostatic Neoplasms; Taxoids; Zinc | 2011 |
[Comment to: "Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel"].
Topics: Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Indoles; Male; Prostatic Neoplasms; Pyrroles; Sunitinib; Taxoids; Treatment Failure | 2011 |
Low-dose docetaxel enhances the sensitivity of S-1 in a xenograft model of human castration resistant prostate cancer.
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Combinations; Drug Synergism; Fluorouracil; Humans; Ki-67 Antigen; Male; Mice; Mice, SCID; Oxonic Acid; Prostatectomy; Prostatic Neoplasms; Taxoids; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2012 |
Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Epidemiologic Methods; Humans; Immunotherapy; Male; Neoplasm Metastasis; Orchiectomy; Prednisone; Prognosis; Prostatectomy; Prostatic Neoplasms; Retreatment; Taxoids; Treatment Outcome | 2011 |
Docetaxel as a vital option for corticosteroid-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Drug Resistance, Neoplasm; Humans; Karnofsky Performance Status; L-Lactate Dehydrogenase; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2011 |
Lycopene enhances docetaxel's effect in castration-resistant prostate cancer associated with insulin-like growth factor I receptor levels.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Carotenoids; Cell Line, Tumor; Docetaxel; Humans; Lycopene; Male; Mice; Mice, Nude; Prostatic Neoplasms; Receptor, IGF Type 1; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Castration-dependent pharmacokinetics of docetaxel: do sex and/or ABCB1 polymorphism also matter?
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Castration; Docetaxel; Gonadal Steroid Hormones; Humans; Male; Polymorphism, Genetic; Prostatic Neoplasms; Taxoids | 2011 |
Insulin-like growth factor-binding protein-2 promotes prostate cancer cell growth via IGF-dependent or -independent mechanisms and reduces the efficacy of docetaxel.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor I; Male; Prostatic Neoplasms; PTEN Phosphohydrolase; Recombinant Proteins; RNA, Small Interfering; Taxoids; Transfection | 2011 |
Prolonged response to early docetaxel in a patient with biochemical relapse after primary therapy for prostate cancer and incomplete response to androgen suppression therapy.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Recurrence; Taxoids; Treatment Outcome | 2011 |
Long-term androgen ablation and docetaxel up-regulate phosphorylated Akt in castration resistant prostate cancer.
Topics: Androgen Antagonists; Animals; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mice; Mice, Inbred BALB C; Oncogene Protein v-akt; Phosphorylation; Prostatic Neoplasms; Taxoids; Time Factors; Tumor Cells, Cultured; Up-Regulation | 2011 |
[Low-dose docetaxel in combination with dexamethasone for hormone-refractory prostate cancer].
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Dexamethasone; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2011 |
[Study to castrate-resistant prostate cancer: AUO study AP 60/10].
Topics: Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Lenalidomide; Male; Prednisone; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Failure | 2011 |
Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Italy; Male; Middle Aged; Neoplasm Staging; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2011 |
Molecular chemotherapy and chemotherapy: a new front against late-stage hormone-refractory prostate cancer.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cytokines; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Genetic Vectors; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Staging; Prostatic Neoplasms; Purine-Nucleoside Phosphorylase; Taxoids; Th2 Cells; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Combined effect of sodium selenite and docetaxel on PC3 metastatic prostate cancer cell line.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cytochromes c; Docetaxel; Drug Synergism; Humans; Male; Peroxides; Prostatic Neoplasms; Sodium Selenite; Taxoids | 2011 |
The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzopyrans; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Taxoids; Transcription Factors | 2011 |
Alcohol intoxication with the new formulation of docetaxel.
Topics: Adult; Alcoholic Intoxication; Antineoplastic Agents, Phytogenic; Chemistry, Pharmaceutical; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms; Taxoids | 2011 |
[Combination chemotherapy of docetaxel and UFT against hormone refractory prostate cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Hormones; Humans; Male; Middle Aged; Prostatic Neoplasms; Taxoids; Tegafur; Uracil | 2011 |
Comparison of active and passive targeting of docetaxel for prostate cancer therapy by HPMA copolymer-RGDfK conjugates.
Topics: Acrylamides; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Docetaxel; Male; Mice; Mice, Nude; Polymers; Prostatic Neoplasms; Taxoids | 2011 |
A population-based study of prostate cancer chemotherapy.
Topics: Antineoplastic Agents; Docetaxel; Drug Therapy; Epirubicin; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Taxoids; United Kingdom | 2011 |
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.
Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Cell Death; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Drug Synergism; Humans; Male; Mice; Microtubules; Oncolytic Virotherapy; Oncolytic Viruses; Prostatic Neoplasms; Reoviridae; Taxoids; Tumor Burden; Ultraviolet Rays; Xenograft Model Antitumor Assays | 2011 |
[Long-term disease stabilization by docetaxel plus estramustine for castration-resistant prostate cancer : report of a case].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Estramustine; Humans; Male; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2011 |
Resistance to docetaxel-induced apoptosis in prostate cancer cells by p38/p53/p21 signaling.
Topics: Apoptosis; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; p21-Activated Kinases; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Signal Transduction; Taxoids; Tumor Suppressor Protein p53 | 2011 |
Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Gossypol; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
[Jevtana: clinically significant improvement in survival of patients previously treated with docetaxel].
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Glucocorticoids; Humans; Male; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome | 2011 |
Severe docetaxel overdose induced by pharmacokinetic interaction with dronedarone.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Docetaxel; Dronedarone; Drug Administration Schedule; Drug Overdose; Fatal Outcome; Humans; Male; Mucositis; Prostatic Neoplasms; Taxoids | 2011 |
A novel histone deacetylase inhibitor, CG200745, potentiates anticancer effect of docetaxel in prostate cancer via decreasing Mcl-1 and Bcl-XL.
Topics: Acetylation; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; bcl-X Protein; Cell Death; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Naphthalenes; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tubulin | 2012 |
Editorial comment.
Topics: Antineoplastic Agents; Docetaxel; Humans; Ketoconazole; Male; Prostatic Neoplasms; Taxoids | 2011 |
Co-administration of piperine and docetaxel results in improved anti-tumor efficacy via inhibition of CYP3A4 activity.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Docetaxel; Drug Interactions; Male; Mice; Piperidines; Polyunsaturated Alkamides; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Aorta; Apigenin; Apoptosis; Cell Line; Cell Movement; Docetaxel; Drug Synergism; Drug Therapy, Combination; Glucosides; Male; Mice; Mice, Nude; Neoplasms, Experimental; Prostatic Neoplasms; Taxoids; Time Factors; Tissue Culture Techniques | 2011 |
[Administration of dicarbamin in the course of taxotere-assisted chemotherapy].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Drug Administration Schedule; Female; Humans; Imidazoles; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Ovarian Neoplasms; Prostatic Neoplasms; Protective Agents; Taxoids; Treatment Outcome | 2011 |
Case report: responses to cabazitaxel in metastatic castration-resistant prostate cancer after extensive docetaxel treatment.
Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostatic Neoplasms; Radiotherapy; Taxoids | 2011 |
Re: Gregory R. Pond, Andrew J. Armstrong, Brian A. Wood, et al. Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer. Eur Urol 2012;61:363-9.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Gossypol; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids | 2012 |
Feasibility of tri-weekly docetaxel-based chemotherapy for elderly patients (age 75 and older) with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Feasibility Studies; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome | 2011 |
New treatment options for patients with metastatic castration-resistant prostate cancer.
Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Denosumab; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts; Zoledronic Acid | 2012 |
Lenalidomide enhances the anti-prostate cancer activity of docetaxel in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; In Vitro Techniques; Lenalidomide; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
Characterisation and manipulation of docetaxel resistant prostate cancer cell lines.
Topics: Acridines; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; ATP Binding Cassette Transporter, Subfamily B, Member 1; beta-Galactosidase; Cell Line, Tumor; Cell Survival; Cellular Senescence; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Profiling; Genes, Reporter; Humans; Luciferases, Renilla; Male; Molecular Targeted Therapy; NF-kappa B; Nitriles; Prostatic Neoplasms; Sulfones; Taxoids; Tetrahydroisoquinolines | 2011 |
Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; Docetaxel; Follow-Up Studies; Humans; Male; Meningeal Neoplasms; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2012 |
Identification of docetaxel resistance genes in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Male; Models, Genetic; Oligonucleotide Array Sequence Analysis; Orchiectomy; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Transforming Growth Factor beta1 | 2012 |
Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel.
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Docetaxel; Humans; Male; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids; Treatment Failure | 2011 |
Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
Topics: Adenocarcinoma; Administration, Metronomic; Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Docetaxel; Humans; Male; Methotrexate; Prostatic Neoplasms; Salvage Therapy; Taxoids; Treatment Failure | 2011 |
Can docetaxel therapy improve overall survival from primary therapy compared with androgen-deprivation therapy alone in Japanese patients with castration-resistant prostate cancer? A multi-institutional cooperative study.
Topics: Aged; Androgen Antagonists; Androgens; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2013 |
[Docetaxel-based chemotherapy for hormone-refractory prostate cancer in Japanese patients : experience in a single institute].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Docetaxel; Drug Therapy, Combination; Humans; Male; Middle Aged; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2011 |
Primary cutaneous nocardiosis caused by Nocardia beijingensis in an immunocompromised patient with chemotherapy for advanced prostate cancer.
Topics: Aged; Anti-Bacterial Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Fluoroquinolones; Humans; Immunocompromised Host; Male; Nocardia; Nocardia Infections; Prednisolone; Prostatic Neoplasms; Severity of Illness Index; Taxoids; Treatment Outcome | 2012 |
Polysaccharide-K augments docetaxel-induced tumor suppression and antitumor immune response in an immunocompetent murine model of human prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Immunocompetence; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Prostatic Neoplasms; Proteoglycans; Taxoids; Xenograft Model Antitumor Assays | 2012 |
[Docetaxel-based combination chemotherapy for castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castration; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2011 |
[Docetaxel for advanced prostate cancer].
Topics: Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Humans; Male; Prostatic Neoplasms; Taxoids | 2011 |
Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized p
Topics: Aged; Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Docetaxel; Estramustine; Female; Follow-Up Studies; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Survival Rate; Taxoids; Tosyl Compounds; Treatment Outcome | 2012 |
MR-guided pulsed high intensity focused ultrasound enhancement of docetaxel combined with radiotherapy for prostate cancer treatment.
Topics: Animals; Biological Transport; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; High-Intensity Focused Ultrasound Ablation; Humans; Magnetic Resonance Imaging; Male; Mice; Prostatic Neoplasms; Surgery, Computer-Assisted; Taxoids; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Targeting aurora kinases: a novel approach to curb the growth & chemoresistance of androgen refractory prostate cancer.
Topics: Androgens; Animals; Aurora Kinases; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Profiling; Male; Mice; Mice, Transgenic; Neoplasm Metastasis; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Real-Time Polymerase Chain Reaction; RNA Interference; Taxoids | 2012 |
Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Cell Survival; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Humans; Hyaluronan Receptors; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Neoplasms, Experimental; Neoplastic Stem Cells; Nuclear Proteins; Polycomb Repressive Complex 1; Prostatic Neoplasms; Proto-Oncogene Proteins; Repressor Proteins; Spheroids, Cellular; Taxoids; Transcription Factors; Transplantation, Heterologous; Tumor Burden; Vinblastine; Zinc Finger Protein GLI1 | 2012 |
Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Congresses as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Palliative Care; Patient-Centered Care; Prognosis; Prostatectomy; Prostatic Neoplasms; Radiotherapy, Adjuvant; Taxoids | 2012 |
A case report of putative autoimmunity to prostate cancer after immune-mediated rejection of melanoma through a shared tumor antigen.
Topics: Adenocarcinoma; Aged, 80 and over; Antibodies, Neoplasm; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Docetaxel; Fatal Outcome; Glutamate Carboxypeptidase II; Humans; Immunotherapy; Male; Melanoma; Neoplasm Metastasis; Neoplasms, Second Primary; Prostate-Specific Antigen; Prostatic Neoplasms; Skin Neoplasms; Taxoids | 2012 |
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Bone Neoplasms; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Metastasis; Orchiectomy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Taxoids | 2012 |
Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Docetaxel; Drug Administration Schedule; Humans; Male; Methylprednisolone; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Bioactive sphingolipids in docetaxel-induced apoptosis in human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Ceramides; Docetaxel; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Glucosylceramides; Glucosyltransferases; Humans; Lysophospholipids; Male; Oxidoreductases; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Sphingosine; Taxoids; Up-Regulation | 2012 |
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Topics: Aged; Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Compassionate Use Trials; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
A shortened docetaxel desensitization protocol for use in special cases.
Topics: Antineoplastic Agents, Phytogenic; Desensitization, Immunologic; Docetaxel; Drug Hypersensitivity; Humans; Male; Middle Aged; Prostatic Neoplasms; Skin Tests; Taxoids | 2012 |
[Analysis of prognostic factor in 52 castration-resistant prostate cancer treated with docetaxel].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Castration; Disease-Free Survival; Docetaxel; Humans; Male; Middle Aged; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2012 |
Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience.
Topics: Aged; Aged, 80 and over; Biomarkers; Disease-Free Survival; Docetaxel; Drug Therapy, Combination; Estramustine; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2012 |
CXCR4 expression in prostate cancer progenitor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Cell Adhesion; Cell Proliferation; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Neoplasm Metastasis; Neoplastic Stem Cells; Prostatic Neoplasms; Receptors, CXCR4; Taxoids | 2012 |
Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Estrogens; Humans; Male; Middle Aged; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids; Tosyl Compounds | 2012 |
Editorial comment. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Topics: Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estrogens; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2012 |
Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Choline; DNA Methylation; DNA, Neoplasm; Docetaxel; Electrophoresis, Microchip; Genetic Markers; Glutathione S-Transferase pi; Hawaii; Humans; Male; Middle Aged; Multimodal Imaging; Pilot Projects; Positron-Emission Tomography; Predictive Value of Tests; Promoter Regions, Genetic; Prostatic Neoplasms; Radiopharmaceuticals; Real-Time Polymerase Chain Reaction; Receptors, Retinoic Acid; Taxoids; Tomography, X-Ray Computed; Treatment Outcome; Whole Body Imaging | 2012 |
Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Feasibility Studies; Humans; Male; Middle Aged; Multivariate Analysis; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2012 |
Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Proliferation; Docetaxel; Down-Regulation; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Repressor Proteins; RNA, Small Interfering; Sirolimus; Survivin; Taxoids; Xenograft Model Antitumor Assays | 2012 |
[Efficacy of standard docetaxel and metronomic cyclophosphamide chemotherapy in patients with hormone-resistant prostate cancer: comparative analysis].
Topics: Administration, Metronomic; Administration, Oral; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cyclophosphamide; Docetaxel; Drug Resistance, Neoplasm; Humans; Infusions, Intravenous; Male; Middle Aged; Pain Management; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
[Support of hematological homeostasis during chemotherapy with taxanes].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caproates; Docetaxel; Female; Fever; Follow-Up Studies; Homeostasis; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Neoplasms; Neutropenia; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Protective Agents; Severity of Illness Index; Stomach Neoplasms; Taxoids; Tongue Neoplasms | 2011 |
Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Resistance, Neoplasm; Fatal Outcome; Humans; Male; Neoplasm Recurrence, Local; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Healthcare resource use in advanced prostate cancer patients treated with docetaxel.
Topics: Adult; Aged; Antineoplastic Agents; Docetaxel; Health Resources; Humans; Insurance Claim Review; Male; Middle Aged; Outcome Assessment, Health Care; Prostatic Neoplasms; Retrospective Studies; Taxoids; United States | 2012 |
[The effect of cell killing by ABT-737 synergized with docetaxel in human prostate cancer PC-3 cells].
Topics: Apoptosis; bcl-X Protein; Biphenyl Compounds; Caspase 3; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Myeloid Cell Leukemia Sequence 1 Protein; Nitrophenols; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Sulfonamides; Taxoids | 2012 |
Prostate-cancer-targeted N-(2-hydroxypropyl)methacrylamide copolymer/docetaxel conjugates.
Topics: Acrylamides; Animals; Antibodies, Monoclonal; Antigens, Surface; Docetaxel; Drug Delivery Systems; Glutamate Carboxypeptidase II; Humans; Immunoconjugates; Iodine Radioisotopes; Male; Mice; Mice, Nude; Polymers; Prostatic Neoplasms; Taxoids; Tissue Distribution; Xenograft Model Antitumor Assays | 2012 |
[Safety and efficacy of docetaxel in prostate cancer patients: based on the post-marketing surveillance in Japan].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Docetaxel; Humans; Japan; Male; Middle Aged; Prostatic Neoplasms; Taxoids | 2012 |
C-reactive protein as a prognostic marker FOR mCRPC.
Topics: C-Reactive Protein; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids | 2012 |
Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Bone Density Conservation Agents; Diphosphonates; Docetaxel; Drug Therapy, Combination; Humans; Imidazoles; Incidence; Japan; Jaw Neoplasms; Leukopenia; Male; Middle Aged; Osteonecrosis; Prognosis; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Taxoids; Zoledronic Acid | 2012 |
Telomere and microtubule targeting in treatment-sensitive and treatment-resistant human prostate cancer cells.
Topics: Cell Line, Tumor; Docetaxel; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Male; Microtubules; Paclitaxel; Prostatic Neoplasms; Taxoids; Telomere; Treatment Outcome | 2012 |
Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis.
Topics: Animals; Antineoplastic Agents, Alkylating; Bone Marrow; Bone Neoplasms; Cell Line, Tumor; Chemokine CCL2; Cyclophosphamide; Docetaxel; Humans; Interleukin-6; Male; Mice; Myeloid Cells; Neoplasm Transplantation; Prostatic Neoplasms; Taxoids | 2012 |
Non-THC cannabinoids inhibit prostate carcinoma growth in vitro and in vivo: pro-apoptotic effects and underlying mechanisms.
Topics: Androgen Antagonists; Anilides; Animals; Apoptosis; Cannabidiol; Cannabinoids; Caspase 3; Cell Cycle; Cell Survival; Docetaxel; Down-Regulation; Dronabinol; Drug Interactions; Humans; Male; Mice; Mice, Nude; Nitriles; Prostate; Prostatic Neoplasms; Reactive Oxygen Species; Receptors, Androgen; Taxoids; Tosyl Compounds; Transient Receptor Potential Channels; TRPM Cation Channels; Tumor Cells, Cultured | 2013 |
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred Strains; Piperidines; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2013 |
The use of LC-MS to identify differentially expressed proteins in docetaxel-resistant prostate cancer cell lines.
Topics: Cell Line, Tumor; Chromatography, Liquid; Cytoskeletal Proteins; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Male; Mass Spectrometry; Prostate; Prostatic Neoplasms; Proteins; Proteomics; Radiation-Sensitizing Agents; Receptors, Androgen; Taxoids | 2012 |
Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; L-Lactate Dehydrogenase; Lipopolysaccharides; Male; NF-kappa B; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Taxoids; Toll-Like Receptor 4; Transcriptional Activation; Tumor Necrosis Factor-alpha | 2012 |
An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Docetaxel; Follow-Up Studies; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-myc; PTEN Phosphohydrolase; Survival Rate; Taxoids; Tumor Suppressor Protein p53 | 2012 |
Significance of docetaxel-based chemotherapy as treatment for metastatic castration-resistant prostate cancer in Japanese men over 75 years old.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Asian People; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2012 |
Comparative chemosensitivity of circulating human prostate cancer cells and primary cancer cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cisplatin; Docetaxel; Green Fluorescent Proteins; Humans; Male; Mice; Mice, Nude; Neoplastic Cells, Circulating; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2012 |
First evidence of sphingosine 1-phosphate lyase protein expression and activity downregulation in human neoplasm: implication for resistance to therapeutics in prostate cancer.
Topics: Adaptor Proteins, Signal Transducing; Aldehyde-Lyases; Antineoplastic Agents; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lysophospholipids; Male; Neoplasm Grading; Prostate; Prostatic Neoplasms; Radiation Tolerance; RNA Interference; Sphingosine; Taxoids | 2012 |
NICE guidance on cabazitaxel for hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Evidence-Based Medicine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Prostatic Neoplasms; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; United Kingdom | 2012 |
Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients.
Topics: Aged; Antineoplastic Agents; Docetaxel; Humans; Male; Middle Aged; Neoplastic Cells, Circulating; Polymerase Chain Reaction; Prostatic Neoplasms; RNA, Messenger; Taxoids | 2012 |
Enhanced docetaxel-mediated cytotoxicity in human prostate cancer cells through knockdown of cofilin-1 by carbon nanohorn delivered siRNA.
Topics: Antineoplastic Agents; Apoptosis; Carbon; Cell Line, Tumor; Cofilin 1; Dendrimers; Docetaxel; Genetic Therapy; Humans; Male; Nanostructures; Nylons; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; Taxoids; Transfection | 2012 |
In vitro and in vivo prostate cancer metastasis and chemoresistance can be modulated by expression of either CD44 or CD147.
Topics: Animals; Antineoplastic Agents; Basigin; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Male; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Monocarboxylic Acid Transporters; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Muscle Proteins; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2012 |
[The factors for continuing docetaxel-based chemotherapy for castration-resistant prostate cancer].
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Agents; C-Reactive Protein; Docetaxel; Hemoglobins; Humans; L-Lactate Dehydrogenase; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Time Factors; Treatment Outcome | 2012 |
[Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Taxoids | 2012 |
Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Follow-Up Studies; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation-Sensitizing Agents; Retrospective Studies; Taxoids; Treatment Outcome | 2012 |
Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Castration; Cell Line, Tumor; Docetaxel; Flow Cytometry; Fluorescent Antibody Technique; HSP27 Heat-Shock Proteins; Humans; Immunoprecipitation; Male; Mice; Mice, Nude; Prostatic Neoplasms; Taxoids; Tumor Protein, Translationally-Controlled 1; Two-Hybrid System Techniques | 2012 |
Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells?
Topics: Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Blotting, Western; Cell Line, Tumor; Cell Survival; Docetaxel; Flow Cytometry; Humans; Immunohistochemistry; Male; Microscopy, Confocal; Nitriles; Prostatic Neoplasms; RNA, Small Interfering; Sensitivity and Specificity; Taxoids; Tosyl Compounds | 2013 |
Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Transformation, Neoplastic; Disease Progression; Docetaxel; Drug Synergism; Gossypol; Humans; Male; Mice; Mice, Transgenic; Myeloid Cell Leukemia Sequence 1 Protein; Orchiectomy; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Signal Transduction; Taxoids; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; M Phase Cell Cycle Checkpoints; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Receptor, Notch1; RNA Interference; RNA, Small Interfering; Taxoids | 2012 |
CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylamines; Bone Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Chemokine CXCL12; Cyclams; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Prostatic Neoplasms; Random Allocation; Receptors, CXCR4; Taxoids; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines.
Topics: Abiraterone Acetate; Androgen Antagonists; Androstadienes; Antineoplastic Agents; Brachytherapy; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids; Tissue Extracts | 2012 |
Treatment decisions for metastatic castration-resistant prostate cancer progressing after docetaxel chemotherapy: the role of cabazitaxel in the continuum of care.
Topics: Antineoplastic Agents; Continuity of Patient Care; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2012 |
Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Survival; Docetaxel; Fas Ligand Protein; Humans; Male; Mice; Mice, Nude; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Receptors, Death Domain; Signal Transduction; Simvastatin; Taxoids | 2012 |
Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch- and hedgehog-dependent tumor-initiating cells.
Topics: Animals; Apoptosis; Cell Line, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Hedgehog Proteins; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Sequence Data; Neoplastic Stem Cells; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Receptors, Notch; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2012 |
Novel and bone-targeted agents for CRPC.
Topics: Androgen Antagonists; Androstenes; Androstenols; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Bone Neoplasms; Clinical Trials, Phase III as Topic; Denosumab; Docetaxel; Humans; Ipilimumab; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tissue Extracts; Tumor Microenvironment | 2012 |
Differential molecular mechanism of docetaxel-octreotide combined treatment according to the docetaxel-resistance status in PC3 prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Gene Expression; Humans; Male; Octreotide; Peptides, Cyclic; Prostatic Neoplasms; Receptors, Somatostatin; Somatostatin; Taxoids | 2013 |
Characterization of the low pH/low nutrient-resistant LNCaP cell subline LNCaP-F10.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; Death-Associated Protein Kinases; DNA Fragmentation; Docetaxel; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Survivin; Taxoids; Transplantation, Heterologous | 2012 |
Functional p53 determines docetaxel sensitivity in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Genes, p53; Humans; Male; Phosphorylation; Prostatic Neoplasms; Taxoids | 2013 |
Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Bone Neoplasms; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Docetaxel; Double-Blind Method; Follow-Up Studies; Humans; Male; Middle Aged; Pain Management; Palliative Care; Proportional Hazards Models; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Radium; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2013 |
NICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Topics: Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Castration; Cost-Benefit Analysis; Docetaxel; Drug Costs; Evidence-Based Medicine; Humans; Male; Practice Guidelines as Topic; Prednisolone; Prostatic Neoplasms; Quality-Adjusted Life Years; Taxoids; Terminal Care; Time Factors; Treatment Outcome; United Kingdom | 2012 |
Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgens; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Interleukin-8; Male; Middle Aged; Orchiectomy; Prostatic Neoplasms; RNA, Small Interfering; Taxoids; Transcription Factor RelA | 2013 |
Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Topics: Apoptosis; Biomarkers, Tumor; Cadherins; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Male; MicroRNAs; Neoplasm Invasiveness; Neoplastic Stem Cells; Prostatic Neoplasms; Spheroids, Cellular; Taxoids; Tumor Stem Cell Assay; Up-Regulation | 2012 |
[Prostate carcinoma with squamous differentiation after combination endocrine therapy: a case report].
Topics: Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Fluorouracil; Goserelin; Humans; Lymph Node Excision; Male; Nitriles; Prostatectomy; Prostatic Neoplasms; Taxoids; Tosyl Compounds | 2012 |
Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-region.
Topics: Adenoviridae; Adenovirus E1A Proteins; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Docetaxel; Flow Cytometry; Humans; Immunoblotting; Male; Mice; Mice, Inbred C57BL; Mitoxantrone; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Xenograft Model Antitumor Assays | 2012 |
[Prostate cancer-the role of docetaxel on castration-resistant prostate cancer: evaluation of efficacy and subsequent treatment].
Topics: Antineoplastic Agents; Castration; Docetaxel; Hormone Replacement Therapy; Humans; Male; Prostatic Neoplasms; Taxoids | 2012 |
[Long-term disease stabilization by Strontium 89 (89Sr) for castration and docetaxel-resistant prostate cancer : a case report].
Topics: Adenocarcinoma; Aged; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Orchiectomy; Prostatic Neoplasms; Strontium Radioisotopes; Taxoids | 2012 |
Using ligands to target cancer cells.
Topics: Antigens, Surface; Antineoplastic Agents; Clinical Trials, Phase I as Topic; Docetaxel; Drug Carriers; Drug Compounding; Endothelial Cells; Glutamate Carboxypeptidase II; Humans; Lab-On-A-Chip Devices; Ligands; Male; Nanomedicine; Nanoparticles; Prostatic Neoplasms; RNA Interference; Taxoids | 2012 |
Bicalutamide-induced hypoxia potentiates RUNX2-mediated Bcl-2 expression resulting in apoptosis resistance.
Topics: Anilides; Animals; Antineoplastic Agents; Apoptosis; Cell Hypoxia; Cell Survival; Core Binding Factor Alpha 1 Subunit; Docetaxel; Humans; Male; Mice; Mice, SCID; Nitriles; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tosyl Compounds; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
[Effect of docetaxel on C-jun and androgen receptor interaction in prostate cancer LNCaP cells and its androgen-independence subtype LNCaP-bic cells].
Topics: Cell Line, Tumor; Docetaxel; Humans; Male; Prostate; Prostatic Neoplasms; Proto-Oncogene Proteins c-jun; Receptors, Androgen; Taxoids | 2012 |
The experience with cytotoxic chemotherapy in metastatic castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Cytotoxins; Disease Progression; Docetaxel; Drug Therapy, Combination; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Prognosis; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2012 |
Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme.
Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Fever; Germany; Humans; Kallikreins; Male; Middle Aged; Neutropenia; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thrombocytopenia; Treatment Failure; Treatment Outcome | 2013 |
Prognostic factors in Chinese patients with metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; China; Docetaxel; Hemoglobins; Humans; Male; Middle Aged; Neoplasm Metastasis; Orchiectomy; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Survival Analysis; Taxoids | 2013 |
Abiraterone and its place in the treatment of metastatic CRPC.
Topics: Androstenes; Androstenols; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Macrophage delivery of an oncolytic virus abolishes tumor regrowth and metastasis after chemotherapy or irradiation.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Combined Modality Therapy; Docetaxel; Humans; Lung Neoplasms; Macrophages; Male; Mice; Oncolytic Virotherapy; Prostatic Neoplasms; Recurrence; Taxoids; Xenograft Model Antitumor Assays | 2013 |
Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
Topics: Cell Communication; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chemokine CCL5; Chemotaxis; Culture Media, Conditioned; Docetaxel; ErbB Receptors; Gefitinib; Humans; Male; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteogenesis; Phosphorylation; Prostatic Neoplasms; Quinazolines; Subcellular Fractions; Taxoids | 2013 |
Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes.
Topics: Cell Line, Tumor; Cell Movement; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Exosomes; Humans; Male; Phenotype; Prostatic Neoplasms; Taxoids | 2012 |
The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Line, Tumor; Chemotherapy, Adjuvant; Disease Progression; Docetaxel; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Immunohistochemistry; Liposomes; Male; Mice; Mice, Nude; Neoplasm Grading; Oligonucleotides, Antisense; Predictive Value of Tests; Prostatic Neoplasms; Protein Array Analysis; Radiotherapy, Adjuvant; Taxoids; Transplantation, Heterologous; Up-Regulation | 2013 |
Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Docetaxel; Humans; Male; Mice; Mice, Nude; Microbubbles; Prostatic Neoplasms; Taxoids | 2012 |
2-weekly versus 3-weekly docetaxel for prostate cancer.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Taxoids | 2013 |
Prostate cancer therapy: going forwards by going backwards.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2013 |
Thermotherapy using magnetic cationic liposomes powerfully suppresses prostate cancer bone metastasis in a novel rat model.
Topics: Animals; Bone Neoplasms; Cations; Colloids; Disease Models, Animal; Docetaxel; Ferrosoferric Oxide; Hyperthermia, Induced; Liposomes; Magnetics; Male; Prostatic Neoplasms; Random Allocation; Rats; Rats, Inbred F344; Taxoids | 2013 |
Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: 'plus or minus' may be a minus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Castration; Clinical Trials as Topic; Docetaxel; Humans; Male; Molecular Targeted Therapy; Prostatic Neoplasms; Taxoids | 2013 |
Castrate-resistant prostate cancer: postdocetaxel management.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Disease-Free Survival; Docetaxel; Drug Design; Drug Resistance, Neoplasm; Immunotherapy; Male; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2013 |
Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Calreticulin; Carcinoembryonic Antigen; Cell Line, Tumor; Colorectal Neoplasms; Cytotoxicity, Immunologic; Dendritic Cells; Docetaxel; eIF-2 Kinase; Female; HMGB1 Protein; Humans; Immunotherapy; Male; Mucin-1; Prostate-Specific Antigen; Prostatic Neoplasms; RNA Interference; RNA, Small Interfering; T-Lymphocytes, Cytotoxic; Taxoids | 2013 |
Increased serum insulin-like growth factor-1 levels are associated with prolonged response to dasatinib-based regimens in metastatic prostate cancer.
Topics: 3T3 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Dasatinib; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Insulin-Like Growth Factor I; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Osteoblasts; Prostatic Neoplasms; Pyrimidines; Taxoids; Thiazoles; Xenograft Model Antitumor Assays | 2013 |
Malate dehydrogenase 2 confers docetaxel resistance via regulations of JNK signaling and oxidative metabolism.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Docetaxel; Drug Resistance; Energy Metabolism; Humans; Malate Dehydrogenase; Male; MAP Kinase Signaling System; Oxygen Consumption; Prostatic Neoplasms; Reactive Oxygen Species; Taxoids | 2013 |
ABCC4 Decreases docetaxel and not cabazitaxel efficacy in prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Docetaxel; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; In Vitro Techniques; Male; Multidrug Resistance-Associated Proteins; Prostatic Neoplasms; Taxoids | 2013 |
[[¹¹C]choline as a pharmacodynamic marker for docetaxel therapy. Response assessment in a LNCaP prostate cancer xenograft mouse model].
Topics: Animals; Antineoplastic Agents; Carbon Radioisotopes; Cell Line, Tumor; Choline; Docetaxel; Male; Mice; Mice, SCID; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Taxoids; Treatment Outcome | 2013 |
Editorial: the coming revolution in the treatment of prostate cancer patients.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Forecasting; Humans; Male; Neoadjuvant Therapy; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine | 2002 |
Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-X Protein; Cell Division; Cell Survival; Clone Cells; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Giant Cells; Humans; Kinetics; Male; Paclitaxel; Phenotype; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tubulin; Tumor Cells, Cultured | 2002 |
Prompt resolution of acute disseminated intravascular coagulation with docetaxel and cisplatin in hormone refractory prostate cancer.
Topics: Acute Disease; Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Disseminated Intravascular Coagulation; Docetaxel; Humans; Male; Paclitaxel; Platelet Count; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2002 |
New study expands look at effects of high-dose vitamin D with docetaxel for advanced prostate cancer patients.
Topics: Docetaxel; Humans; Male; Multicenter Studies as Topic; Paclitaxel; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vitamin D | 2002 |
Inhibition of growth and metastasis of orthotopic human prostate cancer in athymic mice by combination therapy with pegylated interferon-alpha-2b and docetaxel.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cadherins; Cell Division; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Fibroblast Growth Factor 2; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Metastasis; Paclitaxel; Polyethylene Glycols; Prostatic Neoplasms; Random Allocation; Recombinant Proteins; Taxoids; Xenograft Model Antitumor Assays | 2002 |
Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Taxoids; Thalidomide; Venous Thrombosis | 2003 |
Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Topics: Androgens; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Mice; Mice, Nude; Middle Aged; Mitoxantrone; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
Calcitriol and alopecia--is it the hair apparent?
Topics: Alopecia; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Docetaxel; Humans; Male; Neoplasm Metastasis; Paclitaxel; Prostatic Neoplasms; Taxoids | 2003 |
Combined effects of docetaxel and angiostatin gene therapy in prostate tumor model.
Topics: Adenoviridae; Angiostatins; Animals; Antineoplastic Agents, Phytogenic; Cells, Cultured; Combined Modality Therapy; Docetaxel; Drug Therapy, Combination; Endothelium, Vascular; Genetic Therapy; Genetic Vectors; Humans; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2003 |
Cancer gene therapy: lessons learned from experiences with chemotherapy.
Topics: Adenoviridae; Angiostatins; Animals; Antineoplastic Agents, Phytogenic; Combined Modality Therapy; Docetaxel; Genetic Therapy; Humans; Male; Mice; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids | 2003 |
Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Squamous Cell; Dacryocystorhinostomy; Docetaxel; Drainage; Esophageal Neoplasms; Female; Humans; Intubation; Lacrimal Duct Obstruction; Lung Neoplasms; Male; Middle Aged; Nasolacrimal Duct; Ovarian Neoplasms; Paclitaxel; Prostatic Neoplasms; Taxoids; Texas | 2003 |
ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.
Topics: Apoptosis; bcl-X Protein; Butadienes; Docetaxel; Drug Synergism; Enzyme Inhibitors; Flavonoids; Humans; Male; Mitogen-Activated Protein Kinases; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2003 |
Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Neoplasm Metastasis; Paclitaxel; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Taxoids | 2003 |
The mechanism of action of docetaxel (Taxotere) in xenograft models is not limited to bcl-2 phosphorylation.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Docetaxel; Female; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 2003 |
New treatment hope for prostate cancer.
Topics: Aged; Antineoplastic Agents, Phytogenic; Cancer Vaccines; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2004 |
All-trans retinoic acid potentiates Taxotere-induced cell death mediated by Jun N-terminal kinase in breast cancer cells.
Topics: Breast Neoplasms; Cell Death; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Enzyme Activation; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Poly(ADP-ribose) Polymerases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tretinoin | 2004 |
Antitumor activity of irofulven monotherapy and in combination with mitoxantrone or docetaxel against human prostate cancer models.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Nude; Mitoxantrone; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Xenograft Model Antitumor Assays | 2004 |
[Therapeutic options and controversies in the management of prostate cancer].
Topics: Androgen Antagonists; Antineoplastic Agents, Phytogenic; Brachytherapy; Combined Modality Therapy; Cryotherapy; Docetaxel; Forecasting; Humans; Male; Neoplasm Metastasis; Palliative Care; Patient Selection; Prognosis; Prostatectomy; Prostatic Neoplasms; Taxoids; Ultrasonic Therapy | 2003 |
Highlights from the XII European Cancer Conference Copenhagen, Denmark.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Mitoxantrone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Thalidomide; Tomography, Emission-Computed | 2003 |
Highlights from the 39th Annual meeting of the American Society of Clinical Oncology Chicago, Illinois.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Epothilones; Goserelin; Humans; Male; Medical Oncology; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2003 |
Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Middle Aged; Pilot Projects; Prostatic Neoplasms; Risk Assessment; Taxoids; Treatment Outcome | 2003 |
National Cancer Institute intramural approach to advanced prostate cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomedical Research; Cancer Vaccines; Clinical Trials as Topic; Docetaxel; Humans; Ketoconazole; Male; National Institutes of Health (U.S.); Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Thalidomide; United States | 2002 |
Evaluation of antineoplastic action of 5-aza-2'-deoxycytidine (Dacogen) and docetaxel (Taxotere) on human breast, lung and prostate carcinoma cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Cadherins; Cell Line, Tumor; Decitabine; DNA; Docetaxel; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Female; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Proteins; Serpins; Taxoids; Time Factors | 2004 |
Weekly administration of docetaxel in patients with hormone-refractory prostate cancer: a pilot study on Japanese patients.
Topics: Aged; Alopecia; Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Estramustine; Feasibility Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neutropenia; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Soft Tissue Neoplasms; Taxoids | 2004 |
Tumor lysis syndrome following docetaxel therapy for extensive metastatic prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; Tumor Lysis Syndrome | 2004 |
[Intra-arterial docetaxel chemotherapy with high-dose calcitriol in relapsing metastatic prostate cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Bone Neoplasms; Calcitriol; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Humans; Infusions, Intra-Arterial; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Quality of Life; Taxoids | 2004 |
A case of docetaxel-induced erythrodysesthesia.
Topics: Aged; Antineoplastic Agents, Phytogenic; Diagnosis, Differential; Docetaxel; Drug Eruptions; Facial Dermatoses; Foot Dermatoses; Hand Dermatoses; Humans; Male; Prostatic Neoplasms; Taxoids | 2004 |
Docetaxel improves survival in metastatic androgen-independent prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2004 |
Single-agent chemotherapy with docetaxel significantly reduces PSA levels in patients with high-grade localized prostate cancers.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2004 |
Multiple cycles of intermittent chemotherapy in metastatic androgen-independent prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Calcitriol; Disease-Free Survival; Docetaxel; Feasibility Studies; Humans; Lymphatic Metastasis; Male; Neoplasms, Hormone-Dependent; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2004 |
Mechanisms of androgen-refractory prostate cancer.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Resistance, Neoplasm; Gene Amplification; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Taxoids | 2004 |
[Docetaxel enables initial survival time lengthening].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Germany; Humans; Male; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; United States | 2004 |
HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Neoplasm; Docetaxel; Drug Synergism; HIV Protease Inhibitors; HIV-1; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; NF-kappa B; Prostatic Neoplasms; Ritonavir; RNA, Messenger; RNA, Small Interfering; Taxoids; Xenograft Model Antitumor Assays | 2004 |
Chemotherapy for patients with hormone-refractory prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Clinical Trials, Phase III as Topic; Diphosphonates; Docetaxel; Glucocorticoids; Humans; Hydrocortisone; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2004 |
[The synergistic effects of docetaxol and retinoic acid on prostate cancer cell line PC-3].
Topics: Adult; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cell Line, Tumor; Docetaxel; Drug Synergism; Drugs, Chinese Herbal; Humans; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Taxoids; Tretinoin | 2004 |
Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; DNA, Complementary; Docetaxel; Drug Therapy, Combination; Gene Expression Regulation, Enzymologic; Male; Mice; Microcirculation; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tetracycline; Tumor Cells, Cultured | 2004 |
New progress in treatment of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Pain; Prostatic Neoplasms; Quality of Life; Survival Analysis; Taxoids; Treatment Outcome | 2004 |
Docetaxel in androgen-independent prostate cancer: an update.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2004 |
In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cyclophosphamide; Docetaxel; Drug Synergism; Estramustine; Etoposide; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Male; Piperazines; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Taxoids | 2005 |
Chemotherapy for advanced prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Docetaxel; Estramustine; Humans; Male; Prostatic Neoplasms; Survival Analysis; Taxoids | 2005 |
Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Floxuridine; Gene Expression; Gene Expression Profiling; Humans; Male; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids | 2005 |
Combination of docetaxel, estramustine phosphate, and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety, and clinical benefit assessment.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Alopecia; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Diphosphonates; Disease Progression; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Imidazoles; Life Tables; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Proteins; Neutropenia; Orchiectomy; Pain; Palliative Care; Prostate-Specific Antigen; Prostatic Neoplasms; Radiotherapy, High-Energy; Remission Induction; Survival Analysis; Taxoids; Treatment Outcome; Zoledronic Acid | 2005 |
[A case of oropharyngeal cancer with multiple bone metastases from prostate cancer that responded to docetaxel, ifosfamide and cisplatin combination therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Drug Administration Schedule; Humans; Ifosfamide; Infusions, Intravenous; Male; Oropharyngeal Neoplasms; Prostatic Neoplasms; Quality of Life; Taxoids | 2005 |
Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-Associated Death Protein; bcl-X Protein; Bone Marrow; Carrier Proteins; Caspase 3; Caspase 9; Caspases; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Docetaxel; Drug Therapy, Combination; Enzyme Activation; Gene Expression Regulation, Enzymologic; Humans; Male; Membrane Proteins; Mice; Mice, Nude; Osteoblasts; Poly(ADP-ribose) Polymerases; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Stromal Cells; Sulfonamides; Taxoids; Tumor Cells, Cultured; X-Linked Inhibitor of Apoptosis Protein; Xenograft Model Antitumor Assays | 2005 |
Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Apoptosis; Cyclohexanes; Docetaxel; Drug Interactions; Humans; Male; Neoplasm Metastasis; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prostatic Neoplasms; Sesquiterpenes; Taxoids; Tumor Cells, Cultured | 2005 |
Taxotere-5'-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Floxuridine; Humans; Male; Prostatic Neoplasms; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase | 2005 |
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials, Phase I as Topic; Docetaxel; Humans; Imatinib Mesylate; Immunohistochemistry; Male; Piperazines; Prostatic Neoplasms; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Research Design; Taxoids | 2005 |
[Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer].
Topics: Aged; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Diethylstilbestrol; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2005 |
What is more exciting? The activity of docetaxel in early prostate cancer or the successful collaboration between urologists and medical oncologists to complete a study in early prostate cancer?
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Interprofessional Relations; Male; Medical Oncology; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Patient Care Team; Prognosis; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome; Urology | 2005 |
Gene expression profiling revealed novel molecular targets of docetaxel and estramustine combination treatment in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Cell Line, Tumor; Cluster Analysis; DNA, Complementary; Docetaxel; Down-Regulation; Drug Screening Assays, Antitumor; Estramustine; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Taxoids; Time Factors; Transcription, Genetic | 2005 |
Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: a pilot study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Hormones; Humans; Male; Middle Aged; Paclitaxel; Pilot Projects; Prostatic Neoplasms; Taxoids; Treatment Failure | 2005 |
Adenoviral infection of survivin antisense sensitizes prostate cancer cells to etoposide in vivo.
Topics: Adenoviridae; Animals; Antisense Elements (Genetics); Apoptosis; Cell Line, Tumor; Cell Proliferation; Docetaxel; Etoposide; Humans; Inhibitor of Apoptosis Proteins; Male; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Neoplasm Proteins; Neoplasm Transplantation; Prostatic Neoplasms; Survivin; Taxoids; Transplantation, Heterologous | 2005 |
Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitoxantrone; Phosphoric Monoester Hydrolases; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Ribosomal Protein S6; Sirolimus; Taxoids; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2005 |
Efficacy of an intratumoral controlled release formulation of clusterin antisense oligonucleotide complexed with chitosan containing paclitaxel or docetaxel in prostate cancer xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Clusterin; Delayed-Action Preparations; Docetaxel; Drug Therapy, Combination; Glycoproteins; Humans; Injections, Intralesional; Male; Mice; Mice, Inbred BALB C; Molecular Chaperones; Neoplasm Transplantation; Ointments; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2005 |
Prolonging survival in prostate cancer: chemotherapy will have an important role.
Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Taxoids | 2005 |
Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
PAR1-mediated NFkappaB activation promotes survival of prostate cancer cells through a Bcl-xL-dependent mechanism.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Biopsy; Cell Line, Tumor; Cell Survival; Cytokines; Docetaxel; Enzyme Activation; Humans; In Situ Nick-End Labeling; Male; Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Protein Array Analysis; Receptor, PAR-1; Signal Transduction; Taxoids; Transcription Factor RelA | 2005 |
Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Docetaxel; Doxorubicin; Drug Synergism; Genistein; Humans; Lung Neoplasms; Male; Neoplasms; NF-kappa B; Pancreatic Neoplasms; Prostatic Neoplasms; Taxoids | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells.
Topics: Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Bisbenzimidazole; Cell Line, Tumor; Cell Proliferation; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Fluorouracil; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Neuronal Apoptosis-Inhibitory Protein; Paclitaxel; Phenotype; Prostatic Neoplasms; Survivin; Taxoids; Tetrazolium Salts; Time Factors; Ubiquitin-Protein Ligases; X-Linked Inhibitor of Apoptosis Protein | 2005 |
Current management of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Hormonal; Combined Modality Therapy; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prostatic Neoplasms; Salvage Therapy; Taxoids | 2004 |
[Hormone-refractory metastatic prostate carcinoma -- combination improves survival].
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Clinical Trials, Phase III as Topic; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Prednisone; Prostatic Neoplasms; Quality of Life; Randomized Controlled Trials as Topic; Taxoids; Time Factors | 2005 |
Additive/synergistic antitumoral effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Mitosis; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2005 |
[Docetaxel--standard therapy further optimized].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cholecalciferol; Docetaxel; Drug Administration Schedule; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2005 |
[Longer life in hormone refractory prostatic carcinoma].
Topics: Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Survival Rate; Taxoids | 2005 |
Potential role of inhibiting the vascular endothelial growth factor pathway in advanced prostate cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Clinical Trials as Topic; Docetaxel; Humans; Male; Prednisone; Prostatic Neoplasms; Taxoids; Vascular Endothelial Growth Factor A | 2005 |
The identification of senescence-specific genes during the induction of senescence in prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cellular Senescence; Docetaxel; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Male; Microarray Analysis; Phenotype; Prostatic Neoplasms; Taxoids | 2005 |
High-risk localized prostate cancer: integrating chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Neoadjuvant Therapy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Taxoids | 2005 |
Update: NCCN prostate cancer Clinical Practice Guidelines.
Topics: Aged; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Mass Screening; Middle Aged; Practice Guidelines as Topic; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Risk Assessment; Taxoids; United States | 2005 |
[Effective chemotherapy for hormone-refractory prostate cancer: docetaxel-prednisone].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Prednisone; Prostatic Neoplasms; Quality of Life; Taxoids; Treatment Outcome | 2005 |
Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Camptothecin; Ceramides; Disease Models, Animal; Docetaxel; Flow Cytometry; Green Fluorescent Proteins; Humans; Lysophospholipids; Male; Mice; Mice, Nude; Microscopy, Fluorescence; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Phosphotransferases (Alcohol Group Acceptor); Prostatic Neoplasms; RNA Interference; Sphingosine; Taxoids; Tumor Cells, Cultured | 2005 |
Symptoms in cancer patients and an unusual tumor: Case 2. Docetaxel-related ischemic colitis.
Topics: Abdominal Pain; Antineoplastic Agents, Phytogenic; Colitis, Ischemic; Docetaxel; Fatal Outcome; Humans; Laparotomy; Male; Middle Aged; Necrosis; Prostatic Neoplasms; Taxoids | 2005 |
Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Castration; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; Docetaxel; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, SCID; Neoplasm Transplantation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids | 2006 |
The 2005 Leon I. Goldberg Young Investigator Award Lecture: Development of thalidomide as an angiogenesis inhibitor for the treatment of androgen-independent prostate cancer.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Clinical Trials as Topic; Docetaxel; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Taxoids; Thalidomide | 2006 |
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment.
Topics: Animals; Antineoplastic Agents, Phytogenic; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Docetaxel; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Imidazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms; Random Allocation; Taxoids; Tibia; Transplantation, Heterologous; Zoledronic Acid | 2006 |
[Taxotere-based chemotherapy in androgen-independent prostate cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Middle Aged; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Statistical analysis of combined dose effects for experiments with two agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Data Interpretation, Statistical; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Fenretinide; Humans; Inhibitory Concentration 50; Logistic Models; Male; Models, Statistical; Prostatic Neoplasms; Software; Taxoids | 2006 |
Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Mitoxantrone; Prednisolone; Prostatic Neoplasms; Taxoids | 2005 |
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Aptamers, Nucleotide; Capsules; Docetaxel; Drug Delivery Systems; Humans; Male; Mice; Nanostructures; Polyethylene Glycols; Polyglactin 910; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2006 |
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dexamethasone; Docetaxel; Follow-Up Studies; Humans; Male; Middle Aged; Mitoxantrone; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Predictive Value of Tests; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Analysis; Taxoids; Time Factors | 2006 |
Docetaxel pharmacokinetics with pre- and post-dialysis administration in a hemodyalized patient.
Topics: Aged; Antineoplastic Agents, Phytogenic; Chromatography, High Pressure Liquid; Diabetic Nephropathies; Docetaxel; Drug Administration Schedule; Hemodialysis Solutions; Humans; Male; Prostatic Neoplasms; Renal Dialysis; Taxoids | 2006 |
Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3.
Topics: Androgens; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; bcl-2-Associated X Protein; Calcitriol; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Male; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2007 |
Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carrier Proteins; Cell Growth Processes; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Synergism; Genistein; Glycoproteins; Humans; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Membrane Glycoproteins; Mice; Mice, SCID; NF-kappa B; Osteoprotegerin; Prostatic Neoplasms; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2006 |
Genistein-induced neuroendocrine differentiation of prostate cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Differentiation; Cell Division; Cell Line, Tumor; Clone Cells; Culture Media, Conditioned; Docetaxel; Genistein; Humans; Male; Mitogen-Activated Protein Kinases; Neurosecretory Systems; Phosphorylation; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; STAT3 Transcription Factor; Taxoids | 2006 |
Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Blotting, Western; Clusterin; Docetaxel; Flow Cytometry; Genes, bcl-2; Humans; Male; Mitoxantrone; Oligonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Tumor Cells, Cultured | 2006 |
Evaluation of combined (177)Lu-DOTA-8-AOC-BBN (7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Chemical Analysis; Bombesin; Docetaxel; Estramustine; Female; Lutetium; Male; Mice; Mice, SCID; Models, Molecular; Peptide Fragments; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Bombesin; Taxoids; Tumor Protein, Translationally-Controlled 1; Xenograft Model Antitumor Assays | 2006 |
The continuing challenge of hormone-refractory prostate cancer.
Topics: Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Testosterone; Treatment Failure | 2006 |
Sequential combination of flavopiridol and docetaxel reduces the levels of X-linked inhibitor of apoptosis and AKT proteins and stimulates apoptosis in human LNCaP prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Cyclin B; Cyclin B1; Docetaxel; Flavonoids; Humans; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Neoplasm Proteins; Piperidines; Prostatic Neoplasms; Proteasome Endopeptidase Complex; Proto-Oncogene Proteins c-akt; RNA, Messenger; RNA, Small Interfering; Survivin; Taxoids; Up-Regulation; X-Linked Inhibitor of Apoptosis Protein | 2006 |
[Interdisciplinary recommendations concerning the therapy for hormone-refractory prostatic carcinoma].
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Patient Care Team; Prostatic Neoplasms; Taxoids | 2006 |
Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Synergism; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Paclitaxel; Prostatic Neoplasms; Retrospective Studies; Taxoids | 2006 |
[A case of hormone-refractory prostate cancer (HRPC) with tumor fever responding to docetaxel plus prednisolone therapy].
Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Fever; Gonadotropin-Releasing Hormone; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Prednisolone; Prostatic Neoplasms; Taxoids; Urinary Bladder Neoplasms | 2006 |
Efficacy of taxotere in the post-prostatectomy setting.
Topics: Docetaxel; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[AUO study in hormone-refractory prostate cancer. Phase III study on treatment of hormone-refractory prostate cancer (HRPC) with docetaxel: continuous treatment vs. intermittent repetition of treatment after renewed progression--PRINCE].
Topics: Androgen Antagonists; Antineoplastic Agents; Clinical Trials, Phase III as Topic; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Neoplasm Recurrence, Local; Prostatic Neoplasms; Taxoids | 2006 |
[Effectiveness of taxanes-based chemotherapy against hormone-refractory prostate carcinoma].
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Gefitinib; Humans; Male; Mice; Middle Aged; Prognosis; Prostatic Neoplasms; Quality of Life; Quinazolines; Taxoids | 2006 |
Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents.
Topics: Adenoviridae; Adenovirus E2 Proteins; Animals; Antineoplastic Agents; Cell Nucleus; Combined Modality Therapy; Daunorubicin; DNA-Binding Proteins; Docetaxel; Down-Regulation; Gene Expression Regulation, Neoplastic; Genes, MDR; HeLa Cells; Humans; Male; Mice; Mice, Inbred BALB C; Multidrug Resistance-Associated Proteins; Nuclear Proteins; Oncolytic Virotherapy; Promoter Regions, Genetic; Prostatic Neoplasms; Taxoids; Virus Replication; Xenograft Model Antitumor Assays; Y-Box-Binding Protein 1 | 2006 |
Sequential combinations of flavopiridol and docetaxel inhibit prostate tumors, induce apoptosis, and decrease angiogenesis in the Ggamma/T-15 transgenic mouse model of prostate cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Cell Division; Disease Models, Animal; Docetaxel; Drug Therapy, Combination; Flavonoids; Male; Mice; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Transgenic; Neovascularization, Pathologic; Piperidines; Prostatic Neoplasms; Taxoids; X-Linked Inhibitor of Apoptosis Protein | 2006 |
Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.
Topics: Androgen Antagonists; Anilides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Cell Line, Tumor; Docetaxel; Drug Synergism; Endothelium, Vascular; Fibroblast Growth Factor 2; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Nude; Neovascularization, Pathologic; NF-kappa B; Nitriles; Prostatic Neoplasms; Radionuclide Imaging; Sesquiterpenes; Taxoids; TNF Receptor-Associated Factor 1; TNF Receptor-Associated Factor 2; Tosyl Compounds; Umbilical Veins; Vascular Endothelial Growth Factor A | 2006 |
Synergistic cytotoxic interaction in hormone-refractory prostate cancer with the triple combination docetaxel-erlotinib and 5-fluoro-5'-deoxyuridine.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Cell Size; Cell Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Floxuridine; Humans; Male; Prostatic Neoplasms; Quinazolines; Taxoids; Thymidine Phosphorylase; Thymidylate Synthase | 2006 |
Experimental therapy of prostate cancer with an immunomodulatory oligonucleotide: effects on tumor growth, apoptosis, proliferation, and potentiation of chemotherapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Immunologic Factors; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Neoplasm Transplantation; Oligonucleotides; Phosphatidylethanolamines; Prostatic Neoplasms; RNA, Messenger; Taxoids; Toll-Like Receptor 9 | 2006 |
Bortezomib inhibits docetaxel-induced apoptosis via a p21-dependent mechanism in human prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; CDC2 Protein Kinase; Cell Division; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Humans; Male; Prostatic Neoplasms; Pyrazines; Taxoids; Tumor Cells, Cultured | 2006 |
Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel.
Topics: Androgens; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2006 |
Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Small Cell; Deoxycytidine; Docetaxel; Fatal Outcome; Gemcitabine; Humans; Male; Middle Aged; Pelvic Neoplasms; Prostatic Neoplasms; Taxoids | 2006 |
Advanced prostate cancer: at last a role for medical oncologists.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids | 2007 |
The mechanism of methylselenocysteine and docetaxel synergistic activity in prostate cancer cells.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cysteine; Docetaxel; Down-Regulation; Drug Synergism; Enzyme Activation; Inhibitor of Apoptosis Proteins; Male; Mice; Microtubule-Associated Proteins; Neoplasm Proteins; Organoselenium Compounds; Prostatic Neoplasms; Selenocysteine; Survivin; Taxoids | 2006 |
Nuclear interaction of Smac/DIABLO with Survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Docetaxel; Dose-Response Relationship, Drug; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Male; Microtubule-Associated Proteins; Mitochondrial Proteins; Neoplasm Proteins; Prostatic Neoplasms; Survivin; Taxoids | 2006 |
Pharmacokinetics and toxicity of weekly docetaxel in older patients.
Topics: Aged; Aging; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Female; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Prostatic Neoplasms; Taxoids | 2006 |
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.
Topics: Animals; Antibodies; Apoptosis; Cell Cycle; Disease Models, Animal; Docetaxel; Humans; Male; Orchiectomy; Prostatic Neoplasms; Receptor, IGF Type 1; Taxoids; Transplantation, Heterologous | 2006 |
Combination of non-viral connexin 43 gene therapy and docetaxel inhibits the growth of human prostate cancer in mice.
Topics: Animals; Cell Cycle; Cell Division; Cell Line, Tumor; Connexin 43; Docetaxel; Genetic Therapy; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostatic Neoplasms; Taxoids; Transplantation, Heterologous | 2007 |
Late recurrence of a prostatic adenocarcinoma as a solitary splenic metastasis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Diagnosis, Differential; Docetaxel; Follow-Up Studies; Humans; Male; Neoplasm Recurrence, Local; Prostatectomy; Prostatic Neoplasms; Radiation-Sensitizing Agents; Splenectomy; Splenic Neoplasms; Taxoids; Tomography, X-Ray Computed | 2007 |
Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Base Sequence; Blotting, Western; DNA Primers; Docetaxel; Enzyme-Linked Immunosorbent Assay; Humans; Male; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Transplantation, Heterologous; Trastuzumab | 2007 |
Docetaxel and beyond.
Topics: Antineoplastic Agents; Bone Neoplasms; Carboplatin; Diphosphonates; Docetaxel; Estramustine; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy-mediated antitumoral effect.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Docetaxel; Drug Synergism; Fibroblasts; Humans; Male; Mice; Mice, Nude; Muscles; Myoblasts; Piperidines; Prostatic Neoplasms; Quinazolinones; Taxoids; Tumor Cells, Cultured; Wilms Tumor | 2007 |
Editorial comment on: Weekly docetaxel and prednisolone versus prednisolone alone in androgen-independent prostate cancer: a randomized phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Prednisolone; Prostatic Neoplasms; Taxoids | 2007 |
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Blotting, Western; Bone Marrow Cells; Bone Neoplasms; Caspases; Cell Proliferation; Docetaxel; Drugs, Chinese Herbal; Flow Cytometry; Humans; Immunoenzyme Techniques; Lignans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Radiography; Taxoids; Tumor Cells, Cultured | 2007 |
Low concentrations of the histone deacetylase inhibitor, depsipeptide, enhance the effects of gemcitabine and docetaxel in hormone refractory prostate cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Depsipeptides; Docetaxel; Drug Synergism; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Male; Mice; Mice, Inbred BALB C; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Catenated; DNA, Kinetoplast; Docetaxel; Humans; Isoquinolines; Male; Melphalan; Mice; Mice, SCID; Mitoxantrone; Naphthalimides; Prostatic Neoplasms; Protein Binding; Quinoxalines; RNA Interference; Taxoids; Topoisomerase II Inhibitors; Xenograft Model Antitumor Assays | 2007 |
The preliminary results of docetaxel-prednisolone combination therapy for the Japanese patients with hormone-refractory prostate cancer.
Topics: Administration, Oral; Aged; Ambulatory Care; Docetaxel; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Feasibility Studies; Granulocyte Colony-Stimulating Factor; Humans; Infusions, Intravenous; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Staging; Neutropenia; Prednisolone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2007 |
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cytochromes c; Docetaxel; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Taxoids; Tumor Cells, Cultured; Veratrum Alkaloids | 2007 |
The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts.
Topics: Androgens; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Docetaxel; Drug Synergism; Drug Therapy, Combination; Humans; Male; Mice; Mice, Nude; Prostate-Specific Antigen; Prostatic Neoplasms; Quinolines; Quinolones; Survival Analysis; Taxoids; Xenograft Model Antitumor Assays | 2007 |
New treatment strategies in the management of hormone refractory prostate cancer (HRPC): only chemotherapy?
Topics: Antineoplastic Agents; Diphosphonates; Docetaxel; Drug Resistance, Neoplasm; Humans; Imidazoles; Male; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine; Zoledronic Acid | 2007 |
Docetaxel-induced Meibomian duct inflammation and blockage leading to chalazion formation.
Topics: Aged; Antineoplastic Agents, Phytogenic; Castration; Chalazion; Docetaxel; Eyelid Diseases; Humans; Male; Meibomian Glands; Prostatic Neoplasms; Taxoids | 2007 |
Successive therapies may extend survival in AIPC. Interview by Alice Goodman.
Topics: Antineoplastic Agents; Combined Modality Therapy; Docetaxel; Humans; Immunotherapy; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Tissue Extracts; Treatment Outcome | 2007 |
Re: Fabio Calabrò and Cora N. Sternberg. Current indications for chemotherapy in prostate cancer patients. Eur urol 2007;51:17-26.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Mitoxantrone; Organoplatinum Compounds; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids; Thionucleotides; Tissue Extracts | 2007 |
An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone.
Topics: Animals; Biomarkers, Tumor; Bone Neoplasms; Cell Line, Tumor; Docetaxel; Lipids; Luciferases; Luminescent Measurements; Magnetic Resonance Imaging; Male; Mice; Mice, SCID; Prostatic Neoplasms; Taxoids; Transfection | 2007 |
In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Bone Neoplasms; Cell Growth Processes; Cell Line, Tumor; DNA, Neoplasm; Docetaxel; Drug Synergism; Endothelin A Receptor Antagonists; Humans; Male; Mice; Mice, SCID; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrrolidines; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Editorial comment on: prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Humans; Male; Middle Aged; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Possible pitfall in diagnosis: mitotic arrest of gastric epithelium after docetaxel therapy for hormone-refractory prostatic cancer.
Topics: Aged; Antineoplastic Agents; Docetaxel; Epithelial Cells; False Positive Reactions; Gastric Mucosa; Humans; Male; Mitosis; Prostatic Neoplasms; Stomach Neoplasms; Taxoids | 2007 |
Increased expression of cyclin B1 sensitizes prostate cancer cells to apoptosis induced by chemotherapy.
Topics: 2-Methoxyestradiol; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclin B; Cyclin B1; Docetaxel; Estradiol; Gene Expression Regulation, Neoplastic; Humans; Male; Mitosis; Neoplasms; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Taxoids | 2007 |
Methylseleninic acid enhances the effect of etoposide to inhibit prostate cancer growth in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Etoposide; Gene Expression; Gene Expression Profiling; Humans; Male; Metabolic Networks and Pathways; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Organoselenium Compounds; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Weekly high-dose calcitriol and docetaxel in patients with metastatic hormone-refractory prostate cancer previously exposed to docetaxel.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Treatment Outcome | 2007 |
Progression after docetaxel-based chemotherapy in androgen-independent prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Docetaxel; Estramustine; Humans; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Soft Tissue Neoplasms; Survival Analysis; Taxoids; Treatment Outcome | 2007 |
The in vitro anti-tumour activity of zoledronic acid and docetaxel at clinically achievable concentrations in prostate cancer.
Topics: Antineoplastic Agents; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphosphonates; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imidazoles; Male; Minichromosome Maintenance Complex Component 2; Neoplasms, Hormone-Dependent; Nuclear Proteins; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2007 |
Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Docetaxel; Gene Expression Profiling; Humans; Indoles; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sunitinib; Survival Rate; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |
[New treatment approach to hormone-refractory prostate carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Clinical Trials, Phase III as Topic; Docetaxel; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 2007 |
Impact of PSA flare-up in patients with hormone-refractory prostate cancer undergoing chemotherapy.
Topics: Adenocarcinoma; Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Drug Resistance, Neoplasm; Estramustine; Humans; Kaplan-Meier Estimate; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
[Optimizing treatment of advanced urologic malignancies].
Topics: Carcinoma, Transitional Cell; Docetaxel; Drug Resistance, Neoplasm; Education, Medical, Graduate; Gene Expression Profiling; Humans; Lymphatic Metastasis; Male; Neoplasm Staging; Neoplasms, Germ Cell and Embryonal; Palliative Care; Prognosis; Prostatic Neoplasms; Quality Assurance, Health Care; Research; Taxoids; Testicular Neoplasms; Transurethral Resection of Prostate; Urinary Bladder Neoplasms; Urologic Neoplasms; Urology | 2007 |
Chemotherapy in prostate cancer: an update.
Topics: Antineoplastic Agents; Docetaxel; Humans; Male; Organoplatinum Compounds; Prostatic Neoplasms; Taxoids | 2007 |
Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; In Situ Nick-End Labeling; Kaplan-Meier Estimate; Male; Mice; Mice, Nude; Oligodeoxyribonucleotides; Oligonucleotides, Antisense; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Taxoids; Thionucleotides | 2007 |
Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Bevacizumab; Body Weight; Cell Cycle Proteins; Cell Proliferation; Docetaxel; Drug Therapy, Combination; Fluorouracil; Humans; Male; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Organ Size; Prostatic Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Influence of the docetaxel administration period (neoadjuvant or concomitant) in relation to HIFU treatment on the growth of Dunning tumors: results of a preliminary study.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Phytogenic; Chemotherapy, Adjuvant; Docetaxel; Drug Administration Schedule; Drug Screening Assays, Antitumor; Injections, Intraperitoneal; Male; Models, Biological; Neoadjuvant Therapy; Neoplasm Transplantation; Prostatic Neoplasms; Random Allocation; Rats; Taxoids; Tumor Burden; Ultrasound, High-Intensity Focused, Transrectal | 2008 |
Does small-cell phenotype predict the natural history of prostate cancer? A case study in disease behavior.
Topics: Adenocarcinoma; Androgen Antagonists; Anilides; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Cisplatin; Docetaxel; Estramustine; Etoposide; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Nephrostomy, Percutaneous; Nitriles; Phenotype; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids; Tosyl Compounds; Transurethral Resection of Prostate; Urinary Diversion | 2007 |
New therapies for advanced prostate cancer: the nurse as part of the multidisciplinary team.
Topics: Antineoplastic Agents; Docetaxel; Drug Monitoring; Humans; Male; Nurse's Role; Oncology Nursing; Organoplatinum Compounds; Patient Care Team; Prostatic Neoplasms; Quality of Life; Taxoids | 2007 |
[Effects of docetaxel and prednisone for hormone-refractory prostate cancer].
Topics: Aged; Alkaline Phosphatase; Antineoplastic Agents; Docetaxel; Drug Therapy, Combination; Follow-Up Studies; Glucocorticoids; Humans; Karnofsky Performance Status; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2007 |
Enhanced therapeutic effect on androgen-independent prostate cancer by depsipeptide (FK228), a histone deacetylase inhibitor, in combination with docetaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Depsipeptides; Docetaxel; Humans; Male; Prostatic Neoplasms; Taxoids; Tumor Cells, Cultured | 2007 |
Distinct prognostic role of prostate-specific antigen doubling time and velocity at emergence of androgen independence in patients treated with chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Paclitaxel; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Salvage Therapy; Survival Analysis; Taxoids; Time Factors | 2007 |
Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo.
Topics: Animals; Antibodies; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Chemokine CCL2; Docetaxel; Humans; Immunization, Passive; Immunoglobulin G; Male; Mice; Mice, SCID; Neoplasm Metastasis; Prostatic Neoplasms; Receptors, CCR2; Receptors, Chemokine; Taxoids; Xenograft Model Antitumor Assays | 2007 |
Estramustine in prostate cancer: new look at an old drug.
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Estramustine; Humans; Male; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids | 2007 |
Serum HER2 extracellular domain predicts an aggressive clinical outcome and biological PSA response in hormone-independent prostate cancer patients treated with docetaxel.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Receptor, ErbB-2; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Clusterin mediates TRAIL resistance in prostate tumor cells.
Topics: Apoptosis; Caspase 3; Cell Line, Tumor; Clusterin; Docetaxel; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Janus Kinases; Male; Prostatic Neoplasms; Proto-Oncogene Proteins pp60(c-src); Receptors, TNF-Related Apoptosis-Inducing Ligand; Resveratrol; RNA, Small Interfering; STAT Transcription Factors; Stilbenes; Taxoids; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Chemotherapy, Adjuvant; China; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Prednisone; Probability; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Rate; Taxoids; Treatment Failure; Treatment Outcome | 2007 |
Death of a clinical trial: a speculative inclusion criterion gone wrong.
Topics: Antineoplastic Agents; Australia; Chemotherapy, Adjuvant; Diphosphonates; Docetaxel; Humans; Imidazoles; Male; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Zoledronic Acid | 2007 |
Are prostate-specific antigen changes valid surrogates for survival in hormone-refractory prostate cancer? A meta-analysis is needed!
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Docetaxel; Estramustine; Humans; Male; Meta-Analysis as Topic; Mitoxantrone; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Rate; Taxoids | 2007 |
Circulating endothelial cells as a therapeutic marker for thalidomide in combined therapy with chemotherapy drugs in a human prostate cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Synergism; Endothelial Cells; Estramustine; Humans; Male; Mice; Mice, SCID; Neoplasm Transplantation; Prostatic Neoplasms; Random Allocation; Stem Cells; Taxoids; Thalidomide; Transplantation, Heterologous | 2008 |
Pharmacotherapy for prostate cancer: the role of hormonal treatment.
Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Atrasentan; Docetaxel; Gonadotropin-Releasing Hormone; Humans; Male; Models, Biological; Prostatic Neoplasms; Pyrrolidines; Taxoids | 2007 |
Evidence of a novel docetaxel sensitizer, garlic-derived S-allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cadherins; Cell Division; Cell Line, Tumor; Cysteine; Docetaxel; Down-Regulation; Drug Synergism; Flow Cytometry; G2 Phase; Garlic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasms, Experimental; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Transplantation, Heterologous; Tumor Stem Cell Assay; Up-Regulation | 2008 |
Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.
Topics: Aged; Androgens; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Docetaxel; Estramustine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Taxoids; Treatment Outcome | 2008 |
Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1B1; Docetaxel; Estrogens; Genotype; Humans; Male; Mass Spectrometry; Middle Aged; Prostatic Neoplasms; Survival Rate; Taxoids; Tubulin | 2008 |
2-chloroadenosine modulates PAR-1 and IL-23 expression and enhances docetaxel effects on PC3 cells.
Topics: 2-Chloroadenosine; Agar; Antineoplastic Agents; Apoptosis; Cell Division; Cell Line, Tumor; Docetaxel; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Interleukin-23 Subunit p19; Male; Prostatic Neoplasms; Receptor, PAR-1; S Phase; Stem Cells; Taxoids | 2008 |
Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Middle Aged; Neoadjuvant Therapy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Taxoids | 2008 |
Direct and distant antitumor effects of a telomerase-selective oncolytic adenoviral agent, OBP-301, in a mouse prostate cancer model.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antiviral Agents; Disease Models, Animal; Docetaxel; Genetic Therapy; Green Fluorescent Proteins; Humans; Male; Mice; Prostatic Neoplasms; Taxoids; Telomerase | 2008 |
Editorial comment on: combination of bevacizumab and docetaxel in docetaxel-pretreated hormone-refractory prostate cancer: a phase 2 study.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Docetaxel; Drug Resistance, Neoplasm; Drug Therapy, Combination; Hormones; Humans; Injections, Intravenous; Male; Prostatic Neoplasms; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Methylseleninic acid enhances taxane drug efficacy against human prostate cancer and down-regulates antiapoptotic proteins Bcl-XL and survivin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Docetaxel; Down-Regulation; Drug Synergism; Humans; Immunoblotting; Inhibitor of Apoptosis Proteins; Male; Mice; Microtubule-Associated Proteins; Neoplasm Proteins; Organoselenium Compounds; Paclitaxel; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Survivin; Taxoids; Xenograft Model Antitumor Assays | 2008 |
RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model.
Topics: Adjuvants, Pharmaceutic; Animals; Antineoplastic Combined Chemotherapy Protocols; Bone and Bones; Bone Neoplasms; Chemotherapy, Adjuvant; Disease Models, Animal; Docetaxel; Dose-Response Relationship, Drug; Male; Mice; Mice, SCID; Prostatic Neoplasms; Radiography; RANK Ligand; Recombinant Fusion Proteins; Taxoids | 2008 |
Efficacy vs. effectiveness--docetaxel and prednisone in hormone refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Alberta; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Prednisone; Prognosis; Prostatic Neoplasms; Retrospective Studies; Survival Rate; Taxoids | 2008 |
The postchemotherapy PSA surge syndrome.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Docetaxel; Estramustine; Gonadotropin-Releasing Hormone; Humans; Kinetics; Male; Middle Aged; Mitoxantrone; Neoplasm Metastasis; Orchiectomy; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Sesquiterpenes; Syndrome; Taxoids; Treatment Outcome | 2008 |
RAD001 (Everolimus) inhibits growth of prostate cancer in the bone and the inhibitory effects are increased by combination with docetaxel and zoledronic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Docetaxel; Everolimus; Humans; Imidazoles; Male; Mice; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Sirolimus; Taxoids; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases; Zoledronic Acid | 2008 |
Could the efficacy of docetaxel in prostate cancer patients be potentiated by concomitant high-dose calcitriol administration?
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Calcitriol; Clinical Trials as Topic; Docetaxel; Drug Synergism; Humans; Hypocalcemia; Male; Prostatic Neoplasms; Taxoids | 2008 |
Biweekly doxorubicin/ketoconazole as second-line treatment in docetaxel-resistant, hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antifungal Agents; Antineoplastic Agents; Docetaxel; Doxorubicin; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Therapy, Combination; Follow-Up Studies; Humans; Ketoconazole; Male; Middle Aged; Prostatic Neoplasms; Taxoids | 2008 |
Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
Topics: Apoptosis; Caspases; Cell Line, Tumor; Cyclin B; Cyclin B1; Docetaxel; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Intracellular Space; Male; Mitogen-Activated Protein Kinase 8; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Taxoids; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Up-Regulation | 2008 |
The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Docetaxel; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Male; Models, Biological; NF-kappa B; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-pim-1; STAT3 Transcription Factor; Taxoids; Transcription, Genetic | 2008 |
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
Topics: Androgens; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Taxoids; Treatment Outcome | 2008 |
Is chemotherapy the standard for asymptomatic androgen-independent prostate cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Taxoids | 2008 |
Taxotere chemosensitivity evaluation in mice prostate tumor: validation and diagnostic accuracy of quantitative measurement of tumor characteristics by MRI, PET, and histology of mice tumor.
Topics: Animals; Antineoplastic Agents; Docetaxel; Fluorodeoxyglucose F18; Magnetic Resonance Imaging; Male; Mice; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Taxoids | 2008 |
The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Docetaxel; Drug Evaluation; Drug Resistance, Neoplasm; Humans; Male; Mitogen-Activated Protein Kinase Kinases; Neoplasms, Hormone-Dependent; Peptides, Cyclic; Prostatic Neoplasms; Signal Transduction; Somatostatin; Taxoids | 2008 |
Bcl2 is the guardian of microtubule integrity.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Chronic Disease; Docetaxel; G2 Phase; Humans; Leukemia; Lymphoma, B-Cell; Male; Microtubules; Paclitaxel; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Taxoids; Tumor Cells, Cultured | 1997 |
Chemotherapy combination shows efficacy in hormone-refractory prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Administration Routes; Estramustine; Follow-Up Studies; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Treatment Outcome | 1999 |
Docetaxel (Taxotere) in hormone-refractory prostate cancer: a new addition to the physicians' toolbag.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Docetaxel (Taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific basis and design of Southwest Oncology Group Study 9916.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Docetaxel; Estramustine; Humans; Male; Mitoxantrone; Neoplasms, Hormone-Dependent; Paclitaxel; Prednisone; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Taxoids | 1999 |
Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Topics: Androgens; Animals; Antineoplastic Agents, Phytogenic; Blotting, Northern; Blotting, Western; Disease Progression; DNA Primers; DNA, Neoplasm; Docetaxel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gene Targeting; Genes, bcl-2; Male; Mice; Oligodeoxyribonucleotides, Antisense; Paclitaxel; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Taxoids | 1999 |
Docetaxel (Taxotere): a new option for the treatment of hormone-refractory prostate cancer. Proceedings of a symposium. Chicago, Illinois, USA. April 23, 1999.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Humans; Male; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Taxoids | 1999 |
Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging.
Topics: Animals; Annexin A5; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Nucleus; Docetaxel; Etoposide; Flow Cytometry; Fluorescent Antibody Technique; Fluorescent Dyes; Humans; Magnetic Resonance Imaging; Male; Mice; Neoplasm Transplantation; Paclitaxel; Phantoms, Imaging; Prostatic Neoplasms; Sodium; Sodium Chloride; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2000 |
Colitis and docetaxel-based chemotherapy.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Colitis; Diarrhea; Docetaxel; Estramustine; Female; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Vinblastine; Vinorelbine | 2000 |
Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Estramustine; Humans; Inhibitory Concentration 50; Male; Microtubules; Neoplasm Transplantation; Neoplasms, Hormone-Dependent; Paclitaxel; Prostatic Neoplasms; Rats; Taxoids; Tumor Cells, Cultured | 2000 |
Docetaxel (taxotere) extravasation: a report of five cases with treatment recommendations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Edema; Erythema; Extravasation of Diagnostic and Therapeutic Materials; Hand; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prostatic Neoplasms; Taxoids | 2000 |
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |
Different docetaxel-induced apoptotic pathways are present in prostate cancer cell lines LNCaP and PC-3.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Blotting, Western; Caspases; Clusterin; Docetaxel; Glycoproteins; Humans; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Molecular Chaperones; Neoplasm Proteins; Paclitaxel; Prostatic Neoplasms; Proteins; Survivin; Taxoids; Tumor Cells, Cultured | 2001 |
Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
Topics: Adenoviridae; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Survival; DNA, Viral; Docetaxel; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunoblotting; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured; Tumor Suppressor Protein p53; Virus Replication; Xenograft Model Antitumor Assays | 2001 |
Modulation of docetaxel-induced apoptosis and cell cycle arrest by all- trans retinoic acid in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Cycle; Cyclin D1; Docetaxel; Down-Regulation; Drug Interactions; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Tretinoin; Tumor Cells, Cultured | 2001 |
Combination therapy in hormone-refractory prostate cancer.
Topics: Anti-Inflammatory Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Docetaxel; Estramustine; Humans; Hydrocortisone; Male; Paclitaxel; Prostatic Neoplasms; Taxoids | 2001 |
Enhanced transgene expression in androgen independent prostate cancer gene therapy by taxane chemotherapeutic agents.
Topics: Adenoviridae; Antineoplastic Agents, Phytogenic; Docetaxel; Gene Expression; Genetic Therapy; Humans; Male; Paclitaxel; Prostatic Neoplasms; Taxoids; Transgenes; Tumor Cells, Cultured | 2002 |
Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6.
Topics: Animals; Combined Modality Therapy; Docetaxel; Heterocyclic Compounds; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Prostatic Neoplasms; Radiation-Sensitizing Agents; Radioimmunotherapy; Taxoids; Transplantation, Heterologous; Yttrium | 2002 |
Successful treatment of metastatic hormone-refractory prostate cancer with malignant pericardial tamponade using docetaxel.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Cardiac Tamponade; Cisplatin; Combined Modality Therapy; Docetaxel; Humans; Male; Methylprednisolone; Middle Aged; Paclitaxel; Pericardial Effusion; Pericardiocentesis; Pleural Effusion; Prostatic Neoplasms; Taxoids | 2002 |
Severe interstitial pneumonitis associated with docetaxel administration.
Topics: Adrenal Cortex Hormones; Aged; Anti-Bacterial Agents; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Docetaxel; Fatal Outcome; Female; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Paclitaxel; Prognosis; Prostatic Neoplasms; Respiration, Artificial; Taxoids; Uterine Neoplasms | 2002 |